<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8a129d3-5b56-4357-ad74-d4bca40eb389">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e7d512b-5d7b-4064-b013-a6a01d3394d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/061dbf67-4c7d-4138-b413-88166070fe0f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77df7df2-2d38-4800-b0b6-0bd8f33e80c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a9e7914-7b54-4882-8f8c-325dda2c4460"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3dbb539f-af5f-49e7-8884-5ae3311faac4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d">
        <rdfs:label>Symptomatic (C)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59fd34df-b10d-4d20-b06c-690b27883ed2">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1deb1d67-33ff-40d1-aec0-376fdcd8c711"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b55de00-c4bb-4c43-b081-f31de6b77dbd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a60c2cf-9aa8-4515-82b4-8ebbed119846">
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b34b2221-974b-4b0f-a1fb-6a230f7097da"/>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b357b7cb-8e4a-463a-aae5-a1c6d9c11bec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6989caf-f3a6-464b-908d-3d3e86c5d45c">
        <rdfs:label>Delayed receptive language</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
        <dc:identifier>ECO:0000352</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c">
        <rdfs:label>Functional interaction(Mechanistic B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa5172b8-585d-4049-b0c5-36c99dd7ec12">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd7b50ae-d87f-4b61-b45f-5557301166b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e702c7e1-a149-4216-8ae9-392835c177fd">
        <rdfs:label>Developmental delay</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f68522c1-5461-417d-ba0c-5b02c21a9295"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fb9b111f-ad46-48f2-a97a-e83aa7295bef">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20b9a11f-67fd-4e21-bebb-43b62fb8b81e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
    <rdfs:label>battenin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e0d02cd6-e6ea-4db5-881d-a659897fcc5f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a86c7e3a-800e-474d-814f-5edcb2d3d167">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
        <rdfs:label>RXYLT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9Y2B1</ddiem:uniprotId>
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cddba822-b656-411f-8833-bb70f894597f">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ff3d6913-f4ce-4d38-8971-50e5705c58ba">
        <rdfs:label>BCKDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b170b381-b58a-4c1f-90e1-eb66f0d58312">
    <ddiem:uniprotId>Human</ddiem:uniprotId>
    <ddiem:uniprotId>id</ddiem:uniprotId>
    <ddiem:uniprotId>NO</ddiem:uniprotId>
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c7792c7-2177-4ed3-9ca9-0b4888e277dd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
        <rdfs:label>CLN6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e7eaa5f-815b-4ed5-b6dd-21f44c36c0a8">
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57623eca-04db-40bc-bcdc-c59c4ee20b1b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypertriglycridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e155640-cf7e-4d31-8560-0035f4b39fda">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ff596dc9-6f15-496f-bdc9-a88bbfe3ccfa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1fb756ab-76fe-40ec-8c2d-93ec4e05047a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b6ae360-40b1-434d-b8a5-cbefadb59bda"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/327a1931-1207-4254-bf6c-9e85eb83c32f">
        <dc:identifier>HP:0003074</dc:identifier>
        <rdfs:label>Hyperglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0b1acd5-b265-49c2-88b5-5054f03e0842">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2af90029-2556-4e47-8dfc-f8b708e26378"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/18a4f6af-10b9-4964-8af9-ee24162251a0"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0fe891cf-2b55-4e7f-a5bd-ce6f10bd9704">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/139edfc9-2e1f-4d9f-9ad0-2db15102dc9f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c3e5862-4e47-4375-9635-40a80fd8ab19"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75e76c64-a6ee-42e7-b259-8d048b9508c2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>low Hb level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-016-2044-9</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5cb475c0-272a-454f-ae7a-7f5e2df8894a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7991fc51-f953-4535-9e7b-2501f22e18fa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/05fe61f1-6ace-48fd-8b98-933569b46f64"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b854a63a-efee-419a-ab5a-ec93d04405b1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ae5e3f62-155a-4472-8e69-2ed896aeca6e"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c0b7382-ea9b-4c08-bd46-c8ee27eb466f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2eedbff0-31b0-4906-8315-c51af468fa77"/>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7cd05694-ad1a-4dfe-82c8-73fc53f053f7"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64e0e594-db68-4d90-a5fb-1eb2b2d0a505"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/91a20923-4f72-41f5-9bf5-4807734d57ed"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e28611a7-5e77-41bc-a844-74a9a8572917"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e8ce81e0-85a6-44e7-9c05-8b454bdc58ef"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3544212f-cf11-47f3-9b31-6a3a4161bd05"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/196568ad-dc5d-4095-bde7-b5778ede529d">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/37d5266c-ff88-4702-87e5-e5c2f2bc8bc6">
        <rdfs:label>Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0e19abfe-8d10-4806-afd0-5f92f9ae1f3b"/>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b37343e-852b-48cd-a965-bc7974401792">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92f7f465-f60c-4f25-bdf3-dbbb447b4190"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd9a81c1-a8fb-49a4-afc6-b3f78d75ffc4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <dc:identifier>HP:0006785</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle dystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
        <dc:identifier>ECO:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3465fd1e-bd3d-46f8-8aa0-fb77e1c2640f">
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9b4da57b-9a0b-4740-bc6b-d4e5bbe51a19"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:label>Dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/963c55dd-5b14-42fb-b9cd-c4204e8bc6c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f1959e6-e820-449f-985d-dbd12d7fabd4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7a88086-aa02-42ee-8c49-41761147c3d2">
        <dc:identifier>HP:0002072</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chorea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cfb6b7cc-7299-4e37-839a-10949e7e97b6">
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56c1cc9c-d69a-4e69-8abe-6841d7db1690">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18fd63ff-8c61-40c9-8d4a-ea72e8bfbc45">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34efb722-4e72-4898-86c8-48fba4b4e0ff">
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/142a844c-a28e-426a-9983-c85bbf2084fc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/207ea0ac-efdc-4736-b589-b50ea291215f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a952d1cf-a330-488c-9430-c34e37d8a4d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff3ae28d-6aef-4164-bc55-deac02b43721">
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:label>Myoclonus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1608293-1aa7-4018-b327-f538548d5cf9"/>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/db82ad0a-e312-4b26-a75a-76b399bc953e">
        <rdfs:label>POGLUT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/af8e82ec-1c36-41c6-8a74-bb2d77ec2f3c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40bdbbe0-2e06-44f2-96e6-7c8ed13dc0f9">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f08397d5-789a-4857-97ae-6e765c27f6a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca05a0a4-f990-409f-bd4b-f4b60acedc44">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1bda507a-9188-49d6-b428-632ae584597a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/afe6f06c-8749-4ba9-9b72-e8b3297d75b8"/>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de7191ab-978f-4202-8a8a-8644c37044db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a149238-a27c-458c-96e9-be296fb110b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5243864e-e5d7-4831-817c-cd8e20d50b0a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0008315</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3895739d-8d3a-452f-a2c1-d8b74e5d7f44">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/39730b6e-85be-40d3-b624-a33564f01abf">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.51</ddiem:ecNumber>
    <ddiem:ecNumber>1.1.1.178</ddiem:ecNumber>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/beefa597-8c88-4657-b1d8-eb9345546529">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6fcf53bc-2355-4bbe-8f08-73289dd5c1ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b317018-ba6d-4657-a544-dcdbd3691f98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/329502f8-8ac9-40c8-b940-d5c971dfdcec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1d492f99-3fdf-4905-a661-f9419ff76dba"/>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c02d15b-8848-4580-b343-6a93db73ab61">
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b4da57b-9a0b-4740-bc6b-d4e5bbe51a19">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
        <rdfs:label>HPRT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b73002ad-322e-4770-a3a2-5f25404e3f6b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/443808be-bb5d-4b89-9a1c-79ee05083b26"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/561619fd-92fb-42e0-8001-0a11f1494267">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>irritability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <dc:identifier>HP:0000737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd043607-c6d6-45e7-976f-edddd0b6e529">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd7370f3-a83a-402f-8fa8-cfcdd3f62d00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/895b6ae9-0085-40b8-9d95-073c5fd66067"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0aedc6db-d62c-4af6-a338-8e721bf67ca0">
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003657</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d5e7382-fbf0-4d91-a6a4-0cba27ef73f6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected alertness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <dc:identifier>HP:0004372</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd">
        <rdfs:label>Functional interaction ( Mechanistic B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df453285-6710-4e53-b184-3244b3f8d299"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43464ed5-e21d-4c2f-8d62-bfadb5859679">
        <rdfs:label>MANBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c7e289d-b671-42dc-b3ad-0188585ddbae">
    <ddiem:ecNumber>2.4.1.25</ddiem:ecNumber>
    <ddiem:ecNumber>3.2.1.33</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f71dc191-0b90-429d-a363-d76d167a71ad">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
        <rdfs:label>AGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a3a25e5-08e8-48d2-84be-28e893fa62b7">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a87be9a-8f29-46b4-99fc-033dcf3efe94">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1590e331-527f-4af2-96b6-2883a24af72c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b3035a1-3717-41f3-805e-554274e13ce6">
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <dc:identifier>HP:0002014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a1e1892-58c0-43ad-9904-56b0790745c2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Dehydration</rdfs:label>
        <dc:identifier>HP:0001944</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7879242f-c5b7-4b0b-9be3-c22905b80cbe"/>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ace6935-bcc4-44c4-b040-a3471208cac5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e969d5e2-14bd-4c2e-8415-0bad59f7d9cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fd140cd9-fef5-4187-a87a-2043970917c0">
    <rdfs:label>Adenosine deaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bcfe79fe-e04b-4fcc-885a-f5ce89759f86">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
        <rdfs:label>ADA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.4.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f57d5f3c-7356-4fb9-ba07-8167c2189938">
    <ddiem:ecNumber>3.1.3.36</ddiem:ecNumber>
    <ddiem:ecNumber>3.1.3.56</ddiem:ecNumber>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <ddiem:ecNumber>3.1.3.86</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f79e645b-25cf-43db-ab67-5bc1176dca5d">
        <rdfs:label>OCRL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c15aa11a-dcac-40b2-9976-e73809a1c529">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8372f676-01d6-450c-942f-7f732eb1bee1">
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a697a15-d53a-4e6c-a50e-26e67e17838d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f41a926c-4156-45fd-b42f-0fdbc95146db">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010893</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f">
        <rdfs:label>Functional interaction (Mechanistic B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d95a2e01-6560-49d6-b6d0-e70a72c24973">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum  prolactin</rdfs:label>
        <dc:identifier>HP:0040086</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54726add-905d-41d7-adda-79aaabda3f26">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Neurological abnormalities</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22206e1d-588e-472a-8faa-cf85812fcc1a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529">
        <rdfs:label>Direct Interaction (A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2584288d-48ea-4b38-8dd0-b89684ac5a3d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>Study is still recruiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e596c94f-82fe-4d6f-928b-def952eb29ff"/>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a4f8164-bbf7-40c8-b28b-bd232942b1c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1b6e268-002a-416b-b3f3-4fab62430df2"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/207c43bb-8ce7-40b3-bd5a-eda7d0d9e505">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/827d46f4-46e6-4f51-ab85-237dda37150e">
        <rdfs:label>angina pectoris</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001681</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0c59732-5b41-4010-ba4c-8105d69d5674">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
        <rdfs:label>xanthomas</rdfs:label>
        <dc:identifier>HP:0000991</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53ea9b51-e560-477b-a733-21281bf0eef6">
        <dc:identifier>HP:0001677</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/616deabd-5e63-47a8-a9d8-cda54d331609">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c670b535-9706-4d71-b881-dc488ca75711"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb">
        <rdfs:label>Functional interaction (B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb419f1b-bc8d-489e-ac89-ae4e6086174f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e4671e55-18a8-4563-9d4e-f6e1fcb938fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8f411bd-4bca-475d-8d88-e769dc859cf8"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ed26669-f22a-4742-889c-8983eb4de016">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd9a81c1-a8fb-49a4-afc6-b3f78d75ffc4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/37d5266c-ff88-4702-87e5-e5c2f2bc8bc6"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a58ed8a3-ed6c-460f-a3e3-e817ba4f374e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b37343e-852b-48cd-a965-bc7974401792"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/241e13d2-c80e-429b-b58c-b26bf51d0074">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/94a184b6-88d4-4d44-9792-158c86adc118">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25784a00-cd9b-48ad-8cc0-2cd8603f3048"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/18263632-fa3d-4263-b08e-c9d17f006ee4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c6ede1b-b5b1-44bc-adb2-3dbb98b2bf17">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f25ecbad-3741-475c-81a6-a331eb920e72">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
        <dc:identifier>HP:0003162</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f285d3af-74af-45c9-a746-87ca3b7fc5aa">
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2355a8bb-dfc6-44de-b485-37251d9a62d5">
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1aa0ff7a-3d27-41db-ae9b-cb25e6c5e84f">
        <rdfs:label>MLYCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/372047bc-a172-404a-8d51-f7217ca0aa05">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc83c755-541d-4970-a44c-f2955c96a05a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfa1520c-5028-4053-bf3b-9147b8929de8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa1f7d4c-3181-49a4-bf8e-13b2e86eb123">
        <rdfs:label>social interaction defect</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <dc:identifier>HP:0000735</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41a02057-e3d7-44b2-8bde-ea2f853b95c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d46b65b0-9059-461c-8369-40f8005110b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/caa16fc0-dcad-4c35-8515-b81a56d3817a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38b33047-41d7-4934-84e9-a46ee9b1a911">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e2912e6-8163-41bd-9f6e-feb813485298"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/188f2b33-7e21-4ced-8567-b16baabe4d32">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1ae8ddae-925e-4b33-9ce4-ba8ac7e1e28c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9335d89d-c26d-4f10-a30c-a4b2d314f85d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e2eee262-8c5d-4128-9e03-45826a3e726e">
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c4bf1af-b44f-456a-b635-5efdf77b28c6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
        <rdfs:label>FKTN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>fukutin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7068851-4401-42f1-a8bb-05e3928682a0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4956dc5-848f-4b75-95ae-79c57a527f03"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea3c0e8a-9e2a-490e-bbf7-c8d1a8656f2e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/337f098d-182d-48d4-a421-d14e2f1520d0">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>low muscle tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94306293-f216-4abd-9437-bbef53aef341">
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e01f15f5-6b8f-46db-b83e-394f39940a00">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b55de00-c4bb-4c43-b081-f31de6b77dbd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95c9bcf4-1981-4c88-ad09-79f2ff7403f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4b1675a-8e5f-46eb-9e6b-4fa18fe739b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e8013ef4-91e8-4f46-ab4e-714cec567ab7"/>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/6555717a-8a0c-4ffb-8e94-0faa41cf9829">
        <rdfs:label>Direct interaction &gt;&gt;&gt; activity modification</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91b6d65b-c014-4580-a938-64fc384be047"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/222ce919-29b4-4d06-a285-a591fb80b9ca">
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:ecNumber>6.3.1.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/afe6f06c-8749-4ba9-9b72-e8b3297d75b8">
        <rdfs:label>GLUL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6b72fda-778a-44f7-a253-156a1a83099c">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1b94b4a1-a141-47e7-8b70-ba73011309c9"/>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/044e34a5-2b45-49b9-aa45-87a5203847b2"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6e08b7b6-ba94-4c0c-acad-c91190df7b70"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ceb5cf70-3781-4bc0-91ef-e76213bbe647">
        <dc:identifier>HP:0003234*</dc:identifier>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/dbfb4468-e1c9-4306-a994-68245c0ee811">
        <rdfs:label>Functional interaction (B)+Direct Interaction (A)+symptomatic</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca10eb2c-a29e-45da-895d-eb006a3e436e">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Difficulty walking</rdfs:label>
        <dc:identifier>HP:0002355</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7de7156d-ce8c-4446-bee7-e89208f4e464">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:label>Dysphagia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6425f76-0e53-439a-a7f0-1f8d7ce453d6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dce6707-ed31-47c6-b853-1f18fa210721">
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <dc:identifier>HP:0003676</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25224dc6-67c5-41a1-bc4e-ec48e3441852">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08690382-a5d7-4815-8df6-79aba3bb368d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e18bbee-51c6-4e2e-8dea-9324f62cfdbc"/>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2055da76-8047-4577-babc-0ca09c26cb56"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54726add-905d-41d7-adda-79aaabda3f26"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85dc1265-e4f2-4524-85eb-4c8c1e2b8f4e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf">
        <rdfs:label>Supportive (C)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9ecb275-586a-4df0-9936-34ce4b7fbf93">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f302ad57-28ce-416b-9fdc-9621831b297b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/442d4a02-3cfd-4ea6-87fc-14935d47508b">
    <ddiem:uniprotId>P00414</ddiem:uniprotId>
    <ddiem:uniprotId>P00403</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71769888-fc0f-40fc-a017-12aec79f5bb0">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
        <rdfs:label>MT-CO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6c52837b-c903-480c-bdf3-a598e181ec4c">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
        <rdfs:label>MT-CO1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d468e4b-7212-4de2-896b-c96aaa173eb3">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
        <rdfs:label>MT-CYB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.9.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92df5c23-a09c-49db-b593-ae013a837733">
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ecd5bbfb-eaed-4a07-8504-003ac38b7f9b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b84579f-6061-444f-95b6-9e718f83dab4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a9495b5f-6f88-4189-8a73-fd4c7a2e7d0c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc1147dc-38d4-4306-ac78-ba67a5c6d0e6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012444</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
        <rdfs:label>brain atrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <dc:identifier>ECO:0001565</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd63cf97-7c1d-46de-8b49-86b2e5dee017">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4baa83c5-3196-4c5b-a54d-149876019dbc">
        <rdfs:label>Muscular abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <dc:identifier>HP:0012638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d6d8144-5e58-45a1-8d27-6225d152f232">
        <rdfs:label>Neurological abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25224dc6-67c5-41a1-bc4e-ec48e3441852"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/92b1f4bc-e520-4c1f-a94f-25b16d5c2fb2"/>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acf26994-0c8f-4141-b7eb-0751aeb2cca1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <dc:identifier>HP:0000505</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/af8414cf-a637-4156-80b5-301458c10795">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3dbb539f-af5f-49e7-8884-5ae3311faac4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
        <rdfs:label>ASL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f68dd020-3b8d-483c-b5ca-3d851df202e3">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14630c9f-5f7f-486e-a5f8-2c0e19278225">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f349d51d-2014-44ac-a350-d266897eee14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44761478-b01c-47b3-ab25-d33e4361dc15">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b2958ad9-1e39-4b95-91ca-270efaf39241"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736622</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c3d49f1-546a-4092-aebe-b6e44324c5eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ae8c257-3320-450b-a343-066a7b6d6be3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d8aa77da-319d-4963-a9ae-d32251714afd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d190b338-104e-409b-a525-f643ae885538">
        <rdfs:label>MT-TL1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad4d18f8-aae4-456a-90b7-c81de749629a">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
        <rdfs:label>MT-ND1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/32185393-12c1-41f9-b8a1-dabcb98b93e9">
        <rdfs:label>MT-ND6</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc09a7ba-ea87-4cff-b936-b7cc95e78dd7">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
        <rdfs:label>MT-TS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/58fa0fe1-a28d-4b5e-9b38-e71ad76e5e88">
        <rdfs:label>MT-TQ</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a1608293-1aa7-4018-b327-f538548d5cf9">
        <rdfs:label>MT-TK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <ddiem:uniprotId>NA</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b21fc089-4aea-48e1-9873-577691b1df48">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
        <rdfs:label>MT-TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4b23344-3f0e-4e1c-909d-3b94a4c4a52b">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
        <rdfs:label>MTTC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4a791c3e-0678-4a6f-8d74-08403c9073f4">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
        <rdfs:label>MT-ND5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb58e8a1-afb0-4010-8feb-3b57b0ac1759">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
        <rdfs:label>MT-TE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98a80efe-a4c0-4b43-9a1a-7709aa02752c">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
        <rdfs:label>MT-TS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ed903d1-3006-432a-a6ba-7ee23f985f25">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f22ed985-dc1d-4dd5-91b6-8387afbcb033">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
        <rdfs:label>ANKH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7920429e-4f16-4584-9847-071dfd9b5e6d">
        <rdfs:label>COG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:date>4.10.19</dc:date>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3e8fb442-4041-42e8-a739-6b3644436f9e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e7a5b409-5662-4db5-9e29-ecc12335a174">
        <rdfs:label>AMN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f6c3320f-8c83-4de6-aae5-64b487498211">
        <rdfs:label>CUBN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <ddiem:ecNumber>2.7.1.60</ddiem:ecNumber>
    <ddiem:ecNumber>3.2.1.183</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/210b4bfc-d00f-46a3-8603-cbbd5535f5f5">
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/951394ad-fa3b-4fef-8b28-b10c53d8c029">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
        <rdfs:label>APRT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8fb94d03-95f6-4dc0-8947-2c8e88d8746f">
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:ecNumber>3.1.-.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1a749018-193a-4f5d-8dcf-d473b7de5453">
        <rdfs:label>DNA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f9d1a1a-a245-43f1-b67e-9575536ed15b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51a1353b-6316-4a6e-baac-3140c84b567f"/>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/384f327c-bbe2-488a-a940-77d98d1d6f67">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>done</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:label>Hyperurecemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b13f50a-667b-4afe-b57c-a4ba8122b6b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebb6c679-506d-48cb-a0e1-5b8f7fd233ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7bdfe97-96b3-4e4a-b0a6-c50feb976ed0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/baa71e79-1fe3-45de-8e48-c56116d2094f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e0db9642-eb48-4a98-a115-3241bbe08f3f">
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa37fb2c-3585-459a-ba63-7296d07e767b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/471a97f1-4845-4212-b504-886836511260"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5a0ec902-8b23-43e4-845a-d5a90ef11707"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68ca92fa-dc4f-4da0-a260-f732358b5b28">
        <dc:identifier>HP:0002630*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b1662f9-e328-4078-86d0-c86adfb0c79e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efa3e315-338a-432b-9a64-eed38cbf45fa">
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dd5ee97-6cb3-4a55-9444-f95ad90a4075">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal liver function tests</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/866e85fa-abed-4865-88a4-9bdb5a3f6593">
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c7d8b651-927b-49d9-b349-67076c261cc1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
        <rdfs:label>KRT5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/db82ad0a-e312-4b26-a75a-76b399bc953e"/>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6df4ca46-e389-4cb2-8ac9-4bdda581e583">
    <ddiem:uniprotId>Not</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5aa1e0fb-59e6-4ba8-a520-0d940ce918e2">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
    <ddiem:uniprotId>available</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e38f568-3c2d-4ab9-bbc2-198ed29e4559">
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9bdc4c62-cb64-4aa8-a18f-638828b64a80">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a78c9370-38ad-492b-a4b6-36335d6cb111">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/097e2b3b-8631-45c7-b3cd-f0a5faa1b46b">
        <rdfs:label>TH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d771e8ac-6101-4b2f-b67c-52b8bd467691">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
        <rdfs:label>GCH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8b0ef1b-fd26-43b8-929d-4ee619eda43a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
        <rdfs:label>SPR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c267ae9-f017-4728-b1c3-3cddffcb6fa6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e87d82d4-fbb9-488a-b432-108479f2288d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
        <rdfs:label>CPS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec8c0a41-1bf2-48ad-bf0d-12a2419ba350">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5cb3bf57-4b74-4a62-b9ff-333ede91800d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a60cf845-9315-4282-802d-618d0457126d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75e76c64-a6ee-42e7-b259-8d048b9508c2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cb475c0-272a-454f-ae7a-7f5e2df8894a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c0926075-0559-4f9f-acde-e60e7d21181b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b7a3ddd-b229-4f50-8d5b-76a6eb783383">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d81357ba-a8b0-43aa-aaba-505651119a62"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad84c288-317b-4618-9c92-2517b050ebb5"/>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04e7fb6b-d32d-4c26-a959-1bb81081eead">
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:label>Metabolic acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ceb5cf70-3781-4bc0-91ef-e76213bbe647"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a678e01-e6db-46ef-913c-02ea06f4dade">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/826cb97f-9624-4af0-95ed-20999a4456e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/477f6527-9c5d-4711-8404-68cf3dd9692a">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Disease progression</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/591b09da-6601-4b33-8657-da466660f122">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cf21c0d0-051f-4746-ba29-9aa6d7a3ccc9">
        <rdfs:label>PRODH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dc126c8b-2822-422d-8a0e-e6558ca96882">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7db7913b-a657-4702-ac00-6d7d93bf7dc1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e10acb0a-5dcc-4bd4-8339-ac8f961d150e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6f34bc13-1e53-4b80-90b0-bebf683bf43d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
        <rdfs:label>DPM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/197859ed-a3b0-427b-8224-c419d084ce6e">
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/009094a3-8452-4e9a-ad7b-a91ffe791cf1">
        <rdfs:label>PHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/68d04027-294c-4ba9-8fb9-20d372089455">
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8fd83ec4-4035-46ce-9e6f-645735869362">
        <rdfs:label>SGCG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>sarcoglycan gamma</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96ef37f2-19a9-4d89-a308-68b601c13693">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e7fb6b-d32d-4c26-a959-1bb81081eead"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40bdbbe0-2e06-44f2-96e6-7c8ed13dc0f9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5243864e-e5d7-4831-817c-cd8e20d50b0a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a398b94-c171-4e9a-84d2-682d7b5fd080"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca05a0a4-f990-409f-bd4b-f4b60acedc44"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f221dd9-5611-4d56-821a-ab3c588d185d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a7d4f7e-f6e0-45ba-b7a2-603121cfa76b">
        <rdfs:label>Cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30170323-2d64-4c30-94f0-105136dde9e4">
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04f2425a-463e-4492-9fb2-77be8a76e401">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:label>Functional motor deficit</rdfs:label>
        <dc:identifier>HP:0004302</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8615fd07-3f8f-4c4e-890f-767203df92b1">
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0250f88e-8cf1-4441-a0ef-fc469f20e61e">
        <dc:identifier>HP:0025356</dc:identifier>
        <rdfs:label>Psychomotor retardation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b231b2d9-ab0c-4624-97da-0cce5dc08003"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be9930b4-76f3-47d2-8081-7dbed9f82f5e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <dc:identifier>HP:0000967</dc:identifier>
        <rdfs:label>Petechiae</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/676e9654-e47e-49a4-b96d-c7dc927c484f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d0e21e9-0b1d-4a36-b4f0-bf3e65f64842">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3e7bd91f-ca68-49d2-802f-91d53080fbfe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/242bee77-14c6-48b1-bad4-15b45bc3c509"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e8f672c-1a9b-4a85-a6d3-8fdb05cbe8d4">
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>Nephropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe9259a5-581f-4570-93e6-83dedb658601">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8447f94c-a38b-4f2c-b09c-2bbc91a3a4bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
        <dc:identifier>ECO:0007764</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/07d3a9bb-0f25-4140-ad44-4b1799285397">
        <rdfs:label>B4GAT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1937c98e-42c8-41f8-9877-c16720dc88d5">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Oxidative stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f3361cc0-f850-4cd5-b07b-5212f3453ba9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d6732fd4-0d46-444d-8bc1-b50db9afe5d9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6dba3e34-e622-4b0a-9630-d407ede09386">
        <rdfs:label>B3GALNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/73ecfb99-d61f-4584-8748-16f03989a05f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5d407af9-625b-4ad2-bc05-1914a7b65f0c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
        <rdfs:label>FOLR1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Folate receptor alpha</rdfs:label>
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/421b85a0-5d81-4610-a352-d85d3e6f084d">
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/03a1ffae-9d97-4a37-af68-018217c81796">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
        <rdfs:label>GLA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6b92b9c-b283-4c49-9c00-6f4ca1a94a5b">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25d8798b-ac30-451a-937a-8f51d87d5579"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9de9be1e-6147-4a9c-9aa6-1f0e59fe8893">
        <rdfs:label>Short stature</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ecccebda-5cab-423b-885f-434ebe8f1db8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3a17c57-2043-4955-9911-93e789e864f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc47a960-729b-4a63-bfd2-b1befb5448d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e269472b-0cc4-4f07-9ce0-08c41721305d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/998970f9-ee09-4125-b637-d811350023db">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d6d8144-5e58-45a1-8d27-6225d152f232"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e799f0a4-7b38-431d-8d12-b44a55f32a99">
        <dc:identifier>HP:0012535</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0e90800-e081-4067-8ca1-5f0211556cf8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5b270682-cacd-446a-a232-10ec6d3097fe">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b3ac4888-1fc4-424d-8841-746d95d2b257">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/701b8dc4-91e8-4e60-b458-eb2c8870bf67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d2654ec-ef73-445a-a455-3b3f5ad0b5a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6862c928-3bd0-4c26-84c5-e452b04a6da4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3cff328c-9145-455a-954a-eb4007397030"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9de9be1e-6147-4a9c-9aa6-1f0e59fe8893"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29f620f8-8b54-4f0d-9141-28f14fe77166">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34e46d77-fdd7-4908-adbb-1d3aaf90dd96"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf9b45fc-2eb7-4237-ac15-51264b35d723">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1608293-1aa7-4018-b327-f538548d5cf9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d190b338-104e-409b-a525-f643ae885538"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/32185393-12c1-41f9-b8a1-dabcb98b93e9"/>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b21fc089-4aea-48e1-9873-577691b1df48"/>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/58fa0fe1-a28d-4b5e-9b38-e71ad76e5e88"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98a80efe-a4c0-4b43-9a1a-7709aa02752c"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cc09a7ba-ea87-4cff-b936-b7cc95e78dd7"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad4d18f8-aae4-456a-90b7-c81de749629a"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4a791c3e-0678-4a6f-8d74-08403c9073f4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4b23344-3f0e-4e1c-909d-3b94a4c4a52b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c056a95c-796d-409d-bdc3-a5b32322ffb0">
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:label>Stroke-like attacks</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cd3d3b8-0b38-45d1-a613-dba40e6552db">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e60a2eb1-b2c4-4062-9d1f-33223f5d3f2a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20fb0224-55d9-482a-8c00-d4018b0f0ffa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cae2b0a6-6008-403f-b4c9-439a72e16c31">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
        <dc:identifier>HP:0030890</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d6d8144-5e58-45a1-8d27-6225d152f232"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c59a08f7-dc90-40db-8786-8bdbb364f325">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d2476135-1eaa-4393-848c-eb52cb2926e7"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0e1a637-b15c-41f6-a6a4-89ca3bcaf0ea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0762c8c-b57d-4e8e-83d1-cde2a891bb3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b3de35f-1965-4c89-92a3-7352b4f004ae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/947e042b-f0fd-44c4-a005-a55a90b1f7ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <dc:date>3.10.19</dc:date>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fffa4c19-f73a-4ba4-a44e-4b78910a04e5">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8cbeb51e-5ba8-49dc-b76c-f58b1bbf33d7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
        <rdfs:label>POLG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8f15eefa-5905-4a0b-86f3-d1c7584faf1a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74966456-a48b-4b5a-843d-43a62b1cfdc9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ab541d9-6c24-497c-8d9f-933f09394b2d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f558cbc3-34e3-4e6c-a685-a5a93bf8ad40">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>hypercholesterolemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/83fa51dc-4552-4aa6-9628-34b39f1c264e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/000ede91-ccdc-4107-b6ce-cd3608ea117a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9e773f15-3a3b-4ffa-9780-224d1ed2d385">
        <rdfs:label>LDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9ba89927-336a-4664-8bdd-25b92a11a502">
        <rdfs:label>LDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/68a67ea2-4cfc-4675-b384-5f03dc691928">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c426af25-d062-4763-a163-442d14f7525e">
        <rdfs:label>PIGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5733a1ac-f8ba-4f3d-b32d-4742dbee7bf8">
        <rdfs:label>SLC6A19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64dabde9-ba71-447c-9850-720b0ff8089f">
        <rdfs:label>SLC6A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24384d08-6dbd-4ac8-82e3-f4c23ed46f17">
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/439ab8e0-b48a-42ef-b335-0a75a7aea44c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62d962a0-6220-4a5a-a2c9-a81b88eab279">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f5df2783-ff62-446d-a814-be939e5a6d4e">
        <rdfs:label>ALPL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c99d138-0fd2-4bb6-9745-a52ef72e43ce">
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/731a849b-85bd-494e-8fb8-c80c064e3255">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
        <rdfs:label>DHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2383e20a-1ef1-4134-ad69-f6138c799c57">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e71c3603-1d8e-46e7-9210-60f8bcae76e9">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:label>Glutaric acidemia</rdfs:label>
        <dc:identifier>HP:0003530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83fa51dc-4552-4aa6-9628-34b39f1c264e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a678e01-e6db-46ef-913c-02ea06f4dade"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e7d512b-5d7b-4064-b013-a6a01d3394d3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b29116d-621e-44d3-8666-392fdcc823bf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e3e41c5c-8ea8-43c4-8438-4466421c6df5"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a29eecef-f1e7-4867-9749-72ded5b72cf3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34409f2d-aab8-4df2-a688-415c4cd516b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d359000-7e39-48dc-b356-10606baf01e0">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53648b59-c011-442b-a82a-59333a936dc0">
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <dc:identifier>HP:0040088</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52f9b569-ab19-4943-8353-c91ee6fda946">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a13fc37e-5e11-4e38-82f1-27c8f876c0d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4640fae8-e457-4d4f-be79-19c22a6f72d0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c48a650-eb10-4681-aefe-d894a5b9254f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de8326b8-bf33-4466-9b89-e0181d3853d3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e308d52-2668-45b2-bfb5-b7f7c606c9da">
        <rdfs:label>HPD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <ddiem:uniprotId>Q9VQ62</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e28c402c-da7e-4ffb-8cef-ced37e5d64c2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/51c9f8b3-1592-4ddc-a8eb-b1d6eb676d47">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
        <rdfs:label>MMACHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e818784-c014-472a-8e4e-7e26073a0f36">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51c9f8b3-1592-4ddc-a8eb-b1d6eb676d47"/>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ca80593-da6e-4f84-afb2-4702c78ff3e3">
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/8c928675-538d-4f59-8ac6-14799ea79a75">
        <rdfs:label>Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c)+Symptomatic (c)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a61e875-9eeb-4c46-8d0a-82b8d1329b6e">
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8e3ae95-54e4-4ade-8206-48bfdd23eea0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/80e1bac2-26e6-4c0f-ae10-db14e603c8c4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1dbd8860-0374-4a91-8509-8aea12a1aa38">
        <rdfs:label>FXN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9b28cce8-3e57-4252-95fc-ad7d980436ba">
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4c57f42-f4c3-41a7-884f-004caa1d6a0c">
        <rdfs:label>FBP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d6d14e37-88cc-4804-9bf7-8ae4f2182cb1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe8622fa-222f-41a7-aad4-29732dba1a8e">
        <rdfs:label>PSAP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>prosaposin</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8cc4bcdd-e8e4-4f99-9ebe-20eec35e5db7">
    <rdfs:label>Ribonuclease H1</rdfs:label>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8b30ce2-9f6a-4567-81ab-0f990d72c160">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
        <rdfs:label>RNASEH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/61f78085-65f7-42a6-a861-44b533eb504e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4956dc5-848f-4b75-95ae-79c57a527f03">
        <rdfs:label>MTHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8b30ce2-9f6a-4567-81ab-0f990d72c160"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/907d9cf5-13e8-467a-aa18-5b077d622eeb">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ecba6883-2645-40c6-94c3-f7135431fcdf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0321408e-e2be-4045-8834-eb8ac8d23c46">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4e1b9eb-6d0f-414f-aa4a-dbad6035b200"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6cb736c-2abd-4e78-a8f7-1368c98400dd">
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010818</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab">
        <rdfs:label>seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/406039af-4199-4d60-90c0-109cb9835716"/>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in our patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
  </owl:Class>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f31a97d6-7bf9-46ab-a5fe-400bf75d3c3b">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/f8a9d7ba-25c7-4670-870a-1adaab78c069">
        <rdfs:label>Symptomatic(c)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b91a1f52-0b6d-4ef4-b141-e90f5fd10b4d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5483241f-37e5-45bd-b9de-6412f371390b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8cbeb51e-5ba8-49dc-b76c-f58b1bbf33d7"/>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c79e55b5-f1b7-44a4-8432-e529a28a0d6d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/feecd88f-d311-4f86-bb36-e5c3bdfd2af8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0411f252-57b0-4322-88a6-2839d0523dfd">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:identifier>HP:0001250*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e0c364db-0cf4-46c8-b438-1b46906c6510">
    <rdfs:label>calpain 3</rdfs:label>
    <ddiem:ecNumber>3.4.22.17</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/325e3bf2-db3a-4012-9433-b3585969591a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
        <rdfs:label>CAPN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3e134614-816f-466d-b1a0-d21b525712ee">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/04c51f9c-de5c-4d67-94f5-ae918708cfb0"/>
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa37fb2c-3585-459a-ba63-7296d07e767b"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74d556b1-7165-4d27-9c4d-67dadc342800">
        <rdfs:label>The study was terminated</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c9e72a15-911e-4a43-a353-68f09b4a17f7">
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0e19abfe-8d10-4806-afd0-5f92f9ae1f3b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
        <rdfs:label>FKRP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9040b697-aa62-4a6d-94f2-f29aeee593bc">
    <ddiem:uniprotId>P00403</ddiem:uniprotId>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
    <ddiem:ecNumber>1.9.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>P00414</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a1608293-1aa7-4018-b327-f538548d5cf9"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/10f8e6f3-25b8-4a15-ab81-f69d3bf58928">
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d4956dc5-848f-4b75-95ae-79c57a527f03"/>
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fabdbdcb-c9b2-4ac8-a09a-f23f109eaf44">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b395075a-3f14-44b8-bd91-d978f1b7e5d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48e35668-ff0e-44fb-b5ab-22c2470acd5a">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/731a849b-85bd-494e-8fb8-c80c064e3255"/>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f0d7f1f6-192c-4901-a258-e5ca54740941">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d85999b-d938-4368-9262-17650c63bbc3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/91e6196d-0ad5-4fad-8195-c1b1e29c683b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/6fbe00a7-eca6-4616-93af-0980bd9b1c8c">
        <rdfs:label>l‐dopa+carbidop+5-hydroxytryptophan+selegiline</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963c55dd-5b14-42fb-b9cd-c4204e8bc6c1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8372f676-01d6-450c-942f-7f732eb1bee1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8caf5486-04ba-45a6-bd78-9c22c632eade">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cedae5e4-d76c-4880-ab20-0317496b9b70">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
        <rdfs:label>DAG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dystroglycan</rdfs:label>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f3bc7f5e-8371-475b-81b4-8c5f63f1cd49">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/439ab8e0-b48a-42ef-b335-0a75a7aea44c"/>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c48a1a95-8cad-44a6-89c1-23bdb403d5ca">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1af3518-39a7-4d6e-8feb-bee0995304ef">
        <rdfs:label>Delirium</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0031258</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81cc02aa-a104-457d-a8b4-dbd8f93f922f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>Impaired renal function</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00cee8b6-b735-49b7-b607-88be52f791ad">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <dc:identifier>HP:0011025</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a61e875-9eeb-4c46-8d0a-82b8d1329b6e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a7f9472-1de5-46e6-8637-afe7ecadda04">
        <rdfs:label>Spasticity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74e9341b-0805-4cac-9bd6-13b5d155d6d7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:label>Haemolysis</rdfs:label>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9edf4f0-5374-4697-a810-26d4263a3513">
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
        <dc:identifier>HP:0012213</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef80653d-9301-453b-ba9e-c53aa988cfb5">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <dc:identifier>HP:0002395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b695709e-b451-4930-a50a-389b62e8cc19">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Anorexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <dc:identifier>HP:0002039</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ca80593-da6e-4f84-afb2-4702c78ff3e3"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/5c8fc0f4-48da-4d04-9722-946422f10e5b">
        <rdfs:label>Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56f01b65-b6d8-49ad-bc2f-b21b2e55b4e6">
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6e919a9-8e2b-4fc6-bb8c-c2190575132c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
        <rdfs:label>CTNS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b7314bf-7816-49bb-82d2-5a46320fde23">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/500e46a0-e4c4-4e02-af81-5b441245662f">
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:label>Osteoporosis</rdfs:label>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88106314-b868-4b45-b719-46b29bae0b12">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7498a683-41f5-40c7-8fbd-f0ae5bc664dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f71dc191-0b90-429d-a363-d76d167a71ad"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3ba1b215-f151-4e14-80c2-422b50151ddb">
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b464ce07-d9a6-4cea-8cfe-f579d3c78b29">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
        <rdfs:label>BCS1L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f82641f-cc60-4024-ad21-b1685b118801">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c2dcc9b-ffef-4d31-b86a-00cb8054e15c"/>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fcc1e4e6-20cc-42a3-b1bf-c74dc08c6400">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76ee6454-00a4-40a2-aa9e-099431fb5492"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0414b3af-fdfc-4e9c-a738-94e9b6589bc6">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0001889</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:label>Megaloblastic anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6043d43-f1da-4b71-a5a9-5570beb7cecc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d8a24ba-a015-4a9c-bec7-d7fdcba7ed83">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71769888-fc0f-40fc-a017-12aec79f5bb0"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ef014d0-558a-4672-ac70-593f21c12f0e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef6762aa-2e23-4fd0-b8a8-134276e5b5f1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fee9d62-cb3b-4861-a980-8f0531dd165b">
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52f9b569-ab19-4943-8353-c91ee6fda946"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/08ddec0b-c6f6-48ee-9711-fb73495dba17">
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2d3d9ab-35a5-4a45-85c3-9a238c98aa62">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
        <rdfs:label>D2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.9.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59c4554a-b5f2-455a-90e0-070cfdee6c26">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ace6935-bcc4-44c4-b040-a3471208cac5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49f2df6c-f602-4f7e-b720-9cb93cfef979"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e08a5a7c-92bc-4a8a-886d-075fd17bdd61">
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7dc2bd73-e12d-4295-a79b-43741d91251f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9b86a6db-cd0d-4729-b6a1-8d6abf2a7205">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c0f05ea-f44f-4d78-bb4d-34a6c90e200b">
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e702c7e1-a149-4216-8ae9-392835c177fd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c85d8078-9240-470d-aec5-46393ce4a157">
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e1ed5c54-6051-4332-99a2-933601574232"/>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5ed6fdc-819a-4816-a935-b298bd835e1b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a19ed1bf-a34c-42d1-b51b-020f7967532e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:label>Metabolic stress</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26f5fadc-054a-47fe-8dbf-5762e80f6923">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64f76951-e7c6-4d97-9dec-63a7f7f81fb5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e7fb6b-d32d-4c26-a959-1bb81081eead"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1bc1793c-771d-4517-bd71-725510b4de39">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1938f80f-ff9f-4062-b517-78627165ef23">
        <rdfs:label>TOP3A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>5.6.2.2</ddiem:ecNumber>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bb9b2874-a42b-46cc-a16a-d264f235c223">
    <ddiem:ecNumber>6.3.1.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7879242f-c5b7-4b0b-9be3-c22905b80cbe">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
        <rdfs:label>SLC5A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f2da2ac5-e0ba-472f-89d6-eedb85126a30">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/df4b4bfc-c96c-48d5-a409-c4325264c064">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3cff328c-9145-455a-954a-eb4007397030">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7021ceff-3a7a-4dc3-974b-a28dbe8db524">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57623eca-04db-40bc-bcdc-c59c4ee20b1b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fb756ab-76fe-40ec-8c2d-93ec4e05047a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e155640-cf7e-4d31-8560-0035f4b39fda"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3341a299-a100-43cb-8e52-120399b4571f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/486f41f7-035b-4719-9a64-58f83725a4bd">
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca05a0a4-f990-409f-bd4b-f4b60acedc44"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcc1e4e6-20cc-42a3-b1bf-c74dc08c6400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6f34bc13-1e53-4b80-90b0-bebf683bf43d"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05b76586-342f-4aed-bff3-8c6a7b5f4359">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52583d94-ae64-47ca-8c6f-a3a90bc38d7e">
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3fba4b92-a84f-4f69-b1f5-b8a5fab4c990">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13be5ea3-60d0-4cfa-9b28-42580a3b926d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5cdfa7a1-d663-4dff-8d56-5d41dee82897">
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b24e6ca2-4c50-4004-b7eb-fa60f1c1f948">
        <rdfs:label>DNAJC19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6de4662c-5ac0-4303-b518-deaf0fe8aacc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/044e34a5-2b45-49b9-aa45-87a5203847b2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
        <rdfs:label>ETFDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1b94b4a1-a141-47e7-8b70-ba73011309c9">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e08b7b6-ba94-4c0c-acad-c91190df7b70">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
        <rdfs:label>ETFB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9416e866-52ca-471d-98ab-2f4f560b39f1">
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6e015d2-69e3-46f0-b4cd-2ebc22e4f956">
        <rdfs:label>SLC35C1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f08adc35-ea00-425b-901f-c774f27bb630">
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c163a5b3-11fe-4230-8292-fdea583c2f18">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Epilepsy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc832da8-5a42-420c-ae39-d13b0070c1bb">
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001285</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7ce5a9bf-59c4-4667-bcbb-98113eb98568">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
        <rdfs:label>ENO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5aad3e6e-4b6b-4f8e-bea2-2c1dabbe6b3e">
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76f39119-7608-4e5c-96be-a8d04c2a78e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
        <dc:identifier>HP:0007431</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1836f894-dccd-46c0-9040-a8ce6d3713c4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0088ace4-13a7-47d0-bbfe-f1f804124448">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/397e182e-b112-49e6-9bc4-fbb13750de63"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e52df237-5156-4915-ba57-f03202715435">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Itchy skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1dbcab83-61b0-4c8d-8bd9-e401e590d4e0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>Scaling Skin</rdfs:label>
        <dc:identifier>HP:0040189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/becc0482-714c-405b-94c5-7a45d4e02952">
        <dc:identifier>HP:0031517*</dc:identifier>
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43911890-8802-40c0-986f-926810553d3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a171940-edd0-4065-864b-2d8832cf0a82"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/358b77be-8432-4927-8645-15b527eb858c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>VX‐like lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d57d4042-7bc4-4539-a12b-017dd06ec489">
        <rdfs:label>Erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <dc:identifier>HP:0010783</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d798953f-481f-4281-b76d-44976a44c6c8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/84afc12d-e6db-4898-8a4b-4fe4570a427c">
        <rdfs:label>SCP2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c7efdb9-80f5-495c-ad32-eb9916ba48e1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0dbe249-995f-441e-ab7e-850eeb8d78ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a3ba450-d153-4d97-ae82-2f9695df8e44"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc8f7343-fe52-4c21-8f27-7d49e0b5e450">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c82e7677-7deb-45e9-bda7-b2748816bbe3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
        <rdfs:label>MYH2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>myosin heavy chain 2</rdfs:label>
    <ddiem:ecNumber>3.2.1.183</ddiem:ecNumber>
    <ddiem:ecNumber>2.7.1.60</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7929f282-6536-4b03-881f-72d803367e61">
    <ddiem:ecNumber>1.5.1.8</ddiem:ecNumber>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/406039af-4199-4d60-90c0-109cb9835716">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
        <rdfs:label>AASS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d880a0f9-1ad9-4aa0-b500-c98ffb3469f9">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1a749018-193a-4f5d-8dcf-d473b7de5453"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b12adee-c0e6-46cb-85d3-b401cba07c1c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8f0ef3d8-5e1a-4771-9ebd-30eb64e35f73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f8a9d7ba-25c7-4670-870a-1adaab78c069"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a825dc56-2ad1-461f-9b4d-35d4fb41f52d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7537a85-3153-4be6-975b-db855cd8b487"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca10eb2c-a29e-45da-895d-eb006a3e436e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0db83059-f0a1-421c-b74a-7d0f87c713ef">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/962fa797-2707-4659-a5c1-93736397ea5c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/046a33a9-3d81-4a38-b213-f1dec707aa21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af0fdf7d-623f-43a1-86c9-3426a5ac7500"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/968f738f-dd33-4b07-9063-a9d641b0e941">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42cc7367-6ef6-44db-b247-e21431fa9aff"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f038982f-b4c2-402a-a4a3-cb44b6d1fd41">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
        <rdfs:label>GNPTAB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f67b146-bc99-4752-9f0f-258c932b73b2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94a184b6-88d4-4d44-9792-158c86adc118"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f25ecbad-3741-475c-81a6-a331eb920e72"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/514061dd-9bde-4023-9803-2ec557077399">
        <rdfs:label>Sleep disturbance</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8396ee2-b215-4314-8eba-95d103ea1649">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be7f423a-4ff4-41d2-af63-757ca1596301">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG</rdfs:label>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e60a2eb1-b2c4-4062-9d1f-33223f5d3f2a"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/821acb46-1a86-4b2d-92b3-14ce16bb7b39">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b49f131d-d6a9-49a1-9846-e54af9577862">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/371e56d5-0fee-44a8-9b29-938ad77d5fa7"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f6f2555-48d5-466b-8d74-ec320f76f461">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9d33ecb-fd59-4ce8-8943-6363f7f79208"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9ba89927-336a-4664-8bdd-25b92a11a502"/>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/80872821-4998-42e8-bc0e-f1fa892c8fae">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2eedbff0-31b0-4906-8315-c51af468fa77">
        <rdfs:label>RPS7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e28611a7-5e77-41bc-a844-74a9a8572917">
        <rdfs:label>RPL5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3544212f-cf11-47f3-9b31-6a3a4161bd05">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/91a20923-4f72-41f5-9bf5-4807734d57ed">
        <rdfs:label>and</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c0b7382-ea9b-4c08-bd46-c8ee27eb466f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
        <rdfs:label>RPS10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ae5e3f62-155a-4472-8e69-2ed896aeca6e">
        <rdfs:label>GATA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b854a63a-efee-419a-ab5a-ec93d04405b1">
        <rdfs:label>RPS26</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e8ce81e0-85a6-44e7-9c05-8b454bdc58ef">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
        <rdfs:label>RPS19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7cd05694-ad1a-4dfe-82c8-73fc53f053f7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
        <rdfs:label>RPL35A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/05fe61f1-6ace-48fd-8b98-933569b46f64">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
        <rdfs:label>RPL11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64e0e594-db68-4d90-a5fb-1eb2b2d0a505">
        <rdfs:label>RPS17</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7a67ea80-1d85-474f-a199-55bb405cf2a7">
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/41f5af72-0633-4d94-8911-b46689c8f153">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
        <rdfs:label>DPM2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8980326c-6b1d-4b8b-8484-9a41f950e356">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6bc682b6-bc59-48c0-8bc3-b00b702d7bd3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
        <rdfs:label>GNMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9f4e2176-cdd8-4c8d-b6e9-beaa570be2d3">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f5df2783-ff62-446d-a814-be939e5a6d4e"/>
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3ee41aeb-8789-4b22-a275-0b6077877eaf">
        <rdfs:label>ALDH4A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/668025dc-3362-4e61-a88b-3e3354708aab">
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4f6335d8-4bdc-44be-a529-69579e379539">
        <rdfs:label>TF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>transferrin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae99ba36-775b-4c3e-acab-9592da45afbb">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bc95cfed-1ad3-497b-a695-868d27e954f0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-ND4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c27fd40-81f5-4d59-a1e7-b399032ded72">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81c89d69-0314-40f4-ae22-0d4acce8dc89">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <dc:identifier>HP:0006958</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f570193c-9a71-4c6e-8c33-e868b1e27371">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0000712</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <rdfs:label>Emotional lability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1da774db-e307-40c7-8d8b-8bc7932f2119">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/5c8fc0f4-48da-4d04-9722-946422f10e5b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae4206f5-30e1-4b8a-a281-1ea02e75908e">
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Mental impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba121fd9-a156-4d85-a640-c96091f96966">
        <dc:identifier>HP:0000649</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a61e875-9eeb-4c46-8d0a-82b8d1329b6e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca10eb2c-a29e-45da-895d-eb006a3e436e"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de302f6f-9eb9-4a15-8dd1-297ce1740175">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:label>Dementia</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ca80593-da6e-4f84-afb2-4702c78ff3e3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cab81235-e2f7-4b33-a9f5-6f14302e2fd5">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0e19abfe-8d10-4806-afd0-5f92f9ae1f3b"/>
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/225841a5-bfca-4cad-a7c8-a8ff5dfac9e9">
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d612b8a1-4c2a-4108-a0c5-86bdee742a3b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
        <rdfs:label>DNAJC5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a86c7e3a-800e-474d-814f-5edcb2d3d167"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dc6efd2b-0b24-4cf9-8f6d-c777e1c36f6d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e5c31b49-3480-4147-9dbf-d9a4fb8b4f59">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d738419-6d32-4ef9-8907-22aa1009ad89">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76c1dcb0-c971-4d62-84c2-44a1531aec33">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0025546</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30c9dfdc-3eec-4fb2-ac90-8341ac2e7aec">
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0025065</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcc1e4e6-20cc-42a3-b1bf-c74dc08c6400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a778b99-30ca-4cc9-97ae-8d84c7cea1a0">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4a4367c-368f-4597-83b5-62f157b9c749">
        <dc:identifier>HP:0000793</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53621ab4-4b97-4fdb-8ba5-052e37becdea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1ebe3a1-f0c3-4530-9232-e49e9284545f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7cf618c-bb4c-4655-85db-93313b988531">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a79ea345-0e2a-4d2b-a1db-8426f94103fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/23370602-77aa-4521-b907-b981ae7d0f47">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b928683-1c6d-47a1-b074-5091af692575"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ace6935-bcc4-44c4-b040-a3471208cac5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e503d938-b491-4e10-aa3e-f42ba61ef187">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/564134fb-6f11-4a4e-8032-103f673ec74c">
    <rdfs:label>citrin ( protein)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/97eea734-8749-4aef-8800-945191938168">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
        <rdfs:label>SLC25A13</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UJS0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe8622fa-222f-41a7-aad4-29732dba1a8e"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/41f5af72-0633-4d94-8911-b46689c8f153"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/681ca582-5553-419c-b365-3203e45ac8a8">
    <ddiem:ecNumber>2.7.1.60</ddiem:ecNumber>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e5a655b1-5a53-48a8-b523-a65997cd9ced">
        <rdfs:label>GNE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.183</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68773f6f-dd5f-47cf-8a75-bdfcb648a9c4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecfce1d9-963d-49f1-8536-2b66c1aef78e">
        <rdfs:label>Growth abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eb0c12a6-877c-4be5-b062-ebd2a929f04d"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/168e0d62-4d9f-43a2-a63d-06e03051ef2a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
        <rdfs:label>POMGNT2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de2dd5df-6a35-4c1c-997d-b44c6f84e405">
    <rdfs:label>uromodulin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/51a1353b-6316-4a6e-baac-3140c84b567f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
        <rdfs:label>UMOD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c82e7677-7deb-45e9-bda7-b2748816bbe3"/>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fc073c7-ce9c-4639-8a26-01495fe67c53">
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/97eea734-8749-4aef-8800-945191938168"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a833017-d616-4c19-9b00-8cfba5ba899b">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <dc:identifier>HP:0004337*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6e4645e-b557-4e68-b5dd-162cfe3256ce">
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0011966</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff7de543-6d08-4aac-9cd2-3fd68d22baf7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
        <rdfs:label>lethargy</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001254</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92b029ee-d2e4-4a2c-af0d-b7543c435209">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/077ec389-5967-456c-916e-85f38ed1de3f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82844744-5f31-4226-bd3c-bdab0c127144">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>hyperammonemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ff8d514-b359-48ef-80ed-e9b17c718c1c">
        <rdfs:label>Poor growth</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a2dd912-daab-4bdc-9d83-d416650bfa47">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <dc:identifier>HP:0002039</dc:identifier>
        <rdfs:label>anorexia</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e7d512b-5d7b-4064-b013-a6a01d3394d3"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62318890-7395-41c8-99fe-5bf1d3646fd1">
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c1306b3-f215-480d-aaf5-3722eed11f09">
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/350fc530-1a2c-4fc3-b311-7eadc369dd2d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53fbe541-07af-46c9-a9b5-baca268e3e53">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
        <rdfs:label>LBR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c6153e86-3b76-43bd-9f8d-292c57deeed1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466">
        <rdfs:label>Muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ceb5cf70-3781-4bc0-91ef-e76213bbe647"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/3510005e-53f1-4044-906d-99a2cf725b53">
        <rdfs:label>Functional interaction (B)+Direct Interaction (A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcc2612c-73c1-416c-9d29-68dc8df8fcdd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f2b121f4-c38f-4629-b5da-0ada0af8d1d7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
        <rdfs:label>GALK1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c8e50b2-9ae6-4697-886e-f8a293bd7d91">
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ea6fdcf9-1182-456f-9023-fa03fa1c32d2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
        <rdfs:label>PCBD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ad369312-0839-4ede-aa3b-d61d0653c4bf">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7c2675c2-5363-4338-8cab-084aa90aa647">
        <rdfs:label>MAT1A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/658caaa4-fe96-4fcc-8f97-6a6da2aa4d64">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a5c66e2-9f85-4762-8305-5afee1894571">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
        <rdfs:label>GLYCTK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <rdfs:label>d-glycerate kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f01bf4f9-d9b9-4f81-a0d6-254b99568815">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4bd17180-e4b0-4e2a-a430-7ce7f0482c0f">
        <rdfs:label>CYP27A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9589bbef-1649-4b01-84b9-df80d2147f2c">
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eeb44eea-1b87-4500-92d6-468c80326192">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
        <rdfs:label>ECM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4fbfe19b-7b2c-43fc-b0d5-041aed7b23a6">
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c426af25-d062-4763-a163-442d14f7525e"/>
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d9940929-67f8-4028-a380-6bd71664b14a">
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c7af115-46f0-4102-b494-df7f565694df">
        <rdfs:label>CASR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d6aa566d-4e31-4806-a272-dd55564c5e13">
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7920429e-4f16-4584-9847-071dfd9b5e6d"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6fedb43a-4197-4e02-888a-ccb654d274d8">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/51d40475-1ee1-4304-8c93-85450c318efc">
        <rdfs:label>POLG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7bb766ac-ea88-455c-81fa-56133e2c2a22">
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/70aefa26-4d7e-4c6c-bd22-b4c822bf63fd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
        <rdfs:label>AUH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.18</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b5409c7c-4b08-48c4-a1e9-6551e36b6f40">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e596c94f-82fe-4d6f-928b-def952eb29ff">
        <rdfs:label>UGT1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6d877dd8-a39e-4899-b5f6-b9e9068129e9">
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b928683-1c6d-47a1-b074-5091af692575">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
        <rdfs:label>PYGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a91090ec-8984-4cee-9103-395b62b2a73d">
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4871772f-637b-4328-af53-1059db983060">
        <rdfs:label>SLC25A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4e4fac05-352c-49ce-bc7a-b0579a6095ed">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9ed668c-fc3a-46bd-9493-e4f9f33915f2">
        <rdfs:label>hypoglycemia</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81987d81-f7dd-4137-9a53-11aa77836bfc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9d95af2-603d-4e4a-9f76-38c0b980bf7b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0e1a637-b15c-41f6-a6a4-89ca3bcaf0ea"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b242ccec-4613-4e91-9e05-827ca58122ec"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a9c6b01-650a-4e42-8d32-0b088f0687fb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d2902bc-4c3d-4553-adba-963c5f1146f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6995a70c-bd7b-4679-bf52-58fd3e5f3ddc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
        <rdfs:label>MAN1B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb77c95a-1bfe-49b5-ac10-42455c2f802a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2072ac2b-46e8-43a2-916a-f5375cacc491">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94a184b6-88d4-4d44-9792-158c86adc118"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f285d3af-74af-45c9-a746-87ca3b7fc5aa"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f25ecbad-3741-475c-81a6-a331eb920e72"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/11e5ace9-2e25-4563-92f8-a33dedba5240">
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <rdfs:label>Arginase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/26eceb8f-8226-4398-9cfb-eaa94d38e578">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
        <rdfs:label>ARG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f9b26bc-d544-46df-b2ea-850a1fdd83ac">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ace6935-bcc4-44c4-b040-a3471208cac5"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d63c08ce-e097-4dc0-b9dc-622cfc5ee735">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3a58a42-aae4-4b5e-9bd7-617f480c2b48">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/f38d8b57-a0a4-479f-be17-f3d1916e543c">
        <rdfs:label>Symptomatic ( C)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9335d89d-c26d-4f10-a30c-a4b2d314f85d"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c35c02e-ead2-49a1-9eb2-b2f7d902f6ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3688323b-2302-4fd5-a5c0-916b52d72e39"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/719400f5-8e95-40b4-a1f6-1409d40dd65f">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <rdfs:label>Memory impairment</rdfs:label>
        <dc:identifier>HP:0002354</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5db4d44b-fa1f-4e8f-988f-3717d0bdc044">
        <rdfs:label>cognitive imapirment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/121187f4-b0dc-4328-a9d9-7238016ba6a6">
        <dc:identifier>HP:0001328</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Learning impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68c01ecb-ed25-481e-b7e1-270720fe32f1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f5fadc-054a-47fe-8dbf-5762e80f6923"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04486866-277d-4157-9bf5-089d95a15c40">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2514caed-ece6-4583-bbff-c9521876ea11">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939 *</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/40db6fd9-51e4-4afd-95e1-597856f1c950"/>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/01be99e7-03e5-4ed1-95bd-04a2d9efd7cc"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0924c23a-dec6-45dd-8116-051606b7bf74">
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <ddiem:ecNumber>6.3.1.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9d27cb56-425a-47c4-8210-3994ab8e1ce3">
        <rdfs:label>SLC2A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b51dd0eb-5d5d-4f1a-b70f-39b9cadce600">
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9bdc4c62-cb64-4aa8-a18f-638828b64a80"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/42a395f8-cc12-49f7-bb25-d9dc9ad1be38">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
        <rdfs:label>SUMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c8578423-2b96-4a13-acfa-ae3989075cef">
    <ddiem:ecNumber>3.2.1.183</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f038982f-b4c2-402a-a4a3-cb44b6d1fd41"/>
    <ddiem:ecNumber>2.7.1.60</ddiem:ecNumber>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b253cc32-5fcb-49b6-afe1-321548fcd6e7">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b37343e-852b-48cd-a965-bc7974401792"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd9a81c1-a8fb-49a4-afc6-b3f78d75ffc4"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aef03f46-f842-40d5-a1bb-b0ea13ebb213"/>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/37d5266c-ff88-4702-87e5-e5c2f2bc8bc6"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ee3c3e79-f607-43c8-bd96-c93f055e038b">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a1608293-1aa7-4018-b327-f538548d5cf9"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/07d3a9bb-0f25-4140-ad44-4b1799285397"/>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d80ada9b-379f-489c-9a6b-0fd35543d314">
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6d964067-7b42-4b51-bfe6-3fa2743293af">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
        <rdfs:label>DHCR24</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f4de3318-1368-4e7c-bdb8-882a7d311b68">
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b5bda727-183c-4e0e-872e-7e057dd4608c">
        <rdfs:label>HSD3B7</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/870c9a20-ecfe-42f1-a889-f06385617517">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e60a2eb1-b2c4-4062-9d1f-33223f5d3f2a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bc95cfed-1ad3-497b-a695-868d27e954f0"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca05a0a4-f990-409f-bd4b-f4b60acedc44"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c96b18bf-8acc-4f17-b3c2-d05a858e9f6d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
        <rdfs:label>Slow recovery</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012823*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1b67dc89-37c8-4fdc-86b1-3f472201f32d">
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0c4729eb-29de-41f8-905a-4e7caad86dc9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/535d4630-5c90-4e4b-bba5-a9ef69268d54">
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c675b55-fbb7-4dc2-b380-be3b562abbec"/>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0321408e-e2be-4045-8834-eb8ac8d23c46"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/452ad14e-6568-4ec1-b878-a2f3f9ff0be2">
        <rdfs:label>PIGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a230db36-78aa-4699-b4c7-0b9de268ad1d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2f91d088-4668-45b6-8cf6-34355fb343f7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
        <rdfs:label>CPT1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29c8fa21-d41b-4d62-b5b1-883392a3596f">
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e1afade6-0c62-4f73-a7ef-73351e1adde4">
        <rdfs:label>PNPO</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/adc7b95b-9376-4c5a-9e48-10bbf530d6b8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b211092e-7dcd-4e92-852f-708332b87321">
        <rdfs:label>HMBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3c534b67-9a0e-4848-b308-ecd661d29ef0">
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
    <rdfs:label>galactokinase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f2b121f4-c38f-4629-b5da-0ada0af8d1d7"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/92b1f4bc-e520-4c1f-a94f-25b16d5c2fb2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
        <rdfs:label>SAR1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9780d804-2c6f-4f8a-915e-e947904ff5b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f5fadc-054a-47fe-8dbf-5762e80f6923"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/38e09e36-db7b-4e24-b8c8-eb72366e3b74">
        <rdfs:label>Symptomatic (C)+Direct Interaction (A)+Functional interaction (B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ada0d4b1-9d39-4467-9a5c-c45cd55f3ee8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42d6c3cd-e7e1-43de-bff6-12b60f82d0a2">
        <rdfs:label>developmental delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4871772f-637b-4328-af53-1059db983060"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/070bb99d-e14e-4cc4-8439-859663efc32d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f980115-9499-486c-82d7-310bc62d6d43">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <dc:identifier>HP:0045045</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cad47cb6-ca31-4a35-9891-3aec28c53b3d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0dfa0543-4e60-4b9f-ac46-9224e2328e24">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
        <rdfs:label>LMNA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d9e488f4-4f50-4457-8c53-ab85bf0228f1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
        <rdfs:label>OPA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8874094b-a713-44f0-b6e2-9a7f67bc8210">
    <rdfs:label>codanin 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b17380bf-10d2-48a8-b2a6-ad5286eee0d7">
        <rdfs:label>CDAN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c762ae8-b201-4a32-a748-67b22d6a7c94">
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fbe7264e-6f1a-481e-b993-208f44cd6bf8">
        <rdfs:label>MVK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d61cc5fc-1d0a-4f8c-8297-76768e673c9c">
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/721d8be2-79f5-45e2-92a7-88c3c77a30d1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
        <rdfs:label>FA2H</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e2e029db-9b4a-4061-ba42-19e873cf97c2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ab98afa-4df1-46aa-8dca-a54fc17f0ac2">
        <rdfs:label>AVP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/029874f0-9164-4ba1-bf78-0f074c156f1d">
    <rdfs:label>kynureninase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6d96d53-6c35-42d0-87de-3dfe0facb8e5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
        <rdfs:label>KYNU</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/441aaf0f-0098-4feb-95f4-05ab2a9764b1">
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a3bd961-ddd0-4f06-810b-99f6af5fb24e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
        <rdfs:label>OAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9208c43c-baee-4d90-9549-3443b7c7e61d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a53de917-f4d9-4891-88bb-1d65041d7908">
        <rdfs:label>ABCC8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6823467f-3f3e-4ad4-83be-217f73916432">
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4abc7208-cfe6-4b0a-ae71-dca129223b6e">
        <rdfs:label>SLC25A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c76b92cb-a833-400b-a87e-3c1a166f9e5f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4a4e252a-e2ab-47fb-8f3f-ef2bb505a3e1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>PTPS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <ddiem:ecNumber>4.2.3.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5cd22d22-06f7-46f4-ac06-813232b7c4a4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/278e218b-d25c-49ae-a9cf-f23e751a57db">
        <rdfs:label>PGM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/749d3cfd-716f-44f9-9400-3b9c4345b120">
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/006ca4fe-c40c-408e-ad4c-80a81f30ffc9">
        <rdfs:label>PFKM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/05a699b5-33c4-4172-87dd-451ac98aca66">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ac0e8ac-4b55-4d6f-af6a-9699ed579469">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
        <rdfs:label>SLC36A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <ddiem:ecNumber>2.7.1.60</ddiem:ecNumber>
    <ddiem:ecNumber>3.2.1.183</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/64dabde9-ba71-447c-9850-720b0ff8089f"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5733a1ac-f8ba-4f3d-b32d-4742dbee7bf8"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9363242e-27a2-46cf-a58b-c8d5c866def8">
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/183f8bda-005c-49e8-ac3c-1730cb41ab8d">
        <rdfs:label>SERPINA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a58ed8a3-ed6c-460f-a3e3-e817ba4f374e">
        <rdfs:label>POMT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/504ced65-9b3a-4da2-97f8-bbd7593007fd">
        <rdfs:label>ANO5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f41e6d06-ff50-4ea1-af13-9af76992e6ed">
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a42cf673-c4f9-4210-9878-e6ca65185608">
        <rdfs:label>APOA5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e58d4720-1afa-43b9-867f-4760bae06787">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
        <rdfs:label>POMK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2f8b9768-47dd-4761-a720-9c17fc650aa4">
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7dc2bd73-e12d-4295-a79b-43741d91251f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
        <rdfs:label>PHKA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5bf3a587-fe57-4c83-9e00-7a77899d58e7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b34b2221-974b-4b0f-a1fb-6a230f7097da">
        <rdfs:label>QDPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8bab79f2-9e69-4d8c-8d56-446cbdaf12bb">
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a58ed8a3-ed6c-460f-a3e3-e817ba4f374e"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9241a22b-8041-4c1c-a4c6-0e694fd78455">
    <rdfs:label>gastric intrinsic factor</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a4ea7c5-1d5d-4697-bc1d-a2a018a17527">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GIF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cedae5e4-d76c-4880-ab20-0317496b9b70"/>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ab1a555c-54ba-451e-8ef4-14d4c82812bb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45af2b4a-185e-40fe-ba18-14060b0939b8">
        <rdfs:label>CRAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1affb079-b557-4682-91f3-48219fc41558">
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <rdfs:label>solute carrier family 1 member 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4b3b5fd8-c67a-47fa-b2a9-65bcc1fb0313">
        <rdfs:label>SLC1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d53cde75-caeb-4cae-b6e1-b477133e7553">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/93c6c1c1-a9d4-4b4e-a03b-1b09efc2c13d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
        <rdfs:label>HAMP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/abc7ed26-2e34-463d-a1e2-a2c2536df1c5">
        <rdfs:label>HJV</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/04e3d89b-430d-42f2-b6fd-847a0a967832">
    <rdfs:label>dolichol kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/962fa797-2707-4659-a5c1-93736397ea5c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
        <rdfs:label>DOLK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5d89f658-429d-4f9a-be71-efa5afa2f793">
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/443808be-bb5d-4b89-9a1c-79ee05083b26">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
        <rdfs:label>PPT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3a978a8-e4ed-4a2e-a81c-ed71ad92e3b7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12f4d3d0-8efc-47a9-93bd-e5ce56f91a41">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/373cb716-974c-4138-9f74-e8feb7074aa1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a4d52408-b375-4afe-b02d-9f2389235633">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6bac057-5dd3-4416-879a-bba6e1a119ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>hypertriglycernemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf32beca-d2c8-4c9e-bbbd-4d96c4bd5a78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d341aab3-fc9d-4da3-9cc1-59de4105642d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7779eef0-ad95-4198-805d-1dc43bbce773">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b20e6fe7-3be3-4a4d-9855-fde30ad135f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bb996757-b797-42b3-9f12-377faf95c939">
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a2d3d9ab-35a5-4a45-85c3-9a238c98aa62"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f739fb15-fcbc-4a75-9813-2e92b29e0e0f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eeb2a093-19c2-4f16-a542-07dea3d7d313">
        <rdfs:label>MAN2B1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/01265d21-7ca9-4140-ac10-0cd02c4169c4">
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67890f8a-4f17-4093-8d58-594866686c7f">
        <rdfs:label>CTSA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c039713e-ddbd-40e4-9ecb-2a93620a2032">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb74ce1e-64da-4599-8859-d17727ddfa82">
        <rdfs:label>NPC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9VQ62</ddiem:uniprotId>
    <rdfs:label>NPC2 protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4e5b7b1-f8cc-41b0-96a1-c79c1b40b8bc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/833dae77-e29d-4582-8f0c-e6f883ea66a9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
        <rdfs:label>FECH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ferrochelatase</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe876250-8f3e-438b-a326-8b4ba9b80255">
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/242bee77-14c6-48b1-bad4-15b45bc3c509">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
        <rdfs:label>G6PC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/97e8b554-f418-45a8-a156-eef62ff74fc0">
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/371e56d5-0fee-44a8-9b29-938ad77d5fa7">
        <rdfs:label>TFR2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56c1cc9c-d69a-4e69-8abe-6841d7db1690"/>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a11b176-9845-406b-aadf-ce44260e3bbe">
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/04c51f9c-de5c-4d67-94f5-ae918708cfb0">
        <rdfs:label>HSD17B4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53fbe541-07af-46c9-a9b5-baca268e3e53"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0d5e9286-ab05-4d00-aa9d-8afc6db071f5">
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c675b55-fbb7-4dc2-b380-be3b562abbec">
        <rdfs:label>DPYD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8147f0ed-2bba-436b-b656-95b813ee54a5">
    <ddiem:ecNumber>2.6.1.19</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/047e6370-d6c5-41c0-8497-353a0243203c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
        <rdfs:label>ABAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GABA-transaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6a20b5e4-1a80-4d15-963c-e155df1c71ed">
    <ddiem:ecNumber>2.4.1.274</ddiem:ecNumber>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/838150d2-a5c6-4176-80c0-af0164d2d9be">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GALT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e557a314-282f-4ebc-a330-6afb0669c8c3">
    <ddiem:ecNumber>3.2.1.45</ddiem:ecNumber>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a41c8a7f-b60a-49a7-a468-7d4e40f14a33">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
        <rdfs:label>GBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88114771-e11b-44ac-925f-5ee6266158c1">
    <rdfs:label>barttin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7866eb17-449a-407f-8d15-91c1e761f4a1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
        <rdfs:label>BSND</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19ce9ca5-86b7-4d48-acff-7ddf7c66881c">
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8420093-f161-4826-9974-bea50712950b">
        <rdfs:label>HGD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d612b8a1-4c2a-4108-a0c5-86bdee742a3b"/>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6dee7931-5b17-4c5d-91b3-44ba2bb8c06e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
        <rdfs:label>DPM3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/55667667-319e-41a7-9a90-f18d6937aaaa">
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e8013ef4-91e8-4f46-ab4e-714cec567ab7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
        <rdfs:label>L2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/14845d03-40e0-4f89-83a6-42177848860d">
    <ddiem:ecNumber>3.1.12.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1a7359c8-f71e-4f52-9887-a29f37aa4484">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
        <rdfs:label>APTX</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aprataxin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f14e9205-f7f4-488f-a43e-9ee77c9028b1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5db51b68-6012-451d-afe2-2756db0ac8de">
        <rdfs:label>CYP17A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.14.19</ddiem:ecNumber>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9697987a-53e7-4229-b562-3602687a3140">
    <ddiem:ecNumber>2.7.7.40</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d798953f-481f-4281-b76d-44976a44c6c8"/>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f65c992-c581-475e-953a-da6249e2f540">
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9ecbf807-f5de-452d-aab0-836f939b6049">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f5e09eef-eea6-49d7-be83-636d752d67f8">
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1fc8e117-fd69-43ab-ad82-95b900e918c7">
        <rdfs:label>DARS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06affdcf-c6db-4fb9-83d2-6d45e61a9bf3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b231b2d9-ab0c-4624-97da-0cce5dc08003">
        <rdfs:label>ETHE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34bb5f4b-ba39-4462-b6c5-ef2a6dd9280e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/145f2216-ad91-4175-8cdc-aec44cf3fb94"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9f833d8-1992-4f28-9455-de91523fbaaf">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
        <rdfs:label>neoplastic growth</rdfs:label>
        <dc:identifier>HP:0002664</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5f51a5bb-b5c5-4c38-94b3-bf7843d80547">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/512a29ba-a38d-4b21-922a-349a5919c908"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c45ad9c-cd16-447b-9ebf-b88834956795">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fbdec5c-afab-4b60-8a75-0d3ab482109d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2b8fd0e5-5de3-4f8d-922c-21e2a005fd43">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cf10c267-bc97-4a5b-aec6-d2a9acc84352">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
        <rdfs:label>HADH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6e1f3793-c928-4cdf-99f8-4816da170f2e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/46aba8dd-4029-4d7c-bc07-41bffcb4fd38">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
        <rdfs:label>LRPPRC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/46f4ca5c-8017-4dfc-b1ee-03772332772c">
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/84afc12d-e6db-4898-8a4b-4fe4570a427c"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dfaf2b54-f586-4b76-b40d-2746b91b54bd">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/834023fd-d206-47fe-9af3-5bfbc8c12b0e">
        <rdfs:label>APOB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fbcfd9f7-c474-43f9-b953-5ab1ab2e98d5">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/097e2b3b-8631-45c7-b3cd-f0a5faa1b46b"/>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4b3b5fd8-c67a-47fa-b2a9-65bcc1fb0313"/>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/800bac53-24bf-4591-a56f-584a782c144b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd597f84-3ec9-4534-be36-194ed80c9363">
        <rdfs:label>SUGCT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7c997a25-fe7a-4a2b-a39d-d7d1ba3408f8">
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c7138af6-b1c0-47e9-af9f-3c8aeebf60c5">
        <rdfs:label>PAH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3925b2b6-73d6-48cf-9ff6-8fff3bf2c959">
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a9495b5f-6f88-4189-8a73-fd4c7a2e7d0c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
        <rdfs:label>TPP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <ddiem:uniprotId>EC</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62b4b989-b0d4-45d2-aa30-083e1a0cf6ba">
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e100207b-0b08-4de9-9499-a75bbd8f289b">
        <rdfs:label>TTPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6b6cb871-1de5-40c6-9046-f2fcdb909d9f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bedd25a3-3460-47e1-8e5e-b9bd1ef05f6b">
        <rdfs:label>PHKG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/653edae1-40bb-4de7-9bea-ce0d5b83a7e9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5cdab7b3-0645-4925-abee-e30a84d34dc8">
        <rdfs:label>ASAH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>acid ceramidase</rdfs:label>
    <ddiem:ecNumber>3.5.1.23</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f32d93dd-b2cb-4e86-b760-645ef20f2b4c">
    <rdfs:label>hepatic lipase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4bae8e8e-41e4-4603-ad4a-1d2b91f42b12">
        <rdfs:label>LIPC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/30bac9a4-3141-402d-8af7-f520461163b7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6b2ff11-35a7-4108-9ca1-6d51ce8bdb47">
        <rdfs:label>HFE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac2a5c81-eb5a-4206-8603-c3cfff393b3f">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3383664e-c507-4c15-b51b-655cb07b4404">
        <rdfs:label>BCKDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56d6a833-f8f4-42cb-83a7-b6ec3168eddf">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d44d782a-f8f1-4053-9c60-6b3e3626a864">
        <rdfs:label>POMGNT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/74941acc-9b29-4cac-becb-2f49191db5a1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c2dcc9b-ffef-4d31-b86a-00cb8054e15c">
        <rdfs:label>FTCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.3.1.2</ddiem:ecNumber>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/38e0bfa3-88af-40a5-add1-73a4b5e2c8bc">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7ce5a9bf-59c4-4667-bcbb-98113eb98568"/>
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <rdfs:label>enolase 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c3e94602-dddb-4daa-b922-a73f36205331">
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eb029988-9eb5-433b-aa3c-bbe06aa1c22d">
        <rdfs:label>ST3GAL5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/721cbd14-7d19-4c1a-b4cb-0a66d9690484">
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bb449a8d-f480-4f2c-8f3b-40716ad3473c">
        <rdfs:label>DPYS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/17f250da-ac5e-4fe4-8f4c-7c60604528af">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b2e0b631-e457-4288-88f3-5b9b7e841149">
        <rdfs:label>ABHD5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e3a808e-4cfe-437b-a0ed-2163119af39d">
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3643d991-bcf2-4187-bc06-bb267ae9eee1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
        <rdfs:label>GAMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f2fcd7cb-7a04-42a1-ad41-16d18fb3a8db">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73c247db-9239-430e-8f54-b645cf90fc99">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
        <rdfs:label>GBE1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <ddiem:ecNumber>3.2.1.196</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf948c6a-37a3-41d8-bdfb-38cc6943c228">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a42cf673-c4f9-4210-9878-e6ca65185608"/>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <rdfs:label>apolipoprotein A5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/18a7f4fe-1d02-4c5f-b0cf-f8ebb03a76e2">
    <ddiem:ecNumber>3.4.19.13</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca43bd00-bbd3-48ec-b2e3-caf05bf13fcd">
        <rdfs:label>GGT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
    <ddiem:ecNumber>2.3.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d6e5c7b5-82d7-4fe9-8b01-130f97095785">
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/32185393-12c1-41f9-b8a1-dabcb98b93e9"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ad4d18f8-aae4-456a-90b7-c81de749629a"/>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1f72a0b1-7fe8-4664-8c03-55533aabca80">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
        <rdfs:label>MT-ND4L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/39ee8afa-2808-4224-aabf-4667f7621f0d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c82c99ed-e70b-4dee-adc8-6087eaa001df">
        <rdfs:label>AMPD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>AMP deaminase</rdfs:label>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1bbe0aa0-0323-4c6a-a5ff-f5061cd1fda0">
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a19f74af-f856-4591-94b2-23a96291bc34">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0c23ed6d-647f-4ab3-82f9-422c78189cc4">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/452ad14e-6568-4ec1-b878-a2f3f9ff0be2"/>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4cb69383-9df8-4033-9579-7b52cf78428a">
    <ddiem:ecNumber>2.7.1.60</ddiem:ecNumber>
    <ddiem:ecNumber>3.2.1.183</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a3daa475-cf22-4362-b747-9c5e21620966">
        <rdfs:label>HMGCL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>HMG-CoA lyase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1db0605f-b740-4085-8f6a-4b038bbb0fda">
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ffe80dcf-fd3c-473b-b804-0478bd1b2b04">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
        <rdfs:label>PIGN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a99bc3fa-45d8-4b09-89d0-d59cdcc01060">
    <rdfs:label>apolipoprotein E</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8f411bd-4bca-475d-8d88-e769dc859cf8">
        <rdfs:label>APOE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d81f3674-565d-492f-8c97-86e6cb085eba">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2423d547-a4d6-459b-85b5-48ae78a24de0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6fb37306-a211-4d4c-ad00-c929164a4cfc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8fd83ec4-4035-46ce-9e6f-645735869362"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/82bd7c13-fb65-4ca9-8688-8c9169dbc945">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a24d9e23-76ee-4b13-9ec8-7b21e224d56d">
        <rdfs:label>CHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.32</ddiem:ecNumber>
    <ddiem:ecNumber>2.7.1.82</ddiem:ecNumber>
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e16fd0e4-80d7-479d-b86a-c4afdd04b9ab">
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <ddiem:ecNumber>1.1.1.211</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2857ce0-1a4b-4441-b7bf-dccab189cc4a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
        <rdfs:label>HADHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.17</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e614125-816e-4d77-ab85-57dff6dacff2">
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c6e3e85-deba-4bd5-aa37-295f616651b8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
        <rdfs:label>ABCD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c14328b-4f8a-44a3-bc99-69e8cf518faf">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/51d40475-1ee1-4304-8c93-85450c318efc"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88610dcd-1f94-43a5-846f-91ad3d51894d">
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>EC</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5a0ec902-8b23-43e4-845a-d5a90ef11707">
        <rdfs:label>AKR1D1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b65ef94-d3df-475e-ab45-3140cf50540e">
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e1ed5c54-6051-4332-99a2-933601574232">
        <rdfs:label>IVD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e10e8f1-2f0e-4fed-a204-c5e45440b709">
    <rdfs:label>beta-galactosidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d35d5143-5ed3-4c23-87af-3ec136203246">
        <rdfs:label>GLB1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/05ef2e2c-1440-41a9-980f-1e83ee432cb9">
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/145f2216-ad91-4175-8cdc-aec44cf3fb94">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
        <rdfs:label>RET</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7856b5cc-86bd-4b14-b4c6-b6998243085f">
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5a0ec902-8b23-43e4-845a-d5a90ef11707"/>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7db7913b-a657-4702-ac00-6d7d93bf7dc1"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/481be4e5-88b6-4c4e-a3f6-695ce9699461">
    <rdfs:label>sarcoglycan alpha</rdfs:label>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0af6151b-5ad7-44d9-aaa3-9a6624ace52e">
        <rdfs:label>SGCA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c213a5c-b0bd-4969-983f-9b043b65a971">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1ecf7328-81cc-46c8-91d4-8d4c9d716ea9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ADCK3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.3.5.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8d3e33f2-37da-4fbc-b19d-74f195427118">
    <rdfs:label>dysferlin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43ce16bc-d293-4f4a-8b38-dc0958e707ec">
        <rdfs:label>DYSF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/69ec8161-bf93-4208-80e7-4f7813a0da31">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6dee7931-5b17-4c5d-91b3-44ba2bb8c06e"/>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/278769ad-f98a-4135-842c-dab219325c45">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f3361cc0-f850-4cd5-b07b-5212f3453ba9">
        <rdfs:label>SUCLA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d1329c82-f567-47e2-b543-52a9e84bf166">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d5ca22bf-7617-4c2b-83d4-f6f192dfba52">
        <rdfs:label>SLC17A5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e4961ab9-6ad9-4407-9819-870519496137">
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b2958ad9-1e39-4b95-91ca-270efaf39241">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9VQ62</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/60b31bcd-cbbf-4431-a513-5a1836d8491d">
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e596c94f-82fe-4d6f-928b-def952eb29ff"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5db1c799-c7aa-4ce2-a0ba-b33cefbe7d5c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b1a9a8f-8435-478c-85ce-ac0536bee528">
        <rdfs:label>ABCA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa36f762-c2d5-44a1-a5f7-5f9366574aa7">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b5bda727-183c-4e0e-872e-7e057dd4608c"/>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <ddiem:ecNumber>1.1.1.181</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="https://github.com/OGMS/ogms/releases/tag/v2019-04-30"/>
  </owl:Ontology>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1b8f6dc-8fed-4cbd-b441-79112f8a2027">
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c4fda82b-4732-4a2b-b218-19e246e2baa8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
        <rdfs:label>GATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd692792-79d3-4dfa-b521-35ef0e122862">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ab98afa-4df1-46aa-8dca-a54fc17f0ac2"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e369bb82-d986-45f3-97c4-f2c84be9d23e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943*</dc:identifier>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0321408e-e2be-4045-8834-eb8ac8d23c46"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28dd2867-522d-407f-b5b8-3f6542d8fb6c">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>Polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e47a6d0b-dc3d-444c-8ab5-45c2323ed0ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b68f50ad-55fd-4735-ad9c-f28bf9320f4b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/90ded2e0-ae96-4922-8a2e-b58ccb7452c4">
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/43464ed5-e21d-4c2f-8d62-bfadb5859679"/>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c9d41bc-1a32-4013-ab56-e1f18c74646c">
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7af10360-74d1-41f7-9e62-f9f48c0f806a">
        <rdfs:label>LPIN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b2fbafef-fe79-444b-aa8a-03fc32ff6705">
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/18a4f6af-10b9-4964-8af9-ee24162251a0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
        <rdfs:label>LMF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b8b23b2-48f9-4fab-9432-e66f6ddd252f">
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/42a395f8-cc12-49f7-bb25-d9dc9ad1be38"/>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/90df80ff-d3ee-4461-bb08-6c4465236056">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9335d89d-c26d-4f10-a30c-a4b2d314f85d"/>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c282ef6-f380-45d1-b2d3-afc990b5247a">
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a19dd6ad-f1ea-4f38-9b67-71922b7cb864">
        <rdfs:label>DBH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b8aa8a3-b84a-452d-86b9-0098e631eea8">
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d9e488f4-4f50-4457-8c53-ab85bf0228f1"/>
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/494c7177-b989-445f-b8d3-00da98e6b965">
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
    <ddiem:uniprotId>O95461</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aef03f46-f842-40d5-a1bb-b0ea13ebb213">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>LARGE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29737d41-904a-4f7b-944a-5ec6c788e67c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/558ac0c9-9c3b-41fd-86ad-5f86378084d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
        <rdfs:label>GYS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glycogen synthase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c62c0c33-14ad-4a31-bc2b-678a09583305">
    <rdfs:label>thiamine transporter</rdfs:label>
    <ddiem:uniprotId>not</ddiem:uniprotId>
    <ddiem:uniprotId>available</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f4161b73-1295-47f5-b936-628581ef5b4f">
        <rdfs:label>SLC19A3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4b7d961e-07b5-4d5d-b1ca-f3b2ecbc37e7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62444c9b-282a-455f-b2ff-f419c65265b5">
        <rdfs:label>ABCC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6b03f835-c4f8-42ac-af54-4daae2174447">
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/938f0635-66bc-4d61-8f15-f0676dc1374b">
        <rdfs:label>DGUOK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/10a992c0-1deb-4d6c-854f-1896be397d3d">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/504ced65-9b3a-4da2-97f8-bbd7593007fd"/>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
    <rdfs:label>anoctamin 5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1365184b-c32b-46c7-adb2-2b0cd9bd2cd6">
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/639f80b8-3e86-465d-acb6-bc84c12b8659">
        <rdfs:label>NAGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2d381c2f-7803-44d3-a7e4-fd934efce76a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c8be259b-402e-4818-a369-5ca2afd6b2ea">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.1.1.31</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/02c66373-21c9-4ff3-b998-f3104f8630ff">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3c4bf1af-b44f-456a-b635-5efdf77b28c6"/>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <rdfs:label>Fukutin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7323a3fc-9ddd-45aa-89c1-7679fff79a69">
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9238b62f-b7d3-48b6-8c1c-53734213382b">
        <rdfs:label>DBT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/365c3b81-e081-47b5-aa86-799d1204a8d1">
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d61fdbb1-4c38-482a-b744-55158f515eee">
        <rdfs:label>SLC12A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f6ee91cc-3778-475d-94f0-e83021378879">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cc83c755-541d-4970-a44c-f2955c96a05a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
        <rdfs:label>SLC7A7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5ef65c32-e134-4a21-ae12-54928dc529cb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/61d578a2-e049-4440-a688-3a4b0aa8b6ad">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
        <rdfs:label>MTR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methionine synthase</rdfs:label>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6e29c576-5ac4-450c-a937-19e02501d5a7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad84c288-317b-4618-9c92-2517b050ebb5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
        <rdfs:label>GCDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1aa3b6be-057d-4146-859d-576d459a85ac">
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1d492f99-3fdf-4905-a661-f9419ff76dba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
        <rdfs:label>TWNK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/32ab9d99-56fd-4088-af48-5e8ff47e405b">
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6fed7005-e64c-442d-9440-d323d5dc4015">
        <rdfs:label>DDC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1e49bab-f3c8-415d-b1a5-e7d67e47f061">
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d2476135-1eaa-4393-848c-eb52cb2926e7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucokinase-4</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e442c8ca-9f42-47ca-b460-3797e7dd3083">
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
    <rdfs:label>Sar1b protein</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/92b1f4bc-e520-4c1f-a94f-25b16d5c2fb2"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/83725ddb-bbb0-43e7-aaae-b3a4c3478ab2">
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/86f2ca53-c740-4927-b082-4564a5d3b319">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
        <rdfs:label>BTD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>biotinidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5cb5385e-8397-4b12-872e-1566025c7e9a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8e8e75bb-9311-4ad1-a49f-c20b28c7c049">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
        <rdfs:label>SC5D</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6f65dd96-d25b-4ad5-abba-3377e95bb351">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b385034d-f6e2-4bf0-a150-63c5c381b23b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
        <rdfs:label>PYGM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7ffc969f-0290-4bfd-8930-c9776b6f9c72">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e42401b8-ee80-4e29-a620-ab86cb9aa591">
        <rdfs:label>LIAS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/98ad95f1-38d5-4497-84de-177aabfcea69">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0423948a-63e8-4aaf-a898-147990ce268a">
        <rdfs:label>POMT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29fb81c3-4d0b-4dae-a700-35662d7fd855">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fd88f982-45d4-46b2-85bc-f5afa51310ba">
        <rdfs:label>PRPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1905de36-cb06-4b51-86dc-154d5b8d596c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c6c92a1-e6ee-45cb-b0b2-bbbb9cc6478f">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d36d4830-dd1b-421b-94d6-4fa73e6a9f67">
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6995a70c-bd7b-4679-bf52-58fd3e5f3ddc"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2609490d-205f-4345-ad13-e2ff134711f3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4b41753-385b-464a-82c6-aa2d6a768886">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
        <rdfs:label>AGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/872a36e2-b3a0-40a8-a5dc-993d4eeed4e3">
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/01be99e7-03e5-4ed1-95bd-04a2d9efd7cc">
        <rdfs:label>MCCC1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/40db6fd9-51e4-4afd-95e1-597856f1c950">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
        <rdfs:label>MCCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aeb2bf09-7c8a-4e73-bd5b-780ab813e656">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e58d4720-1afa-43b9-867f-4760bae06787"/>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/274a2ebc-0dd0-4c0b-90d9-c1af5c5ecce1">
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5e0cb279-eb5a-4bfc-a3ce-71faa3e94126">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de72e0b3-7d62-412d-8083-faf66719fdb9">
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c7d5bb9-8738-4f4b-be1c-538f2aa3674c">
        <rdfs:label>AP2S1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84622581-cf62-490a-a899-cfc2053bdcdb">
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9364c808-917e-4855-ae7c-8d2f683f5520">
        <rdfs:label>PIGT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/af041431-8c0c-44c5-9f3e-275706c01a57">
    <ddiem:uniprotId>Q3US15*</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1836f894-dccd-46c0-9040-a8ce6d3713c4">
        <rdfs:label>NSDHL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62b32cb5-2f03-43d1-b6f8-050c44177184">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/23f1a1c2-5242-4f95-b9bf-de9d00d04cab">
        <rdfs:label>CP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ferroxidase</rdfs:label>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ac0d4a96-566c-401c-b5c5-f77b538225cf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d90035c2-478f-4091-b585-2c355b6dd337">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ffdc05bb-7189-4c17-9975-2db9128b57d2">
        <rdfs:label>LCAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13846f30-d3ef-4e18-b4d5-1981aa3d8de2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b242ccec-4613-4e91-9e05-827ca58122ec">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
        <rdfs:label>GLUD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e193433-bfaf-4d4c-84d2-b63b073aece4">
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/26d63f54-1fcb-459d-968d-35a907a064cf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
        <rdfs:label>GSS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glutathione synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/076dcba8-d72f-49d6-8e91-80152b5692c0">
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/85d545c4-5921-4ce3-b09e-1770e50ca8e4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
        <rdfs:label>MTRR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/511e375d-7631-49d1-a8e3-0eb3b8c77b13">
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d771e8ac-6101-4b2f-b67c-52b8bd467691"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eb5028ee-6b2c-42d9-a2b8-e63ac252b9df">
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/455a34cf-8bdb-44de-895e-e781a301c20d">
        <rdfs:label>RRM2B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0ce94e7c-d372-4336-9cdd-91a5fb3b2f9e">
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/78e4b784-47a5-41b0-a96e-d0d99517f166">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
        <rdfs:label>ATP7A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6df9b83-d3db-427d-8668-0a891993a66e">
    <rdfs:label>Glycerol kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec97cc7d-5864-443c-90c8-87d3e0ed814c">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd6a4759-5d35-41ba-a21f-67b82f0f2992">
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <rdfs:label>uroporphyrinogen decarboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b971db0a-e518-4c32-b0e4-14019319305c">
        <rdfs:label>UROD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bcb7cfad-b416-4272-8778-0d29030c13f8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b9266ba-e15f-4bc9-bee9-aaa610d5987c">
        <rdfs:label>ACADSB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.178</ddiem:ecNumber>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29f0e6da-5a88-4e06-91c2-c059d74e79c1">
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e3e41c5c-8ea8-43c4-8438-4466421c6df5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
        <rdfs:label>ATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.11.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cc693d2c-0ab2-462e-8dd8-ce533952a335">
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e18bbee-51c6-4e2e-8dea-9324f62cfdbc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
        <rdfs:label>MTTP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ddb9f13-556b-45d3-84ce-949e4566b372">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/419816bb-1e80-4e9a-9ac6-25f86033ee3d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
        <rdfs:label>CBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1eff3cb2-b86a-4e20-8c9d-5ea858d212e2">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b34b2221-974b-4b0f-a1fb-6a230f7097da"/>
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/21233efd-80fa-4620-a9ea-1c5715c5bbfd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c190f298-646e-42e7-8866-291579be72e4">
        <rdfs:label>PHKA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f90d3c5-289d-4208-9965-2eb6b501d123">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/310ac723-1421-46c1-bbb0-525b13784332">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
        <rdfs:label>MPI</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc602a7a-9141-4e4d-8223-ce6e807b025f">
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ac0d4a96-566c-401c-b5c5-f77b538225cf"/>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/46cffd26-7493-4cb2-b661-4bf64bc29d6f">
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25d8798b-ac30-451a-937a-8f51d87d5579">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
        <rdfs:label>IGF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/81596967-0e19-4bfa-acf1-bd85712539db">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3ee41aeb-8789-4b22-a275-0b6077877eaf"/>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb449a8d-f480-4f2c-8f3b-40716ad3473c"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8dacbb09-2267-4c1b-8e0a-eb9fc319d3e1">
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/168e0d62-4d9f-43a2-a63d-06e03051ef2a"/>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/479a9ef6-e417-480d-8b7a-4a9d80d0c813">
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eb0c12a6-877c-4be5-b062-ebd2a929f04d">
        <rdfs:label>ACAD8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6b5f7601-0ee0-4af6-9e1c-9d1d727dfb24">
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f4a23f2-63fc-4b93-9268-0e1a763f1547">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
        <rdfs:label>SLC25A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e80a5da-7569-4363-a446-7f7ed00d9fc0">
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/36070c3d-776e-4e93-8768-8ecb4ed589df">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e8299d80-3c74-4a29-ab30-98df6ef56a37">
    <ddiem:uniprotId>Q9VQ62</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/af49d5e9-d7ba-4867-b5ff-7be824232469">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
        <rdfs:label>CTSC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cathepsin C</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8bbaa602-f735-450d-b7fc-cb409bac407a">
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c129cd2-8c29-46ac-bc78-974112979135">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
        <rdfs:label>GNA11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P21278</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c5c1c533-c4ea-4c45-8f97-7a77c5134ff0">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9ba89927-336a-4664-8bdd-25b92a11a502"/>
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9e773f15-3a3b-4ffa-9780-224d1ed2d385"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0015f72c-b269-4c0c-9511-d084864a0b63">
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1d492f99-3fdf-4905-a661-f9419ff76dba"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/513fd4ef-4527-41e8-8bb1-b4a4ad177606">
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/780e340a-2ec5-4827-bd9f-d4b5f24b7069">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
        <rdfs:label>CHST14</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea4bed7a-b5d9-4a10-b402-401019c8351f">
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/18263632-fa3d-4263-b08e-c9d17f006ee4">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/128d8f96-76b8-4caf-8459-3a87af06f688">
    <rdfs:label>Prosaposin</rdfs:label>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fe8622fa-222f-41a7-aad4-29732dba1a8e"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/710824e2-3856-461d-a179-8e14a2c6e89c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/855a0db5-766c-4246-84d2-6ff812a979bc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
        <rdfs:label>PLA2G6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <rdfs:label>Phospholipase A(2)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a72937d2-545e-4d2c-8642-98cc3aa44041">
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f0e7b1c7-63b3-49ff-bc56-f83afd7ed319">
        <rdfs:label>SLC39A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4dbbf1a1-3926-4ca4-8c57-60b089736b84">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ef2cb476-ff7a-4004-973e-5ef04b57f5d6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
        <rdfs:label>FUCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <rdfs:label>a-L-fucosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/66a0cf89-2c19-471e-a1e2-9af925987634">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e6e015d2-69e3-46f0-b4cd-2ebc22e4f956"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa84f0c1-f778-4f61-996a-44f5a63c427d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56d4bd28-691e-4f71-9685-f14bfcaf0ce1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
        <rdfs:label>CTH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/af4b1a4d-ded5-4881-9117-f28c0e93408c">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/855a0db5-766c-4246-84d2-6ff812a979bc"/>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1dd9b56c-a17c-42cf-8a13-f41543b8adf5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c862be5d-5930-44f0-97cc-f7e280b5c5c3">
        <rdfs:label>KCNJ1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d0c481f6-0921-4bf7-b60d-111edc7c6427">
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3cff328c-9145-455a-954a-eb4007397030"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ccbccb8-2797-4258-99d6-8d984cff6f73">
    <rdfs:label>atrophin 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6892d187-710f-4d07-8ea8-48ddb591b7aa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
        <rdfs:label>ATN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9843bcd-1f93-4437-ad3d-164b56850a56">
    <ddiem:uniprotId>Q9VQ62</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5733a1ac-f8ba-4f3d-b32d-4742dbee7bf8"/>
    <rdfs:label>system B(0) neutral amino acid transporter 1 (B0AT1)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0d2be9d-f438-4cc2-8124-9c4736850860">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001260</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:label>dysarthric speech</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f00ab340-0d18-4179-9b54-48ef837ddffc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e5a655b1-5a53-48a8-b523-a65997cd9ced"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd7e9bf7-cd3e-41fa-88bd-4a6a86735801">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d408236-27d5-41d4-a14c-bc4be7b6218e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd01c540-40a3-475d-8e73-c5ac9695e229">
        <dc:identifier>HP:0012350</dc:identifier>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/67bbb41d-6282-4609-be32-d0aca9bbe8b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e0c5f3d0-1e16-4efc-bc39-37a0b5a6e8de"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
    <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1aa0ff7a-3d27-41db-ae9b-cb25e6c5e84f"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ede570b-6f51-476a-96a9-58d4eda85063">
    <rdfs:label>Prokinetic agents</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/38fa8888-0a8c-40a9-b404-3b1cf72669a4">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3fd2d7b-37e5-4493-b413-de4c28df9423"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a030ba63-e599-47a8-8dff-28278d3f36c4"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4f8690f-53c6-4474-9bb4-561420bda81a"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1971eaf0-feb0-4692-9b28-b2bd258eb433">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0e19abfe-8d10-4806-afd0-5f92f9ae1f3b"/>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/322f49f1-b82f-4ee5-99f6-5963865719ff">
        <dc:identifier>HP:0100614</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myositis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca10eb2c-a29e-45da-895d-eb006a3e436e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85f2bc9c-800a-4092-a663-2247a9a5901a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>Abnormal muscle function</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd9a81c1-a8fb-49a4-afc6-b3f78d75ffc4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff140f7c-2c16-445b-9702-bd7e7a5af52e">
        <rdfs:label>Rapid progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7cf618c-bb4c-4655-85db-93313b988531"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/174bb898-6e26-473e-b24d-fa2eb995ccd9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
        <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040081</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bc9f375-a10d-48c1-9170-40c45276aaf6">
    <dc:identifier>HP:0012211</dc:identifier>
    <rdfs:label>exercise intolerance</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be75654b-1db9-4e70-b5e0-deb8aa78bfeb">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
    <dc:identifier>B02BA</dc:identifier>
    <rdfs:label>Vitamin K</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c7fcdba-a839-44bf-b66d-e8e64d6ad3ce">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e31ba36-7ba1-4264-9de0-3c58277c32c7"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5feed48-6f99-414a-9b22-479b4c7584e1"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d35e16a3-42ef-43c4-a7c2-14760e27fe8a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0caaebcd-7355-40db-b3d6-3597ae05121b">
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
    <rdfs:label>Poor appetite</rdfs:label>
    <dc:identifier>HP:0004396</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d04d45c5-b938-4efa-9eff-64d6e382ed75">
    <dc:identifier>HP:0011031*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
    <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4a83cf8c-65f8-4f68-b2ee-ff23b3041844">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a42cf673-c4f9-4210-9878-e6ca65185608"/>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e155640-cf7e-4d31-8560-0035f4b39fda"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6862c928-3bd0-4c26-84c5-e452b04a6da4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba8e0be8-9ac5-4e3b-bbcf-f31130ab2ae6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d2654ec-ef73-445a-a455-3b3f5ad0b5a1"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00328</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a29a02dc-75c0-4b28-8f76-ea9036953e63">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d2654ec-ef73-445a-a455-3b3f5ad0b5a1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd6c5b1b-6fd7-478c-868c-e9da8e26aa79"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42d6c3cd-e7e1-43de-bff6-12b60f82d0a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eff6029a-acce-4856-98c3-29ad85472527"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8ea12ab-fbfc-4a1d-ac00-31c6b88fc97e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Indometacin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5ebe417b-e364-437c-9d45-3c00760d677d">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc464821-d0ef-4b5f-93a9-be77bb50f3e8"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/589e302f-e390-413b-8be8-dd8bbf1c9e9e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d2654ec-ef73-445a-a455-3b3f5ad0b5a1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34279e2f-a0a7-4493-bb45-4609affac1ec"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7bd391cd-7c1f-4a98-a4f5-adb2384394be">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0568a54-7e33-460b-8f04-27442148471e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/697df3ab-4542-4497-bbf4-a48cbbb18b2a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/740b80c6-21c0-46ae-bfd4-9c87a889bb28"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d2654ec-ef73-445a-a455-3b3f5ad0b5a1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f83aa633-4a41-4eb5-9d40-4d39678e993b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd0d090d-e56f-4370-9bc7-21ba6f320665">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Exfoliative erythema</rdfs:label>
    <dc:identifier>HP:0001019</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88447146-9290-42e4-9efb-4d40769788ab">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <dc:identifier>HP:0002180</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b35dd9f8-bbf1-4d73-956c-14e21fda535a">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2c0a37b-72f8-4187-996f-1dd153794e3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4da3e29-ff5c-47c4-9621-3e824a396182"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ceb5cf70-3781-4bc0-91ef-e76213bbe647"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a678e01-e6db-46ef-913c-02ea06f4dade"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0f223a4-e76a-4ea0-b245-e31753bc4165">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <rdfs:label>Brain damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2fef2e3-b1c4-4625-a606-68e15e6c6a1d">
        <dc:identifier>HP:0100021</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <rdfs:label>Cerebral palsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7a3cd9e-b218-435f-a63b-375a34f4bed0">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea97c67e-3eb0-44ea-97d6-61bc28e51f77">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89d643f3-d1e6-49ec-a4f3-86bc75f23e79"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e92fe973-a19d-4f01-b33d-2defcb5e285d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
        <rdfs:label>No result was added</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100851</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7d97699-c575-4804-af6b-4b5a174f8b29">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/90477b13-2a62-4d93-9daf-08e09dc5a897">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d97a4b64-26fd-4f1c-bae3-7c47b2de7624"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/175c7eda-3a4c-42bf-9062-e8c7b59dde65">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <rdfs:label>dopamine deficiency</rdfs:label>
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dad418c4-3650-43f9-8112-e1006e9775e9">
        <rdfs:label>behavioral disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a08f1a1-3476-4bfc-86b5-7d72c28bb7d7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperprolactinemia</rdfs:label>
        <dc:identifier>HP:0000870</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022510X16303495</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a31839e-5a57-4882-8226-3188fef4d4ce">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>movement disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe520161-0116-4d4c-99a8-305c0caee9d4">
    <rdfs:label>verruciform xanthomas</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0031517</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3d489b84-d3f9-45d1-8fc7-c05539939901">
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <dc:identifier>DB14933</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3033e672-6a9a-4e11-b083-9dd8817a3817">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10aedd86-0ec3-4441-87d1-ae489a1d43d2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d186861b-849f-4750-b51c-f889404fe366"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/41528aed-b9dc-4aea-978a-7e2be0646317">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cb475c0-272a-454f-ae7a-7f5e2df8894a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-016-2044-9</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c98d000b-68ee-4954-924b-f736ee1cf5dd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
        <dc:identifier>HP:0012130*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9155b698-596a-4d71-9974-de9faf68dced">
        <rdfs:label>erythroid progenitor depletion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
        <dc:identifier>HP:0025034*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcb93c2f-4120-4815-b380-55b0631a4c9b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>low hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f08d965c-01bb-433f-9404-15dc6e3e1cce">
        <rdfs:label>Pathological apoptosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09ec8e50-ed84-406b-8d2f-592f85a08aeb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low quality of ife</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68e9ff88-48c9-4c20-8046-5f22ade97b1b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e5b1ee9-9cfb-4eff-a7cb-ba5b6cbfa425">
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:label>myoclonuic Jerk</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfc51531-94d8-49e6-b7b2-12977ae05f0f">
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Poor intelligibility</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/671cf815-c62d-4820-9785-b5038294095b">
        <dc:identifier>HP:0012477</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Voice tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/968f738f-dd33-4b07-9063-a9d641b0e941"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/956a501e-a0d5-48c2-8595-14cee3ce1af7">
        <rdfs:label>Poor fine motor skills</rdfs:label>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/515af704-c3b7-47ed-9c31-0147eb98fc01">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc7c950d-7ea7-426c-bc29-cf9d15494223">
        <rdfs:label>Decreased hemoglobin</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4f6335d8-4bdc-44be-a529-69579e379539"/>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73120ca0-7b92-4fda-9eb8-495663512f5f">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>High ferritin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40d63d73-655a-4a7c-8537-0700e0fa1c27">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc7d0361-14f1-48c9-9a89-74464e7a6737"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adb3a65e-6547-4739-a3a3-64ddcbd62b35">
    <rdfs:label>Amyloid deposition</rdfs:label>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <dc:identifier>HP:0003216*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/20cbe9f8-5f94-4a06-956c-ac3a2fdd6771">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92b029ee-d2e4-4a2c-af0d-b7543c435209"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82844744-5f31-4226-bd3c-bdab0c127144"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/daca2d57-268c-43d9-ad4b-0677deaa894c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7c0b4c8-2209-472c-ad32-d58821d8585d">
        <dc:identifier>HP:0003254</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73120ca0-7b92-4fda-9eb8-495663512f5f"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f">
        <rdfs:label>Functional interaction( Mechanistic B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18757d82-93ed-4876-b508-5959a64c1a5b">
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aaa973f1-ed17-4bae-81a8-62662803d7c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55560033-36de-4fbb-a0a0-58cdf052d742"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b975e96-cbb0-4fd7-a810-6eeb785da172">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>Tiredness</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbb1af51-8424-4499-ad9c-18163af85c1b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Frataxin expression level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b55de00-c4bb-4c43-b081-f31de6b77dbd"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1dbd8860-0374-4a91-8509-8aea12a1aa38"/>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49bbe408-6d1f-4483-adf4-26db8dc844c4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e28f8445-a5d0-4aab-b992-a8a42f380929">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4a1e7d9-fc56-43d8-93bc-0d2a4b466877"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8f9e53b9-ac04-42cd-bbf4-f43795d642b9"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01325</dc:identifier>
    <rdfs:label>Quinethazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6d75e87-f7fc-4002-801c-7ac4fa8729fb">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0bdf0f24-0d76-41dd-b500-faedf22ced35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08a2ecb7-97d2-4049-8a33-39c6f2dad14d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4243aa2a-8d9d-478f-b584-6abb0dab110d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df254261-b0fc-4771-8230-837a19ec4dbb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f0e7b1c7-63b3-49ff-bc56-f83afd7ed319"/>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4524093-c9e8-4b23-95cf-f3d83d59b8a0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/092a8b58-3215-49ce-95da-9922330b5d52">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0100660</dc:identifier>
        <rdfs:label>Dyskinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/32312dee-8af4-4fef-9fba-3109a858775c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b22590e-504d-4668-980b-1fe520b20656"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c45a623-4fc7-4395-aace-83a06755444d">
        <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2851f05b-3e8f-48f5-b1a6-51c3cc6aac39">
        <rdfs:label>movement disorders</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
        <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9d27cb56-425a-47c4-8210-3994ab8e1ce3"/>
        <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5872ac73-d01e-4eff-a800-568e6454591e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>EEG with focal spike waves</rdfs:label>
        <dc:identifier>HP:0011197</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/10635361-7ccc-4424-997c-4a5d56cf43fe">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e877c9ff-2782-4bf0-b64e-d878482df659">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce262905-1075-4499-ae9a-8b9b2e308760">
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0011015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41cab147-8711-498b-ba41-3edb6d2f325b">
        <rdfs:label>Failure to thrive</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e503d938-b491-4e10-aa3e-f42ba61ef187"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/532cbffe-cd10-493f-beea-3078a668633d">
        <dc:identifier>HP:0004322</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>short stature</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/575d43c0-bdf1-471e-8f5e-8aa1a9b96540">
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3bd5b06b-6326-42ca-8b50-43768936c1cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d74c55d-6294-4889-b500-1dd8df810749"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca97ae36-de5b-48e7-9356-b2f99dccc9c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
        <rdfs:label>metabolic acidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2857ce0-1a4b-4441-b7bf-dccab189cc4a"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa03ec81-a2d4-4d2b-a892-360dd84ddaf3">
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4f6c58b-5129-499e-8dec-f4de4bdd8bb2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e89fa9a-1159-4fb3-ae97-bc01cec5f52a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57623eca-04db-40bc-bcdc-c59c4ee20b1b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8fd1947-c929-47c5-9bc9-61a683f82522">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a513bc79-2e4a-4e4e-b879-70a408e51265">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c206308e-19ca-401d-bc25-f18f93f7aa55"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a34c7f25-f0da-4040-9657-69a60e14e025"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29c7eba7-cf37-4dcd-996a-b9f67a204420"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <dc:identifier>DB01393</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/afbc8fc8-abea-449f-adc8-cf5ace27f37b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99f1a093-a4c3-47fd-abc5-8d3503bcb7d0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c206308e-19ca-401d-bc25-f18f93f7aa55"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36fc7adf-418e-430a-bca6-8e5477b2de2c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b21eb15-2590-4370-bd2a-90d2cc09fadb"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/aa0a5e30-b9b2-46fc-8901-6947ab8f1aac"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/121af46e-9161-4909-8cd3-9844e9c3c1c4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a9f8929-e421-4748-b949-ae7c8f89c1ee"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad9d29ff-882a-43cb-a21e-0d9f793c9aea">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/30dc15e4-6b1b-4ef8-9fd9-f63153fd8174"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25fbb71-9f92-432b-9c27-85be69eee181"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Bezafibrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c72fe4f-0955-4509-9aff-0c7dbafd0c72">
        <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c141ec3c-313c-49ff-899f-98f6654747f8"/>
        <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8337a560-7901-4298-8453-ac6ef28d8291"/>
        <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c206308e-19ca-401d-bc25-f18f93f7aa55"/>
        <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
        <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
        <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8e3ae95-54e4-4ade-8206-48bfdd23eea0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82df95b6-ed30-4958-a704-ab31e528c77f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236270"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00200</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d22e48b7-0ec2-4ae8-8ea5-b1ede20212ca">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2665b99-1372-415b-8104-889af46c02b7"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0414b3af-fdfc-4e9c-a738-94e9b6589bc6"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e702c7e1-a149-4216-8ae9-392835c177fd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc38db20-873b-4db0-8f03-93986a5ecb72"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ccbfb2ab-610e-4fe6-98b0-7ff32162853a"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52ac3698-bd54-429a-b20b-c7d4796236b0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d6d8144-5e58-45a1-8d27-6225d152f232"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b24cdbda-7d05-4f54-919a-6bf1d50c7f22">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b643351b-f9f6-432c-9167-b3e57280f5d7"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df13bbc7-cea2-44e3-8aaa-5d65cbe57253"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0414b3af-fdfc-4e9c-a738-94e9b6589bc6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de302f6f-9eb9-4a15-8dd1-297ce1740175"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/496616db-696e-4d45-8d4e-dfecdb582f7b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65e53768-e2fd-4f9a-93a9-071944dab71c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0dff98d2-8a58-4f46-a231-33ca90693d52">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9be0b219-7698-4c5f-9cbc-13ef2923a7f7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
        <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d83ceff-f6f2-4c78-8990-7a341998443d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22f5db6c-acd6-45a1-9410-bc2969dbf3f5"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e64c081c-0428-468c-a4cd-ca6da36fa15f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbdbc56f-671b-45c2-8248-9ca71c9a5382">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b0f6749e-d14c-41fe-b70a-494de89ac665"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c3fa03e-11eb-4864-90d6-e30c012b06f1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:label>involuntary movements</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33c9a9ab-e788-4e9d-a627-9cc3cd1dee9a">
        <rdfs:label>parkinsonism</rdfs:label>
        <dc:identifier>HP:0001300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef9ea9ee-2331-41fd-9ad9-1269e32cf96d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <dc:identifier>HP:0001251</dc:identifier>
        <rdfs:label>Ataxia</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a0710b6-a667-4063-b365-1768a32a5edd">
    <dc:identifier>HP:0001298</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <rdfs:label>Encephalopathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c7d5bb9-8738-4f4b-be1c-538f2aa3674c"/>
    <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51af49fe-d133-4b04-a96e-0ffa8d2d9f28">
    <rdfs:label>abnormal liver function</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48740ff4-d633-4b5b-a1da-4b7aa17d031d">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf32beca-d2c8-4c9e-bbbd-4d96c4bd5a78"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b6f6c9a-b554-4c88-8cb0-d037b9c3ff07">
    <rdfs:label>Cinacalcet</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/656bbdeb-2a23-433c-ad60-5ea9ec34af71">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5230fc35-1da2-4732-81f0-956199d2d923"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84b82f1d-4cf5-4860-9dd1-064a11c811fd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145981"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6fe0e1b-96dd-4f63-b776-650a8280e0b1"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b911cbb-ac2a-4725-bfb6-2b251980abae">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5230fc35-1da2-4732-81f0-956199d2d923"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6fe0e1b-96dd-4f63-b776-650a8280e0b1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a004e260-3c8b-4c08-9db8-fd773522913c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84b82f1d-4cf5-4860-9dd1-064a11c811fd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600740"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01012</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7570e11d-ad77-4589-a1a8-61e15f14ab66">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145980"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a730fd9-ddbc-431a-86b8-60620a2da25c"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5230fc35-1da2-4732-81f0-956199d2d923"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57e9e981-61ee-4e21-858c-4a70107550e3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2c3fa2d-fb06-411b-b738-882d1f13f2ae"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9dc16b1-2d24-44f6-aa4f-d6339a0b9587"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2c13d52-6338-433f-b6e3-3e1758053001">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5d11388b-761a-4697-ba56-e9dc7b4c25cd">
        <dc:identifier>DB09115</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/980c4f7f-cc7b-48e1-80c5-73b4cd54c5b7"/>
        <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8971df7-fe06-43da-84dd-5fc0010555df">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c488013-00cb-419f-9f25-3117c225d78c">
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77436b6a-0982-4717-9ea3-bf4f4b572f70"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc30a970-5ec9-47fe-9a70-3cf0477f0e63"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a65f183e-325b-4cd8-a18d-923516d9ba17">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f649a370-4122-4249-be2b-51ad88be2caf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008373</dc:identifier>
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5db51b68-6012-451d-afe2-2756db0ac8de"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1022c11-fd20-43cd-ade9-f04b09b57d4a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/439bda36-94a2-4b89-9d75-60617032cf70"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/471a97f1-4845-4212-b504-886836511260">
    <dc:identifier>DB02659</dc:identifier>
    <rdfs:label>Cholic Acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/33fb334b-3724-4190-b1a6-2a215f0437b4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d8a627b-fcd7-45e2-89ca-4ba5769c5056"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/482f947b-0e01-454d-8ca3-966cfaccae08"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a432c56-ede8-402a-9b0a-5c5582a09028"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acc093ed-0569-49ec-abc2-ad9bc8658a6c"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47c60a56-041c-45fc-94bf-07887e8c2748"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/354a137c-966f-4f68-a7a0-0bd6dea0f0bd"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03a944aa-43cf-4501-bfeb-7d5f7943a4cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54e97738-0584-4a1a-9a0c-30c8af99780f"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c319ebe-fb0d-47a3-aa30-48cff96d8239"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2d00d37-d967-4f1f-91af-fb8cbb9fc306"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76d9a712-1929-4776-9b88-dd4618133737"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b59fa50-b427-4b99-9ac8-216ccca1a94d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3939180-0c9a-458f-b238-c014cc3418b4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa37fb2c-3585-459a-ba63-7296d07e767b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6bbc6e71-c92a-42db-9034-a07b1162b729">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2da3ba8-1650-4988-a822-d3a801ebd7ae"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34130dd3-165f-4128-a6a8-963cf049f2ef"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6570e767-4e17-4246-bca4-b8962c193bfb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c668746-e624-48a9-b69d-eab376f489da"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e56cafda-61c2-4628-add0-360ae0b209ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa37fb2c-3585-459a-ba63-7296d07e767b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a432c56-ede8-402a-9b0a-5c5582a09028"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9de2cde7-5b3b-4e79-85c6-fb67e0d28e5d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c319ebe-fb0d-47a3-aa30-48cff96d8239"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa14e9d5-0456-4625-b481-245a5d090c79"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1734853-727a-4f5b-9a27-0e360ea3aaa5"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93cc75f7-0a85-4d4d-9f9b-2d6c7a56f8ab">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c9c27db-93c6-42be-8246-6213daaa9ad4">
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>abnormality in bone mineral density</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a841794-3b74-4b21-961a-fbeec306a8e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee8fdde1-9581-4b6b-b1e7-29df5d604a6b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51675609-660b-41a9-9007-077d5cbcae8a">
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>anaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/456903d3-1271-44b3-8a31-fc30ea125562">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5">
        <rdfs:label>Direct interaction ( Mechanistic A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7da3cbb7-8615-4d67-8a99-b1c0eccd0dc1">
        <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
        <dc:identifier>HP:0100712</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0bd948b-9b4e-45e3-9d61-4fbc143bd3da">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>growth faliure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89e14cde-b42f-4bef-b5a7-0d206d906b4f">
        <rdfs:label>Bone pain</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
        <dc:identifier>HP:0002653</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31a28101-243b-4aff-9e9c-cb84c426c9ec">
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:label>thrombocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84098313-829e-41f8-9646-0232062a938f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
        <rdfs:label>avascular osteonecrosis</rdfs:label>
        <dc:identifier>HP:0010885</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a41c8a7f-b60a-49a7-a468-7d4e40f14a33"/>
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b1199da-ee21-4fa4-9486-54816c00d0a2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67d0286d-0f8b-4295-a8d7-8d4b5cc6bce6">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a6dc88d0-400c-4834-83bb-cbb43cce9d70"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1adc5155-9e48-4461-9ef7-8d3bd32bd808"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <rdfs:label>Thalidomide</rdfs:label>
    <dc:identifier>DB01041</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e55f8a1b-b285-44a2-8872-d42302f79497">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a6dc88d0-400c-4834-83bb-cbb43cce9d70"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8c246bc-d9a6-4167-8bd4-d6b98234e003"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6fe2afd-5ded-49a1-a5b5-7c3e760428a5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faca736a-6e93-4d0c-beba-bcd1af0ae2a8">
    <rdfs:label>Bradykinesia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
    <dc:identifier>HP:0002067</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/126e3917-7cfb-4528-98a4-c39cf8501207">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01d7fba3-2e18-4d48-b8c2-45bf5ccf2e10">
        <dc:identifier>HP:0001941</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:label>acidosis</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e19a6237-87ac-4d7c-a49f-dfade7f69e94">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e484d02-6c95-4731-988f-9af5cbaa6a47"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6e919a9-8e2b-4fc6-bb8c-c2190575132c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f4fb1f9c-9626-4384-b78d-b2ec0b235203">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6fed7005-e64c-442d-9440-d323d5dc4015"/>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee9d3ddd-cefb-460a-892c-d64a835e541b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c10d81b9-6384-49c5-8e47-2fb56586b8ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1aad4316-6054-43e7-a804-03181478c53a">
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/206e66a9-afcc-49e4-94e2-7429eb17cf55">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2d3d9ab-35a5-4a45-85c3-9a238c98aa62"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b1d4f38-d6f7-454b-b178-93d035470c50">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/330905d0-5495-4e4e-9af5-90cfbc2da88e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29d052f8-dd0b-4804-9a95-389276d2ac04">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f22ed985-dc1d-4dd5-91b6-8387afbcb033"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/162b7fe8-ce43-44a1-aeb6-eb4bfea46b31">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd511d1d-32a8-4c73-95d7-5de83256bd0d"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97d06def-a9da-448d-a80c-c0fb8f33ba13"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9510667e-10a2-4127-9c00-43820f9f5b6a">
        <dc:identifier>HP:0031375</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Refractory Arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cf178bb-acb0-4b1b-a318-b7f3d58cf178">
        <dc:identifier>HP:0001369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:label>Arthritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0b11a52-3d1d-4954-abd8-6688070ebf24">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Synovitis</rdfs:label>
        <dc:identifier>HP:0100769</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a143d0c3-c299-458b-ae4e-093575eef873">
        <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
        <dc:identifier>HP:0025303</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a50902b9-56d1-4079-b55e-eaa9696d12e0">
    <rdfs:label>L-Leucine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f858f3df-5584-47f0-92aa-23cc604c33e5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/427edd5f-3514-4154-9242-97e4dc8f3360"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b9c238a-a388-4b17-a5f4-c3d193b3e9a1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d29f1d8-570e-481b-b2b0-1e7f64b639ff"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66987ed2-170b-4720-b974-d66f639c9dc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00149</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c2a1c51-d334-46b2-8752-7c94604df545">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/630a16bf-720d-4c7f-a538-9e88f9219858">
        <rdfs:label>Increased plasma triglycerides</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74966456-a48b-4b5a-843d-43a62b1cfdc9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
        <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5e0cb279-eb5a-4bfc-a3ce-71faa3e94126"/>
        <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93e173d5-53ba-4207-943c-fdd7bf9592b9">
        <rdfs:label>Increased LDL cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <dc:identifier>HP:0003141</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e06c02c-69b8-4d14-8d49-af244b7cddb5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>Increased total cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07f67640-1537-4015-8690-ecdee18b6b80">
        <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85b4b2d2-9999-4f84-9218-2b45db8658ec">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/832655f7-ac80-422b-89f4-ed9fb9d0a553">
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal liver function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6a0fe4d0-f109-4f60-a4ef-3e0bf2f2c7a0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79d1c31d-b23c-4237-9d2c-3517745e02c8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2d65b44-2a9a-474a-a69c-73fd4aae4a41">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Dyslipidemia</rdfs:label>
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d7e870c-6a03-45e8-8cd3-5636d1ceb6f1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <dc:identifier>HP:0004348</dc:identifier>
    <rdfs:label>Defect of bone mineralisation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9559855e-02b8-4456-852b-c12d44867af6">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4bd17180-e4b0-4e2a-a430-7ce7f0482c0f"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a9f8929-e421-4748-b949-ae7c8f89c1ee">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/227759d8-f192-4672-a22b-42f3db108207">
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a5484ec-b5a8-4483-941c-5d1c456102b2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <dc:identifier>HP:0020062</dc:identifier>
        <rdfs:label>Low Hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/72cf5c5d-0e75-4cf6-8028-7c8ee6f192ea">
        <rdfs:label>Functional interaction(m</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a4ea7c5-1d5d-4697-bc1d-a2a018a17527"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d595058-c184-4891-b342-ef5be04fd136">
        <dc:identifier>HP:0004312</dc:identifier>
        <rdfs:label>Abnormal reticulocyte count</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d488560-8111-4270-a573-e10ba44b607c">
        <dc:identifier>HP:0025548</dc:identifier>
        <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca05a0a4-f990-409f-bd4b-f4b60acedc44"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bff1cc5c-264e-4eb3-b96a-4e5504e23390">
        <dc:identifier>HP:0100502</dc:identifier>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67ccc672-456f-438c-8e25-b31f90804163">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32312dee-8af4-4fef-9fba-3109a858775c"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82ab794a-4dd4-469d-8e4f-0ab627e15804">
        <dc:identifier>HP:0003326</dc:identifier>
        <rdfs:label>muscle pain</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cdd869d-dab4-48d2-a390-d386b8ee966b">
        <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff94e1a8-c1de-4783-8408-875b753c9b0e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
        <rdfs:label>rhabdomyolysis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003201</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0c4729eb-29de-41f8-905a-4e7caad86dc9"/>
        <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57cb0db2-b93c-401f-a6b0-3d84637f4d5b">
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
        <dc:identifier>ECO:0000305</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afe4339a-f6ee-493d-a1a4-3f93669438c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/286d184c-7fe2-48b0-866d-e382c191c95f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/793cb987-85aa-479f-af5c-e6ee7212044a">
        <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5cdab7b3-0645-4925-abee-e30a84d34dc8"/>
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04de1bcf-b85a-46e2-a277-e8897756125c">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:0001943</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5956549b-a603-4e88-9ab8-2e155f3b130b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
    <dc:identifier>HP:0005180</dc:identifier>
    <rdfs:label>Tricusped incompetence</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5952510-ff93-477a-80b2-44d544ecf9de">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cac47dd-cfda-4402-9647-a70114529097">
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b0f8bfd-ac6a-41f2-8464-f2e8c850c049">
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95aeeb80-7b66-4a45-94f2-dc2b0bc01c78">
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79e43660-6a00-4501-9a28-5e2e88c7cd44">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
        <rdfs:label>glomerular damage</rdfs:label>
        <dc:identifier>HP:0000095*</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd7370f3-a83a-402f-8fa8-cfcdd3f62d00"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7013e6e6-1b28-4f01-a82b-f0bf46fde4c4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>Delayed growth</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb3e3009-5086-4abc-94d1-c6f161616fc6">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:label>renal function declines</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d957e1d5-69bd-4cff-a6cc-eb0832c36b9c">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>shorter life expectancy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a89cc19-c135-48fd-a0bf-1699b2ae2767">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <dc:identifier>HP:0000821</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>hypothyroidism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3d57f17-551e-485f-a8ce-64ea3087b16b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000613</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:label>Photophobia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f64bdee9-9dee-4ea2-b92d-970d30ee39e2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
        <dc:identifier>HP:0010918*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7d3b711-eb7a-4eb6-a7e2-a2169157824d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
        <dc:identifier>HP:0003358</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a7a3722-10c7-4385-b850-4d8ff49d27ec">
        <rdfs:label>corneal crystals</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96a8bb2f-7070-4218-9e18-351b59aeea31">
    <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <dc:identifier>HP:0025201*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/728b0bd6-11f2-419a-8cf3-06957214383c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b1a9a8f-8435-478c-85ce-ac0536bee528"/>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03508b92-8516-4ab4-b790-0024729e0603">
        <rdfs:label>Vasculitis</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
        <dc:identifier>HP:0002633</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9abb9c1f-2c1f-48e5-aa25-7900f6453623">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bb6760b-e3bb-40b4-923d-a9988ec19798">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>Arterial pluque</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <dc:identifier>HP:0002621</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47311e91-d976-4332-beba-a4038680109c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
        <dc:identifier>HP:0031799</dc:identifier>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
        <dc:identifier>ECO:00055442</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f14575ce-a382-47af-91a3-52301ca48330">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2b06dcc-afc7-458d-bcb7-88ac6e247bfc"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d4568b1-88c3-4970-b86d-7b4e84db2912">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f9da657-1ab8-42a8-a46a-ca2728d159c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab403396-5654-410d-827f-d0e2a5032e25"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a3bd961-ddd0-4f06-810b-99f6af5fb24e"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8db0f1a0-7c51-4b0c-ac97-55b07b7372bb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
        <dc:identifier>HP:0011506</dc:identifier>
        <rdfs:label>choroidal neovascularization</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b83b9720-cff2-4b00-914f-e038b605b603">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>decreased visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38432999-8bd6-4c9b-b871-e5ae684e9df0">
        <rdfs:label>abnormal central vision</rdfs:label>
        <dc:identifier>HP:0000504</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1a2223f-609b-4955-b11c-230219435ab2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c557636-8ab4-46d6-98de-38fc2c0e9e14">
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83fa51dc-4552-4aa6-9628-34b39f1c264e"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7129746b-94a7-4701-b363-c2a635fce432">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
    <dc:identifier>CHEBI_113373</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/61c242f2-82cc-4a35-accf-7bc99e11c010">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bdda5d9a-28d2-4062-a7e9-e091f28f0ad9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90c23faa-e9ad-4f72-8613-70c610a79aa3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c43373cc-2bda-4cca-bde8-f62dc088dfbd"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/962378fc-b62a-4346-93d7-374c285f0ad0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d82eaed3-d297-41af-9e8b-02593e314664"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b702a324-f5ec-4cd5-b6a2-a12454ed5ac4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dd5ee97-6cb3-4a55-9444-f95ad90a4075"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e467dd89-702b-4178-8d38-d1dfaafb2caa">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012029</dc:identifier>
        <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4de87f25-32bf-47f6-a8cf-aab30d2cc919">
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Pruritus</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f85633b-f102-4cda-ba4c-2bcded562cc0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b5bda727-183c-4e0e-872e-7e057dd4608c"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/763d15af-cf1c-4012-a2cc-178c6e415dbd">
        <dc:identifier>HP:0012030</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
        <rdfs:label>Abnormal urinary steroid level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51109cc8-01d1-4670-bb39-fc54c452c8b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c79e55b5-f1b7-44a4-8432-e529a28a0d6d"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4c526e2-f30c-444d-aaef-4981bab709df">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1a4f8d78-a230-4431-86ac-a54e3ee5d41b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/03cc2936-2604-474d-a249-ca2365f76c01"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/049e2718-6497-4b73-9edc-089febd6256f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
    <dc:identifier>HP:0000010</dc:identifier>
    <rdfs:label>Recurrent urinary tract infections</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/827e32bf-84d6-4064-a18f-17cf3bfd3c09">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6bbb9e10-4d06-4080-9d7d-2238cf70c57a">
        <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/679e1a97-8763-47ce-be51-0c66d649bdeb"/>
        <dc:identifier>DB09422</dc:identifier>
        <rdfs:label>Soybean oil</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15d30fd1-f492-4b95-bc88-ebaece2e7b1b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ca993c3-d580-4df9-887b-819a071ac321">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90a25a3b-6d86-4a8d-9a6e-7828ba185e8a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e780f6f9-5072-4c68-8df4-78799778a338">
        <rdfs:label>Albuminuria</rdfs:label>
        <dc:identifier>HP:0012592</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ace870cf-fd1d-4fe3-9397-98473d1b4154">
        <dc:identifier>HP:0000100</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>glomerular proteinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6c678d8-b780-4021-92ec-f3e7019be13e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbd054e8-feb2-4a22-bf7f-8c7850f6d69c">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
        <rdfs:label>Pregabalin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc55fe2b-e57e-401f-813f-15bb16aa6f09"/>
        <dc:identifier>DB00230</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c1f8d2f-9d16-4e9f-b6f2-f73715481168">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003254*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09016d02-4bff-44b2-a4fc-f789a7dc5b6f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cc0dc31-27e4-4564-90b8-e241db240ec1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002156</dc:identifier>
        <rdfs:label>Homocystinuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/419816bb-1e80-4e9a-9ac6-25f86033ee3d"/>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02c5fd9a-5227-4e7c-86ec-ef5f4f72472b">
        <rdfs:label>Abnormal Hcy level</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0">
        <rdfs:label>Direct interaction (A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13e1eab2-6073-432c-ab4e-6c0e31048b67">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f18659c-d8a9-4a2f-bef7-498570d14417"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/513555a9-ba7f-4fef-8802-7ed7f3bcae00">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941*</dc:identifier>
    <rdfs:label>high-anion gap acidosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83f7ff20-441f-4449-a82f-ed05f36996a4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Delayed motor skills</rdfs:label>
    <dc:identifier>HP:0002194</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f949960-9885-47a2-9fba-bfed230b826a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc8a2591-8b61-4af5-969a-9d8bd8c98749">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29ff9efa-3945-4a64-bea8-24b568cf4e64"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/833dae77-e29d-4582-8f0c-e6f883ea66a9"/>
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90f743b9-3e6e-4ec1-aeb5-07aa2a6e208e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7f395ca-836c-42c3-9698-d0c6cee44553">
    <rdfs:label>electrolytes</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <dc:identifier>B05BB01</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f5eb4e05-55b0-4d15-a71e-e122df7add2e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43ca6394-adec-468d-bf8c-62561e8c706a"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a2e2f25-813a-44e7-9e9b-3a150751f142"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f897cef-c710-4b2f-b084-5593f848a2fc">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6754a9c9-2508-4fbb-85e3-f051e5232ed6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab1db195-0851-4a64-a8bf-4f7756559356"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d2540c5-6ad5-47dc-8bd8-682a52cb4f0d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>Cutaneous photosensitivity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d57d4042-7bc4-4539-a12b-017dd06ec489"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e18f31bd-f843-4f65-91cc-f03ee3dcaf68">
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66f64069-1bc5-4e34-a619-c9b7304e141f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/efed1505-2912-4a47-9205-7a3c5a26b5bf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f42e4ec6-b15a-4e28-b7be-e25c010fcfbe">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Low serum ICFBP level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9ed668c-fc3a-46bd-9493-e4f9f33915f2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78055f2f-ae09-4ddd-852e-c2f817cf5524">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4df3718-ede7-42e2-9c63-2e14b48c03e4">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b197a78c-4448-4f9f-806d-a86d2f1bf40e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11820a92-6d3c-46d1-a0b2-ae8f37c89a9a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00451</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
    <rdfs:label>Levothyroxine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/376e4ac6-5ba2-4c63-b5ce-57d13fe1e14b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11820a92-6d3c-46d1-a0b2-ae8f37c89a9a"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a89cc19-c135-48fd-a0bf-1699b2ae2767"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2a4bba5-3a02-4c96-9a65-533bfa58d6a4">
    <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c341e687-0cc5-4120-97d0-61d02586ac98">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a070f37-d377-4c9f-91ad-469457bedeb4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba76e665-1cfe-41a2-a55d-8fa85ccf3892"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e596c94f-82fe-4d6f-928b-def952eb29ff"/>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae183ba0-2828-4518-8508-cd64e481082c">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/77bbb0da-9dba-40cf-b18b-f483a03a550b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7e75df5-ea63-44d9-9d59-9deb990b9dc6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/671a2df8-8d98-435e-ad75-a3284f1e6e60"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2bea37c-01fa-49b5-99a4-dde509a77b98">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002902</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
        <rdfs:label>Hyponatremia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/013f6b6b-1492-4274-a378-75bc3fee77b1">
    <dc:identifier>HP:0001640</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
    <rdfs:label>cardiomegaly</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7a643c76-7a31-495c-be03-115fdd2388ab">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a41c8a7f-b60a-49a7-a468-7d4e40f14a33"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31a28101-243b-4aff-9e9c-cb84c426c9ec"/>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47114980-fca1-4ead-8284-307b5f069108">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <dc:identifier>HP:0025547</dc:identifier>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/188f2b33-7e21-4ced-8567-b16baabe4d32"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd416ef0-4fde-43fb-b4c5-9ba38e7a02f0">
        <dc:identifier>HP:0003656</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>abnormal glucocerebroside level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/330d0bb4-ef66-4e70-abcd-c8bf5d1cc986">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7590432-ece5-4760-9522-f31bfac92902"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ed37cde-8e4f-4ac0-a020-6cbcfce47328">
    <rdfs:label>Speech problem</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4441361a-966b-4f9f-8ebf-36048488dedc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66637553-61a2-4efd-a2b6-c332f2343915">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfcb39eb-58fc-4515-90d4-01d07341d1bc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07934d8c-73eb-4064-910c-969a0f41b565"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/135a6093-cfc7-4a37-a07c-ee851e0b7e8f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90d006ef-18e0-4631-8d97-0d0813bc362a"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0003304>G11778A</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d44300c2-7889-4d35-a843-114ffe6d1af6">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>neutropenia</rdfs:label>
    <dc:identifier>HP:0001875</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/573cd4dc-8cca-48e5-adf2-7e49d8190c63">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/da0d6a13-fd17-40b0-ad92-adcb25ee78fb">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56dc4162-eca0-47c4-902c-871c14627909"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ecaa35e6-895c-4ca5-9a00-9ad5d95dd6cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd00eef5-b4bc-4954-9b66-dd1a097afc44"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c17eef7d-a745-4897-93b1-9e15428ea6bf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfc5ea67-787d-42d1-88a9-c507f821584e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e19bbb3-82d6-4ca9-bffc-d1a7cf88e308"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0acb0814-23dc-4337-924f-4219e8e559b4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9e25ac1-a96f-4620-8981-39c84751a1d8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4ddd9f2-3b17-4638-8de2-e334e3d7d482"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32e4844a-4f74-4ecb-951c-4c330292931b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5877a283-483f-4cc0-b617-acae37101dd4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e060a518-a6a2-4277-abf3-d2d25ee9e1c0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/788b079a-7dc0-4a66-a88b-af07729e657d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/679e1a97-8763-47ce-be51-0c66d649bdeb">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8eb566a-5173-48b9-ae11-724684546117">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fat malabsorption</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/827e32bf-84d6-4064-a18f-17cf3bfd3c09"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bec3c482-aa6a-4b34-ba40-07c063672017">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e87d82d4-fbb9-488a-b432-108479f2288d"/>
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b0a99a5-f9ab-437a-9938-26a74bc8b48c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:label>Acidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a53ac49f-5b64-41c5-bce3-c62bd8f1313f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/481dd176-520a-4c5e-b493-2a0881573d15"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf572e57-ce0d-4622-9485-6d1917100ba4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
        <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/780e340a-2ec5-4827-bd9f-d4b5f24b7069"/>
        <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f5b5ac63-3cb4-4407-abc4-1bae4a51acc1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e769d3d9-42ba-4c0a-8ca8-7ac06e25ceec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69ea067b-d9d1-4fd2-ad9a-1d293d07fe09">
        <rdfs:label>constipation</rdfs:label>
        <dc:identifier>HP:0002019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc9dd885-7b35-4297-8c6f-8c9bf8e238b5">
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:label>pyruvic acidemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1a7359c8-f71e-4f52-9887-a29f37aa4484"/>
    <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
    <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9b94e3f6-cab1-409f-a1c0-7a9e596106d9">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87761e2e-c823-43b7-8655-24a17f32f90d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5528b298-c81b-4b5b-bb30-cf8dc0f5a493"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b385034d-f6e2-4bf0-a150-63c5c381b23b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bc9f375-a10d-48c1-9170-40c45276aaf6"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
    <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/310ac723-1421-46c1-bbb0-525b13784332"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f87df335-4a20-4e34-b62f-3c4aca7f471b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>deambulation</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4fd8fece-b6b9-40d0-b94a-6a2bd08bcfc0">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7bdfe97-96b3-4e4a-b0a6-c50feb976ed0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2849b940-cb2d-4918-a4c3-216932c691e0">
        <rdfs:label>gouty arthritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
        <dc:identifier>HP:0001997</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d0f885d-1dd3-4ae8-95e9-6ddf596813c6">
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <rdfs:label>hyperuricemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7042efc5-07ca-438a-b824-4dca85d7b6d7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e7fb6b-d32d-4c26-a959-1bb81081eead"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1903f271-2b82-48d2-898a-2538edeb7be4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8181a2b6-6436-4f84-9d42-4ec2b20aa576">
        <rdfs:label>flavanols</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07254fbf-77d9-4ba5-989c-ba6ee3aa1bf7"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38bde5f4-921f-4e68-9b59-ca6bdd38fc66">
    <dc:identifier>HP:0000010</dc:identifier>
    <rdfs:label>urinary tract infection</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba71be0d-79b1-46c3-8c7c-3ce03641bb99">
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2eaa7d02-9762-4d40-a1ea-e1f8a4441605">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f47ab9b5-c35d-445d-88b1-a676a9d875ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
        <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
        <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a19dd6ad-f1ea-4f38-9b67-71922b7cb864"/>
        <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a9f26e5-6f16-4d02-b795-ce3454b1c045">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>orthostatic hypotension</rdfs:label>
        <dc:identifier>HP:0001278</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95f9aca1-ca64-4725-bea3-2061fe27c7a6">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/90f5e5db-160a-4f57-bfe9-192234171ed5">
        <rdfs:label>Functional intercation ( Mechanistic B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e51e606-2a44-48b9-8988-142cd2f9dff4">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Bacterial glutric acid production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd597f84-3ec9-4534-be36-194ed80c9363"/>
        <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a81571a4-4929-4ec6-8a99-7f041f49e6ba">
        <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
        <dc:identifier>HP:0002013</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
        <dc:identifier>ECO:00007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7f6c646d-e508-4185-b580-ba0e1d56ec5f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edafd2f1-25d9-4f54-9e4c-90f332f6cb7e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb620330-1da2-4464-9b93-762b460f6039"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b511db0-0811-4f57-8448-e3bbadb4ce1c">
        <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <dc:identifier>HP:0001945*</dc:identifier>
        <rdfs:comment>The phenotype has been reported in association to treatment with baclofen as</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3184996e-cf6e-4093-9d01-de56a7f004f7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
    <rdfs:label>motor malperformance</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002275</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a3f69f81-8f2a-49f7-9ff9-4237758826c4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8149888-582d-430d-8153-7dc18c82a908">
        <dc:identifier>HP:0008897</dc:identifier>
        <rdfs:label>Growth impairment</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/75d10995-db10-42f1-9a88-e44a9946d0c7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41290a5a-1158-43ee-87c4-14d478fbb026">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ff7e7f98-6e16-40e8-9d37-e7c9c5aaec9b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78e729df-5b9d-460f-ac6c-6327913d04d2">
        <rdfs:label>cognitive deficits</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/99eaaa1c-d844-4dad-bd9d-d8d5a467887f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9913d785-92eb-401d-aa17-5eebd420e215">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Retinal degeneration</rdfs:label>
        <dc:identifier>HP:0000546</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d48e35fc-0e8b-4666-91fd-9e7c4cdcef75">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
        <dc:identifier>HP:0003434</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4acb9ea2-17ba-4a07-9046-16bec1bace8c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
        <rdfs:label>Central nervous degeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007009</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
        <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/834023fd-d206-47fe-9af3-5bfbc8c12b0e"/>
        <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0891584915002671</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88447146-9290-42e4-9efb-4d40769788ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2f8faf6-aaec-4456-889c-2f08dc8de8f6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d27b3af-1bf2-4709-8e4d-0d4cb40ea0c0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pruritus</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6711055-ae79-40c1-95cd-4e4f4266b21b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc17910f-b30c-4abb-aa17-d852cf073c87"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ebafb4b-343e-4d98-896c-0536bfa1ffcd">
        <rdfs:label>hyperbilirunbinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3182d26-bb04-475d-a744-b624c0897e8c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f853bb4b-c293-4766-ab10-61b4dc43af7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff01196d-fa1a-4aca-9d9b-25d9be336c6e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
        <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
        <dc:identifier>HP:0012202</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f82f95b-de4c-4c93-a55a-d204e26470f5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
        <dc:identifier>HP:0003155</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high serum alkaline phosphatase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62444c9b-282a-455f-b2ff-f419c65265b5"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
        <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/788c170c-0c44-43e3-a0dd-e5b9de247085">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4956dc5-848f-4b75-95ae-79c57a527f03"/>
    <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
    <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
    <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd29449f-86b1-42cb-8a49-6f11f8cb131c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
    <rdfs:label>Low serum testosterone levels</rdfs:label>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:004017</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f68522c1-5461-417d-ba0c-5b02c21a9295">
    <dc:identifier>DB02959</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9d60a1c2-0a00-4abc-94a5-4a498d0704cb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a60c2cf-9aa8-4515-82b4-8ebbed119846"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9842c6d6-1971-457b-9cd9-bbc077e54e4a"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2546b362-45c9-4593-9625-08f453e1e8eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffae1b3e-e3e6-467a-9015-0fbea1464cd3"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d6d8144-5e58-45a1-8d27-6225d152f232"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e799f0a4-7b38-431d-8d12-b44a55f32a99"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Oxitriptan</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/818bfdf3-b261-4cab-82ae-f2174d52f447">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd3bf135-2ba3-411b-ac71-ad7768366e34"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a750532-6796-4cb7-8a94-8f4ef3205672"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/273af10d-e00e-40ec-a105-b0c7899335d7">
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e799f0a4-7b38-431d-8d12-b44a55f32a99"/>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b26e7667-122a-46ed-bcb2-a59dc3a10b23"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/576dca4e-9579-4b7f-becd-4975dbcf216b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>acute congestive heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b05c422-0e12-44bc-9184-03dd94b833de">
    <dc:identifier>CHEBI_26537</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ade9c07b-d272-4353-90af-13bd24bf8814">
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bca2f07-6cf5-4544-8696-292c8b4cfa56"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1dbcab83-61b0-4c8d-8bd9-e401e590d4e0"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
    <rdfs:label>retinoid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8aee9fb1-1133-4d6e-b057-c1d47d1bc34b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c318666-b7f3-4116-8794-2825207342b7">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4b41753-385b-464a-82c6-aa2d6a768886"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7db22083-d62b-49dc-9449-e1d15552ddb8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6c8fd60-0ba7-4c03-a958-17742503540d">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
        <dc:identifier>HP:0000924*</dc:identifier>
        <rdfs:label>pathology in many somatic tissues</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62d18dcb-780a-495e-ba07-953a85df90d3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f46b1be-7c6d-4863-9b21-a3edccf1df0c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/689dc1bf-6763-413b-97c8-71d88e8cceb7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a952d1cf-a330-488c-9430-c34e37d8a4d0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7cd7cbc-4bd2-4725-97ae-e4cb12b27780">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02933213-3feb-45f4-8028-0bbf3a59d6d7"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a05725ee-9f7c-41e0-a211-9b7e29d0d554"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9559855e-02b8-4456-852b-c12d44867af6"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8c97df4-de81-4dcb-9b9d-ada7ff73fcff">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a571cf88-d282-4cec-8fa7-b89a77c7367c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c364e48c-79f1-43c1-985b-5ee891393655">
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/06bc49d3-2f90-47bb-8fcd-3d578ef6be21"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7523c82d-5142-4012-a189-099d6bda55da"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16769aff-7565-4efe-8d5d-ba31e0901993">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/832655f7-ac80-422b-89f4-ed9fb9d0a553"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/206a04b3-cc53-4549-9444-712db02a1470">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f29b74c-86a7-4686-aee4-0f60ec2c62bb"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2128c19b-b28d-4e2c-b94b-3c8919edfd45">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/121af46e-9161-4909-8cd3-9844e9c3c1c4"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58d6b6a0-d77d-4f19-811e-5471b0864342"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17f8841c-9479-44bc-ba47-28fde7a9bd6d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddaeadcc-6db7-4de4-95ec-57370b299c37"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdf29ec9-4056-4460-b4b2-71a48d2e21ba"/>
        <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a4944e4-addc-4c23-84df-1fdea209ebbd"/>
        <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
        <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/723b751e-d7af-41ea-bae8-45d0d91c067c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff3ae28d-6aef-4164-bc55-deac02b43721"/>
        <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
        <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
        <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bc9f375-a10d-48c1-9170-40c45276aaf6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4feb2d46-081d-4511-831f-1084adb78ca5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/496f2ed3-605d-4326-a768-6520e41103ca"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cee8b6-b735-49b7-b607-88be52f791ad"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6933a463-da21-46fa-95c7-02bfe6c725df"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0d2be9d-f438-4cc2-8124-9c4736850860"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e7767b5-663f-4532-ad76-de0073766c5f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ed37cde-8e4f-4ac0-a020-6cbcfce47328"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1030db8-094e-4f07-a1fe-50eb684e7015">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208920"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b219d3d1-7b2c-4ef8-b238-bcbabdc696a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/62efde38-8b77-4ff0-9eb7-ec1cadf32013">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07f8248b-3aae-4939-b09c-498f1f4860cc">
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c636e29-97ca-4dda-bd45-09ce599fc81b"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/513555a9-ba7f-4fef-8802-7ed7f3bcae00"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Ubidecarenone</rdfs:label>
    <dc:identifier>DB09270</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0dabff3d-4ab1-4c4a-beb2-2b79fdb3338e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a070f37-d377-4c9f-91ad-469457bedeb4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b8e7923-68f0-45ef-9a9d-0fc4aba83398">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0011009</dc:identifier>
    <rdfs:label>Acute attack</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f60bce6a-ccd3-45a0-b6a0-75ce3f721d75">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1aad4316-6054-43e7-a804-03181478c53a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1179e7a-9ffe-450e-9abd-8d084873d6ba">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74966456-a48b-4b5a-843d-43a62b1cfdc9"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c557636-8ab4-46d6-98de-38fc2c0e9e14"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2ef1564c-781a-4c09-a4fa-986b8ee5db37">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f87df335-4a20-4e34-b62f-3c4aca7f471b"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11f90c25-f805-43b0-912a-76ee8605e2ee">
        <rdfs:label>Low 5‐MTHF level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe8622fa-222f-41a7-aad4-29732dba1a8e"/>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b446f29e-50f8-4994-b610-97420e2b914b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>White matter alteration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <dc:identifier>HP:0002500</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ecc40647-4fbf-4000-a933-118dc522cb11">
    <dc:identifier>DB00594</dc:identifier>
    <rdfs:label>Amiloride</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69f25729-deca-4317-b9b2-7a9fa898d1fe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/466f7bee-d490-465c-9e62-32ef3af4a847"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b179bee8-f4b5-4f99-9915-baff5b83324d"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a07d6df9-ce5e-44f7-8537-28c44b85a2b2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/099b0e28-fa75-4b93-b3a3-3cd3530fcc0c">
    <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26020857-9014-4c98-b5f1-673a7bfa8414">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
    <dc:identifier>HP:0008765</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>auditory hallucinations</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/261cd740-b486-4d44-bec7-a5278245b8c2">
    <rdfs:label>High serum iron</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
    <dc:identifier>HP:0003452</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08c519ff-9a40-4618-ba5f-233b821783d2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe384f4e-cd79-4c52-9cbb-6c53bee42d92">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2929df0d-a370-427c-808b-f4633442f0aa">
        <dc:identifier>HP:0001635</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>congestive cardiac failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5868116c-f747-48e4-8673-be28e7938bbc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
        <rdfs:label>tachypnea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002789</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60b2e6be-c370-4a87-8d6e-57cfcfee7ab6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1dea9928-68d3-4a73-b9f3-c61d5dc348ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0423948a-63e8-4aaf-a898-147990ce268a"/>
        <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f38d8b57-a0a4-479f-be17-f3d1916e543c"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3725f076-7992-40a5-ba10-52ba50ebe2b3">
    <rdfs:label> Softeners, emollients</rdfs:label>
    <dc:identifier>A06AA</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7a7e16d-ee20-4831-b9fc-3cdc0c9d04a2">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c60ccc82-fba8-4846-9cae-fc1b03fa90c1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/848274c8-1485-4963-b5d5-381415f5586d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc23d225-ae21-495e-a700-faa4b4cf2d9e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9bd4706-beee-469b-a931-528043535f97"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed3d3c84-d84b-4f75-891e-51b5b6a47c52"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e053dac-a343-4bf1-9e74-cb3a9a3850e5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/848274c8-1485-4963-b5d5-381415f5586d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9f37edb-ad99-4a42-a257-5e90111d6be0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8817c366-2167-4eee-8280-f4e491c4d73d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dde37bac-58d7-4e34-9540-d72e1ef5e417"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c60ccc82-fba8-4846-9cae-fc1b03fa90c1"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4b5bd14-516b-45f1-92d1-8964d876d6d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d57d4042-7bc4-4539-a12b-017dd06ec489"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e441fa8c-a6b1-4dda-90cc-3bb1c312b38d"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a2bf7c0-6494-42f5-8c0c-4071531eaa5e">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c190f298-646e-42e7-8866-291579be72e4"/>
        <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81987d81-f7dd-4137-9a53-11aa77836bfc"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29c7eba7-cf37-4dcd-996a-b9f67a204420">
        <dc:identifier>HP:0003546</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <rdfs:label>Exercise intolerance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57be792f-37c7-4b9f-ba3c-7a382f05676a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/384f327c-bbe2-488a-a940-77d98d1d6f67"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b13f50a-667b-4afe-b57c-a4ba8122b6b8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fcf626d-4579-4f61-aba8-846a83724ae2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
    <rdfs:label>Chloroquine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8c4a628-a13a-4ddf-bdf0-98cdd05daf36">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a1100e73-3414-4fd0-903b-b024e11fcd2b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9886b31-b59c-4c0c-b34b-ccdd68f83490"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/832655f7-ac80-422b-89f4-ed9fb9d0a553"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/614dbcf7-f4c7-46f2-8479-783991e83cd1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf6d6cb3-4b13-4696-90d5-19092d8e5a0b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02131381-d6b4-45be-bdc5-e6c53b4a78e6"/>
        <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ba16de3-db71-4b22-9ea2-503aa1a28c6a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1f64353-95fb-427d-9a51-1a78c014171b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <ddiem:failedToContributeToCondition>C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0003304>C282Y/H63D  heterozygosity or compound heterozygosity</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00608</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a42d0636-0798-48bf-b515-86a56356fe16">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:label>Photosenstivity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eacb8d93-0f4e-48aa-9547-b078d1b0a9ed">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a80af979-2a98-4f0a-9a35-08c360909091">
        <dc:identifier>DB00695</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/062b87aa-358e-4cf5-af79-5576af48a9dc"/>
        <rdfs:label>Furosemide</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ea407c5-0927-4972-98d5-58730f7f8788">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd3c991c-e44d-4ad4-873f-c0fb57634b24">
        <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4b936aa-71db-4966-8127-1d5e86199a35">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mislocalization of R8L</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/733ed2a4-cc2f-4644-8106-b6cecc325a96">
        <rdfs:label>Metabolic alkalosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <dc:identifier>HP:0200114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/978524f0-1395-4e35-ab67-7881074be020">
        <rdfs:label>Hypokalemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7866eb17-449a-407f-8d15-91c1e761f4a1"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6e0e0b6-d6d8-4e87-a879-96460dc692f1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f9bb6d0-60ea-4908-866c-aae3eb1035c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/612790f8-cc8a-4700-b6e9-f7cd99636b00">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <dc:identifier>HP:0000407</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d4be59e-6c95-4e55-90d0-4ee3b1acb32c">
        <rdfs:label>ER-associated degradation of R8L</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d404daba-3386-4df6-9b88-8bf8d49c8739">
    <rdfs:label>Mortality</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <dc:identifier>HP:0040006</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4e77ef4-4817-4e52-a9f3-a8c3e456a1d3">
    <rdfs:label>failure-to-thrive</rdfs:label>
    <dc:identifier>HP:0001508</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d47338f-4153-4eac-964f-690714e5f82b">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd5ac0da-9c73-4664-b0b2-6f17cee2a581">
        <rdfs:label>strabismus</rdfs:label>
        <dc:identifier>HP:0000486</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a74a69d-30e6-4262-91ac-ce995ad371df">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17dbf8f9-0494-48e8-b7a8-0cb0db89a2f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
        <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d44d782a-f8f1-4053-9c60-6b3e3626a864"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9a8820f-6867-4191-9f30-097cdee3b59c">
        <dc:identifier>HP:0000565</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
        <rdfs:label>esotropia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e609f1ba-a5f6-4232-9455-600acc5fb9ee">
    <dc:identifier>HP:0002719</dc:identifier>
    <rdfs:label>Recurrent infection</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ccb4c8e-66f0-49cb-9dbd-a3c00269aa36">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5097669a-e1e6-4838-a555-c04ab11ed0b9">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0c92e37-da62-4859-8618-8526879e41c7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1fc8bfd-42a8-4147-bb08-79efb7c0e057"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3020a77e-b6b3-4f3e-a9f8-f41b0f3a776e"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34e46b8f-bf29-46cc-a9ae-2a83b6329880"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0446bca-e24e-4f85-b414-16cc8d68b0cb"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Hydrocortisone</rdfs:label>
    <dc:identifier>DB00741</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eb626643-78dd-4adc-b467-e63d5517c3de">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86c4551d-e5ef-4599-8ec7-c02eaef32484">
        <dc:identifier>HP:0001386</dc:identifier>
        <rdfs:label>swollen joint</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f1127fd-c8e1-4221-8bd1-1e634f8ebc62">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:label>Arthralgia</rdfs:label>
        <dc:identifier>HP:0002829</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06894a87-2ba0-4928-99d8-3779ac65c659">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
        <dc:identifier>HP:0003040</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84cec8bb-9f0b-408a-9dc1-ce2a916612eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0b4f2bc-e6ab-4e85-bc9d-c863c4fd6d30"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/487991fd-fecc-4a8b-97eb-53979bb903d3">
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cb475c0-272a-454f-ae7a-7f5e2df8894a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cf178bb-acb0-4b1b-a318-b7f3d58cf178"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/522f15d0-758a-419c-ace3-3920c1471692">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2751edd7-6c88-496c-96aa-05f25cc5bb24">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4cfddb2-e1d9-4fa1-b0aa-8213a16f3454"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f3b9792-e035-408b-8051-eec04aa166e1">
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/22f73f35-759b-4b70-956d-ffd1f0322e10">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd7370f3-a83a-402f-8fa8-cfcdd3f62d00"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b162a96-bcc7-4627-af3f-e60b02ccbf51">
        <dc:identifier>HP:0000819</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7bf822b4-bb96-4430-b2d9-017cd9ba58c1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1002dc5-68e8-40ec-87f9-3876818808df">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <dc:identifier>HP:0001824</dc:identifier>
        <rdfs:label>Weight loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89e14cde-b42f-4bef-b5a7-0d206d906b4f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8e15b1b-ea6c-4c4a-a271-f160908a2a21">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
        <dc:identifier>HP:0003199</dc:identifier>
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf2fb43b-75da-4e9f-88df-229b3ddaf64a">
        <dc:identifier>HP:0040063</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78bd40d5-6bc1-4447-8aa1-f937a2f5c7f4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Progression-free survival</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/a44ccc1a-ea61-44c1-8fd8-7718d1ddad7e">
        <rdfs:label>Direct interaction (Mechanistis A)&gt;&gt;&gt;Activity modification</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7611ab1-59f3-464b-ac14-58ba7b6b7602">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e16d954f-337b-4e8f-9fa2-28a27132bb16">
        <rdfs:label>Increased plasma CEA</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
        <dc:identifier>HP:0031029</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0b04ddc-cd3b-4512-8c86-e74756b06d20">
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9105992b-8a9b-44af-acdf-b469f9a8f1da">
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0283957-6713-434f-8813-979b630da0c7">
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <dc:identifier>HP:0003528</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c45ad9c-cd16-447b-9ebf-b88834956795"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b30bb01c-ca19-431d-8c6b-4efe4808c0a0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>Pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/990c9cea-9de4-4df3-b0c1-1d2f8dc303e9">
    <rdfs:label>Decreased lung function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0005952</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba76e665-1cfe-41a2-a55d-8fa85ccf3892">
    <rdfs:label>Fenofibrate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/583e5c7d-06a6-4038-af35-4d12298ac9fc">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a070f37-d377-4c9f-91ad-469457bedeb4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/630a16bf-720d-4c7f-a538-9e88f9219858"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dabff3d-4ab1-4c4a-beb2-2b79fdb3338e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <dc:identifier>DB01039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c341e687-0cc5-4120-97d0-61d02586ac98"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ae050b2-d9a0-4d69-baba-5e8c4d2e6523">
    <dc:identifier>HP:0001300</dc:identifier>
    <rdfs:label>parkinsonian symptoms</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c76f4aa-85e2-44bc-a4c4-a716b5f00f4e">
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85c542c8-6c1c-4c27-80c8-8429b22bedd7">
    <dc:identifier>HP:0003119</dc:identifier>
    <rdfs:label>abnormal plasma lipids levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5128cfe-a7ac-426a-aade-d96f2adabbf4">
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/78e4b784-47a5-41b0-a96e-d0d99517f166"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee1d26f3-6989-4f9c-bd45-c0acb08b4bc1">
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f75f376-606b-4969-a2db-ef91d30ba9ba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43a34a61-f5f5-4431-88ab-7029d6e73477"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/027ad5c0-aef4-4e0d-b593-b21edd0d07c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12a205b0-56c9-414c-9d41-9578c008035f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3a17c57-2043-4955-9911-93e789e864f4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <dc:identifier>DB01277</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8acf0fef-628f-4ced-8e0a-956d1852c10b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55ba0edd-7acc-4253-af5b-6ff0cde31a1c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5147c19-505c-4a7a-abd0-8e955eda9330"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aea21e72-62c3-4131-8661-77d3520edac3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0811275c-2c98-4256-9e56-16a9e8fe96ca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b6da577-4d02-4a2f-ada2-d71ec2d6a125"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f87bcf1d-0829-4065-9181-e4eb49881013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29193417-bcd8-4e56-a538-305bcf3b28ab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bea927a9-438a-4d60-9c60-b1cb3224230c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af134d3b-16cb-40c6-bfff-785eafd5f256"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ecccebda-5cab-423b-885f-434ebe8f1db8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62735b54-e884-4f80-b4f0-1387add60cb7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Mecasermin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1e7b0dc-5020-4440-b316-4991caa7260e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e22dff6-7b14-486f-9f1c-26df2863d85e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e28f01e-d830-4b5c-bcf0-396ec99a6294"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/353df1ca-4071-4a6d-9c08-8d799e95c995">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Poor head control</rdfs:label>
        <dc:identifier>HP:0002421</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b22e24a3-5b2a-4d60-9b57-78437ec71d7a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:label>Oculogyric crisis</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0010553</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fe5dcb1-e882-48da-a055-c2f1a8f76911">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baa6c9cc-6bcc-44e8-83ee-31ea74516af6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
        <dc:identifier>HP:0002459</dc:identifier>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9428dfe1-55ca-40a3-9ae3-f330f35d6f33">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Hypotonia</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51ad65a5-8acc-4175-a633-590248a8d254">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a83b0729-6a3d-45ba-ac13-0b8aef1ce841">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e9786e2-fe04-4d8b-8e56-9c9bb2065b5c">
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:label>Abnormal CSF folate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/228f838c-49ab-4d82-8549-050fef4e760f">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
        <dc:identifier>HP:0001980</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c8beb85-1dd2-49e0-9dff-0dee8ca07ad6">
        <dc:identifier>HP:0025454*</dc:identifier>
        <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14362154-2848-48fe-8b75-67f05ba3617e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <dc:identifier>HP:0040087</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Low total RBC folate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0414b3af-fdfc-4e9c-a738-94e9b6589bc6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97c7d5cd-7b82-48d1-839b-2cd81a3c5a64">
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Low 5-MTHF level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b24e6ca2-4c50-4004-b7eb-fa60f1c1f948"/>
    <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
    <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cf10c267-bc97-4a5b-aec6-d2a9acc84352"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0456293d-9c62-44e1-94ed-07ff9683ad14">
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15e9708a-8ffb-46c4-b74f-506c3f53452d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>High serum bilirubin level</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8220606e-e6e5-4f23-bd70-5a9b8a271660">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0833065d-3171-4718-83c9-fa1740308de3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/63be63ad-a56b-424b-9489-cad02b98fdaf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/343be2f8-cba0-4661-ab96-13ae2487d62c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34998226-9f15-4b80-a009-d8252ca8fe14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdec12c4-0d23-4912-a433-59f8f06c6096">
        <dc:identifier>HP:0008282</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b5d4296-6546-495d-a529-38c88663093f">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0008282*</dc:identifier>
        <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc9220c0-dbe1-4f7a-95e1-11b31fed16c6">
        <dc:identifier>HP:0002570</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
        <rdfs:label>increased fecal fat excretion</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fe49400-3e73-4612-ac5a-af317cbf4ff5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
    <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012187</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f90de47b-f971-49dc-bed9-e666b05cc886">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d715a27d-8561-409b-9dbe-bd7255e74fb7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Brain lysosomal storage disease</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d29ffe89-e8f8-4ff3-82de-db9ac0025a18">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e81b078f-e011-468c-8b5d-a36fb12b3c45">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Low expression of AGA enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0eee686-2398-40e2-b252-bf4f0f2ca793">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f17ae95-ff90-4b33-aefc-f3d3b077bfec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac5f52e9-17de-4509-ab0e-494f3c49660d">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c00fd328-c3fb-4423-b4c3-5f92737031f0">
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64">
        <rdfs:label>Hepatomegaly</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002630*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31a28101-243b-4aff-9e9c-cb84c426c9ec"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccc2641b-1725-4088-9930-77d26ceae038">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
        <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
        <dc:identifier>HP:0000841</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3230db4-c700-4fd9-a370-3650cddf5ec5">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/992c4919-b160-4c1c-b337-9c2c45960a66">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001903*</dc:identifier>
        <rdfs:label>primary low heamoglobin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba78a3cc-1d35-4851-8558-34f6a1bf40ac">
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/824fb755-3048-4f46-a463-315843e8ae4c">
        <rdfs:label>splenomegaly</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d22e9b2-5f15-4003-9658-78c3c9393874">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/501a7047-52eb-4724-926e-5e120fa75cc1"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f484622-05ef-4767-afda-b1625dd08563">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/46aba8dd-4029-4d7c-bc07-41bffcb4fd38"/>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfb28466-b11a-4f27-95f8-bebdbe9af80b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
        <dc:identifier>HP:0011923</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d05d348e-189c-4f54-b67c-a22147fc56c7">
        <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
        <dc:identifier>HP:0008347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bade294-b4f6-45b4-83f7-a2e8c621cc02">
        <rdfs:label>PL-induced cytotoxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eefd9131-7c76-4bbf-a0d5-32896250d9eb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Increased ROS production</rdfs:label>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54801ed8-7ed9-46cc-926b-adade0561e92">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6e919a9-8e2b-4fc6-bb8c-c2190575132c"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a7a3722-10c7-4385-b850-4d8ff49d27ec"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd7370f3-a83a-402f-8fa8-cfcdd3f62d00"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7586e4b3-2fe6-411a-a5b7-fdd73dc5f12e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2ae46e9-7a35-4829-b6ad-96d151f54d4d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Impaired social interaction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e18d5669-3cfd-4d0f-b70a-29fc47cb9c0a">
        <rdfs:label>astatic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
        <dc:identifier>HP:0010819</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bf3eec1-0b28-4ea6-9344-50637c052eb4">
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Movement disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e11e8506-789f-4288-95a6-88da9b3187d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>Myoclonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613068"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e35668-ff0e-44fb-b5ab-22c2470acd5a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/286d184c-7fe2-48b0-866d-e382c191c95f">
    <dc:identifier>DB00321</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57cb0db2-b93c-401f-a6b0-3d84637f4d5b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
    <rdfs:label>Amitriptyline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/501f93ab-8e95-4fd1-898f-793fc48eb575">
    <rdfs:label>Biotin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c10d7a7-ace9-4cbf-90db-99d7c010b97c">
        <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bfeb1a4-bff5-464c-abb1-7abe6543e15a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10bd68ea-2787-4ab4-833a-09610155f737"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/363920b5-1ac5-40f5-afd6-c7426cb54166"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8defb044-6246-4f54-8c63-6922a95729af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/91c2a0e3-f78f-48c9-857a-656b6d8841f5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8defb044-6246-4f54-8c63-6922a95729af"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e35668-ff0e-44fb-b5ab-22c2470acd5a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3961ab74-d7f0-4fb3-ba5d-a32a042122b0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41194f20-dcba-42df-bf73-c1c61cb142e6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8defb044-6246-4f54-8c63-6922a95729af"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00121</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cffcf57e-9cfe-4163-9ced-d9cc736d88bb">
    <rdfs:label>brain ventricular dilatation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0002119</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/df12d611-a087-455b-b820-0554ee370665">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62ce1705-c7e7-4197-b423-006d5db332c0">
        <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
        <dc:identifier>HP:0003679</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f251a2e-9545-4efa-9374-af3e6c4b1808">
        <dc:identifier>HP:0031544</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <rdfs:label>High blood malonylcarnitine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e9c1db9-401c-4323-8616-39657f60dc74">
        <rdfs:label>Failurre to thrive</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f1eae83-4464-4bec-9ee8-a71d20ec55e9">
        <rdfs:label>Low endurance</rdfs:label>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea5e0423-17c1-4d99-8c77-c2dfeb053151">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d190b338-104e-409b-a525-f643ae885538"/>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb58e8a1-afb0-4010-8feb-3b57b0ac1759"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1608293-1aa7-4018-b327-f538548d5cf9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/385e70b5-f33b-4846-a28f-bbe8f75273d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/630bcce4-8efb-4ae3-8cf6-5b5421b0318f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca05a0a4-f990-409f-bd4b-f4b60acedc44"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dee6e873-97d2-411d-9b9d-0acf5e5ff644">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
        <rdfs:label>Diabetic polyneuropathy</rdfs:label>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <dc:identifier>HP:0001271</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/451f02ce-ef9f-438f-95cd-308038626a12">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c045b948-8a4a-4123-9f97-b19447fcc448">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurological damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
        <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2f91d088-4668-45b6-8cf6-34355fb343f7"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9ed668c-fc3a-46bd-9493-e4f9f33915f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/65fe98a9-966b-4299-90cc-56270af79338">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d51a53e-c2df-4d6b-9836-1ec72a71ebd9">
        <dc:identifier>HP:0011123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:label>Dermatitis</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3b7df5c-6ae0-424b-a5e4-587df22f6154">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18ae7761-29b1-4ba8-b68e-c786f60c5277"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc30a970-5ec9-47fe-9a70-3cf0477f0e63">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pseudoexon activation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ffbba9f-698a-49c4-a82f-b5a7582275e3">
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b30bb01c-ca19-431d-8c6b-4efe4808c0a0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/962ede59-d46b-4942-87a1-1fb3f6545627">
        <dc:identifier>HP:0001945</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Fever</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f604c7d-982d-4366-9abd-d603fbf92200">
        <dc:identifier>HP:0001945</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:label>Oral ulceration</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a06a2905-176e-49b7-a6e3-1d2e86a2db05">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d66dbb29-ec24-4409-a207-56883f080747"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ef650f8-a5b3-4721-b1ab-009f5a2ac5a2">
        <dc:identifier>HP:0012649</dc:identifier>
        <rdfs:label>Inflammation</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fbe7264e-6f1a-481e-b993-208f44cd6bf8"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cee8b6-b735-49b7-b607-88be52f791ad"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e31ba36-7ba1-4264-9de0-3c58277c32c7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/860b35d9-3c0d-403b-bfeb-1ec5c140c499">
        <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c7fcdba-a839-44bf-b66d-e8e64d6ad3ce"/>
        <dc:identifier>A11EB</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28acc487-b711-478a-83fe-11b260e3abd0">
    <dc:identifier>DB05386</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21af1fb1-8906-4944-a377-1cac17b1b0b4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22328166-38c4-48a5-ad95-4f18a089b9ba"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202959df-faa9-4092-b4c1-dc5e712a7645"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ae89f49-3b83-40e7-84b8-444cd4c108b7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <rdfs:label>Regramostim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1087d67e-c1b7-47cf-9bc4-d0afac01c5c4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
    <dc:identifier>HP:0012758</dc:identifier>
    <rdfs:label>neurodevelopmental delay</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fa125ff-cdaf-4102-9059-37771626a446">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9e5383e3-c20b-4994-a658-862b14ac20ca">
        <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52f16157-a792-4bcc-a286-d802f7ff664a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82f7ea61-5a63-4e55-80e3-b05dad441491"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a61f5b31-e374-47fb-8d35-b14c909382c3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00123</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d00b08fc-2034-4823-97d0-e11603cd6d1c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52f16157-a792-4bcc-a286-d802f7ff664a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f484f26-ca66-482d-88af-f3999ab3c38f"/>
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>L-Lysine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93860759-4365-4b8c-8cad-7935770cf612">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af25a28a-3cd1-4450-ac84-3e3973e8ff5a"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e67184bb-0021-4d94-8e09-b6ca48ebf7a6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a01e3fb-c5cc-457e-ab51-b171b98ca46a"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f484f26-ca66-482d-88af-f3999ab3c38f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea86426b-5633-4a56-bb8a-d1660112cd2b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ccd27b8-2974-40a1-a513-4ddf6530b10e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c79e55b5-f1b7-44a4-8432-e529a28a0d6d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd468ddb-7103-44a2-8931-02a29a23237a">
        <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
        <dc:identifier>HP:0031951</dc:identifier>
        <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b25fbb71-9f92-432b-9c27-85be69eee181">
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44a73a99-e538-46c2-8037-e0f1dfd24d93">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>defected excertion of 3- MCG</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
    <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/855a0db5-766c-4246-84d2-6ff812a979bc"/>
    <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f55f2a7-1db1-4490-8cd4-5ba962bf2d26">
    <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af60ad1a-7997-4245-87dd-e779362477da">
    <dc:identifier>HP:0012759*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Low developmental score</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8e827c8-69d5-4626-88ab-77b1a72b9056">
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Abnormal mental status</rdfs:label>
    <dc:identifier>HP:0100543</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5f98d29-2ae5-4509-82b5-b405eba66203">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5aa1e0fb-59e6-4ba8-a520-0d940ce918e2"/>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45ed5c59-27de-4f82-877f-582744bd0aa9">
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:label>Low myocardial function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43288620-a88b-481d-bd46-db27428cf791">
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:label>hyperuricaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c0862c81-88a1-4248-988c-cda180095e41">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f64a3ca-8c57-4a2c-bb3b-92e1c41045f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39790884-2461-45ca-a210-fbf3075caf07">
        <dc:identifier>HP:0005135</dc:identifier>
        <rdfs:label>T wave abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51756e88-4576-4d8c-b7ba-b1e77abbebec">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed Growth</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6298bf2a-b40e-43eb-a5c7-6ee514e033c6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neutropenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca4db41f-6dba-4d1e-bf98-27a3c81770a3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
        <rdfs:label>hypocholesterolaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003146</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e07cc79-7fac-4998-9920-9eb217e3495c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
    <dc:identifier>HP:0000164</dc:identifier>
    <rdfs:label>Dental Defects</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1ebe3a1-f0c3-4530-9232-e49e9284545f">
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c22d873d-586e-4be9-a2d0-2a9456c98011">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f90c82ee-8cd8-4916-a538-0e939f6c417e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53621ab4-4b97-4fdb-8ba5-052e37becdea"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00688</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e208b472-b35e-48a1-b851-5b51150cc7e6">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/703a8835-1417-4017-8834-da42b09f5e50">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61b5fbce-d459-4407-a7f4-8e06bd04e4eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfaf29cf-df43-4ef8-879b-523ec10e0573">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
    <rdfs:label>schizophrenia</rdfs:label>
    <dc:identifier>HP:0100753</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc464821-d0ef-4b5f-93a9-be77bb50f3e8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Salt wasting</rdfs:label>
    <dc:identifier>HP:0000127</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54a526a9-07d3-4265-9a14-a16d8c9cb8fa">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/060f6eab-1c9b-4450-b892-fe4d8002f139">
        <rdfs:label>Methylcobalamin</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b97393d2-a1dd-4a03-9dd7-f77436979d72"/>
        <dc:identifier>DB03614</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3556e1fb-891a-4bcf-a118-01770c5308cc">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/721d8be2-79f5-45e2-92a7-88c3c77a30d1"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a74a69d-30e6-4262-91ac-ce995ad371df"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9384cd2c-ca86-40d9-ba13-2f5578a19bf8">
        <rdfs:label>abnormal muscular co-contraction</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/135a6093-cfc7-4a37-a07c-ee851e0b7e8f">
    <rdfs:label>Functional interaction(Mechinistic B)</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/927fd94d-0361-48a5-af90-3e4e3cf67644">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e702c7e1-a149-4216-8ae9-392835c177fd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e1afade6-0c62-4f73-a7ef-73351e1adde4"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee9d3ddd-cefb-460a-892c-d64a835e541b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6ddc6eb-6082-4880-a117-dd13c8d3eeba">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/968f738f-dd33-4b07-9063-a9d641b0e941"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73a666df-e030-4cc5-95b1-83eec04e022d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
        <rdfs:label>Involuntary movement</rdfs:label>
        <dc:identifier>HP:0004305</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72e82757-9232-4ee1-9c13-20642fb649a4">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32c752ec-a03d-4cad-b0cd-be32aec48012">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2fe98491-d858-4ee2-97fd-9ef4c93e8390"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5117547a-5a0f-4f78-8cc2-235818387feb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5228076a-bc72-4012-81ce-89b210a91dfb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
    <dc:identifier>H02</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/938999ba-7585-459a-aaa7-e86759a7eb62">
    <rdfs:label>Low weight</rdfs:label>
    <dc:identifier>HP:0004325</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/790a4a29-ee5b-43f0-96e9-384ffce727cf">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8e2984b-5b41-42bb-8c00-74755e9c24ec">
        <dc:identifier>HP:0200125</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10e4d739-7dfd-42a4-85af-167bc2b1fdd9">
        <rdfs:label>High serum GDF15 level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acbc18a9-5f28-47d1-bc1f-37b684241dd9">
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22a67bac-9f32-4c77-84c4-db5d52959301">
        <dc:identifier>HP:0002151</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
        <rdfs:label>Elevated serum lactate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92b029ee-d2e4-4a2c-af0d-b7543c435209"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2be704aa-a220-4d2d-a44b-2b0c769bd8a6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16bc5c22-d054-466a-a8f5-7c103dc15d97">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3182d26-bb04-475d-a744-b624c0897e8c"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dd5ee97-6cb3-4a55-9444-f95ad90a4075"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c24e2a39-cca1-4446-9f46-ca8fab90fddc">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/39730b6e-85be-40d3-b624-a33564f01abf"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aab831e6-5ace-4783-8131-6c35486ccb3e">
        <rdfs:label>Abnormality of the nervous system</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/270a1177-14e9-425c-b2c3-1483ba9fa450">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1702a0f5-af6a-40d6-9b95-e5124dbeb719"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/995c2dee-3880-4558-a368-12d6a01aff2d">
    <dc:identifier>HP:0000819</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <rdfs:label>Diabetes mellitus</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ab4308a-385a-4f0c-8d80-3fdddb85d88a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5df2783-ff62-446d-a814-be939e5a6d4e"/>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3b19bab-c631-414d-8354-26a5d8ca646e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000867</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
        <rdfs:label>secondary hyperparathyrodism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27f3b09c-2dee-46ca-9119-fb555780a457">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e60a2eb1-b2c4-4062-9d1f-33223f5d3f2a"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f996b6ed-a5bd-4da0-b1dd-1e79ea0df1d9">
        <dc:identifier>HP:0011925</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f2649810-45b5-4421-9d59-4a221e8abe41">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f804977-6536-4047-9661-6cf2a1c15797">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88106314-b868-4b45-b719-46b29bae0b12"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/500e46a0-e4c4-4e02-af81-5b441245662f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6e7d522b-9ea7-4a8e-a293-8e90ec3c12ba"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00169</dc:identifier>
    <rdfs:label>Cholecalciferol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1b41297-14b5-4bff-8778-743c6d419a98">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/42eecd84-129f-4955-8936-d3e3a3256f15">
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b82cebf4-cf29-4169-9678-9469fa4867cc"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb11f77f-9633-46ad-b2d3-d6dac8a60167"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>purified recombinant human -GalWT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a01e3fb-c5cc-457e-ab51-b171b98ca46a">
    <rdfs:label>intracellular defect of arginine</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bc202c2e-a4bb-44e4-bf36-ea32027829e2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8da064a-40e2-4a26-8aee-db05feeb039d">
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0100513*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e100207b-0b08-4de9-9499-a75bbd8f289b"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/888ee92c-dbb0-4553-9f96-1634dfff8728">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalitis</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/354a137c-966f-4f68-a7a0-0bd6dea0f0bd">
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef9ea9ee-2331-41fd-9ad9-1269e32cf96d"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a5e5378b-52c3-41f0-950d-5eb4424706d6">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73741e0a-4c53-429d-b7d0-8d9ec33e98c8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d35e16a3-42ef-43c4-a7c2-14760e27fe8a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f758dd65-7c8b-4a42-9ed0-9c95ffd9a187"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53134350-d979-48e9-965a-ebe3e6a95152"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>mitochonic acid 5</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/016d4451-daaa-45cc-8c5e-80e891b61a64">
    <rdfs:label>retinal dystrophy</rdfs:label>
    <dc:identifier>HP:0000556</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb76efb9-1a5b-46af-87f6-6659e2aae056">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/855a0db5-766c-4246-84d2-6ff812a979bc"/>
        <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
        <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d4def10-e870-4340-8e2b-ae37f5912084">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5d804cc-09d5-44a3-b667-3ceeda2fef26"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f1b1ed3-942f-4c78-bac4-31aac0054958">
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/462b21b9-6bae-4da9-aee6-14ac996b433e">
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Neurodegeneration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9dec9c7-1584-4832-9022-13a5bfd310b3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43911890-8802-40c0-986f-926810553d3f"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdeebd93-1902-4051-821c-9a904b5670bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:label>waxy scaling plaques</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3125b6fc-e1f2-43de-a7cf-176c68f9235d">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
        <rdfs:label>inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001845</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da70d5e7-0a44-4bbc-bf95-5db0480855bd">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ea0f5a1-b332-4dee-bc5c-adff9f0d0003">
        <rdfs:label>skin thickening</rdfs:label>
        <dc:identifier>HP:0100725</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3c39c8e-9047-485d-bcd4-f091a28c9d36">
        <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a6be55c-d881-4c6e-91bf-9d0d36ae24e4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26681d9f-8b2c-4f9a-8a9b-1cbd7823f925">
        <dc:identifier>DB00404</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
        <rdfs:label>Alprazolam</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f876ed4c-1628-4238-aa99-f386bb0ab3bc"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a94df39-39c0-46e6-a51d-bd96cfd2efc6">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f876ed4c-1628-4238-aa99-f386bb0ab3bc"/>
        <rdfs:label>Diazepam</rdfs:label>
        <dc:identifier>DB00829</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/950c3391-dff8-4e25-b162-1ce3a2a6017f">
    <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
    <dc:identifier>HP:0003676</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7edc0dad-712b-4115-be7f-391af5bae7a3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b91a1f52-0b6d-4ef4-b141-e90f5fd10b4d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d1eb83a-70b1-48c4-8d47-48bf3e3a2fe8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78bd40d5-6bc1-4447-8aa1-f937a2f5c7f4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/43537de3-3910-4626-8c60-f0b227216904">
        <rdfs:label>Direct interaction (Mechanistis A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a6e768b-37ab-4505-8b3f-e8916d1edcb7">
        <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
        <dc:identifier>MP:    ....</dc:identifier>
        <rdfs:label>overall survival( premature death)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f328d23-e220-49e9-a94d-9ee2f675d1e6">
        <rdfs:label>phospholylation of RET</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/899094ce-f524-4998-82db-35af197b4a2a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/616392e7-20f3-4d9d-a8fc-422999e5f4cd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00aff911-be35-4a35-bcd5-1b4822795805">
        <rdfs:label>Low tumor response rate</rdfs:label>
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0283957-6713-434f-8813-979b630da0c7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c670b535-9706-4d71-b881-dc488ca75711">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad9d29ff-882a-43cb-a21e-0d9f793c9aea"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1994be68-ec7b-4720-baf3-1bd58b34c919">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/118e7baf-0387-424f-9738-d140462ce689"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/616deabd-5e63-47a8-a9d8-cda54d331609"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad818b91-31cb-477a-aaea-e9223a44d54f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e42fcd2-2659-4501-b314-1bd0c265efb1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc4717f1-b41c-499f-9ea8-89dd6b1b2628"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fff8b107-bf75-413f-81a8-08f20603db07"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd0ecf30-f7dc-4dd4-a342-ad3c7929379a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08fcd069-d2bb-48cc-942e-829e2295729b">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
        <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/616deabd-5e63-47a8-a9d8-cda54d331609"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee6ad6a6-ff1c-4922-921e-0d5c80df982f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
    <dc:identifier>DB01076</dc:identifier>
    <rdfs:label>Atorvastatin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe6a0265-afc3-49d9-a7e9-71d887e797cf">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98cdae13-37ee-4da2-ba3a-77f3cf878803"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6642369-4491-4a88-9224-e22c99f81f7c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8b3662f-f74c-4877-8d44-b1e8216f356e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8db24bb7-330d-4d7a-8aba-d92431c6e515">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cae401f-bee7-4dd1-83bb-897de04a536e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fe49400-3e73-4612-ac5a-af317cbf4ff5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5bd0a1c-7880-4495-ad7d-c8ec24d6ef84">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d07e994-e1c5-4d77-a017-9143d36d29fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08e75cc4-dc35-4204-9f3a-6220d796e9cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/89b119ad-4494-4438-82c7-5e88b8c42899">
        <rdfs:label>Direct Interaction ( Mechanistic A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/832655f7-ac80-422b-89f4-ed9fb9d0a553"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c784c32-25fb-4aa9-a2b6-5a8249b0a25d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>hypertriglycemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/cholesteryl-ester-storage-disease</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2d65b44-2a9a-474a-a69c-73fd4aae4a41"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47d87604-2dfe-40d5-892c-543165c6deea">
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003107</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13e18586-3d83-4d67-9880-0918b469fc4b">
    <dc:identifier>HP:0002069</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2a55d33-d0bb-4757-9803-d987d98a6119">
    <dc:identifier>HP:0012656</dc:identifier>
    <rdfs:label>Low dopamine level</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05a45cb5-7a01-4c19-a1e4-1013db8c4018">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/047e6370-d6c5-41c0-8497-353a0243203c"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04f2425a-463e-4492-9fb2-77be8a76e401"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9e9cd99-412f-44cd-84ee-58582133a72b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e2cc1bf-fb4e-4942-a80a-b8d16d95555e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c84f4b9-9a4a-4779-b618-8f70ddfc3f83">
        <rdfs:label>hypersomnolence</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <dc:identifier>HP:0100786</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc49dc4f-ad8f-41c1-bb06-6a864876b0ff">
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>excessive adventitious movements</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f92a3ab-95ea-4ab1-9bbe-236723f9b575">
        <dc:identifier>HP:0002329</dc:identifier>
        <rdfs:label>unalertness</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bfeb1a4-bff5-464c-abb1-7abe6543e15a">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>EEG abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e702c7e1-a149-4216-8ae9-392835c177fd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d8eb2f1-d022-4267-b7d5-a273f0f35f9c">
        <dc:identifier>HP:0000657</dc:identifier>
        <rdfs:label>Oculomotor apraxia</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76d9a712-1929-4776-9b88-dd4618133737">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bce223f8-4234-42f8-911d-99f64d3477a4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17db5bc6-5b58-4a14-841e-e2ad23dfb6e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69d3cb4b-33ce-4ee9-bee6-387aeb1b5f41"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e11e8506-789f-4288-95a6-88da9b3187d9"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a4944e4-addc-4c23-84df-1fdea209ebbd">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001337</dc:identifier>
    <rdfs:label>tremor</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c5f87ba-3633-4b35-b5d2-007b3b87409d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ef4a14f-0e13-4e54-9c5e-882d3e8339b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/102ce6ff-adbe-46fd-a6e3-6e3bb64fb142"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d250ec79-a91b-4d22-bbdd-c2cdf3af63ee">
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6efa5999-dc67-465a-871c-0c79bad3e028">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b7a3ddd-b229-4f50-8d5b-76a6eb783383"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a7f9472-1de5-46e6-8637-afe7ecadda04"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cca49989-ef0a-402b-b56c-bb2c830d1328">
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:label>Delayed motor milestone</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f79fb67c-2a5e-4047-b1e2-bfb6dfa7901b">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/acbe7a71-c7c6-4047-8092-d44961fb4c01">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbec6364-2abf-4001-a533-538d2644494c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd3bf135-2ba3-411b-ac71-ad7768366e34">
        <rdfs:label>Depression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efbacaef-e06c-447c-803b-5fd7b095c4c7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fba9330a-65a3-4252-9f82-d7e5404a3b62">
        <rdfs:label>Ployuria</rdfs:label>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83fa51dc-4552-4aa6-9628-34b39f1c264e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22191344-f5bc-436b-98db-37e85afeee0c">
        <rdfs:label>Hyposthenuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
        <dc:identifier>HP:0003158</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4748622c-7197-495e-8f4f-713a47c51bd8">
    <rdfs:label>Jaundice</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
    <dc:identifier>HP:0000952</dc:identifier>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d184d1bc-ad5b-456f-8630-1a60ebeed2d3">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f79e645b-25cf-43db-ab67-5bc1176dca5d"/>
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07aea979-a697-41e3-a68a-c092823caa6c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c75bc6ab-41b1-4ed1-a868-fce709f5d350">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
    <rdfs:label>Exercise-induced myalgia</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0003738</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/25b61c9d-d43c-4f41-839f-7fb990c0d7b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2728d31-78d4-46ca-a9e3-530655e13300">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>cognitive impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66a4f26f-e331-439b-992b-c530cbea5c4e">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>cardiac dysfunction</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
        <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/45af2b4a-185e-40fe-ba18-14060b0939b8"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeb56446-edf2-4a70-8970-24b3f36b3693">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
        <rdfs:label>fasting ketogenesis</rdfs:label>
        <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7013e6e6-1b28-4f01-a82b-f0bf46fde4c4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd0ecf30-f7dc-4dd4-a342-ad3c7929379a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <dc:identifier>HP:0003124</dc:identifier>
    <rdfs:label>High serum total cholesterol</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/47e2f0d0-967a-4566-8118-5fa56fbfcc8f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee37232e-3629-49df-ad43-331752a246be">
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e08bd3d-8753-4230-9348-8cf6b48a3d23">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/32e98999-6217-41a9-9c83-6569f5d1f9dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/03a1ffae-9d97-4a37-af68-018217c81796"/>
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1841706e-5473-4478-9346-011942fdee74">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78f6b395-a3da-4f7f-ad5e-cb4ed9585768">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/daad40fd-d737-448d-84a2-7d8f29d9633a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/995c2dee-3880-4558-a368-12d6a01aff2d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d8a24ba-a015-4a9c-bec7-d7fdcba7ed83"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/80ff69f9-330e-4ae7-8cec-200e09cd9a85">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
    <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
    <rdfs:label>CYSTATHIONINURIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56d4bd28-691e-4f71-9685-f14bfcaf0ce1"/>
    <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b62b74fd-8351-4201-994c-54d5696cfb8e">
    <rdfs:label>gait abnormality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0001288</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05252866-f210-488b-b910-c8828fb09262">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0ff87e1-7015-4315-b889-7d6b1dd2737d">
        <rdfs:label>depletion of cerebral folate</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <dc:identifier>HP:0012446</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d771e8ac-6101-4b2f-b67c-52b8bd467691"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0aba5e67-2b20-42f4-87d1-b0710558b150">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
        <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
        <dc:identifier>HP:0012335</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
    <dc:identifier>ECO:0005242</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
  </ddiem:Evidence>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62735b54-e884-4f80-b4f0-1387add60cb7">
    <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
    <dc:identifier>HP:0031034</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46018fa7-f853-4fc1-a16a-7c89ad27f155">
    <dc:identifier>DB09105</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29f53f88-990e-4056-9db1-ff745832c135">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e90ca154-9c08-46bd-8e2f-7116b3efc2bc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19a0637e-950b-4d7d-9a0d-a94a2eac41bb"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
        <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2728d31-78d4-46ca-a9e3-530655e13300"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c537ed0d-a654-4110-8fe8-0940a8f1f212"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ab3206c-b382-4713-a6ba-e23597594245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea120e83-cc95-4c2f-9664-01815df9a633"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7e9e287-6b94-4d0c-9021-b2f91c4f815e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62318890-7395-41c8-99fe-5bf1d3646fd1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d7e870c-6a03-45e8-8cd3-5636d1ceb6f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a9f8929-e421-4748-b949-ae7c8f89c1ee"/>
        <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2716d27a-cb3a-468f-92e5-b0b2141f9cae"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7681a435-5661-4b73-82a6-2ee72588ab73"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Asfotase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad26df0d-4eb3-43b3-b545-26a2bdee8678">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/388e1c4b-ce16-4f14-9df7-b223909d2940"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7681a435-5661-4b73-82a6-2ee72588ab73"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08e6343d-ae9b-4cee-a92c-93f6a26c4dcc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4e77ef4-4817-4e52-a9f3-a8c3e456a1d3"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68878919-b73f-4d18-897f-4bb6098e4415"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e07cc79-7fac-4998-9920-9eb217e3495c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a79ea345-0e2a-4d2b-a1db-8426f94103fd">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24c4b84e-0c17-4c76-ae40-95a9c1a0ed26">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7cf618c-bb4c-4655-85db-93313b988531"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51ac32c1-b15f-407e-85ed-3aea4c6e755a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6cbfbee-7994-4308-81e4-3ade1abff890"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0340fb63-4a9c-4e19-8638-bba89b12984e"/>
        <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
    <rdfs:label>Prednisolone</rdfs:label>
    <dc:identifier>DB00860</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1971eaf0-feb0-4692-9b28-b2bd258eb433"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d56997f4-9954-419b-91a3-56bfd9f241c2">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f45e76fa-a8a5-4a94-98c0-fa0706f806a1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7cf618c-bb4c-4655-85db-93313b988531"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e688e7be-3e87-416a-aaba-a23f8a7c676b">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/330d0bb4-ef66-4e70-abcd-c8bf5d1cc986"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4510b6f6-93e8-4bba-adc3-2400709c9133">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c64de613-b0db-445a-91bc-c9b2f94793b6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aaa973f1-ed17-4bae-81a8-62662803d7c0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51675609-660b-41a9-9007-077d5cbcae8a"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fcc1e4e6-20cc-42a3-b1bf-c74dc08c6400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6fd57cad-a1e0-4b52-96e2-1875700f7e95">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc741eac-8119-4577-aa3a-1cafbfa2548c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9dc16b1-2d24-44f6-aa4f-d6339a0b9587">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
    <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
    <dc:identifier>HP:0004732</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7ce2a9bc-7ebe-4b00-972a-2650b65a12c6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
        <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1938f80f-ff9f-4062-b517-78627165ef23"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf72bc11-095b-4694-a8e2-b3efa7f66e7e">
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7450109f-4adc-4f6a-8605-1e1f449b3224">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
        <dc:identifier>HP:0030532</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/571621ff-2090-4064-9a91-949d146d72a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17e9173b-a355-4e80-a620-502996bad47d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c2d295c3-3721-477b-83b2-63d1732805fe">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7faa8557-5fe7-4334-a4a1-5993b04ba883">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
        <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
        <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
        <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c7138af6-b1c0-47e9-af9f-3c8aeebf60c5"/>
        <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f73e461-bbda-46ef-82fa-f181a6d776ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f79679b-666f-480e-bbfc-abe08b834162"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c591a1ca-a039-4148-9670-7f3cb547d675">
    <rdfs:label>Benzbromarone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <dc:identifier>DB12319</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c198056-3a51-42a3-bbcc-c20f857ef429">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77d73f13-24e7-4254-8e47-39765d3b2b27"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/384f327c-bbe2-488a-a940-77d98d1d6f67"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7bdfe97-96b3-4e4a-b0a6-c50feb976ed0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31e2dbc7-19f1-4960-8c93-6ba9467f6ec5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low pancreatic zymogens</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2658f70b-22f9-40a7-96f0-2f0b5eb36319">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/473c7857-c4c4-4885-b08b-7e65b27e2423">
        <dc:identifier>HP:0002344</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <rdfs:label>progression of neurodegeneration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd7370f3-a83a-402f-8fa8-cfcdd3f62d00"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/80634b18-afdc-43e5-b7a2-d60c4eb9ae2c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/864c1582-52b4-47f2-8038-735d16ff9c9d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defect in skeletal mineralization</rdfs:label>
        <dc:identifier>HP:0006462</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/135a6093-cfc7-4a37-a07c-ee851e0b7e8f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e6cc028-cb4b-4978-9dae-1d09024468a0">
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
        <dc:identifier>HP:0003239</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/954946f3-e667-40da-ae04-b2efd83e37f0">
        <rdfs:label>mobility problems</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001376</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <dc:provenance>https://academic.oup.com/jcem/article/95/12/5174/2835157</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ca19481-2f28-4eda-9a06-f933f82c7cd9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <dc:identifier>HP:0001832</dc:identifier>
        <rdfs:label>metatarsal stress fractures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00198-015-3272-1</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/689dfb0c-b793-449f-a87a-bc1459b9c084">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6fbb43c7-c4be-4630-a962-ab8c36fb21ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/034866b4-66b0-4017-8ab6-b409e13588d0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
        <dc:identifier>HP:0100036</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/498b4608-a558-43b7-8394-91a88446e7c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High bone turnover markers</rdfs:label>
        <dc:identifier>HP:0003260*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b30bb01c-ca19-431d-8c6b-4efe4808c0a0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04dac68e-19f0-4f22-8c13-0fa4ce75c552">
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
        <dc:identifier>HP:0002756*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52b72614-bd5e-424e-9215-83a8c3a2ce5d">
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f84f01bb-37b1-49c6-8c1f-ec5513079034">
    <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8bd1863-97f4-400e-8846-42b1feff1b02">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0011227</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
    <rdfs:label>Elevated C-reactive protein</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a88b218-e141-415a-be6a-59fa2672f0a4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e7bf4a6-f36e-44ac-9e04-46ec34fcd993">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>myoclonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db42f61a-fca6-4989-afb7-fd4d2db39dde">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8b0adc4-3309-4fca-a982-c70650c73739"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6892d187-710f-4d07-8ea8-48ddb591b7aa"/>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4ba795c-b075-4c2b-b859-c09fd4e888cc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Diminished intellectual abilities</rdfs:label>
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f7ceceb-6d2e-444b-a381-942eb62d7c2f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:label>inability to walk</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43ce16bc-d293-4f4a-8b38-dc0958e707ec"/>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc35ab5a-bed5-4b95-b464-5f38c5c56e5c">
    <dc:identifier>DB13245</dc:identifier>
    <rdfs:label>Thiram</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bcd307de-8a68-4cfe-a5a2-3bf1d9ce917f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c76f4aa-85e2-44bc-a4c4-a716b5f00f4e"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/baca6bac-a0ac-409b-a249-fdf1b91c94cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3325c26-5ce7-4609-9155-01ab6591572b"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2748fed4-6a26-4787-b36d-9822e50aabe3"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
        <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/027ad5c0-aef4-4e0d-b593-b21edd0d07c1"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd60e879-4154-406d-9bbf-53d9ce3426c6">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cee8b6-b735-49b7-b607-88be52f791ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a05ebb8d-8c6b-48ba-a416-54005ea753e9">
        <rdfs:label>Myalgia</rdfs:label>
        <dc:identifier>HP:0003326</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32312dee-8af4-4fef-9fba-3109a858775c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f735d3e-e779-4a60-9b9f-cca9a810ad6b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>Abnormal cardiac function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab014fcf-6d3c-4c09-baea-0e5b49c90ac1">
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3e5c95e-33b1-4ef5-82c0-8d55f6245650">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4923d94d-61f9-4863-986b-0aa7b2584b2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcf69254-e433-44f7-baaa-e259b26f4f8d">
        <dc:identifier>HP:0001941*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidotic crises</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71e3b855-bc2c-4422-9abb-95a3bbb5c3ab">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low COX content and activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3fc69a73-128a-4dcb-9eb7-0acce3c7d48d">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5734042f-c5d3-4c97-9e79-312ddcf6e80a">
        <dc:identifier>HP:0001954</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Periodic fever</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43911890-8802-40c0-986f-926810553d3f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8447f94c-a38b-4f2c-b09c-2bbc91a3a4bd">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/16c606d6-144e-4b1d-8d0a-80a7115e27bd">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610198"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eacb8d93-0f4e-48aa-9547-b078d1b0a9ed"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a08511c5-8804-43f8-bb35-2413dd68614e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe9259a5-581f-4570-93e6-83dedb658601"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31fcf179-bf75-47a8-a7e4-67cda339b0d0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>C09C</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab9a3e49-abe4-4fad-832c-01ee8db452d1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e7d30fc-2f03-4ee7-aca9-d32961fd3c9d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe9259a5-581f-4570-93e6-83dedb658601"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
        <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e3999c4-70d9-4df8-b0e7-2f4ef8b471d7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04c4dcb0-2c5e-44c7-bd10-a33f0e26014f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6298fc76-76da-40a0-b814-950b5f992c49"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/844b1df4-ae13-4ce0-ac16-6d93da7bdca1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7585b9b8-34e3-4134-a6b5-68a36ed49db4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe9259a5-581f-4570-93e6-83dedb658601"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f1eb36c-6c6d-4748-a60f-84ed00ee560e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5238d7d7-6c66-43c1-9c0a-0bc9ca369aa9">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95d12a22-0123-4bc9-84c4-66d10f7f21d4"/>
        <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
        <dc:identifier>S01BC</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f47ab9b5-c35d-445d-88b1-a676a9d875ef">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba71be0d-79b1-46c3-8c7c-3ce03641bb99"/>
    <dc:identifier>DB06262</dc:identifier>
    <rdfs:label>Droxidopa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19042206-17a1-4a91-a094-ea7fc597e1f2">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4bf34a76-cc7c-4030-bdd2-46c59fcf4ff4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0206d427-84af-405f-b548-b676f81c6d34"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81331d08-ea4f-49b5-ac65-bc9bf0b82138">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/709f6d19-23d6-4cd9-9442-d33ea6f8da60">
        <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12df71af-dc1c-4ec9-9160-c43200029b3e"/>
        <dc:identifier>DB09539</dc:identifier>
        <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28c66d2a-9127-4995-8372-0d149fbf91f7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/978524f0-1395-4e35-ab67-7881074be020"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d942990-5b9c-4d16-80a3-21ac28e1e559">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76a313cd-ae36-4508-a7b7-6858301c496f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34b4a50a-0d05-4d24-bb33-cb63dd2d6d36">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29074d69-6545-4555-aed2-fef92d3816e6">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e52f5d92-ba6d-4448-8565-b95f1ceb5fbc"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <rdfs:label>Vatiquinone</rdfs:label>
    <dc:identifier>DB11917</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5fbc3df-28f3-4ab6-98d7-805418e75afe">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277410"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e52f5d92-ba6d-4448-8565-b95f1ceb5fbc"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c19e6257-0ea6-42cd-a3a7-32ab485ee7e8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7450109f-4adc-4f6a-8605-1e1f449b3224"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/354a137c-966f-4f68-a7a0-0bd6dea0f0bd"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e52f5d92-ba6d-4448-8565-b95f1ceb5fbc"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09f6b97c-e01f-4c00-b446-1039f2f3b004">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e155640-cf7e-4d31-8560-0035f4b39fda"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c690b63e-2025-4da0-b301-ab9598dae8e6">
        <dc:identifier>HP:0003233</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1690c457-7b44-45ab-b27b-c35a86ab27aa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8db24bb7-330d-4d7a-8aba-d92431c6e515"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2d65b44-2a9a-474a-a69c-73fd4aae4a41"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/832655f7-ac80-422b-89f4-ed9fb9d0a553"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43911890-8802-40c0-986f-926810553d3f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d6e351d-547f-4073-a099-20bc04e9c05e">
    <rdfs:label>low intracellular cysteine*</rdfs:label>
    <dc:identifier>HP:0010918</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b9266ba-e15f-4bc9-bee9-aaa610d5987c"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/895b6ae9-0085-40b8-9d95-073c5fd66067">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2658f70b-22f9-40a7-96f0-2f0b5eb36319"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <dc:identifier>DB00847</dc:identifier>
    <rdfs:label>Cysteamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54801ed8-7ed9-46cc-926b-adade0561e92"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5952510-ff93-477a-80b2-44d544ecf9de"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22f73f35-759b-4b70-956d-ffd1f0322e10"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28465ca9-8cb1-4550-9ace-4d1c1dbb81c7">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0003394</dc:identifier>
    <rdfs:label>Muscle cramps</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d18d681f-8fef-4bd9-be25-5fdefafa8b06">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dafd88ff-2e6b-46b7-9ea0-5bf334682ecf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>edematous</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67890f8a-4f17-4093-8d58-594866686c7f"/>
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b62b74fd-8351-4201-994c-54d5696cfb8e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7409733d-ce0c-4082-8c83-d783671a0b23">
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:label>incoordination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40c35fb9-7ffe-4186-95ac-d4729d6087c7">
        <dc:identifier>HP:0000789</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
        <rdfs:label>infertility</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8448fa22-9702-488a-bdcc-3fde24888bd1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8630acb-bbc6-4393-bfb1-a5b93fb73be3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/408fe1f1-b115-4d23-91f9-3d2b1ac6d688">
    <rdfs:label>Low PBGD expression in liver</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f3c0986-d758-4eaf-8030-1814f0afc5ce">
    <rdfs:label>mitochondrial toxicity*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0012103</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bfcb3652-3b21-4c5d-821f-9101ad5af387">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/862b333d-a5bf-4e8a-8df5-b84a60bc7d67">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
        <dc:identifier>HP:0011729</dc:identifier>
        <rdfs:label>Abnormality of joint mobility</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d05fdbd-74a2-46ea-9d6b-e4bef72ec4a7">
        <rdfs:label>low exercise endurance</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e32f3816-6ed2-40a0-bdc2-0e17c943d342">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0010444</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
        <rdfs:label>pulmonary regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ea37770-44ae-4a3c-bc55-6d87c1dc5abd">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:label>low quality of sleep</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50c89310-b4a0-4a69-be33-827558be1c2e">
        <rdfs:label>pitting edema</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <dc:identifier>HP:0000969</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5953b7c9-385c-4b7c-8503-bafa59194b27">
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cffcf57e-9cfe-4163-9ced-d9cc736d88bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/188f2b33-7e21-4ced-8567-b16baabe4d32"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70296f90-1ee6-4194-84cc-7359497750f0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002877</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34635dc5-3bf5-4584-8eca-8e3d47328c44">
        <rdfs:label>white matter abnormalities</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a7f31c6-ba03-4bbb-b223-296d4ba3ff3d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/431a931c-3513-4f7a-9cee-17ab0095f273"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1837273c-4c0b-4958-adf2-749a84fd235d">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Daytime somnolence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
        <dc:identifier>HP:0002189</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0fb019f-4fd9-4dbd-b9cb-1157f2505ca2">
        <dc:identifier>HP:0030953</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>conjunctival irritation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb77035c-60fd-43e6-8ff1-50c3d6efbf9e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <dc:identifier>HP:0000613</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>photophobia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a4554dd-b1af-49af-92e3-41f838eb91fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:label>brain MRI abnormalities</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0002500</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b9db8ab-18e2-46b1-a399-3e2ee558db07">
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <dc:identifier>HP:0003541</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c64e23ce-5f14-4f89-a3b3-c42260e495ae">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:label>tricuspid regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bff2a42-6307-4fe6-a6a2-583d7d8918ca">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08ff4fd9-eb62-4e2e-a230-18edb0e17139">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <rdfs:label>Sleep apnea</rdfs:label>
        <dc:identifier>HP:0010535</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9bdc4c62-cb64-4aa8-a18f-638828b64a80"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f935a85-1ff0-4759-83bd-a1ccd19d243c">
        <dc:identifier>HP:0012763</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>dyspnea at rest</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5cfd7ba1-7903-4f75-816c-f9f1f23d55ed">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/48197716-599c-4ad3-b117-2cc88e9062db">
        <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da591ac0-6dee-454f-a99f-06547750785b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f42b990b-a1e2-4b59-9e09-c3eb7110c4e8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/990c9cea-9de4-4df3-b0c1-1d2f8dc303e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609f1ba-a5f6-4232-9455-600acc5fb9ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <dc:identifier>DB05481</dc:identifier>
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7db2426-f749-4410-836b-d13fbb45be8a">
    <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001112</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34de21b3-f486-4e9e-9de3-55a88df48f67">
    <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003141</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7d582c7-9fff-4220-b5ed-98dad4c96026">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a841794-3b74-4b21-961a-fbeec306a8e2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc7c950d-7ea7-426c-bc29-cf9d15494223"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31a28101-243b-4aff-9e9c-cb84c426c9ec"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93ac11c2-18fe-4a4b-aa5a-477dc5daab13">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>High spleen volume</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0dd76065-ccaa-4fbb-9200-6f75826c3a20">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>high liver volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96368655-4daf-4554-a024-916e07fd679e">
    <rdfs:label>dementia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
    <dc:identifier>HP:0000726</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eadfc0ae-57fa-40f7-a063-ccc67049dcc8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d3cd721f-941e-417d-b84f-3f46e599238f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9c47ccf8-8063-4cbf-aab9-a4f257c0c5e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/197dea48-add5-4df9-b9e8-e3d734f7ccb8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/abfcf26a-961d-4ccf-bd30-a6d9c52e62dc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2396583-188e-4e44-9a1a-ad71576e84bd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
        <rdfs:label>defected phagocytic function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010977</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51956292-fd63-432d-a75b-b2a6b45128ee">
        <rdfs:label>atypical psychomotor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6298bf2a-b40e-43eb-a5c7-6ee514e033c6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39466b25-a3ee-4e53-bd40-e7c29a7365b9">
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5948d9e6-669a-46b3-b27a-433879edcd6a">
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53fe2925-e771-4548-8023-d84e2658e893">
        <rdfs:label>recurrent infection</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf76f3bc-ca5e-48a5-876d-b9dc759f87dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f03bf0fa-abb9-413e-9137-402b9ee84fe5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6e015d2-69e3-46f0-b4cd-2ebc22e4f956"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2fcbd60-20e6-4c49-9d95-0624b4f603f8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9643c253-5beb-4a5c-bed6-381714e56083">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low neutrophil count</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/099b0e28-fa75-4b93-b3a3-3cd3530fcc0c"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ccfbb051-ce1f-4627-82b1-5b9622b5fe64">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/266c36e3-59c0-4f6b-baed-a9ba6f368e13">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
        <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
        <dc:identifier>B01</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1fdfcb7-7e73-413f-a71e-25a0f8a43f20"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7537a85-3153-4be6-975b-db855cd8b487">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba4b9388-4899-4519-b2c9-8b1a02c156f3">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a825dc56-2ad1-461f-9b4d-35d4fb41f52d"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bc9f375-a10d-48c1-9170-40c45276aaf6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f1e4770e-62c1-4abe-a07a-b9b327a0c642">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a825dc56-2ad1-461f-9b4d-35d4fb41f52d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13a9b172-af59-4c4b-888e-f6060a2bcbe5"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f219a649-5d9d-43ce-9abc-b7b7619a6a84">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f62c5437-e7b2-4a70-af89-262b227eeb0e"/>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec31c786-449f-4c62-b890-02190679c272"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3a309b9-8910-4ce4-8eb0-3d4ca502405e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602360"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af60ad1a-7997-4245-87dd-e779362477da"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14508116-4129-4f11-b621-c497f2f1a281"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2df8b7d1-9fd0-4f7e-a4e3-3f1c1e14d806"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09720555-a62f-4ac4-bbd9-46108df38b19"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a9f8929-e421-4748-b949-ae7c8f89c1ee"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1087d67e-c1b7-47cf-9bc4-d0afac01c5c4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/135a6093-cfc7-4a37-a07c-ee851e0b7e8f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c428cea3-2292-4609-91ad-a7377932720a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a947db3d-695c-43f1-a6f0-81f0588746d9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47da26eb-fea7-4b38-bed8-518024b9c727"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/219f71de-e558-4d04-8360-02f1364eb78f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a825dc56-2ad1-461f-9b4d-35d4fb41f52d"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37332461-3577-41eb-b090-d6210efc9222"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Creatine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44252a05-b376-49b8-a774-ff2083d9fcb1">
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a825dc56-2ad1-461f-9b4d-35d4fb41f52d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2b2b3f0-36f3-4b09-9fa0-74e9051c78ef"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00148</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cc1205ff-f3bc-49f1-8e1b-4c8d2636f94e">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e162152b-685f-4ec9-8955-124db29591eb">
        <dc:identifier>HP:0003281</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>High serum ferritin</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6b2ff11-35a7-4108-9ca1-6d51ce8bdb47"/>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
        <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71c02bed-7471-47e5-ae09-9d79a10e5eb8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/119c7fc1-44b2-41ce-9976-1fceb31c8a33"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/49e72aff-85c2-48e7-b5d6-e9d8119f85db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fcf53bc-2355-4bbe-8f08-73289dd5c1ef"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffe80dcf-fd3c-473b-b804-0478bd1b2b04"/>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ca630396-7440-4008-9df8-989f95967822">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3274a09-0671-4f18-b504-f70372b20315">
        <dc:identifier>HP:0002011</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>nervous system abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e7e0b3c-a496-4439-afaf-1404fb8f18fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurologic dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c59e816-b08d-4eb7-bb98-ccdc33dd3909">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <dc:identifier>HP:0000488</dc:identifier>
        <rdfs:label>Retinopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8337a560-7901-4298-8453-ac6ef28d8291">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <dc:identifier>HP:0004359*</dc:identifier>
    <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71d99b3c-43b0-4d15-ac31-fc1ab1b76bd0">
    <rdfs:label>Hyperchylomicronemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
    <dc:identifier>HP:0012238</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8c8a22d-cda5-435c-a666-b34a4b65e980">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b7bb152a-4fcc-45ff-9e8d-598ade2c0d90">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69415f99-77ba-4e7c-816d-62df50e4fc5f"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
        <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ecdee5f0-3f7a-4fe2-8575-e14b8c5d0c69"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Tolbutamide</rdfs:label>
    <dc:identifier>DB01124</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9c50667-acff-4549-b45b-3bf29748d979">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1df0891-f5af-46b2-9a71-2bbbc789e283">
        <dc:identifier>HP:0012187</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fd57cad-a1e0-4b52-96e2-1875700f7e95"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52f16157-a792-4bcc-a286-d802f7ff664a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fa125ff-cdaf-4102-9059-37771626a446"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c488cae6-1f81-4ab9-8877-344098c98be1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
    <dc:identifier>HP:0000787</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>urolithiasis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43d43020-95c9-4e49-a7d8-9afd6d5e3c85">
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>failure to thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07254fbf-77d9-4ba5-989c-ba6ee3aa1bf7">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1903f271-2b82-48d2-898a-2538edeb7be4"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d04d45c5-b938-4efa-9eff-64d6e382ed75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b908dacc-8e30-4beb-ab0c-d821f658ee49">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ce7a3c5-d3cf-4b2e-9eb9-024c5b34eabf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f80dbe02-41a9-4830-9df7-10958a6d7553"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d35d5143-5ed3-4c23-87af-3ec136203246"/>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8b7bea3-79a3-4d13-b411-f8f64670938a">
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/517283ec-1b8d-4696-acd4-68d4668cc106">
        <rdfs:label>Direct action (Mechanistic A) Replacement</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8122435f-d7cf-4378-bef3-e86babcdb739">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Oxidative Stress</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b97393d2-a1dd-4a03-9dd7-f77436979d72">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a2401a6-1b28-4644-921f-ae15b9675ac8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Normocytic anemia</rdfs:label>
        <dc:identifier>HP:0001897</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6e02850-4dfc-4414-a92d-e173c655f37f">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased liver enzyme activities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cf1c4bf-e3d6-46a8-b617-6543730669a3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Megalobalstic anaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <dc:identifier>HP:0001889</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/770b0d37-5145-4df6-9054-1d03ccacf44f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
        <rdfs:label>Low level of serum B12</rdfs:label>
        <dc:identifier>HP:0040126</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9affe2d8-b88d-4450-8871-85e3ddcbb8dd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperpigmentation</rdfs:label>
        <dc:identifier>HP:0000953</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc131cde-e668-45a0-bf42-e616b9702877">
        <dc:identifier>HP:0012120</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54726add-905d-41d7-adda-79aaabda3f26"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
        <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f6c3320f-8c83-4de6-aae5-64b487498211"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e7a5b409-5662-4db5-9e29-ecc12335a174"/>
        <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54a526a9-07d3-4265-9a14-a16d8c9cb8fa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40a6be18-1f75-4e21-b003-7174664535f4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
    <dc:identifier>HP:0030764</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>ochronosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82b76ce9-e67a-40f3-a0bc-390fbc8c9e91">
    <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0003455</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44094529-1cbc-49b6-a57a-d2e97ec10bae">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6415051-d36b-44c4-a4f8-898fbc1bc585">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>epileptic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcdaef7c-09c0-499a-b433-3d07696ce1db">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <rdfs:label>Hyperinsulinism</rdfs:label>
        <dc:identifier>HP:0000842</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9ed668c-fc3a-46bd-9493-e4f9f33915f2"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0e1a637-b15c-41f6-a6a4-89ca3bcaf0ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/183204dd-78ba-4f2f-b183-e637f3947f32">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
    <dc:identifier>HP:0025373</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c1c3ae7-35f1-4821-9848-d3d9c030ac19">
    <rdfs:label>High plasma citrulline levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
    <dc:identifier>HP:0011966</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5384e76f-00ce-475d-9b64-3ec063f4d375">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
    <rdfs:label>high ornithine level</rdfs:label>
    <dc:identifier>HP:0012026</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57e9e981-61ee-4e21-858c-4a70107550e3">
    <dc:identifier>HP:0003072</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypercalcemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc06b12b-1345-4085-8ced-4df2b590eab0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
    <dc:identifier>HP:0009071</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Inflammatory myopathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4c57f42-f4c3-41a7-884f-004caa1d6a0c"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2d00d37-d967-4f1f-91af-fb8cbb9fc306">
    <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
    <dc:identifier>HP:0001396</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/002a3528-35db-45e2-8f2a-a94ce8a8bb02">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c43373cc-2bda-4cca-bde8-f62dc088dfbd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>cardiomyopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7d4b2d6-b11f-477c-8236-470d3b656c0a">
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fb8024e-efe4-43e6-be69-077d0ed09726">
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0004359</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7281ad7-0278-4b82-80e4-540ae608b3ed">
        <dc:identifier>HP:0011025*</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f06b3430-7c85-4230-83f8-790fb9ba30b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3edb39c7-77ca-426b-9239-910a2901c72e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2df73eb5-5112-498a-8e05-b98ff854711a">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/305c7b20-888f-4267-bb5d-a9db5b61af18">
        <rdfs:label>high creatine kinase</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5821452-7da3-4e1b-acf8-eadf36bbf252">
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb618899-676a-4500-89a0-e46fd7b5f6b6">
    <rdfs:label>crystalline nephropathy</rdfs:label>
    <dc:identifier>HP:0000112</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da6b009e-6c6c-40c1-ae16-e51c84ff3bb9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22b22009-9fe6-4556-b1eb-2670c94c8f60">
        <rdfs:label>GNE gene lipoplex</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/391c9b3e-f64b-498b-8f64-cb9e86ce9f60"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/79ac7c23-8042-47d6-b140-50f95156d001">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f906aa3-6a0f-499c-b94c-30e6f125e884">
        <dc:identifier>HP:0001010</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
        <rdfs:label>Hypopigmented skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7f268f9-80cd-480e-8e49-39ceb3e52ab3">
        <rdfs:label>Woolly hair</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
        <dc:identifier>HP:0002224</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33636ca0-1447-45f9-a151-25be0812cb0e">
        <dc:identifier>HP:0002344</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Neurologic burden</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee1a713d-0b1b-4e26-94c6-a6c15a402cad">
        <rdfs:label>Rapid disease progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6a78a552-2816-4668-9833-91046614a65f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e50735d-3d4d-47d4-a18c-e6262b051b8a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/665436a5-f152-4eaf-ad05-838305705b38">
        <dc:identifier>HP:0001290</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Low muscular tone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/102e2f9b-33db-4968-b47c-497c96a34d15">
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Poor weight gain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85ea71bd-c8bd-4653-94da-de3afdedfb16">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalities.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50e4349a-9f73-4f02-be10-eb4b38f81ee1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
        <dc:identifier>HP:0012389</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca789c82-8107-4bf0-8d7c-6c50ee6f8d5d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/183204dd-78ba-4f2f-b183-e637f3947f32"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afc8c23d-7fea-45c5-9214-a327c9f30832">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7e9e287-6b94-4d0c-9021-b2f91c4f815e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>growth delay</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001510</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/baca6bac-a0ac-409b-a249-fdf1b91c94cb">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/720f39d3-6fee-49d7-abea-ea090f3be7ed">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bcd307de-8a68-4cfe-a5a2-3bf1d9ce917f"/>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
        <dc:identifier>CHEBI_84293</dc:identifier>
        <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a147f77c-c9e7-46ab-9d83-87fd24147a71">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5124200e-194e-4a91-a548-f0a39b56a7b9">
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
        <dc:identifier>HP:0000722</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/418326ba-9369-4716-b5ad-8070076c974a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00e2ac00-84c2-418b-9363-f7128ba9d16e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8b0ef1b-fd26-43b8-929d-4ee619eda43a"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/097e2b3b-8631-45c7-b3cd-f0a5faa1b46b"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d771e8ac-6101-4b2f-b67c-52b8bd467691"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd3bf135-2ba3-411b-ac71-ad7768366e34"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ae8c257-3320-450b-a343-066a7b6d6be3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <rdfs:label>Miglustat</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e7cd9bf5-9033-4dfe-882b-c9c260f14833">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/380e84fc-3246-4290-82c7-c2768da2fd25"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d22e9b2-5f15-4003-9658-78c3c9393874"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dca82d92-e7a5-4ea6-96a8-99e4c2e6eee0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c3d49f1-546a-4092-aebe-b6e44324c5eb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13e18586-3d83-4d67-9880-0918b469fc4b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/afaca43b-f6ac-4bfa-be79-27e7a86c4994"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d5d457e9-e19c-4c2d-aebd-347fa0226a02">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/496f2ed3-605d-4326-a768-6520e41103ca"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b70b97bd-96fd-4343-9e93-37954a23c9d5"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c3d49f1-546a-4092-aebe-b6e44324c5eb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00419</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7492dc96-6c26-4497-b79d-6f1ded45de1a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c862be5d-5930-44f0-97cc-f7e280b5c5c3"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7272b6a3-ea25-4071-96ec-5cd58a219a3a">
        <rdfs:label>hypomagnesemia</rdfs:label>
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0470a48-23b7-4987-8392-91d07602e762">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b801defc-8238-4cfb-abd2-459200e10839"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/861d9089-6a42-4734-9858-8bd5e943ac8b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b3b7047-9b0f-48c6-af75-8cf64332a2e1">
        <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d90bff51-169f-4402-b36f-10f78da3a92e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ef87dd1-294c-47ad-bdde-05696327cfa9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51e97d0c-25a8-4e33-8418-2941b24203fb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
    <dc:identifier>HP:0002529</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Neuronal death</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b69fa687-f621-471b-89ca-af01d1e70a68">
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54f8285e-aa19-48e7-9ea0-ee0525d75abe">
        <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35933da9-3bf7-447a-b27e-9339f2bbb6d2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fd88f982-45d4-46b2-85bc-f5afa51310ba"/>
        <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cab835a4-1e0f-447e-8e27-46ebedbec067">
        <dc:identifier>HP:0004369</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
        <rdfs:label>low levels of purines</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d28b51a2-521e-45ae-bf4b-6abeef73ee7b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77ac675a-9c80-482a-945c-fd044f640ef6">
        <rdfs:label>frequent hospital admission</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609f1ba-a5f6-4232-9455-600acc5fb9ee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b683aebe-01d4-47c4-b25d-c9290384595f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002098</dc:identifier>
        <rdfs:label>Noctornal difficulty breathing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c63a4ba0-50a4-4346-9f1e-ad8033f54f75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/952ff5b0-c842-4b7e-8a44-438cb7e1a49e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f59d1c3b-eaed-475d-99b5-8e62278f3e83">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b634e75c-5211-4e52-85b9-3865727fe00f">
        <rdfs:label>hypokalemia</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b179bee8-f4b5-4f99-9915-baff5b83324d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56c5d4b5-5ae1-49dc-af58-45e52d2d4036"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32a3d69a-a65f-4151-9489-b8950da7623f">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.degruyter.com/view/j/jpem.2016.29.issue-1/jpem-2015-0132/jpem-2015-0132.xml</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7">
        <rdfs:label>Direct interaction (Mechanistic A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e308d52-2668-45b2-bfb5-b7f7c606c9da"/>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b972dbe-1b51-455a-b2cf-9cd5273c4083">
        <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77017954-35a9-4b60-a669-84cb1bc7216e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>Developmetal delay</rdfs:label>
    <dc:identifier>HP:0001263</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4867831-ea3a-4ab8-95c5-02e042f15717">
    <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
    <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
    <dc:identifier>HP:0008344</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/00f95c0f-f868-4c73-81d0-bd97a1a4237a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0b1acd5-b265-49c2-88b5-5054f03e0842"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e19bbb3-82d6-4ca9-bffc-d1a7cf88e308">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100614</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
    <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
    <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/097e2b3b-8631-45c7-b3cd-f0a5faa1b46b"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/50c482d9-9865-4742-bd18-e7348b084a31">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6bc682b6-bc59-48c0-8bc3-b00b702d7bd3"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ddfd868-0269-41af-8425-a25f9a0fbee5">
        <rdfs:label>Liver steatosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb2deae7-6a3b-4ff9-ad8b-291700e29d81">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:label>Fatty liver</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a29eecef-f1e7-4867-9749-72ded5b72cf3"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96acf874-6c25-437d-be07-72a37599d54a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001395</dc:identifier>
        <rdfs:label>Liver fibrosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/676e73e8-8ee5-48d5-b684-9da3aeeace1c">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>DNA hypermethylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9db809be-77bd-4456-950f-a837e7112b0a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>osteopenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a03ff07-3590-4a98-8eb3-875c8cae8331">
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3149f698-5226-4121-b04c-1717354096f1">
        <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9ed668c-fc3a-46bd-9493-e4f9f33915f2"/>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0e1a637-b15c-41f6-a6a4-89ca3bcaf0ea"/>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9682d45b-45a5-469c-9602-1ce3e2fc5d78">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3b213e2-4861-4abf-8ffd-4ee0b3d35711">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2def9dfc-4a42-4ff7-8c0d-82bed4b42e89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7882ce89-9643-477e-9dc2-90874b7468c7">
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3051d9e2-4115-46b1-a44d-33bfa5557f06">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29964d9a-3f90-4743-8f14-17b42483acb5">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>High VLDL triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43911890-8802-40c0-986f-926810553d3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c557636-8ab4-46d6-98de-38fc2c0e9e14"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3492aa71-772d-4e77-bb5d-daf670843fba">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:label>Abnormal liver function test</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/28eae774-f6cc-4e07-961f-e9e064f2ec75">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cbcde1b-cc16-4021-aabc-9c0d0c515c23">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db9693f1-d03b-402e-80c7-8324436c63d7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a41c8a7f-b60a-49a7-a468-7d4e40f14a33"/>
        <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
        <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e5120c3-6fea-440f-9944-7891d0bd2ee3">
        <rdfs:label>No result is  added</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/47c90eb3-d80f-457f-bc68-7a496548b90d">
        <rdfs:label>Direct interaction ( Mechanistic A) ERT</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7abce59-cca3-4b05-b689-03d9118debef">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4606bcf1-d82c-464e-94e1-b4c73a6c0e4a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aaab541d-e5aa-4270-8e78-5959baf14ac2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b166f9b0-b9d4-476f-bd27-1dd6a76a1932">
        <dc:identifier>HP:0002028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chronic diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
        <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5733a1ac-f8ba-4f3d-b32d-4742dbee7bf8"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a5e7492-6f6e-4360-906a-90b4cf5a8f90">
        <rdfs:label>Hypoalbuminemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003073</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd0d090d-e56f-4370-9bc7-21ba6f320665"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ab27fd3-6a46-4fcf-b989-465f6bcc3d4f">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/761c7a9b-afbb-4436-9f17-8023ac2b6541">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e06054b-877e-49ba-b833-05027d3ea8da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d04d45c5-b938-4efa-9eff-64d6e382ed75"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4037b5b-1473-4bc9-8983-d1e4059db5e1">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b45018e1-4e3a-4184-95cd-1c443f61512b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7aefa3e-fe52-4d3f-acc1-264e5a38e4bc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fba9330a-65a3-4252-9f82-d7e5404a3b62"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2abeb702-8b37-4ae6-b211-a842556c0a99"/>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea0687f6-39f1-4ffd-b8e6-0628c2b6ef59"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Indapamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
    <dc:identifier>DB00808</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c5ab16d-fef5-4d65-bd84-9522a12f6d01">
    <dc:identifier>DB05018</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b8d7212-0c86-462f-a4c0-65187ee02085">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82c4c8ed-2d13-496f-9ea7-dcd5293a8650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
        <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e60d7ef-96df-463e-ab19-057437870102"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46c7a888-e8b9-43d8-ac2d-e485eb1f61e2"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b02cbc0f-30af-4cf5-9d41-c649c76fc69e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Migalastat</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51207dc2-db5b-44b6-8930-4d125002a2a0">
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b02cbc0f-30af-4cf5-9d41-c649c76fc69e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d646baea-1cf3-46b0-9102-a24896b54496">
    <dc:identifier>HP:0002375</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
    <rdfs:label>hypokinesia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6c49420-d065-44cf-8e3e-d8ed83dd6356">
    <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
    <dc:identifier>HP:0040144</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcb4d338-6dea-4076-a927-b270e5cb50b8">
    <rdfs:label>oxidative injury*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
    <dc:identifier>HP:0025463</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf6ab6e9-baf8-4caa-ba7b-cbc040a3f435">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33c9a9ab-e788-4e9d-a627-9cc3cd1dee9a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f45e76fa-a8a5-4a94-98c0-fa0706f806a1">
    <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
    <dc:identifier>HP:0004295</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/28165ec0-f618-4900-839b-b83e5c4b93a3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8db12b3c-b968-457e-8871-9fa22b73a142">
        <rdfs:label>Olanzapine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee3f8cf0-f2ff-4969-a65c-c09e80595f15"/>
        <dc:identifier>DB00334</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/964cd8c1-907e-41dd-a1d5-353f30369d08"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37332461-3577-41eb-b090-d6210efc9222">
    <dc:identifier>HP:0003648</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high lactic acid level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ada3db3a-cf5d-455a-b47e-594b35e4a365">
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8e827c8-69d5-4626-88ab-77b1a72b9056"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2891522-3af8-4c05-bb0a-78f33ea29171">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52b6493b-4ebf-4098-bb2e-5ab0602b48d9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e90ca154-9c08-46bd-8e2f-7116b3efc2bc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
    <rdfs:label>respiratory insufficiency</rdfs:label>
    <dc:identifier>HP:0002093</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d83d7ff-e006-45be-9468-7a0f0e0715b2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04c054eb-f972-4185-a472-b2f5b6e33d04">
    <dc:identifier>HP:0012446</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
    <rdfs:label>cerebral folate depletion</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb985dfd-2317-43d2-84f5-42ac61ec847c">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc47a960-729b-4a63-bfd2-b1befb5448d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f98c619b-dec5-4287-b3c1-0eeab492320b">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>retarded growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdb14891-e5e7-49ea-89a9-a4a4b2647d27">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>low phosphate reabsorption</rdfs:label>
        <dc:identifier>HP:0000117</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08e75cc4-dc35-4204-9f3a-6220d796e9cf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5bd0a1c-7880-4495-ad7d-c8ec24d6ef84"/>
    <dc:identifier>DB11563</dc:identifier>
    <rdfs:label>Sebelipase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98df723d-a510-4756-b284-3b3ee443c4cc">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Decreased visual acuity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <dc:identifier>HP:0007663</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/10d95793-3e2d-4e49-8563-bbfd5feba260">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/139edfc9-2e1f-4d9f-9ad0-2db15102dc9f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/477f6527-9c5d-4711-8404-68cf3dd9692a"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a1e0f59-1fbc-49f6-9c24-1fe69800bcb0">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6053861-d251-4492-8d9f-3f48018bc392">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff38406e-a3c2-4d4c-aaf2-923088d716cd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9855b64c-0556-4922-8b2f-4031388689be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe5c3bd6-708d-4793-a498-d9bbe4073c09">
    <dc:identifier>HP:0000648</dc:identifier>
    <rdfs:label>Optic atrophy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8eaf2857-7edc-4759-892f-6e3fdcc681c8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8591b1ff-bf76-4a22-b6f9-cce23b3c6ee0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3cdf6fce-5a3a-43df-9a4e-7e5ca4c317d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fba9330a-65a3-4252-9f82-d7e5404a3b62"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc2ebf01-5452-42f2-a1ea-3872af84f312">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
    <dc:identifier>HP:0002401</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>Stroke-like episodes</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4834e83f-b302-4c11-a414-2e3ce5de3a21">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d197f215-3feb-4f98-90a3-5592a8a94b44">
        <rdfs:label>Status epilepticus</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51d40475-1ee1-4304-8c93-85450c318efc"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
        <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5b5ac63-3cb4-4407-abc4-1bae4a51acc1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf0cd83f-c09e-4c1b-9e75-c70d02e2e141">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c5a232d-3846-456c-8f5c-22bbe2344f04">
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <dc:identifier>HP:0001943*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/780529e3-babb-4826-9eff-d482b293b11b">
        <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
        <dc:identifier>HP:0002360*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/558ac0c9-9c3b-41fd-86ad-5f86378084d6"/>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94a184b6-88d4-4d44-9792-158c86adc118"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bcc235f8-9490-46f8-a40a-df0e232aa287">
    <dc:identifier>HP:0000739</dc:identifier>
    <rdfs:label>anxiety</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f2410792-5eb3-4b01-9ff7-fa57c88ef327">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e7d512b-5d7b-4064-b013-a6a01d3394d3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db1f0790-341c-4b8b-b8da-88a1c413ca32">
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:label>Acute hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89f30017-2fda-4d62-9076-ab5af9c94453">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
        <rdfs:label>Low plasma arginine levels</rdfs:label>
        <dc:identifier>HP:0005961</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3018570f-99ed-4a5c-a87c-5d28ab8e1e86">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>abnormal hepatic function tests</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7327bec6-617e-41ad-b987-b3d809522bf9">
    <rdfs:label>Potassium Citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d3d83b4-c9ec-41a4-b9ec-ce23aaf7acfb">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/214b58aa-ffd2-4c80-af40-e775830c1db9"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/978524f0-1395-4e35-ab67-7881074be020"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9f4e2e0e-7fc8-4baf-ad28-757e08ef3b87"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/92eb1de2-83e5-46a3-bf96-f89472e4e876">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9f4e2e0e-7fc8-4baf-ad28-757e08ef3b87"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6c49420-d065-44cf-8e3e-d8ed83dd6356"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de75fab7-ae6e-47db-b31f-4e06af29808c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71ffd057-ad11-4d2d-875b-6ef56a7f6779"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/602c86e0-72e3-4f47-a238-3fa293d0595a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615182"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB09125</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1a7843bf-3fbf-4e21-a175-ab709350782a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41cab147-8711-498b-ba41-3edb6d2f325b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e56cafda-61c2-4628-add0-360ae0b209ba">
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57c8baa6-00df-4887-82c8-4fccc28f197e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb3fe4a6-2d3b-4798-901a-7f3c2911f5fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/15637c24-5fdd-46e8-8357-bfc596a71328">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/531d35f9-d7cb-44e4-81b7-23a3acca6413">
        <rdfs:label>Colchicine</rdfs:label>
        <dc:identifier>DB01394</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad3e5340-44fd-4478-9973-407ee8cbf883"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/197dea48-add5-4df9-b9e8-e3d734f7ccb8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d3cd721f-941e-417d-b84f-3f46e599238f"/>
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a750532-6796-4cb7-8a94-8f4ef3205672">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003117*</dc:identifier>
    <rdfs:label>Serotonin deficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9d33144-9d01-4862-8174-0bcaeee32c3f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b6f7363-3b12-4cad-8635-772b7aa86a02">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/741cf7da-bb9f-4b51-83c4-f743ec5e59ed"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/478a748b-a662-41a2-b44b-e39b6ce5ca0e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09dd32d5-6775-4944-b191-9a0757e4018e">
    <dc:identifier>HP:0001324</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>abnormal muscle strenght</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13b78dea-d041-458b-b6cf-1859ce85c708">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d108862-f2b8-4c7c-a6ae-7095fbb88900">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bec19ade-e499-476b-b9e5-639eb59c5776"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d698586-1ab1-4516-b9e2-a1758221d2c6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5c5512f-757f-4eed-b3f8-6c3aa7a42109"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB05990</dc:identifier>
    <rdfs:label>Obeticholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a9edbf5-ae71-451f-b4af-8287775ca9a6">
    <rdfs:label>high  HbA1c levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
    <dc:identifier>HP:0040217</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45bf99ac-5b5c-497d-842c-a201df2c33bf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54fa5884-69a5-4942-bd12-e4538c4ef386">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003111</dc:identifier>
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b3ac4888-1fc4-424d-8841-746d95d2b257"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29f620f8-8b54-4f0d-9141-28f14fe77166"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0a3fff7-d9db-49e8-a7d9-d88e4e93f789">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a23a6ee-9608-49ea-842d-bcbe5aea5949"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d61fdbb1-4c38-482a-b744-55158f515eee"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5875a23-82dc-49c1-a699-6f23624391cd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
    <dc:identifier>HP:0000737</dc:identifier>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Irritability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6602a827-3d5b-4a24-a72e-45450a5c2e87">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a9c6b01-650a-4e42-8d32-0b088f0687fb"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d913833-0412-47cf-a6b7-9bf0c939eab6">
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:label>photosensitivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d69186d1-975c-4e97-afcb-a501da431a3a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4243aa2a-8d9d-478f-b584-6abb0dab110d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a36ea738-a089-46f3-a479-8c1b95abc487">
        <rdfs:label>tissue damage</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/071d37bd-86e6-4106-8643-ad7a1db45d89">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
        <rdfs:label>Liver dysfunction</rdfs:label>
        <dc:identifier>HP:0001410</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/23f1a1c2-5242-4f95-b9bf-de9d00d04cab"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/169a5036-f577-423b-9cd7-efc0aa36720e">
        <rdfs:label>pancreatic dysfunction</rdfs:label>
        <dc:identifier>HP:0001738</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aaab541d-e5aa-4270-8e78-5959baf14ac2">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/29d08046-4c23-4f95-b173-ab7190291d98">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98cdae13-37ee-4da2-ba3a-77f3cf878803"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3b0394f-e730-47df-bc70-1d13e0f75206"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfb261b3-440a-4876-8f97-873aba82015d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbc2870b-b417-457b-a1a8-db7dc664e3b0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac779e9f-6b77-4bca-ad96-987b9f1a2c80"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4606bcf1-d82c-464e-94e1-b4c73a6c0e4a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7abce59-cca3-4b05-b689-03d9118debef"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84a94083-f32c-4bd1-9034-aabac3b8b46d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7dc1850-be44-477b-ad4f-3c039f337ee5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96368655-4daf-4554-a024-916e07fd679e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0b97b67-8f0d-4b4a-afef-613e699cfdaa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2019216/pdf/archdisch01582-0040.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4606bcf1-d82c-464e-94e1-b4c73a6c0e4a"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c349a9e-936f-457e-a7bf-71c891dad5f9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c99a1bb3-b00d-4b28-8d7c-2309429da57e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4606bcf1-d82c-464e-94e1-b4c73a6c0e4a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c690b63e-2025-4da0-b301-ab9598dae8e6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d1e5066f-bd3f-4841-a3ed-1c37aeabf477">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4606bcf1-d82c-464e-94e1-b4c73a6c0e4a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00627</dc:identifier>
    <rdfs:label>Niacin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c2666fd-311f-4bc2-bc5a-143dc90bdac6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/247aa14c-82f2-4ba5-87e8-9e577e76241c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
        <dc:identifier>HP:0002180*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/919753dc-8f9f-417a-98a1-ede9acc1b30d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
        <dc:identifier>HP:0004371</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9bdc4c62-cb64-4aa8-a18f-638828b64a80"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99c64690-dc87-4f71-94bf-15a9ebe84922">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af009c5d-c92d-4c2b-a92e-0ded1118e437"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42cc7367-6ef6-44db-b247-e21431fa9aff">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
    <dc:identifier>DB01068</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6ddc6eb-6082-4880-a117-dd13c8d3eeba"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dfd58194-ac56-42e3-8bb7-0504a8f16e30">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76a83d0c-2184-40a9-8573-74183513375d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Clonazepam</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4e50316-fa3a-480c-97c0-029d09d49fb3">
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/968f738f-dd33-4b07-9063-a9d641b0e941"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0473cc96-6147-44bd-917e-fccda698913f"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/35c66082-055c-4727-b043-bfc1aefee1de">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1cea9fbf-6289-48dc-9ff7-1debe270aff5"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75fcabf9-7683-4f2f-9654-b4927cd29eba"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/68e9ff88-48c9-4c20-8046-5f22ade97b1b"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cfe30704-7f09-4092-9dfd-b6cece3beac8">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/968f738f-dd33-4b07-9063-a9d641b0e941"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0915bf85-93fe-4e88-8933-9c2e68dfa7fb"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6709c710-d21d-4cc9-96c2-a1812fb5f376">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ARGININEMIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/26eceb8f-8226-4398-9cfb-eaa94d38e578"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77df7df2-2d38-4800-b0b6-0bd8f33e80c3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95d12a22-0123-4bc9-84c4-66d10f7f21d4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6f5f1b4-0fcb-4380-b628-6d4c0c5a3d76">
        <rdfs:label>Abnormal walking distance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66997fe9-2071-4383-91b8-8a0d2fcaf83e">
        <rdfs:label>Lower limb pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012514</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f692752-3988-45cc-b122-5584d0afc541">
        <rdfs:label>Abnormal prostaglandin level</rdfs:label>
        <dc:identifier>HP:0011023</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f285d3af-74af-45c9-a746-87ca3b7fc5aa"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f1eb36c-6c6d-4748-a60f-84ed00ee560e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c813c55-d6c4-4ed1-9d22-a4349805c846">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/625a9e66-a89a-4992-9b93-d85979a1d5fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d187914-0efb-47a2-8d55-3b6fadf86270"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/463f8145-28ef-49fe-a9f4-c32f17d0af1d">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-published-open-label-study-showing-brineura-cerliponase-alfa-reduced-the-rate-of-clinical-decline-of-children-with-cln2-disease-a-form-of-batten-disease-300635669.html</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/894938bf-035f-44ab-aab6-78b4cb7898c7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e155640-cf7e-4d31-8560-0035f4b39fda"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfb261b3-440a-4876-8f97-873aba82015d">
        <rdfs:label>Elevated LDL-C level</rdfs:label>
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fd17c06-a09c-4229-aea8-578b1bdeb585">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
        <dc:identifier>HP:0001013*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71d99b3c-43b0-4d15-ac31-fc1ab1b76bd0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac779e9f-6b77-4bca-ad96-987b9f1a2c80">
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7997883b-bc72-4006-871c-e440f64591b1">
        <rdfs:label>High total plasma cholesterol leve</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0012238</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbc2870b-b417-457b-a1a8-db7dc664e3b0">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a42cf673-c4f9-4210-9878-e6ca65185608"/>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/329799e3-bd36-45c5-9cbd-8e20ff417470">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9a52a47-03b5-431c-bf82-7ef0dcae8547">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50450c1d-626b-4d96-9f5b-f33260916415"/>
        <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8e554fc-81e2-4bf9-ade4-1c8b8e0081b2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f81cbd7-2ced-4134-8a44-0e71ed2d111f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0577dd89-fdf3-48c7-aa49-dff1172a01b2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/087bb3e9-2138-44cd-b5c3-b88f885e3514"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2cf8bec-afce-4a44-b40e-89ffff59dfd9"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/106a2d9c-37d5-4f7b-b335-4e897cfea926"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Ambroxol</rdfs:label>
    <dc:identifier>DB06742</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7199489f-c6b3-49a4-950b-ccdae4b5fc20">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf751982-bf92-4f3f-94fa-c1af5deab8ae">
        <dc:identifier>HP:0001888</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
        <rdfs:label>lymphopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bca81cd8-e7c4-4948-843a-5007ab538094">
        <dc:identifier>HP:0002960</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/027fc568-3547-4445-8fc8-38f216b40e2b">
        <rdfs:label>Elevated liver enzyme levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77d49f0b-21c9-4ffa-8f78-0823687ce776">
        <dc:identifier>HP:0001879</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/456903d3-1271-44b3-8a31-fc30ea125562"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31d019bf-0362-41dc-b306-a7ffb7b4235d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7643bd4-3684-454b-b878-c8132c93ee1e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/277964df-13e0-416d-8be7-ab24a7245e40">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Hemolysis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/938999ba-7585-459a-aaa7-e86759a7eb62"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d73a805f-c408-44f6-a7a9-1a79abf07a76">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:label>Abnormal immune function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bcfe79fe-e04b-4fcc-885a-f5ce89759f86"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0b97b67-8f0d-4b4a-afef-613e699cfdaa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>dermatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eee5c2d6-73b0-46c5-ae55-a0f5ea0f32d9">
    <rdfs:label>Oedema</rdfs:label>
    <dc:identifier>HP:0000969</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/747ff943-5fe0-4dee-9f81-2f32dea1834b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6dec226-ca90-49e0-9865-d646e846e35e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65b9ecfa-6e9e-4eaa-8ee9-53bfe00509ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fcf53bc-2355-4bbe-8f08-73289dd5c1ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e42401b8-ee80-4e29-a620-ab86cb9aa591"/>
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17661033-fb0e-44d0-9c25-311c7103247d">
    <dc:identifier>DB00396</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ec9fb36-648a-4317-8b38-ee53971a67fb">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/38e004c0-1bdc-418a-9e29-fd756527edac"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b51962c-bb68-42a4-92ec-a908daa5c67e"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <rdfs:label>Progesterone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d2f6c59-a3ec-4d6b-b06b-ef4d88794e1e">
    <rdfs:label>limb hypertonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
    <dc:identifier>HP:0002509</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dedfdf4-02c8-4898-9d2e-983d7cb238e1">
    <dc:identifier>MP:0009587</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f096527-b7fa-471b-80b4-bb4d7b43b2e5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
    <rdfs:label>extended G1 interval</rdfs:label>
    <dc:identifier>HP:0011018</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8420093-f161-4826-9974-bea50712950b"/>
    <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
    <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/460503c0-3725-420f-825c-22044f7b2d24">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/47fff9f5-2013-4648-86f4-f44ad60e0c6b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e20303ff-75bf-445e-b589-6d783e8be9ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5d2872a-2bb8-4035-b1ad-084bed1615fa">
        <rdfs:label>neurological malfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c605894b-49fd-46b4-a093-79acae984d80">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
        <rdfs:label>immune dysfunctions</rdfs:label>
        <dc:identifier>HP:0002715</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f121ca91-a9b4-4592-a638-46d78046eaf0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef6d09a7-3e1e-43d5-b5a2-1042961e806b">
        <rdfs:label>high serum phenylalanine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1485288c-df23-48b0-8573-2143c0659909">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09645442-b18e-474a-9e64-0247aa037d6e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Fukutin function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c4bf1af-b44f-456a-b635-5efdf77b28c6"/>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60b2e6be-c370-4a87-8d6e-57cfcfee7ab6"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ce22cc0-d1e7-409d-bfd3-aeaf207977f3">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b945d1fd-25ef-4dc0-8cb7-efa967f90da2">
        <rdfs:label>Muscle necrosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003713</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eab6decb-1cac-4e4b-a06d-549ac44e3fc2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <rdfs:label>Muscle inflammation</rdfs:label>
        <dc:identifier>HP:0100614</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b6f7363-3b12-4cad-8635-772b7aa86a02"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/241a8fb6-80ed-4b3c-8952-dea58c13f92e">
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b2e0b631-e457-4288-88f3-5b9b7e841149"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89fd78a6-7231-4133-b443-c005a5c0efe7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>steatohepatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3182d26-bb04-475d-a744-b624c0897e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f693bb7e-af5e-43e9-a3d3-9f44c8cfe559">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8d8adb6-e51c-4d72-8215-fe1739503d9c">
        <dc:identifier>HP:0002150</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High calcium excretion in urine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84d8af88-ae5a-435f-abbb-eff3b1bd995a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9df0788-ba4c-4cdd-8eb5-556daca3ba73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf6016ae-fdeb-4ad7-8d79-03478a2c6ce5">
        <dc:identifier>HP:0003566</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
        <rdfs:label>Elevated prostaglandin E2</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/978524f0-1395-4e35-ab67-7881074be020"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e94bf477-2a7d-4c1f-94d4-72027f460a61">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9def095b-edc1-4ad6-8180-4d530dfc4688">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0001596</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <rdfs:label>Alopecia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f29b237-c1ef-4b28-bcfd-c2e930794f51">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000713</dc:identifier>
        <rdfs:label>Agitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/561619fd-92fb-42e0-8001-0a11f1494267"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0811b206-4536-4d87-98cc-dfbdf74f2752">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <rdfs:label>emotional disturbances</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000712</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4243aa2a-8d9d-478f-b584-6abb0dab110d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ece9133-1430-4ddd-bf3e-1cf4c0117b89">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:label>skin inflammation</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c465c716-5091-4cf9-82a5-d8d9a5b49edf">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:label>diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14508116-4129-4f11-b621-c497f2f1a281">
    <dc:identifier>HP:0012113*</dc:identifier>
    <rdfs:label>Low cerebral creatine content</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b7cc369-42cb-423a-9095-0bde91d90601">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb419f1b-bc8d-489e-ac89-ae4e6086174f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da6ac73e-a8ba-402d-94af-4e4b96e9b0fd">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormal AGA processing</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d83fbf30-e45c-4cfa-acaa-bba9e2566867">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4dea370c-9597-4cdf-9053-984f1f4576b9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
        <dc:identifier>HP:0008028</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Macular cystoid changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7450109f-4adc-4f6a-8605-1e1f449b3224"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f17a899a-9264-46e4-a088-07c5b88e7f8f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
        <dc:identifier>HP:0000479*</dc:identifier>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b2d222ba-64e8-4a35-8e58-5ecd1b6e3a4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2245d406-03ae-4c4e-916e-fd85bb47b605"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ebc319b7-e7e0-45d6-8da2-03c328a7eaf2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fb756ab-76fe-40ec-8c2d-93ec4e05047a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad331ebf-11ef-4eac-8108-c71f19081b83">
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient .</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea8e995f-9556-4fab-86cb-4300a4b8d939">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb5a5e4d-a274-4dc8-99ca-a85595dbb4f8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/928882bc-8944-4656-b368-260dc3bb5d7d">
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>elevation of creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
    <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c7af115-46f0-4102-b494-df7f565694df"/>
    <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85dcd7fb-2d2b-4cd5-965b-368f26d47655">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a7d4f7e-f6e0-45ba-b7a2-603121cfa76b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6c49420-d065-44cf-8e3e-d8ed83dd6356"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2320c69e-4a64-4d0e-81dd-11ac7b7254a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:label>Poor motor coordination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/066f54dc-e412-42d6-ac9f-d226c8885b11">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86c4551d-e5ef-4599-8ec7-c02eaef32484"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1127fd-c8e1-4221-8bd1-1e634f8ebc62"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e71a565-eea7-48b6-8ab3-1dadcb6de107">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4203f9b8-4439-4c55-ae73-2e9b95a4d2c9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c22d40d1-a9e3-47b7-a3c2-96e8774b1207">
    <dc:identifier>DB02053</dc:identifier>
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5f3d100-b71f-4def-ba62-40d886045753">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28465ca9-8cb1-4550-9ace-4d1c1dbb81c7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af788f64-c3a5-4041-b7ac-064679ac4c34"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17db00cd-724d-45ec-8ec9-f89272c7dead"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/321c1804-142c-41a3-b530-00e5385cf0c0"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c75bc6ab-41b1-4ed1-a868-fce709f5d350"/>
        <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615511"/>
        <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/455a34cf-8bdb-44de-895e-e781a301c20d"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f576a263-3aec-4eb3-b83e-5321e7f892c1">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/384f327c-bbe2-488a-a940-77d98d1d6f67"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ca6cd6b-809c-4e69-8688-375f08a3fce5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Growth failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79363411-1bc5-4a2f-8994-3ce97ac1e7e7">
        <rdfs:label>Hypertriglycerdemia</rdfs:label>
        <dc:identifier>done</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/533d5a8a-62cb-42a0-8df4-445ce2759e2b">
    <dc:identifier>HP:0000105</dc:identifier>
    <rdfs:label>Enlarged kidney</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e57f8965-1e3c-4a2c-852d-82d3d91263cb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b634e75c-5211-4e52-85b9-3865727fe00f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/df4b4bfc-c96c-48d5-a409-c4325264c064"/>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3cff328c-9145-455a-954a-eb4007397030"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b179bee8-f4b5-4f99-9915-baff5b83324d"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d44672bd-088c-4172-9cbb-b346057d947b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>secondary carnitine deficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <dc:identifier>HP:0003234*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdda5d9a-28d2-4062-a7e9-e091f28f0ad9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
    <rdfs:label>paralysis</rdfs:label>
    <dc:identifier>HP:0003470</dc:identifier>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b395075a-3f14-44b8-bd91-d978f1b7e5d8">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44e170d2-27fb-4896-8a6d-b803489de573">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5acabb53-93b6-4011-8048-2ae177096911">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5e0660e5-e75d-48ec-8699-dbdb43682430">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0473cc96-6147-44bd-917e-fccda698913f"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea6a5e1b-6e57-4c2c-b3bf-497b86e77af9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c71eb46a-234c-4ccd-a448-82ed291f4aa6">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85ff3d99-ab2a-4e24-8742-be3a77b89eca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
    <rdfs:label>Phenobarbital</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfd58194-ac56-42e3-8bb7-0504a8f16e30"/>
    <dc:identifier>DB01174</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff8f3129-8e06-4ca0-9e40-e6f34dc85b1a">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0a26ed75-03be-429b-98d3-e4152490a016"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ad52fbc-2aae-43e6-8daf-bff28551cee9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc47a960-729b-4a63-bfd2-b1befb5448d4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9de9be1e-6147-4a9c-9aa6-1f0e59fe8893"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a583724e-d071-4175-aacb-0f096036f1d3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/91bdf09c-7055-40c8-b9ba-01e5b8cc0976">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e98c9bdc-a6eb-43d4-9f86-3be7cd317aa4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb13b61b-cb35-461f-8a5c-75ac58a35786">
        <dc:identifier>HP:0003281*</dc:identifier>
        <rdfs:label>high brain and liver iron stores</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3f44ab3-7f46-4dbc-8da2-a78eafe0fc48">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>high serum ferritin concentration</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7dbd10d-9aa9-4b3e-ab4e-80128290c8ff">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/435eb176-0b21-4fee-9f27-e20122165fc0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
        <rdfs:label>abnormal thiosulfates level</rdfs:label>
        <dc:identifier>HP:0011943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00199ff9-4fdf-40da-8dd1-0f7e4aa1bf47">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee047e33-5c09-4472-b3ee-562717af981f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/207ea0ac-efdc-4736-b589-b50ea291215f">
    <rdfs:label>Levetiracetam</rdfs:label>
    <dc:identifier>DB01202</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4c084a8e-ed1e-4826-a66d-2ee22c177bfb">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78a97571-6fa3-489f-a40b-975fe88500c9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f5591fcd-5cdc-4a33-b1d4-240789b97746">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1beb0f9f-1486-4856-8307-ccc8f28572c9">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80db5ce0-48c1-4ad2-9dce-f8577ed73b45"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35c66082-055c-4727-b043-bfc1aefee1de"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c37dda14-7823-4afa-868a-4024cc0c2894">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e12b629c-7b67-46d0-8887-c867f95b7b42"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80ff69f9-330e-4ae7-8cec-200e09cd9a85"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e691c81-488a-4577-b584-7b382080f028">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e987dcf-b7c2-4bfe-9e1b-305c47461b1a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002572</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <rdfs:label>recurrent vomiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4feb2d46-081d-4511-831f-1084adb78ca5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Neurological abormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad8c1865-972b-4c68-bdfc-3db67ca11ab0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d22594d5-943b-4884-ab8a-765f12c26cdb">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26b71192-2540-4244-8fcd-48f96f8a26af"/>
        <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee09b8f6-85e1-4c81-9480-d83b14d724b5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Givosiran</rdfs:label>
    <dc:identifier>DB15066</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76a83d0c-2184-40a9-8573-74183513375d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42cc7367-6ef6-44db-b247-e21431fa9aff"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b395075a-3f14-44b8-bd91-d978f1b7e5d8"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ecba6883-2645-40c6-94c3-f7135431fcdf">
        <rdfs:label>Valproic Acid</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfd58194-ac56-42e3-8bb7-0504a8f16e30"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4cd4296-dc41-47ee-b288-9da5433e3c2f"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2390357-0423-4ef7-9118-f2d74ae711bc"/>
        <dc:identifier>DB00313</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e6258a5-6cfc-4db8-93aa-80d464d01234"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/feb3e8ef-5525-42de-bbf2-efcf97c43f59"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d83d7ff-e006-45be-9468-7a0f0e0715b2"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02d7020e-b832-4f60-b2e8-a7d8453fcc41"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51ad65a5-8acc-4175-a633-590248a8d254"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/19542000-b010-43c5-a617-41219fbc3a75">
        <rdfs:label>Midazolam</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dfd58194-ac56-42e3-8bb7-0504a8f16e30"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
        <dc:identifier>DB00683</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0107a5a9-d7fd-4b82-95a2-58286042500e">
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d404daba-3386-4df6-9b88-8bf8d49c8739"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7bdfe97-96b3-4e4a-b0a6-c50feb976ed0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/950c3391-dff8-4e25-b162-1ce3a2a6017f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/384f327c-bbe2-488a-a940-77d98d1d6f67"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1d911676-b7a3-42f6-84b1-32e4f7d96e53">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b3f9bd6-8640-4376-b349-f7ff7459bfa7">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57188ad0-c322-4c4b-9583-da9f19b86ccb"/>
        <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2d08bb30-c7fb-4c1c-9b62-29684f51b0ff">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ab86056-cf44-4dbd-ab68-5d49b6afeacb">
        <rdfs:label>high Lactic acid</rdfs:label>
        <dc:identifier>HP:0003648</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b357b7cb-8e4a-463a-aae5-a1c6d9c11bec">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2256a2c3-5256-4068-af13-8c95b891f72a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4111aa2-0200-4307-8333-65713d816308">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cee8b6-b735-49b7-b607-88be52f791ad"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d03887a0-d600-4cea-ab46-39555131582a"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66341a89-6357-42ce-8a72-9c903b635d32"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19bb7150-d4a5-47e3-95f8-b94cca9b8af3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2994c194-5289-4e25-a4ac-f0d37adb78bd">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f8a9d7ba-25c7-4670-870a-1adaab78c069"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d03887a0-d600-4cea-ab46-39555131582a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ce2a9bc-7ebe-4b00-972a-2650b65a12c6"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b5ee026-7c0e-4daa-90e6-3545904347aa">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f202f51e-67a5-4eb3-9dab-077ad3edea58"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04f2425a-463e-4492-9fb2-77be8a76e401"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/72060168-b946-4ed7-8bbb-394d3a56e160">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/458cb60a-76af-463b-9104-c5dad78d0c5a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/96549245-513d-4a79-bb50-36e3f26e419f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>Abstract</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0cc81310-704e-4f38-b85d-4422a646750a">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fdff207d-4fa0-4f18-8ad9-4bbb31b16b5c">
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d03887a0-d600-4cea-ab46-39555131582a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f8a9d7ba-25c7-4670-870a-1adaab78c069"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/31311939-e2e9-4531-98c4-1931b6a10b47">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf6ab6e9-baf8-4caa-ba7b-cbc040a3f435"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f291e412-5605-45fb-a217-9e3983cdf052">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b1f510b-de4f-435f-a719-eba086a18287">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8b86f04-0aa2-48bf-afff-2357242f95e7"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e799f0a4-7b38-431d-8d12-b44a55f32a99"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bf3eec1-0b28-4ea6-9344-50637c052eb4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/54534ec7-baa8-44b2-8608-2fa96dbe9621">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6933a463-da21-46fa-95c7-02bfe6c725df"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/add7e764-cb78-45cb-8542-7ae7b607a0a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d03887a0-d600-4cea-ab46-39555131582a"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/157640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0fd0c32c-7429-41a0-bc67-b8c73bc1482f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/faca736a-6e93-4d0c-beba-bcd1af0ae2a8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ed70b0e-224c-4241-82d8-ce49b6ff9aa6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bc66e37-e42b-4bf7-b3b7-c5996831b52c"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f8a9d7ba-25c7-4670-870a-1adaab78c069"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9c7817c8-d367-4c81-b325-94d9b38c5076">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49fc19ae-e16a-4007-8c31-fe6ff34236ac">
        <rdfs:label>verrucous lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccaea157-c711-4cd0-94e3-976bc7b67d29">
        <dc:identifier>HP:0001072</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
        <rdfs:label>Elbow skin thickening</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09c5b0a1-4b3f-428a-8b57-bd7b7bb936c1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Skin papules</rdfs:label>
        <dc:identifier>HP:0200034</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/321b27cb-2e02-447c-ad99-5f3d83a1fec1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
        <rdfs:label>Hoarseness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001609</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69bf950d-30b8-4d39-8acd-d969566bc5d0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011122</dc:identifier>
        <rdfs:label>Skin lesion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf1117c0-17bd-4ff5-827b-ef9a311802ef">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
        <rdfs:label>Mucosal lesions</rdfs:label>
        <dc:identifier>HP:0200034</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
        <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eeb44eea-1b87-4500-92d6-468c80326192"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e441fa8c-a6b1-4dda-90cc-3bb1c312b38d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5acb33e-fdf1-4c67-a874-89597236a600"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee4be9e7-397a-44f7-98e4-c37dc3f5d46f">
        <dc:identifier>HP:0000962</dc:identifier>
        <rdfs:label>hyperkeratosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a162481-7ffc-4a86-bb26-669eccdefc07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53648b59-c011-442b-a82a-59333a936dc0"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55916924-2242-47ee-b996-764a97c04d4b">
        <dc:identifier>HP:0010975</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
        <rdfs:label>Abnormal number of b cells</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d73a805f-c408-44f6-a7a9-1a79abf07a76"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609f1ba-a5f6-4232-9455-600acc5fb9ee"/>
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0ba06c7-bbaf-41f0-8460-98d9b977443d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59c280fa-c11a-4b5f-96a4-dd61736e3248">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28b497ab-abca-4125-afca-d04977da9cc2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/865011ae-0f5c-4944-9fba-00eb660f67d9">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67b27e12-0661-48b9-8128-299412cbde6b">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001386</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <rdfs:label>joint swelling</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1127fd-c8e1-4221-8bd1-1e634f8ebc62"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce3dac4f-25ba-4908-a336-62c94e826947">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97d06def-a9da-448d-a80c-c0fb8f33ba13"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e836bd56-f0d2-48a4-b567-1a2ffbfee872">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b20acb6-0a85-464a-8360-611707c3fc0f">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27c58f43-c5e3-473e-896b-34443448bcb1"/>
        <dc:identifier>DB14507</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
        <rdfs:label>Lithium citrate</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/776eca51-aacb-4232-a698-a32c325d86c2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf85adf4-bb34-46da-8503-8f4209332a14">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6360dece-590c-4a98-94f9-c6482b8f52ab"/>
        <dc:identifier>C07</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5f39291-0137-46eb-bc13-7bbc58d9fb4a"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a3c06a5-6a17-4080-92f1-33c51c71ceb4"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
        <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5d51280-43b8-495f-9cf3-8a88eb71f44f">
        <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6360dece-590c-4a98-94f9-c6482b8f52ab"/>
        <dc:identifier>C04</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a23a6ee-9608-49ea-842d-bcbe5aea5949">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45bf99ac-5b5c-497d-842c-a201df2c33bf"/>
        <dc:identifier>C09A</dc:identifier>
        <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6360dece-590c-4a98-94f9-c6482b8f52ab"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a3c06a5-6a17-4080-92f1-33c51c71ceb4"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81b693a5-9602-4002-a5d5-1f98b8fd9c75">
        <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6360dece-590c-4a98-94f9-c6482b8f52ab"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a3c06a5-6a17-4080-92f1-33c51c71ceb4"/>
        <dc:identifier>C09CA</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a149238-a27c-458c-96e9-be296fb110b2">
    <dc:identifier>DB00126</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/50a7da1b-a654-41a5-a1be-12d623b5c4ad">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd50cea7-a6c4-4b37-88e5-0ece4987125f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32a3d69a-a65f-4151-9489-b8950da7623f"/>
    <rdfs:label>Ascorbic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f88a8cde-c67d-46ab-b13a-8dbb19edebdd">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e274456-2d99-403e-ae40-c40c4d724656"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08a85584-675b-45fa-8c8d-754647283822">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/898d6cc8-d398-40b2-9bbd-537930ddbd8b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/759b8704-2b48-4dbb-b91e-58f1e93dcde4"/>
        <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/354a137c-966f-4f68-a7a0-0bd6dea0f0bd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e527095-7116-4393-933c-51af12915300">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/489e243f-5dd2-425d-9bd6-a5a6a16a5f1b">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/046a33a9-3d81-4a38-b213-f1dec707aa21"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de946b65-07f1-460e-8dd9-123092c279ec">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/69f57502-acda-424a-a20b-822eb42d87d7">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/531c78a8-068c-4189-b071-591be3127a26"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/aa0a5e30-b9b2-46fc-8901-6947ab8f1aac"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99f1a093-a4c3-47fd-abc5-8d3503bcb7d0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eeea444f-7060-436c-8fbf-0802db073f25"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
    <dc:identifier>DB08834</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1e521f0-505e-497f-ab9b-80f40e321638">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
    <dc:identifier>HP:0001931</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low hemoglobin concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
    <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/278e218b-d25c-49ae-a9cf-f23e751a57db"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/934e9240-8165-4685-8b03-9a9658682dbb">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c50b6b8-56b8-4654-b9f5-821c0328fb35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8b37a7d-133e-447d-a81a-d54045205450"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/860e9a68-57ed-4ea5-8ac4-bf96eaa40c1a">
        <rdfs:label>Delayed Develoment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
        <dc:identifier>EC0:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eb029988-9eb5-433b-aa3c-bbe06aa1c22d"/>
        <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
        <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/517283ec-1b8d-4696-acd4-68d4668cc106"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e6258a5-6cfc-4db8-93aa-80d464d01234">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7c2675c2-5363-4338-8cab-084aa90aa647"/>
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/164a23c9-a0f3-470a-9b48-008010994116">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Myoclonic epilepsy</rdfs:label>
        <dc:identifier>HP:0002123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2c3fa2d-fb06-411b-b738-882d1f13f2ae">
    <dc:identifier>HP:0001959</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Polydipsia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3fb96d82-ebfc-4421-bfee-ec887313d56d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9863740f-863d-4d87-af3e-2d69ef08d40b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/beb77d71-e65c-4b51-8fc7-8fc8a43c635f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c5d904d-621e-448a-90c0-fe40d5a57e96">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d35e16a3-42ef-43c4-a7c2-14760e27fe8a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/89b119ad-4494-4438-82c7-5e88b8c42899"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13611b1d-8eca-4c5f-a370-c9b158bda1c5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/58c4e1bc-60ab-4bac-a543-31e94d348bf5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b17380bf-10d2-48a8-b2a6-ad5286eee0d7"/>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1e521f0-505e-497f-ab9b-80f40e321638"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6bd3cd76-b7e2-4638-a834-3bbf1a18ed2d">
        <dc:identifier>HP:0011031*</dc:identifier>
        <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04b91e80-161f-4538-b2c9-2ed639785e4f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2fed4429-ded2-4283-afcc-6c6bfffdc775"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a75347cc-d2fe-4ebd-9fb3-85236b741a69">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b0ac8735-1ee7-4bf6-aebf-02825ca3ade1">
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66a4fd58-ad13-4644-a54f-e587af572f5f"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2df8b7d1-9fd0-4f7e-a4e3-3f1c1e14d806"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70578cc8-4ca2-4835-b5f8-0378efeb95f0"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63b255b0-ffc7-4837-b5e2-5a6fb276c735"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/4765302d-b1b7-4642-8795-3e8be44d3af6">
    <rdfs:label>Consider PLP trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https:,www.ncbi.nlm.nih.gov,pubmed,25001633</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/9a632f47-e14d-40fc-ba37-f5d8694805ca">
    <rdfs:label>Direct Interaction (activity modification)*</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd3cc103-b00a-4489-afa4-19f4d6118048">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b6f7363-3b12-4cad-8635-772b7aa86a02"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4de87f25-32bf-47f6-a8cf-aab30d2cc919"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b30bb01c-ca19-431d-8c6b-4efe4808c0a0"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8caf56ec-f70f-4dc3-8003-180ceaf1dc1a">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c8e9723d-3bc9-4ab9-85d7-0496706282a4">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68ab0b0d-fa9d-4b6f-bb65-d75cd100e423"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Gene Therapy ??</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed0ef6ae-29ff-4641-b538-521ad4710bde">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001987</dc:identifier>
    <rdfs:label>High blood ammonia levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
    <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c426af25-d062-4763-a163-442d14f7525e"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95255f1f-79b8-4357-9a30-fa185c19fd59">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7796593e-bda1-410f-b3f6-372d7faf7c5d">
        <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
        <dc:identifier>HP:0100660*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbdbc56f-671b-45c2-8248-9ca71c9a5382"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08e6343d-ae9b-4cee-a92c-93f6a26c4dcc">
    <dc:identifier>HP:0005952</dc:identifier>
    <rdfs:label>deteriorating pulmonary function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/109101dd-657e-4945-a064-6ee9d5105007">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a815989-1a40-4f1a-9d66-d919ab5075f2">
        <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b88225d-86a4-4261-a220-59604248bc73"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
        <dc:identifier>DB09449</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b8d0502-f87b-4bad-9e93-38695e8888b0">
        <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b88225d-86a4-4261-a220-59604248bc73"/>
        <dc:identifier>DB14502</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b65dcf7-b7e2-47c0-852e-2af79b95107a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb7ab111-8c61-44b2-871c-f906780be4ef">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>protein-losing enteropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
        <dc:identifier>HP:0002243</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d91f857-9d3c-4b60-877f-482f46c0bf1c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e785dc9-69f0-40e9-9768-744a43822b0b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>Metabolism abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/268eb669-66cb-4ddd-978d-0a033eb83764">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>hypoglycaemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cf8eb05-a527-4ea5-86e9-4e9b174afe79">
        <dc:identifier>MP:0005567</dc:identifier>
        <rdfs:label>hypoproteinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44902158-542a-4b70-bf48-3b6b2dce85da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f09e9c53-7c0e-4caa-8dc4-5784b6ee497a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602579"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21944a14-0b1e-48ad-ba09-e9156ff743e3">
        <dc:identifier>HP:0001928</dc:identifier>
        <rdfs:label>blood coagulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38bde5f4-921f-4e68-9b59-ca6bdd38fc66"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e20e8608-956b-4165-9750-e57c4bbda863">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1221fc9-cb87-4410-9933-dbfd2d93ad66">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1868fe00-ed6f-47f7-ab13-3bf26ea8e8f1"/>
        <rdfs:label>Etretinate</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
        <dc:identifier>DB00926</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2a11fc1-6d90-4e4c-9159-b0b2c3890ea9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
    <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80bb87c2-3a23-48f9-a4ae-da0598c75646">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0564ceea-ec19-4e02-a7bb-f00be3f45725">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1da71e14-002c-4827-b8c2-b82ae1da40c5"/>
        <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87d40994-ba51-4a73-b82e-8b61dcef1dc4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25f123f6-c9ad-4a02-b7da-f75975b219b1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/caadcd7e-0960-4452-be41-c1c6b0ab6c67"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b1599a0-d914-4a09-b7a7-7844e9a0a44b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34bb4c4c-49ed-48fc-888c-64504e0ec6c2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2466699-b961-45e6-a222-60362d3c7be0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
    <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
    <dc:identifier>HP:0001976</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79b20a54-351d-475d-ad62-83d63d9584e3">
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <dc:identifier>HP:0003128</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <rdfs:label>lactic acidemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60c10465-2003-403a-b13a-12e5326f3ab5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:label>dysarthria</rdfs:label>
    <dc:identifier>HP:0001260</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f49f71a4-7d8c-44cc-8e8a-691bda34deee">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/009094a3-8452-4e9a-ad7b-a91ffe791cf1"/>
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04de1bcf-b85a-46e2-a277-e8897756125c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e08a5a7c-92bc-4a8a-886d-075fd17bdd61"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d650dd3-15dc-418f-b21d-9ea1855460e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7795ce4b-d92b-40f3-8ba1-3351e2026bc4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fecf705-5154-4699-a555-7c1b2b4ea830">
    <dc:identifier>HP:0012011</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
    <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d74c55d-6294-4889-b500-1dd8df810749">
    <dc:identifier>DB03756</dc:identifier>
    <rdfs:label>Doconexent</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/575d43c0-bdf1-471e-8f5e-8aa1a9b96540"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20fdd993-9dc9-4930-a2fd-88a2813459ac">
    <rdfs:label>high EMA levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
    <dc:identifier>HP:0003219</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d12ebba3-0757-4a67-bbcc-c5d2285a2f25">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdcba89b-fcb3-4b76-9ac0-a760eed0e342">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f489ca49-628b-4bab-b13a-535333ccad13"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbfdd227-ec19-49c3-b577-48a65f050c10">
        <dc:identifier>HP:0002749</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
        <rdfs:label>bone weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ca7a38a-df70-4c20-b8c5-0c1c30f4dc62">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031429</dc:identifier>
        <rdfs:label>low bone formation biomarkers</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb491d27-3559-4afc-a203-7d3cb9af68d0">
        <dc:identifier>HP:0002757</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>bone fructure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f90acc2-db67-44de-8989-767628066880">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004349</dc:identifier>
        <rdfs:label>low bone mineral density</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4cd4296-dc41-47ee-b288-9da5433e3c2f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fecf705-5154-4699-a555-7c1b2b4ea830"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6716d8b1-8623-4ebd-b5bc-aedc59d942d9">
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Speech and languague delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68f45f95-9ebf-4955-bfcd-14121054c602">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:label>Developmental impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>HP:0000750</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8db4389-76c2-4563-9ae9-66d74d26bd5d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>Generalized muscular hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc1660c5-6a5f-43e9-b68e-baf283a860e4">
    <dc:identifier>HP:0003119*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e657eaf4-99b8-47c7-8247-b7501d4f1c28">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8defb044-6246-4f54-8c63-6922a95729af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/501f93ab-8e95-4fd1-898f-793fc48eb575"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08242c29-fb9b-424c-8623-9b2cc1026e20">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>Abnormal movement</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4a26bd8-5b78-438a-99d3-775bbbab9902">
        <dc:identifier>HP:0001347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:label>Abnormal reflexes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e808559-b0f9-45dd-ad57-576aa2eeed85">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
        <dc:identifier>HP:0030178</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>signal abnormality of the cortex</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02019224-3dc8-4232-b3cc-2ff6b7e669d0">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>encephalopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f4161b73-1295-47f5-b936-628581ef5b4f"/>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7f47eeb-403d-4d6a-82c5-db265741d4f8">
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
    <dc:identifier>DB14476</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8c00cb70-dcd2-4b32-9675-e6616ec44977">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42f599dc-d8e5-46a6-a60c-a1a68a891e8a"/>
        <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a2067a-fc86-4418-bf05-1adb555a8557"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f2b4851-a363-497d-b374-54e603d0a0c4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bd7aa9a-73d7-4ff4-b9c7-622458fe4373"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5314f7cd-6548-48c9-b90b-f5fe76709653"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432805003657</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10a3261d-4597-44f8-bef2-3ae7314426f0"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e807a5b-dfa0-42c7-8cbd-1dcf41090250">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/825492c5-1b59-4bb5-9303-9a14865ca602">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:label>Incoordination</rdfs:label>
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3682dc5b-a5d8-47c9-8f33-7acaf4426878">
        <rdfs:label>cataracts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000518</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39065f05-c685-40b3-8a59-00b741352dd1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Xanthoma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <dc:identifier>HP:0001114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ca908a-6ca5-4dbc-8340-a942068c4667">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurological dysfunctions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1e968b5-7dba-4ebb-8f96-4a84f97deb11">
        <dc:identifier>MP:0001665</dc:identifier>
        <rdfs:label>chronic diarrhoea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b15971c-12ab-4950-bcf8-7f89dbf8e0e8">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e35668-ff0e-44fb-b5ab-22c2470acd5a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bf3eec1-0b28-4ea6-9344-50637c052eb4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be0496e5-c94c-4326-b1ce-698ed95ddd88">
        <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <dc:identifier>HP:0040129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6eeefa16-bc4d-4dc9-a4e2-ec9c64b66023">
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:label>abnormal gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a7d4f7e-f6e0-45ba-b7a2-603121cfa76b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f854260c-056a-41a7-8281-972da3cdf809">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>EEG abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/531c78a8-068c-4189-b071-591be3127a26">
    <rdfs:label>High triglyceride levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <dc:identifier>HP:0002155</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45be5923-2f46-42d6-bb80-b9128990de54">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0321408e-e2be-4045-8834-eb8ac8d23c46"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a6dc88d0-400c-4834-83bb-cbb43cce9d70">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b1199da-ee21-4fa4-9486-54816c00d0a2"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9974ab6a-d0ee-41d5-a0a6-7a7a3b7cb09e">
    <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ddbcf39-2660-4e13-814e-613f67634d0f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/38b33047-41d7-4934-84e9-a46ee9b1a911"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5f78800c-d43b-41db-b16c-e83a65615255">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546">
        <rdfs:label>dystonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001332</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/a6e18f20-4035-454d-9a98-bdb87ab1c977">
        <rdfs:label>Functional interaction(Mechanistic B)+Supportive (C)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6c49420-d065-44cf-8e3e-d8ed83dd6356"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d325af64-08fb-4c8a-afcb-55fe0d986bcd">
        <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95c9bcf4-1981-4c88-ad09-79f2ff7403f6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d04c8a12-7d0c-4704-ba01-5fd612539f66">
        <rdfs:label>Leukodystrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <dc:identifier>HP:0002415</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b55de00-c4bb-4c43-b081-f31de6b77dbd"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd150e9c-8605-4f59-92b2-d48b54ceb3d9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4748622c-7197-495e-8f4f-713a47c51bd8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52eb6e71-95af-41e7-8b13-2661527bbe33">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Hypersomnia</rdfs:label>
        <dc:identifier>HP:0100786</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a6792d2b-fc8f-4e6e-a194-8a812f80f2b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93cf5086-ff00-4e82-a141-49eef9a3f28c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6fa1033-1d28-449b-9182-1d7514aca7d5">
        <rdfs:label>Carnitine deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0003234</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9428dfe1-55ca-40a3-9ae3-f330f35d6f33"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6099d63e-78bd-4598-a7f7-a282b902990a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <rdfs:label>Pyridoxal</rdfs:label>
    <dc:identifier>DB00147</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb57cd50-c24c-41fd-bb1a-3ae1697b207d">
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bb87e4e-2361-4b36-a089-205a3aa26e09"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea6eaf7c-8af7-4171-a769-0877720e6ced"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17f0354c-958c-4bfb-b871-d6c7bba08470">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fe521dd-7701-4d12-8172-38907e8e97cb">
        <dc:identifier>HP:0004364</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
        <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e95cfa73-9357-4980-8557-d51defae0fc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ea4f499-efdf-43a0-9fe5-1e19f32d80ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6570e767-4e17-4246-bca4-b8962c193bfb">
    <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ae309c0-ac14-4d1f-9f6b-e6f151987a8a">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/590a1ee3-713f-427c-aaba-30804fc2f670">
        <dc:identifier>HP:0040300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a">
        <rdfs:label>Symptomatic(C)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8c0bff3-5f41-4616-b1a5-95ca1443f86b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ff1bccb-d240-46d0-98fe-ed81ace66794"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0dfa0543-4e60-4b9f-ac46-9224e2328e24"/>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a9edbf5-ae71-451f-b4af-8287775ca9a6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45106cab-e51a-49cc-9474-8ba0f7addc5c">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
        <rdfs:label>abnormal fasting glucose</rdfs:label>
        <dc:identifier>MP:0013277</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5151c06-b6ca-4fec-8c77-8ea3edae9458">
        <rdfs:label>high facial soft tissue volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
        <dc:identifier>HP:0000287</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5bae5631-7169-444b-a8ab-b41f6b291ef2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2590c66a-4a92-494f-8cfd-eefede827042">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c48e0dec-9a54-45c6-8b08-2051b7a7dcdc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a143d0c3-c299-458b-ae4e-093575eef873"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59c7bb09-2f0a-4579-a7d4-86c077d4a9c0">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c35c02e-ead2-49a1-9eb2-b2f7d902f6ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b72b831-6707-4a3c-b653-e34b402505d1">
        <rdfs:label>hypochromic anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <dc:identifier>HP:0001931</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b85865d5-c203-4e6e-8959-b97409518f74">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
    <rdfs:label>Diclofenac</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0e670f12-df84-4e37-a5b3-d9311eecfcf6">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ae6378e-e1ed-4f02-b3bf-c99ac2722897"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82f7ea61-5a63-4e55-80e3-b05dad441491"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81ff3eef-471a-4d79-b5d1-6c6e35418f30"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00586</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2839aa44-5e60-41a7-80fc-596376209b58">
    <rdfs:label>Impaired nerve conduction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040129</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1af2ffc4-a737-455b-b175-6694f2277323">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cdcd2ca8-3723-4265-9096-0881fa890126">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e36c9e4-c1cd-4665-9939-9fd1a1f29963"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a0710b6-a667-4063-b365-1768a32a5edd"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9238b62f-b7d3-48b6-8c1c-53734213382b"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4867831-ea3a-4ab8-95c5-02e042f15717"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56c51a73-d97b-48b2-8b3b-73f11c252403">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>High α-ketoisocaproate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e2d0803-eee9-4228-84d0-29eacea91874">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83fa51dc-4552-4aa6-9628-34b39f1c264e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/095b0197-65d9-4646-a4e6-9b949fb835cf">
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb627306-bef0-42b9-bece-fa5804bb0ff1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41290a5a-1158-43ee-87c4-14d478fbb026"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c711460-2654-4dce-953d-151ed7a6f689">
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de93f441-bb76-4521-9693-151fd5e58312">
        <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78e729df-5b9d-460f-ac6c-6327913d04d2"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f484f26-ca66-482d-88af-f3999ab3c38f">
    <rdfs:label>hypolysinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001987</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8baf6428-97c3-4cf4-85a4-4d24d27b4f3e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b13f50a-667b-4afe-b57c-a4ba8122b6b8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b687827a-459a-40e1-8168-ce1ebef30d92">
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
    <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
    <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe8622fa-222f-41a7-aad4-29732dba1a8e"/>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a593c3d-d176-4761-bb09-acd38eedc280">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/50f513c4-dd58-49f8-a53a-d08ed02d7ff5">
        <rdfs:label>Symptomatic (C) + Functional interaction( Mechanistis B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3182d26-bb04-475d-a744-b624c0897e8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69e172c6-cf4d-4d9c-a13d-6e8eaaeca005">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Abnormal gait</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25224dc6-67c5-41a1-bc4e-ec48e3441852"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e56cafda-61c2-4628-add0-360ae0b209ba"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd28b2b3-fa6d-41ca-8d66-64b8ee7ba451">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10b362d8-c742-485f-8309-1cd0cac521ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6933a463-da21-46fa-95c7-02bfe6c725df">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <dc:identifier>HP:0001288</dc:identifier>
    <rdfs:label>Gait abnormality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dcb5b8f7-ed4c-45a5-b2e2-8623f746cecf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68340dc1-ba7b-41b7-8f1a-00830115ba2b">
        <rdfs:label>Acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001941</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e95cfa73-9357-4980-8557-d51defae0fc5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a19f74af-f856-4591-94b2-23a96291bc34"/>
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4f8bb291-d3b2-435d-866f-6925d37da2bb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4a4e252a-e2ab-47fb-8f3f-ef2bb505a3e1"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85c80078-4996-4224-aa06-4218f4866dfd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
        <dc:identifier>HP:0012075</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Personality disorder</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a60c2cf-9aa8-4515-82b4-8ebbed119846"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cd53384-53f8-4297-a05f-5fdd3e7b7cd4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>Behavioral abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/277c7006-059c-45f3-a9fe-44e59bb6a1af">
    <rdfs:label>Zonisamide</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/071422a1-c4ba-4a2c-933f-90722c0620e9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7aee37f3-4ad0-4cd8-b68e-57656b39f73c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dcda867-8d16-48d5-88e6-dd56c01c1f63"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00909</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35c66082-055c-4727-b043-bfc1aefee1de"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fde88acf-1b95-4c62-bd99-82e088ea6c40">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7aee37f3-4ad0-4cd8-b68e-57656b39f73c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7041d57-f48d-494f-920f-9ec8176b4a68">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edb3ed95-9e03-4f82-a5f6-ebd47eb17a09">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:label>Fluid retention</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000969</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f0ef3d8-5e1a-4771-9ebd-30eb64e35f73">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0c323d14-8244-44ac-a640-0adce81c1642">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2b12adee-c0e6-46cb-85d3-b401cba07c1c"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a9f8929-e421-4748-b949-ae7c8f89c1ee"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a0710b6-a667-4063-b365-1768a32a5edd"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB08809</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e63c2959-4141-4195-b936-e38979b741a0">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1d15e1a-83ec-4a68-ad7b-86b1598b236c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6557496b-476a-4611-83c6-7cfb0878a42d">
        <rdfs:label>abnormal microtubule assembly</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42b12d85-8034-4896-a149-2051ec07b5ff">
        <dc:identifier>HP:0002718</dc:identifier>
        <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c6c0a51-f0a8-4597-93c6-f1e1758f0a26">
        <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
        <dc:identifier>HP:0001874</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa2a25d3-d662-49c9-af14-07ed8e9a6ee1">
        <rdfs:label>CNS damage progression</rdfs:label>
        <dc:identifier>HP:0007367</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/016d4451-daaa-45cc-8c5e-80e891b61a64"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6298bf2a-b40e-43eb-a5c7-6ee514e033c6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce02324b-441d-40e9-9feb-4e5e7cea54d2">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b106c6be-9816-45db-b877-611b43f842fb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69b3fc66-250a-4ae3-b010-dd67186394ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/133469c8-2123-4b28-b5ae-b2b9e2f909d5">
        <dc:identifier>HP:0001298</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain pathology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d35d5143-5ed3-4c23-87af-3ec136203246"/>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc741eac-8119-4577-aa3a-1cafbfa2548c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
    <rdfs:label>Iron</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9c50667-acff-4549-b45b-3bf29748d979"/>
    <dc:identifier>DB01592</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4bbdcbf-93c4-48c4-817b-14e57d326ca6">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50450c1d-626b-4d96-9f5b-f33260916415"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fd57cad-a1e0-4b52-96e2-1875700f7e95"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca05a0a4-f990-409f-bd4b-f4b60acedc44"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a571cf88-d282-4cec-8fa7-b89a77c7367c">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0003198</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
    <rdfs:label>myopathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fe96f09-ab72-442d-9b28-d6b1ac41b165">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0010919</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
    <rdfs:label>High total homocysteine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/528cc740-5ff7-4eb4-b6d1-7f6231d37f02">
    <dc:identifier>HP:0012187</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2055da76-8047-4577-babc-0ca09c26cb56">
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5829689f-d297-441f-abd5-1b7df7e331cf">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ca6cd6b-809c-4e69-8688-375f08a3fce5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a4ce962-a24f-4213-96f4-ff8c179f8f76"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3f69f81-8f2a-49f7-9ff9-4237758826c4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9762412-8297-4686-908d-70931449df00">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17def98a-815e-49f5-9115-afa735086de1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4108a8b-9d15-49ba-a4e1-6d5fb14cdb15"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43d43020-95c9-4e49-a7d8-9afd6d5e3c85"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d7e9e287-6b94-4d0c-9021-b2f91c4f815e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f576a263-3aec-4eb3-b83e-5321e7f892c1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/451f02ce-ef9f-438f-95cd-308038626a12"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b425d04-1dca-4439-a917-7a200a790b10">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c1c3ae7-35f1-4821-9848-d3d9c030ac19"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ceb010c-a278-4985-8fd8-186a5a6b7c60"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac40f659-bd72-4398-b2e0-dd107b43688b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/441a3644-6e1f-4ebb-a6fe-637f06c71706"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df12d611-a087-455b-b820-0554ee370665"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/47b8bead-66f5-48c1-bd45-34a34dad34a9">
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42d6c3cd-e7e1-43de-bff6-12b60f82d0a2"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/903f618e-670f-43da-89db-b64c69826cbc">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5699fc71-07d0-435c-a7c6-d0b33f16f39a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c04293c-cf06-40ac-baaf-a217dc0cb0e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a76361bb-e2d0-4ade-a592-df3db255106a"/>
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2383bcb-4c71-41c0-bc8a-1659c306cfbd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9d66741-25ff-438a-b151-85dc3fd12d31">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
    <dc:identifier>HP:0011118*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0dbc3e60-44b7-4b22-94ab-f44be1688fa8">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75af55a3-8962-4f86-861d-d8506b8586dd">
        <rdfs:label>choreoathetosis</rdfs:label>
        <dc:identifier>HP:0001266</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/769b2ce1-3370-4102-ae65-e196fdcc7fdf">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0010553</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:label>Oculogyric crises</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6389043c-4a62-4cb3-afe7-dcdcb359890b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96842997-0ce4-4292-b551-25413e5ed32c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d94e4499-0c59-408c-8a46-21ef7534da7d">
        <dc:identifier>HP:0008936</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
        <rdfs:label>axial hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/353df1ca-4071-4a6d-9c08-8d799e95c995"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d2f6c59-a3ec-4d6b-b06b-ef4d88794e1e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be64dcc6-4535-4f93-9c42-32bdac310c27">
        <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa6c9cc-6bcc-44e8-83ee-31ea74516af6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d646baea-1cf3-46b0-9102-a24896b54496"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f18659c-d8a9-4a2f-bef7-498570d14417">
    <dc:identifier>DB11991</dc:identifier>
    <rdfs:label>Oprozomib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09016d02-4bff-44b2-a4fc-f789a7dc5b6f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0918ef2a-6d85-42e7-88e8-252d2bb21ac0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
    <rdfs:label>Digoxin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59072e55-a3c0-40e2-93be-4650a13c6873">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a08511c5-8804-43f8-bb35-2413dd68614e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/324ae299-4415-4320-b3ad-5b0c55a0533f"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5956549b-a603-4e88-9ab8-2e155f3b130b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31fcf179-bf75-47a8-a7e4-67cda339b0d0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00390</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ddade836-8e67-4033-b848-0530bfcb6f47">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59074469-582c-4106-80be-0f2036c0e0c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/039126b8-28aa-4975-9dc3-5f3415dbacbe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8df45af2-eb15-4c20-891f-b7a8fe7faaaa">
        <rdfs:label>NA</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001877</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12a32e84-cda4-43b5-9ee7-cd2b35685e70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7eee91ad-fd8a-421a-bf13-5e03937b097d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/454a1cef-dff1-4ab8-b5ec-3b95f87baa24"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37e5f456-1db6-4cef-be40-81e678ee24c7">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Imapired muscle function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://academic.oup.com/hmg/article/22/15/3003/652530</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd1ed8c3-6416-4a61-9a19-6cb466510f27">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e16c5322-7f53-4ccf-9520-7755f48f7982">
        <rdfs:label>Six Minute Walk Test</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ef95d73-30cb-4211-95c7-d676b26d19e3">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <dc:identifier>HP:0010535*</dc:identifier>
        <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3a7f31c6-ba03-4bbb-b223-296d4ba3ff3d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bde5c6ff-e655-4224-90ed-0c914d5336d3">
        <dc:identifier>HP:0002111</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0de6aa1-029f-4ffd-991f-e6ea6656c819">
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fdc7759-569f-4466-92cc-48183077cf1e">
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7795ce4b-d92b-40f3-8ba1-3351e2026bc4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08379e2c-053f-49e5-a74f-8a0ee659cf9e">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3ce173f-8a70-4a99-82fa-985351dc601c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/313d1b45-5014-46a2-b010-52f2f5218323"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41cab147-8711-498b-ba41-3edb6d2f325b"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d650dd3-15dc-418f-b21d-9ea1855460e6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e503d938-b491-4e10-aa3e-f42ba61ef187"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00509</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f49f71a4-7d8c-44cc-8e8a-691bda34deee"/>
    <rdfs:label>Dextrothyroxine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b38da6a8-4b16-4c98-ac7a-90d6882be8f8">
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/d3ad8d1d-159f-43cd-acfb-bd0fa86ad991">
        <rdfs:label>Direct intercation (Mechanistic A)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ccedd29-ee56-4729-a244-3a5616e17c71">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0002333</dc:identifier>
        <rdfs:label>Abnormal neuromotor function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b211092e-7dcd-4e92-852f-708332b87321"/>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2ecc45a-d0c2-4a9b-9739-901450e9f6a0">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74c5b93b-f696-45d2-a846-1c4bf872358d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/476a68f4-59e4-49df-900c-02ffab8c2364"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2cffd568-648c-4dca-b937-c9f7fc243f3c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70578cc8-4ca2-4835-b5f8-0378efeb95f0">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>neurological abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d77490e6-c623-4fed-8d8c-ff8eeadb7b58">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abormal liver size</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f839a777-c598-4263-8bf0-08566682a47a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Muscular hypotonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
    <dc:identifier>HP:0001252</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/022a79fc-6891-4601-bd01-cb93db9eb748">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0004348</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/894527d4-b53a-4ec9-95b3-03587e59c6a8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f5fadc-054a-47fe-8dbf-5762e80f6923"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22153b12-64ad-4e7e-8f9c-af1ad9c0bfca">
        <rdfs:label>Low AGA activity</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9cbba85e-9a12-46ba-8113-e882e21da037">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/174bf0f2-080d-4d98-967c-6a1029e5edff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a03bbd04-cbc7-4ae9-8799-85bc64887e25"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9974ab6a-d0ee-41d5-a0a6-7a7a3b7cb09e"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52a7f49b-08c1-4d12-b85c-3f8319e315cb">
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/82ba87ee-eb53-4ae6-828c-99b9ff7dc6ca">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e539ccd4-c39c-4039-9dfa-5fd9a28bb0b5"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51ac32c1-b15f-407e-85ed-3aea4c6e755a"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68875907-2da3-4157-a9c2-4aeaacf5830b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
    <dc:identifier>DB14644</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58501ecf-379f-4fa7-b8e3-fdb1e09720e2">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:label>low physical activity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a6e84942-30ba-4c08-a6fd-b2a75bcec64b">
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bc46967-a0dd-4453-b7e9-f99068659eb2">
        <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bc9f375-a10d-48c1-9170-40c45276aaf6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a58b6b31-eacb-4d5b-b45e-aaefa1305119">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0003547</dc:identifier>
        <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003547</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/162dbb94-56e4-498a-82f4-447c32defb08">
    <rdfs:label>Hypomagnesemia</rdfs:label>
    <dc:identifier>HP:0002917</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02e04429-9438-4fc7-ae56-358e4f63c91a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8e554fc-81e2-4bf9-ade4-1c8b8e0081b2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0001744</dc:identifier>
    <rdfs:label>Splenomegaly</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa05b873-44ce-421d-8275-f7e2dd14b375">
    <dc:identifier>HP:0002621</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
    <rdfs:label>Atherosclerosis</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7263897-6af2-4147-8839-7093f16ca467">
    <rdfs:label>dyslipidemia</rdfs:label>
    <dc:identifier>MP:0003949</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e0b072cb-5662-4120-981f-2a7aa977b41d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eedde906-0e97-4d4c-8830-83076046b73c">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0007266</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
        <rdfs:label>Brain demylination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0caaebcd-7355-40db-b3d6-3597ae05121b"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/279c68a3-a1f9-4151-97ad-dabec9d59d7f">
        <rdfs:label>Abnormal Awake EEG</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5875a23-82dc-49c1-a699-6f23624391cd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/102e2f9b-33db-4968-b47c-497c96a34d15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a56e833-5b3d-452f-bcd6-1ed87991640b">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0001347</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:label>Hyperreflexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/357bd54b-9ced-4c52-a13e-c409af7691ac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfba1b3e-1ca5-4e69-b0ce-5c070771ad81">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioural abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e48aed8-f835-44a2-8b5c-2ebab610b4bb">
        <dc:identifier>HP:0012449</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
        <rdfs:label>Delayed mylination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef3a4439-1383-4986-9958-9c4b6ed88b38">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>Delayed development</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c63a4ba0-50a4-4346-9f1e-ad8033f54f75"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae5434d5-b684-41f8-aee3-12697425016c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a865ff23-f975-4b5b-9c1a-588b1fb54f29">
        <rdfs:label>Low IQ</rdfs:label>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fea8714e-9f72-4ad2-a41b-5ee1594fd2ff">
        <rdfs:label>Foot clouns</rdfs:label>
        <dc:identifier>HP:0011448</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e77c532a-ee5e-4b9d-8dd3-3d6319812dfb">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <rdfs:label>Poor traction response</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5ce9a25-bb4b-429d-a8e6-16867f062c2c">
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffae1b3e-e3e6-467a-9015-0fbea1464cd3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cca49989-ef0a-402b-b56c-bb2c830d1328"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ede96b04-5695-4da8-8962-9d6cb40f5f40">
        <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1f8caa2-6cfe-4c9a-9a0e-07568e1efa75">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/0b77f1bb-42f5-4ef1-aa8f-2f90fa42799d">
        <rdfs:label>Direct interaction( Mechanistic)&gt;&gt;&gt;Activity modification</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8887c610-c349-4f45-aee4-e8e73754215a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
        <dc:identifier>HP:0031377</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal cellular proliferation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fad966a0-e824-475b-bbeb-2c06f8e8c1bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7fa2da6c-74db-43fd-931d-dea09c38825f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1141e494-12c6-4f08-b2e2-9a92364606da">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90e68388-d963-4812-8d5b-bd3deaaf76ef">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
        <dc:identifier>HP:0000704</dc:identifier>
        <rdfs:label>Periodontitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/af49d5e9-d7ba-4867-b5ff-7be824232469"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
        <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
        <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e441fa8c-a6b1-4dda-90cc-3bb1c312b38d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d17d3120-13d4-4e80-a38f-e6e3f1d1918c">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c8be259b-402e-4818-a369-5ca2afd6b2ea"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a97299c2-b244-4aba-b669-c771c7df74e1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:label>acidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28b497ab-abca-4125-afca-d04977da9cc2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a162481-7ffc-4a86-bb26-669eccdefc07"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <rdfs:label>Pegademase</rdfs:label>
    <dc:identifier>DB00061</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4267174f-89ea-46f0-98f1-f90de341bd57">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94cbd721-a2a0-490a-aac5-0bd6043ae8fc">
        <dc:identifier>DB00103</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
        <rdfs:label>Agalsidase beta</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/866c408a-8a29-48e7-bd52-08ec234ba1bc"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e89ed383-88ca-4862-8f6f-d35958903903"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dab3d0dd-0638-45ed-87a6-6b3195d6889b">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56a9d506-ac81-4868-854e-bfde207d3dcc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1126f5c-a04b-4d93-8a69-11468ec7d3bc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7c4d086-2fe8-48e6-ad28-29ec0eebac38">
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cce25150-edf9-4260-a9f9-5d43c60efb8a">
        <dc:identifier>HP:0003343</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>GSH deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
        <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca43bd00-bbd3-48ec-b2e3-caf05bf13fcd"/>
        <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
        <rdfs:label>GLUTATHIONURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d6e351d-547f-4073-a099-20bc04e9c05e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89582e11-27f3-43b5-ba67-e94f3ec232b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8b35a9f-8151-4f00-97ea-b44443b80ca8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41290a5a-1158-43ee-87c4-14d478fbb026"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70578cc8-4ca2-4835-b5f8-0378efeb95f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f5e3fee8-9af7-4940-b230-6ebbfa0c486b">
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/747c3b81-b2ed-4d57-b90b-3a2b39f544bd">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2f44f29-0377-423d-94aa-4d748859eeff"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f08fa5f1-28af-4496-8ce9-304fd52d54d9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/095b0197-65d9-4646-a4e6-9b949fb835cf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/832655f7-ac80-422b-89f4-ed9fb9d0a553"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85d92e39-45b9-43f1-9859-cde450437a99"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7dc84ed-6e35-4f7b-9585-c55189d4537a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cb3bf57-4b74-4a62-b9ff-333ede91800d"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75e76c64-a6ee-42e7-b259-8d048b9508c2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ff7dbbe-792a-4ead-8364-9c6afbf79009">
        <dc:identifier>HP:0031851</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced hematocrit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ef2cb476-ff7a-4004-973e-5ef04b57f5d6"/>
    <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
    <rdfs:label>FUCOSIDOSIS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0cc3466a-ac8a-4cd0-aca7-3eaa1be80daf">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e7c16b0-3756-436f-aea9-e07de919e06c">
        <rdfs:label>Pegunigalsidase alfa</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
        <dc:identifier>DB14992</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a24c5361-66ed-4cff-87b7-af0df95598fe"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/866c408a-8a29-48e7-bd52-08ec234ba1bc"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6ba0a24d-30ff-40b4-bee2-f092c6e67398">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/123b7d36-c3a3-482e-ad1c-5edc4c7850f3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e5ebfef-7e60-4652-9098-8ebe5e65c45e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d35e16a3-42ef-43c4-a7c2-14760e27fe8a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea55395d-e2b0-4840-8f36-46c1f93ffcf7">
    <rdfs:label>tachycardia</rdfs:label>
    <dc:identifier>HP:0001649</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/085e63bb-5a70-49d1-bb9c-a6322bdd1941">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25224dc6-67c5-41a1-bc4e-ec48e3441852"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9913d785-92eb-401d-aa17-5eebd420e215"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90921a76-8314-46d5-8f1d-e9c1c944b43a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <dc:identifier>HP:0000817</dc:identifier>
    <rdfs:label>Poor eye contact</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15a1b823-0a78-40fd-a3de-1532ce6c7e92">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78ffa152-f7bb-4de6-92a3-1746e291f42d">
        <rdfs:label>high fasting triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b8e9ed5-da27-45f4-a388-f119428d1ea3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b4d3833-37da-4a92-b3f9-49557ed64eee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5b8a826-db9a-44fa-a5e5-9bde849b80a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97afabdc-84a5-4b7b-9148-6b19b7500925">
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:label>High LDL level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7041d57-f48d-494f-920f-9ec8176b4a68"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96a8bb2f-7070-4218-9e18-351b59aeea31"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98cdae13-37ee-4da2-ba3a-77f3cf878803">
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypertriglyceridemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf32beca-d2c8-4c9e-bbbd-4d96c4bd5a78"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2b2b3f0-36f3-4b09-9fa0-74e9051c78ef">
    <dc:identifier>HP:0002071</dc:identifier>
    <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8ec28fce-bbae-4895-b9fb-719a1a00ebd3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b75ef22-74d9-49e7-9864-fa7dbb43aaa6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>Short Stature</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc47a960-729b-4a63-bfd2-b1befb5448d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4abc7208-cfe6-4b0a-ae71-dca129223b6e"/>
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
    <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/439ab8e0-b48a-42ef-b335-0a75a7aea44c"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e79df711-0b81-41ce-b776-16b072f2d7f5">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bc64080-9846-4932-88f5-5eb5974d1ecf">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc9609f1-0034-4d4f-abeb-01989939a276">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ea5b264-d8b2-4789-b115-c79199e24555"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
        <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bb74ce1e-64da-4599-8859-d17727ddfa82"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52ee7e19-a7a7-48e5-ac1a-25655124ffae">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c31794d-825a-4242-b049-686f7edd3f08">
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb3fe4a6-2d3b-4798-901a-7f3c2911f5fd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a7843bf-3fbf-4e21-a175-ab709350782a"/>
    <rdfs:label>Glycocholic acid</rdfs:label>
    <dc:identifier>DB02691</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/452ad14e-6568-4ec1-b878-a2f3f9ff0be2"/>
    <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
    <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/119f4380-b782-463a-bc3d-0926f339fdda">
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>defective heart function</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8b12b36-695e-4b50-b5d1-bbcad4b4dbb5">
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>affected functional activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0f8bae24-e4e6-4c3c-895a-d261b017ff7c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77128786-c792-4cd7-a73d-a1230162e435">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a11b24a-8838-448d-9f8d-e3f0e8b97fe9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfdf0a76-2bde-4f41-9b5c-3d6e5da8c136">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
        <dc:identifier>HP:0006530</dc:identifier>
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/963c3f8c-583f-4661-a836-5a8474d970b6">
        <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
        <dc:identifier>HP:0002086</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/183f8bda-005c-49e8-ac3c-1730cb41ab8d"/>
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9172be3-ce3e-49e0-b57f-a07ef422afd5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Difficulty breathing</rdfs:label>
        <dc:identifier>HP:0002098</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/701b8dc4-91e8-4e60-b458-eb2c8870bf67">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <rdfs:label>Spironolactone</rdfs:label>
    <dc:identifier>DB00421</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45bf99ac-5b5c-497d-842c-a201df2c33bf"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/abbefb84-724d-4cef-897f-6a95ea04acc1">
    <rdfs:label>Sirolimus</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3ef1e0d8-21af-4a76-8ec5-1466ec7bf240">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27e305ea-20f7-4bb8-b069-8e3ababc2fa5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e274456-2d99-403e-ae40-c40c4d724656"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/209e5568-7bdc-4730-ad2f-9014ef353677"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/613f6c1d-030b-45e4-a227-6dace7cf3c31">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c0960c2e-2c66-48f7-850d-fed3d011d866"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/729aa4b0-0de7-4157-9bd0-28bd4efb6ee0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/8a5c5203-9f9e-4654-9e6c-6c5d565397b6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27e305ea-20f7-4bb8-b069-8e3ababc2fa5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
    <dc:identifier>DB00877</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf6d6cb3-4b13-4696-90d5-19092d8e5a0b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <dc:identifier>HP:0010472*</dc:identifier>
    <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f64e7e1-d3e4-4197-8583-960ed881b4f9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/a1100e73-3414-4fd0-903b-b024e11fcd2b">
        <rdfs:label>Functional interaction (mechanistic B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>http://www.malacards.org/card/hepatic_lipase_deficiency</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613521">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>UROPORPHYRINOGEN DECARBOXYLASE; UROD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b971db0a-e518-4c32-b0e4-14019319305c"/>
        <dc:identifier>https://www.omim.org/entry/613521</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31e2dbc7-19f1-4960-8c93-6ba9467f6ec5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b53c5042-04e9-4929-8ce5-278ca84fc4ff">
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002574</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2751edd7-6c88-496c-96aa-05f25cc5bb24"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6360dece-590c-4a98-94f9-c6482b8f52ab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/776eca51-aacb-4232-a698-a32c325d86c2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5117547a-5a0f-4f78-8cc2-235818387feb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7fc1183e-8d93-40d8-95c5-a6d3c8142712"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca81faa1-f0a2-4e1b-bae6-c018ff538aea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005110</dc:identifier>
        <rdfs:label>Atrial fibrillation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b137d29-2b98-48e0-a157-c34b277aed18">
    <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04867fff-a7a3-43b0-b97b-017dca6f339b">
    <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0011013</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5967fb6e-8294-4128-95d0-d5982de07a06">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32312dee-8af4-4fef-9fba-3109a858775c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82ab794a-4dd4-469d-8e4f-0ab627e15804"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/119f4380-b782-463a-bc3d-0926f339fdda"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed195bae-f4c9-4d5f-8481-7235934f09f2">
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Lack of energy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73c247db-9239-430e-8f54-b645cf90fc99"/>
        <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9aa8579d-c385-44cf-a6ef-619a52bf6ac0">
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c16584fd-9c1f-41a3-a877-5e0ac04b40d1">
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/b3a200b4-7565-4d77-99db-3b7288f174c3">
        <rdfs:label>symptomatic (C)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52f9b569-ab19-4943-8353-c91ee6fda946"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12dbc0ac-a2b1-4074-9c2e-f66505fa91d2">
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f17d3168-31e3-4d37-a223-ff2591a58549">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Muscle atrophy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
    <dc:identifier>HP:0003797</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1787471c-d7e9-4447-8cbe-dfd09b8a2267">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd1bd4c8-b9c5-4ef9-acb9-656776713290">
        <dc:identifier>HP:0001507*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <dc:provenance>PMC2676979</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78557d5a-2904-426c-977f-47c3b2259b55">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe5c3bd6-708d-4793-a498-d9bbe4073c09"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/535204ef-5d71-440f-a75c-2090edce5763">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low ATP synthesis</rdfs:label>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7450109f-4adc-4f6a-8605-1e1f449b3224"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8dc4f6c9-1406-4db3-be29-7114207a5a1f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/501d7208-c4ea-4ff3-98df-93924ac3f99c"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/30f1a5d2-8bd3-4c75-9e89-3d46babb1a38">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d677e605-208b-4b88-837a-5f03a3fbcd0d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
        <rdfs:label>Abdominal pain</rdfs:label>
        <dc:identifier>HP:0002027</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc23d225-ae21-495e-a700-faa4b4cf2d9e">
        <rdfs:label>Pruritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <dc:identifier>HP:0000989</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3492aa71-772d-4e77-bb5d-daf670843fba"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbfed508-c4e5-467d-8de0-241662856d56">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fd6273a-1e4d-4712-be8c-672f3912b847"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a42d0636-0798-48bf-b515-86a56356fe16"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/252248e8-db37-4a1a-93a1-e9361453dc11">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatotoxicity</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/edb3ed95-9e03-4f82-a5f6-ebd47eb17a09"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0b4f2bc-e6ab-4e85-bc9d-c863c4fd6d30">
    <dc:identifier>DB01611</dc:identifier>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb626643-78dd-4adc-b467-e63d5517c3de"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/46d64f6f-c14f-46d6-b02d-4064f3eb7e41">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eab3040d-f5b5-41eb-b34b-5a1946a83b3a">
        <rdfs:label>acute hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008281</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a9c6b01-650a-4e42-8d32-0b088f0687fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd31a16a-7d16-4153-ad4c-23514e72f344">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a21244c8-5099-4e44-81cd-ae38f5ff3917">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b8d8397-921e-4d0c-9b0d-dd0d12c332f0"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c8d5f5ea-d98b-46b0-bc18-ec80f7def9ee"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Phosphorus</rdfs:label>
    <dc:identifier>DB14151</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/59679ca1-a103-4fe8-b759-4891b72638a8">
    <dc:provenance>https://pubs.acs.org/doi/abs/10.1021/bi1008112</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed3e2857-ea8e-4ad9-bc53-3f49cdbd97fd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e3afd75-ea2a-4af6-b5c0-921533356eee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f48a5fa2-1672-4e7d-8a7a-2b5199efa48d">
        <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
        <dc:identifier>HP:0012378*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b59fa50-b427-4b99-9ac8-216ccca1a94d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c5feed48-6f99-414a-9b22-479b4c7584e1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/be75654b-1db9-4e70-b5e0-deb8aa78bfeb"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7991afb-2131-445a-8114-cd7a9e6b0633">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9de9be1e-6147-4a9c-9aa6-1f0e59fe8893"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc47a960-729b-4a63-bfd2-b1befb5448d4"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41cab147-8711-498b-ba41-3edb6d2f325b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71b1ad99-fd66-4b44-b12c-bcd4724e7f6e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased serum IGF‐1</rdfs:label>
        <dc:identifier>HP:0030353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/32d0c744-861b-43c3-a787-7c9143a01af5">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b75ef22-74d9-49e7-9864-fa7dbb43aaa6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4fdfcb3d-7c14-4197-8cfc-0ac54a5112e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7cc7b8b9-2189-4643-85e6-cc663c660b4f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e08a5a7c-92bc-4a8a-886d-075fd17bdd61"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6273daab-e42f-4493-bf1a-c6a1cfa92ab6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14a4893d-6b6a-4102-b333-8b86dc75c541">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83f7ff20-441f-4449-a82f-ed05f36996a4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/353df1ca-4071-4a6d-9c08-8d799e95c995"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9aabef16-045e-49aa-b06a-95573b53c953">
        <dc:identifier>HP:0002194</dc:identifier>
        <rdfs:label>lack of gross motor function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3f58cf6-9257-4166-aa95-d4c3cd8dd444">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>lack of eye contact</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605407"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c29a4360-0425-429f-87ce-75cb421137e6">
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003785</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7392f01-b87e-46a2-9199-a2f557225466">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>Delayed mental development</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d85999b-d938-4368-9262-17650c63bbc3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22199fd2-9081-4df0-a13b-7e9d2320c70a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
        <rdfs:label>Hypokinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a49cc6c4-7ae3-4cae-998d-11dd371ad2c0">
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8209a33a-1724-4913-ade1-e080cfcceedf">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70e8c000-20a1-4fd6-a3d5-be496dd27c21">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d618f96a-a2bd-4a1b-82a5-065aec810882"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8dd343c1-064a-4a20-abd8-cf6d3a2a4e26"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
    <dc:identifier>D07A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/accbcc8c-506b-4ce2-9960-5204a2bd5973">
    <dc:identifier>DB00542</dc:identifier>
    <rdfs:label>Benazepril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5f2145f-ccc9-441d-b5ec-78a2ca06184a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25ef6ee0-43a7-4955-94c3-9e3b7ce47696"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01798aaa-db2f-412e-b019-1e77b407fc49"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5444b628-c213-4ff3-aa04-80fa5acc3320"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9931cc2b-1020-4fc3-83ba-029337a45022"/>
        <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac5c34d8-6059-4fa6-b8f1-2d64e96e3686">
    <dc:identifier>HP:0003805</dc:identifier>
    <rdfs:label>Rimmed vacuoles</rdfs:label>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5985e590-daed-497a-8774-dbad0e6276f3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a3daa475-cf22-4362-b747-9c5e21620966"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/362ba8cc-9da2-4132-b2d7-4173f031df9a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>Decreased plasma carnitine</rdfs:label>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/477f6527-9c5d-4711-8404-68cf3dd9692a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d3e06cf7-047f-4080-a5ef-d457af4d921b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e47a6d0b-dc3d-444c-8ab5-45c2323ed0ef"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fba9330a-65a3-4252-9f82-d7e5404a3b62"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a0b6ab3-af7f-4aa3-91c0-fe42047d0a4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbbf499d-0489-4025-9ae5-23697c819972"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7bd5425-9430-405b-8992-8433c2bd1f42">
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d07b6d7-6b37-4d7c-a17a-4e1154d0d3a6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <dc:identifier>HP:0012535*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b028578d-9bd5-402f-b9c2-6169885bd86c">
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0003287*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1863fdb-16ff-465d-a167-2a238b072a6e">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <rdfs:label>Abnormal growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cd53384-53f8-4297-a05f-5fdd3e7b7cd4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d0b816a-99d1-4d2d-9a82-22b38b6b71e2">
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9376c0fc-05c5-4853-bc4f-cf2e4a84827a">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalties</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43f68efc-21a6-45bd-9692-41df4b4991b6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c362fa10-c157-4ecc-884c-99579225ebf3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab78e219-f998-4c6e-8b6b-88812750c900">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed3e2857-ea8e-4ad9-bc53-3f49cdbd97fd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/40a6be18-1f75-4e21-b003-7174664535f4"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab623e2f-08e3-4c62-86a7-62ef5029f60f">
        <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/354a137c-966f-4f68-a7a0-0bd6dea0f0bd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e067629e-174f-4e79-9d4a-7eb51945b5c7">
        <rdfs:label>Joint disesae</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
        <dc:identifier>HP:0001367</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97d06def-a9da-448d-a80c-c0fb8f33ba13">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/865011ae-0f5c-4944-9fba-00eb660f67d9"/>
    <rdfs:label>Anakinra</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
    <dc:identifier>DB00026</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29d052f8-dd0b-4804-9a95-389276d2ac04"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/062b87aa-358e-4cf5-af79-5576af48a9dc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d77490e6-c623-4fed-8d8c-ff8eeadb7b58"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2bbcd62-8ff1-4a2e-92b8-6f950e2714e7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced ejection fraction</rdfs:label>
        <dc:identifier>HP:0012664</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3daaa37e-dc5d-43f1-a4bb-c077ad69f5ea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0fded85d-241e-4b0e-93ea-3bda1b0e2492"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab2e5251-772d-44cb-b0e7-d8834d69e917">
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a08511c5-8804-43f8-bb35-2413dd68614e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0918ef2a-6d85-42e7-88e8-252d2bb21ac0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eacb8d93-0f4e-48aa-9547-b078d1b0a9ed"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77017954-35a9-4b60-a669-84cb1bc7216e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6e4e093-86cc-46c7-b291-f55c876be834">
    <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
    <dc:identifier>HP:0011990</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b6452738-c9a9-416d-97f5-d13b34325407">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e96e2f4-ec26-40c1-bc23-b3fab50cd2d4">
        <dc:identifier>HP:0000938</dc:identifier>
        <rdfs:label>Vitamin D insufficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9db809be-77bd-4456-950f-a837e7112b0a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c046c97-4480-4352-85f2-dbfde55f1cf3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f9522dc-d148-4a2b-9afd-9bcbfea29fd8">
        <rdfs:label>unalertencess</rdfs:label>
        <dc:identifier>HP:0002329*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963c55dd-5b14-42fb-b9cd-c4204e8bc6c1"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42d6c3cd-e7e1-43de-bff6-12b60f82d0a2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9125b6a-0395-4b39-8d83-ce284f51f935">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c12e5ac6-394a-4b54-b80b-51da618cdfba">
        <rdfs:label>Receptive language delay</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/5b44ec3f-b313-43b4-a30f-7c67b3b72143">
    <rdfs:label>Symptomatic (C)+Dietry restriction</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad3e5340-44fd-4478-9973-407ee8cbf883">
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1127fd-c8e1-4221-8bd1-1e634f8ebc62"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/15637c24-5fdd-46e8-8357-bfc596a71328"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cf178bb-acb0-4b1b-a318-b7f3d58cf178"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f188eb5-b6d3-45bb-874b-9e32911034f6">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7779eef0-ad95-4198-805d-1dc43bbce773"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffdc05bb-7189-4c17-9975-2db9128b57d2"/>
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5f86f56-a4e0-43b0-934d-b076fbe1e321">
        <rdfs:label>decreased cholesterol absorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
        <dc:identifier>MP:0002647</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
    <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4662a688-ddbd-41fb-bdce-37b5a7824011">
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eb367fc-a122-4164-92c2-e0c762b4ad8a">
        <rdfs:label>Aggressive behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <dc:identifier>HP:0000718</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4710f2be-9873-4269-b020-2802f85ee243">
        <rdfs:label>Self-injurious behaviour</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100716</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c63a4ba0-50a4-4346-9f1e-ad8033f54f75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdf29ec9-4056-4460-b4b2-71a48d2e21ba">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <dc:identifier>HP:0003128</dc:identifier>
    <rdfs:label>hyperlactatemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f64a3ca-8c57-4a2c-bb3b-92e1c41045f4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5f98d29-2ae5-4509-82b5-b405eba66203"/>
    <rdfs:label>Pantothenic acid</rdfs:label>
    <dc:identifier>DB01783</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2eeaa608-1538-49e0-bf66-925d372a632c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c396d4d4-a79a-4489-b0b4-c4ec5aa63d6f">
        <rdfs:label>oromandibular dystonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
        <dc:identifier>HP:0012048</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b911231c-15a7-4c3c-b2f1-b10d04c0e9f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f381f732-7077-4249-b9eb-40bd1dc482ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae63e0ef-43a9-4de7-a9b6-7f980f2a1268">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
    <rdfs:label>Curcumin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f6b5a807-d7e5-44f9-9a58-a31bf8cd68e9">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfcc01dc-8b49-4989-9b81-67c21050fcca"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB11672</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3878b3e7-f8f8-4051-9220-8822decb7f94">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/049e2718-6497-4b73-9edc-089febd6256f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb618899-676a-4500-89a0-e46fd7b5f6b6"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/951394ad-fa3b-4fef-8b28-b10c53d8c029"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4af5bd5d-26b3-4ad1-8e8b-e62e46bc796e">
        <dc:identifier>HP:0100518</dc:identifier>
        <rdfs:label>Dysuria</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cfd995e8-8136-41b8-8c46-e9670baf6edb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dee52ca0-7b59-4acc-b9c0-438c6ec5696b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c488cae6-1f81-4ab9-8877-344098c98be1"/>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/773f5849-91ef-4a20-87c2-a579196dcd00">
        <rdfs:label>Chronic kidney disease</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012622</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c35b774e-7c86-4b4d-9fb5-b62f3a3920f0">
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012622</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c05f998-3f56-452d-912f-5600ac0e29e3">
        <rdfs:label>Hematuria</rdfs:label>
        <dc:identifier>HP:0000790</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
    <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c6e3e85-deba-4bd5-aa37-295f616651b8"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d21f7a8e-885f-4b7a-8c96-0bd3be1ad93d">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/18a7c0ba-95dc-4cd7-8a72-5c8fd3c8fbbe">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc497e80-de01-484b-b4c3-67c0442a91b2"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15c5b047-7d23-44e1-8664-946d7151a0d5"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41b31e9b-b999-428b-a2e9-5a0ad65ca5de"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/514061dd-9bde-4023-9803-2ec557077399"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1590f4ea-9706-4f46-a7ea-6379d576a96e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
    <dc:identifier>DB04159</dc:identifier>
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3008e8a6-4db5-42fb-ab32-05e1e81d06c9">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efa0430b-a387-49d0-977a-3c27bc7aa7b6">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/087ff044-e52a-4256-bd10-15d3772fa840"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c56f47d-2a5c-4d92-98f6-cbd303b45e91"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4dea370c-9597-4cdf-9053-984f1f4576b9"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>L04</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6f51e618-8e40-4863-b96a-76f2af1d8761">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4e45998c-9f4f-4872-ab6e-4ee29b83a0d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/934a3af2-f6f5-45e4-9f0c-e6e92fa8aff9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22328166-38c4-48a5-ad95-4f18a089b9ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
        <dc:identifier>HP:0006517</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/202959df-faa9-4092-b4c1-dc5e712a7645">
        <rdfs:label>Low pulmonary function</rdfs:label>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a127a566-0960-4bfd-a1bb-169afcd816e5">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f17a899a-9264-46e4-a088-07c5b88e7f8f"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3306e91b-6dfc-4d16-91df-1b5e234a5636">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f39a51fd-8a15-45cc-9857-dc361ced023a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/feadf5cd-8857-4585-9898-f0aedcf952c4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82844744-5f31-4226-bd3c-bdab0c127144"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e596c94f-82fe-4d6f-928b-def952eb29ff"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d46b65b0-9059-461c-8369-40f8005110b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/510455a0-0c91-4640-b2b2-46aa154c35ff">
    <dc:identifier>HP:0001324</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/46f6c146-38e1-4f60-a6df-b73e0842cd1e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7272b6a3-ea25-4071-96ec-5cd58a219a3a"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5b5ac63-3cb4-4407-abc4-1bae4a51acc1"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baa43f63-f825-4af7-97ee-599a8684b189">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
        <rdfs:label>chondrocalcinosis</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0000934</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0568a54-7e33-460b-8f04-27442148471e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
    <dc:identifier>HP:0004324</dc:identifier>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>weight gain</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6d964067-7b42-4b51-bfe6-3fa2743293af"/>
    <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
    <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7f87fe3-8b0a-4ce2-8cb4-6b62ff6787d4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc06b12b-1345-4085-8ced-4df2b590eab0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60c10465-2003-403a-b13a-12e5326f3ab5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cb475c0-272a-454f-ae7a-7f5e2df8894a"/>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ebc7a4f-7eef-482f-bafd-77d1c465421e">
        <dc:identifier>HP:0000467</dc:identifier>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>neck muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3a35812-c6c4-4624-bd87-d7b802f8a263">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>dysphagia</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/84b648b7-2148-42a3-9292-f18c4d89e645">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c79e55b5-f1b7-44a4-8432-e529a28a0d6d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d81357ba-a8b0-43aa-aaba-505651119a62">
    <dc:identifier>DB00181</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6efa5999-dc67-465a-871c-0c79bad3e028"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/52ed314b-f3e6-4a4a-8c93-cdf8e491f3d7">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a7f9472-1de5-46e6-8637-afe7ecadda04"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546"/>
        <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b7a3ddd-b229-4f50-8d5b-76a6eb783383"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <rdfs:label>Baclofen</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7fa2da6c-74db-43fd-931d-dea09c38825f">
    <rdfs:label>Dexamethasone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7c31cf58-614e-44f4-8ef5-938ca2abc53e">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/978524f0-1395-4e35-ab67-7881074be020"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fad966a0-e824-475b-bbeb-2c06f8e8c1bd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c981a156-8200-4016-b8f7-14d483b6805e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34e46b8f-bf29-46cc-a9ae-2a83b6329880"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1fc8bfd-42a8-4147-bb08-79efb7c0e057"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0446bca-e24e-4f85-b414-16cc8d68b0cb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01234</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1f8caa2-6cfe-4c9a-9a0e-07568e1efa75"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ae13332-cacc-440e-84f7-84d8e83c42c2">
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
    <dc:identifier>HP:0012100</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e42fcd2-2659-4501-b314-1bd0c265efb1">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/388e1c4b-ce16-4f14-9df7-b223909d2940">
    <rdfs:label>Decreased physical function</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb065332-2430-4a70-adaa-233b51cb020e">
    <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0100022*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66a8589e-9aab-4d27-af71-23ab4a6b7536">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b083ab9c-dde4-4a24-b66c-323d4afb9769">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82844744-5f31-4226-bd3c-bdab0c127144"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99fdb40e-5044-4068-ae9a-36b520f71f61"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <rdfs:label>Phenylacetic acid</rdfs:label>
    <dc:identifier>DB09269</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2696ae7f-8a38-44c0-b59f-33290768b2c9">
    <dc:identifier>DB02745</dc:identifier>
    <rdfs:label>Uridine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5bf328dd-e454-45ca-a461-2cc5ca6d79bd">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a647e5cf-d3b5-4a0f-b4e0-0c8cd97f619f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6e4e093-86cc-46c7-b291-f55c876be834"/>
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cbae0b4-5167-4b99-ae08-907fb78ed175"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecfda120-8e45-4a6c-a83b-247569ed0f0b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma MCP-1</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4f6afc3-704c-43c9-9e33-b64f85822eff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f92a3ab-95ea-4ab1-9bbe-236723f9b575"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ebbf0db-3150-4eba-859d-8c749f577d05">
        <rdfs:label>Abnormal EEG results</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b143eb2c-37b0-4040-ad7d-f9719a2c9f31">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0030213</dc:identifier>
        <rdfs:label>Lack of emotional expressions</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/90f5e5db-160a-4f57-bfe9-192234171ed5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01c7bfad-0f1d-4f0d-82b4-18f2ceacb441">
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acc050a7-6a3a-4c95-9496-9ba61b2c5f25">
        <rdfs:label>Low brain glutamine concentration</rdfs:label>
        <dc:identifier>HP:0030980</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5932562-fc74-4239-8cbe-a2d51d57de2f">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <rdfs:label>Low CSF glutamine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <dc:identifier>HP:0030980*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7116dd76-b93c-4dbe-be3e-0f79bc7277b8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a678e01-e6db-46ef-913c-02ea06f4dade"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c66ccb3a-0846-408f-83e5-8475ac51816a">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0470a48-23b7-4987-8392-91d07602e762"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9364c808-917e-4855-ae7c-8d2f683f5520"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6e4d5da-c386-4402-9d13-1f373bc85541">
        <dc:identifier>HP:0002872*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
        <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5cbe6e73-6477-49ca-984d-dbee55537552">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3924107a-9d33-4b15-8674-bf6a7591da0a">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
        <rdfs:label>polydipsia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001426</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1089e9e7-81b4-460b-bb10-0b96c441a3b2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001959</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <rdfs:label>thirst</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/174340a9-a574-45ed-8cd7-a7a933dbc383">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7fc06979-e87c-4073-9de8-3984a972c6af"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b373dff-dbfd-4c4a-8f40-888e6343404c">
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccba3b5b-6e18-4212-a72d-c3839dfed13c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0000002*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a04f4d0-cbdc-490a-8940-f5168a8fc318">
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>Enlarged size of the liver</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2379a48-6b61-41d6-b323-fae2ca05df64">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
        <rdfs:label>hypoglycemic seizures</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0002173</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a9e7914-7b54-4882-8f8c-325dda2c4460">
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <dc:identifier>DB06819</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b1732bea-a829-48d7-90f4-d23cdfad6935">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/995b5b0d-dec1-42f7-aa81-41948904efc6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33132c69-823d-41b7-89fc-78e3ba48f16e"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77df7df2-2d38-4800-b0b6-0bd8f33e80c3"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/79a18315-a9a4-426b-a6df-10c1501cd7bd"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6709c710-d21d-4cc9-96c2-a1812fb5f376"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44e9a66c-9937-4a77-921c-baa9b0dd0a2f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82844744-5f31-4226-bd3c-bdab0c127144"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77df7df2-2d38-4800-b0b6-0bd8f33e80c3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/86098704-403f-4a5b-beda-3189a8b3d9fe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77df7df2-2d38-4800-b0b6-0bd8f33e80c3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
    <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8e8e75bb-9311-4ad1-a49f-c20b28c7c049"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ff1bccb-d240-46d0-98fe-ed81ace66794">
    <rdfs:label>Metreleptin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ae309c0-ac14-4d1f-9f6b-e6f151987a8a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <dc:identifier>DB09046</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee68e44b-6e60-46ac-903f-f98d06c7ed7b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/951a01f5-18ba-4391-99ac-24239abb3b3e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08fe3809-6032-4a9c-a999-27242ca644db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a13178b-3838-48b8-b62d-4b6fff6f2540">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000867</dc:identifier>
        <rdfs:label>Hyperparathyrodism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2004a07-ef35-49fb-baa8-a01b8a05ffb0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:label>Renal rickets</rdfs:label>
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54da1121-fea9-4695-9d22-671075b458f7">
        <dc:identifier>HP:0002148</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypophosphatemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5fd7149-21e8-47ad-9c5d-1ba7854c7042">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9798132-b289-4207-b7e7-d7568cbd0909"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d0bbd8d0-f8c9-45f9-9058-48844d6432eb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0470a48-23b7-4987-8392-91d07602e762"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
        <dc:identifier>EC:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98cce2c8-3514-4b0c-a40e-9ada2e39bcca">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/733ed2a4-cc2f-4644-8106-b6cecc325a96"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f08397d5-789a-4857-97ae-6e765c27f6a9">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88b1a88c-049b-48ce-81ea-2ee81f0cc6eb">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89fd78a6-7231-4133-b443-c005a5c0efe7"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2c8a7d81-4e1a-41ae-835c-d63e07e82ab7">
        <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d44300c2-7889-4d35-a843-114ffe6d1af6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0ba06c7-bbaf-41f0-8460-98d9b977443d"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f8b51e8-a442-41c4-b19d-1aae5d16bfe6">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aaee9be4-10ac-4cb2-a9c8-b15691441ba0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24b36b18-ffb7-496c-97be-ce3e6371b712"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2b45f7b-7779-444f-9e8f-e1a0bd96157b"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
    <dc:identifier>DB00163</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc202c2e-a4bb-44e4-bf36-ea32027829e2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cffd568-648c-4dca-b937-c9f7fc243f3c"/>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99eaaa1c-d844-4dad-bd9d-d8d5a467887f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca630396-7440-4008-9df8-989f95967822"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e63c2959-4141-4195-b936-e38979b741a0"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e0ad35c-86ab-44ed-adf0-0f7de4eb340f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c9e4650-cd6a-4d80-b212-7b4327533b3c">
        <dc:identifier>HP:0001735</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <rdfs:label>Acute pancreatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3da79edc-a99b-4314-9b7c-15ba7d5a822a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35754a89-cff5-49fd-b7f5-37bdceec798c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9ef773f1-59f7-49f8-879c-1e31889f64f4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2514caed-ece6-4583-bbff-c9521876ea11"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44a73a99-e538-46c2-8037-e0f1dfd24d93"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f5fadc-054a-47fe-8dbf-5762e80f6923"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/427edd5f-3514-4154-9242-97e4dc8f3360">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:label>low heamoglobin leval</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5483241f-37e5-45bd-b9de-6412f371390b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7d654b7-ac7a-4c23-a66b-d5a5985dd0b5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b91a1f52-0b6d-4ef4-b141-e90f5fd10b4d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <dc:identifier>DB00252</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7edc0dad-712b-4115-be7f-391af5bae7a3"/>
    <rdfs:label>Phenytoin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96879685-e4a7-4172-8721-2f6695c3ee67">
    <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
    <dc:identifier>HP:0000855*</dc:identifier>
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb3234bb-f809-465a-9dfb-de517e7c0939">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4bae8e8e-41e4-4603-ad4a-1d2b91f42b12"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d021067-58b1-48b8-ab94-576de789029d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4e79990-7a65-447e-93e5-2de3666e221f">
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>http://www.malacards.org/card/hepatic_lipase_deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf32beca-d2c8-4c9e-bbbd-4d96c4bd5a78"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc1660c5-6a5f-43e9-b68e-baf283a860e4"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/21dd77ff-a98d-425d-a8ff-28486f1b497a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ebfb236-e503-427c-b296-9dd688bacf17">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <rdfs:label>skin photosensitivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f51a5bb-b5c5-4c38-94b3-bf7843d80547"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/528cc740-5ff7-4eb4-b6d1-7f6231d37f02"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d168145-d4f1-45e8-9566-bf9856d280e2">
        <dc:identifier>HP:0010473</dc:identifier>
        <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
        <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c6c92a1-e6ee-45cb-b0b2-bbbb9cc6478f"/>
        <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ddb0e71-7af2-4aac-a2b5-2e097b0d7403">
        <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6dba3e34-e622-4b0a-9630-d407ede09386"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/667a2cf2-ae5a-48e1-968a-ccaec21094c1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca97ae36-de5b-48e7-9356-b2f99dccc9c1"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b20e6fe7-3be3-4a4d-9855-fde30ad135f7">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/70212f3b-aa90-413e-9584-7c3ab66dec6e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34de21b3-f486-4e9e-9de3-55a88df48f67"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c690b63e-2025-4da0-b301-ab9598dae8e6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
        <obo:RO_0003304>R219K</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c99a1bb3-b00d-4b28-8d7c-2309429da57e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7779eef0-ad95-4198-805d-1dc43bbce773"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a5e55b1a-36f8-4c7f-98cd-273f3180806e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7779eef0-ad95-4198-805d-1dc43bbce773"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b15971c-12ab-4950-bcf8-7f89dbf8e0e8"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39065f05-c685-40b3-8a59-00b741352dd1"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/477f6527-9c5d-4711-8404-68cf3dd9692a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <rdfs:label>Pravastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f188eb5-b6d3-45bb-874b-9e32911034f6"/>
    <dc:identifier>DB00175</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cacb5a96-26b1-4eb0-bd92-f5ae8d3021b6">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0af7efac-d047-4ce0-85f5-026d2d2f395a">
        <rdfs:label>Naproxen</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c490b291-e9cd-4600-98c0-0f924bf0a347"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c18bcbf9-de38-4409-9d6d-bfe0356c6653"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76c565cb-1a60-406a-85db-a71b378dd3d6"/>
        <dc:identifier>DB00788</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1deb1d67-33ff-40d1-aec0-376fdcd8c711">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e0facaf0-1618-4ee7-876e-7b0e31f2a3b1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4223bbe-20aa-459e-80e8-17f6f6d382e9"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6291b26f-9583-47d4-ac5b-e304930e26f5">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d6d8144-5e58-45a1-8d27-6225d152f232"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6edfa81-646b-4258-ab5c-15290cf294cc"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f121ca91-a9b4-4592-a638-46d78046eaf0"/>
    <dc:identifier>DB00360</dc:identifier>
    <rdfs:label>Sapropterin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a2e1a39f-9448-4107-95c7-58a6d85976e9">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/c7817e8d-7dad-4faf-bd73-b72916ed1ded"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
        <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a60c2cf-9aa8-4515-82b4-8ebbed119846"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f8bb291-d3b2-435d-866f-6925d37da2bb"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c41d953-4aaa-4a91-af0f-47bb5d5c9ab9">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a60c2cf-9aa8-4515-82b4-8ebbed119846"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ec9666b-11e1-41d1-9759-1f18e7397497"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f839a777-c598-4263-8bf0-08566682a47a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-012-9506-x</dc:provenance>
        <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ca6cd6b-809c-4e69-8688-375f08a3fce5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a61f5b31-e374-47fb-8d35-b14c909382c3">
    <dc:identifier>HP:0007663</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low visual acuity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1a078f3-9356-4faf-99f4-e67df531dd52">
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/377a7b12-6c8c-452b-b9b8-40893a15d10e">
        <dc:identifier>MP:00011911</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74966456-a48b-4b5a-843d-43a62b1cfdc9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0088ace4-13a7-47d0-bbfe-f1f804124448"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76f39119-7608-4e5c-96be-a8d04c2a78e1"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2def9dfc-4a42-4ff7-8c0d-82bed4b42e89">
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9682d45b-45a5-469c-9602-1ce3e2fc5d78"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98bbacc8-4f7a-4c2a-9980-95f43b63e396">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa9d7210-1c08-4c39-ae47-5c2363c8d193">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c05c42d-372f-481f-b684-0ead2e134586"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac02d71c-3d0c-4c6f-ada3-dd6aa3a49743">
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Developmental abnormality</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c3618c8-26d6-4ae1-b4f2-ab293e9ee340">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8ea12ab-fbfc-4a1d-ac00-31c6b88fc97e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <rdfs:label>Abnormal serum renin level</rdfs:label>
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6b066c4-9622-4f1a-b4cb-ffe718941caf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d45de092-5bd8-48a7-b463-931c736e0016"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a07d6df9-ce5e-44f7-8537-28c44b85a2b2">
        <dc:identifier>HP:0002900*</dc:identifier>
        <rdfs:label>Refractory hypokalemia</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eff6029a-acce-4856-98c3-29ad85472527">
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0004319</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57e5b0af-d7cb-48c9-80db-31c07b33b73d">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0116e57-7ee6-471c-9f39-eced871a0945">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5bc999a5-790c-418a-846e-23122589ed6f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e468dbc-1b16-40ff-a20c-dc4637342a07">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Seizure</rdfs:label>
    <dc:identifier>HP:0001250</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f83aa633-4a41-4eb5-9d40-4d39678e993b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000103</dc:identifier>
    <rdfs:label>polyuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fbe6d1fe-4a16-4529-8a28-363c77bd6958">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7882ce89-9643-477e-9dc2-90874b7468c7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/388b0ff8-b4d2-48d7-839d-7f67b559bd49">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3031f12-62c5-4633-bc6a-6e36ff11a250"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04c4dcb0-2c5e-44c7-bd10-a33f0e26014f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/916a4420-7eca-4fa0-b44f-9942f06ad342">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0340fb63-4a9c-4e19-8638-bba89b12984e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13fb3185-4fb7-4660-939b-0745c656a1a9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
    <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a24d9e23-76ee-4b13-9ec8-7b21e224d56d"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
    <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a82483a0-3807-481b-bed9-2ed76278daa1">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bffa8a57-e55d-44ae-8340-ce052d123ced">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5da39d12-0dc5-465b-bcdf-75d3a94d8053"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75e76c64-a6ee-42e7-b259-8d048b9508c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2665b99-1372-415b-8104-889af46c02b7">
        <dc:identifier>HP:0001873</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>Thrombocytopenia</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f3b011d-8aeb-47e1-9882-2bc2e25be642">
    <rdfs:label>Glutathione</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6715f8da-c832-4b8e-80b3-b958bbf2d36b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
        <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3a9e63e-7408-4d02-8c09-759b1375b94a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00143</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8384844d-551b-4160-aff6-c516b1e273a4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd29449f-86b1-42cb-8a49-6f11f8cb131c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a6deae4-abbf-4095-8fdc-f691f8899f35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e47f7ab-f1ef-4e49-bc7c-311fbbfabfd5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f97109b6-cdb2-4c38-9b16-f5cee826d62a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bda1077b-42e6-4f39-b5ac-89eced8461ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <rdfs:label>Lactic acidosis</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bc9f375-a10d-48c1-9170-40c45276aaf6"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29c7eba7-cf37-4dcd-996a-b9f67a204420"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3f62d7b-3b60-4f3c-ac34-90bc3ad7ce38">
        <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <dc:identifier>HP:0003200</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/121af46e-9161-4909-8cd3-9844e9c3c1c4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <dc:identifier>HP:0003198</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ce37eb27-be26-4b8d-8049-6bfd2c21b9d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3bb207f-3917-4af5-bbd5-559342ff4661">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100851</dc:identifier>
        <rdfs:label>No result was accessible</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25b347ab-1c9c-4701-bcef-50838e9e3b48">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/316de402-f21d-477b-b6b4-1bf30fb95ef4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e28f01e-d830-4b5c-bcf0-396ec99a6294">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f9bccbd-d658-41ea-88a3-f2a871a861a6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e22dff6-7b14-486f-9f1c-26df2863d85e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33c9a9ab-e788-4e9d-a627-9cc3cd1dee9a"/>
        <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1e7b0dc-5020-4440-b316-4991caa7260e"/>
    <dc:identifier>DB01186</dc:identifier>
    <rdfs:label>Pergolide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3f44e4a-4b40-47e2-9002-ae57a35247d2">
    <dc:identifier>HP:0003455</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5f39291-0137-46eb-bc13-7bbc58d9fb4a">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a248dd60-5996-41ff-8638-e62452d35bde">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf85adf4-bb34-46da-8503-8f4209332a14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed6111bb-e290-4cd7-a6c9-8038d1bf2827">
        <rdfs:label>Cardiomyopathy</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/15a5d261-67a4-4bdb-9dfb-fefbabde9869">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c19163f-bf66-4599-b334-2303cd2dafd1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e886ce0f-0aef-46ff-8b58-4ee481bd3701">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7a88086-aa02-42ee-8c49-41761147c3d2"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9b8ac15-99a1-4248-af0f-f9b533c9921a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/098b00b8-16f5-4bcf-88d9-7ad835e4c088"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5514cd12-3095-4f27-a3bb-6d6a57c79eff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df453285-6710-4e53-b184-3244b3f8d299">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d08bb30-c7fb-4c1c-9b62-29684f51b0ff"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb979b08-4c4e-4447-802c-22421222be2b">
        <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04875cf6-9f7a-4d36-bbe0-fe0f671fcb33"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4569b34-5a70-4971-a619-21120c4ab111">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ef650f8-a5b3-4721-b1ab-009f5a2ac5a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9d66741-25ff-438a-b151-85dc3fd12d31"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56ada6b6-4999-4c78-bbbb-a13cf3821baf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d298291f-4703-41d0-aa17-997fac25921b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <dc:identifier>DB06151</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/387e8c2c-057d-44f5-9830-9435087647ab">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7013e6e6-1b28-4f01-a82b-f0bf46fde4c4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e190cf80-899b-4fa9-9a48-63aa50419d2c"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dad64159-30f0-4bff-978a-49f7fce6ad6f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6a0b35db-aa43-40ea-a6dd-355444e43fd2">
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0bf19dea-4a9d-4f85-a946-e6faac700903"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cbf59a84-80e9-4a2e-91eb-182d5b5daba8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b3d85a4-c82d-410f-a092-cea8694f322b"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca97ae36-de5b-48e7-9356-b2f99dccc9c1"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df07ad80-d7c3-49fc-bbf7-20a21cb3a40d">
    <rdfs:label>Kidney stones</rdfs:label>
    <dc:identifier>HP:0012622</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d45ea0f0-ae06-4916-91a8-a10c200f68de">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8ce88cd-ad49-4dec-a8c8-e0419ba7aab4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b4319f33-602e-4b19-b320-9b3ec5de8bea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/237e13ac-c940-47ba-b08f-f47258e84606">
        <rdfs:label>delayed growth</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c43373cc-2bda-4cca-bde8-f62dc088dfbd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a571cf88-d282-4cec-8fa7-b89a77c7367c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a789c1d6-efb1-4d28-87ce-eaed1cf78c77">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66ea6f7d-c6ae-4edb-a930-dc6b90bb94dc">
        <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96969229-02b7-4073-9c2a-94812ed67786">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <dc:identifier>HP:0003077</dc:identifier>
    <rdfs:label>hyperlipidemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a2e2f25-813a-44e7-9e9b-3a150751f142">
    <rdfs:label>Renal salt wasting</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <dc:identifier>HP:0000127</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a6a3637-a904-406d-bae1-88bbbc5978c2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>decreased male libido</rdfs:label>
    <dc:identifier>HP:0040306</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af788f64-c3a5-4041-b7ac-064679ac4c34">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c22d40d1-a9e3-47b7-a3c2-96e8774b1207"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79465ef0-e5da-4300-aa51-83de6b0cbaee">
    <rdfs:label>Vitamin K insufficiency</rdfs:label>
    <dc:identifier>HP:0001892</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fd4a349-1ef0-4927-9838-71b3cd67960f">
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal aspartate transaminase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1c96456f-8834-4b09-9934-1dca23bade97">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a93065a4-677a-45f2-9dd3-0e8416f5bed3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7cd753b8-b2f1-445e-9e61-b1716b317e66"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/142a844c-a28e-426a-9983-c85bbf2084fc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fa45e000-08a7-4414-b310-98fcfb387b01">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6fa1033-1d28-449b-9182-1d7514aca7d5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
        <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41cab147-8711-498b-ba41-3edb6d2f325b"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d17d3120-13d4-4e80-a38f-e6e3f1d1918c"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27b1ba0e-a31c-4b0d-bf07-f9540fdac6a3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60312aa3-2b4c-4b3d-b918-4087031fd42f"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5514cd12-3095-4f27-a3bb-6d6a57c79eff"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57b7a9fb-25c6-4e77-a505-5938e466ed23">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8f1692e-929f-4ef2-9a95-0170452421fa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ab2d816d-e483-47fe-9bf7-274991d7674a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3cca4fb-888e-4aa0-8517-27135f79cfa5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/599f5ef9-8eee-440d-a626-3ca5109c37c4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d44672bd-088c-4172-9cbb-b346057d947b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e282ff08-2ab4-4df8-8def-a7f90206d857">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d625efb6-815c-4ad8-bae9-7dc5d8a11cbc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe22ddba-cf16-4b27-84d0-eae2bbfb7cbb">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/600721"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bf5c46e3-36c3-4d7b-be3b-4fd2f8227189"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c1f8d2f-9d16-4e9f-b6f2-f73715481168"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcb4d338-6dea-4076-a927-b270e5cb50b8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/defed2c1-5031-42fd-a9f8-7426c0c0033c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d184d1bc-ad5b-456f-8630-1a60ebeed2d3"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8726f051-df76-4139-87f3-bba8bd97a469">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ae13332-cacc-440e-84f7-84d8e83c42c2"/>
        <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7723b402-f3aa-4f6b-8e8b-4dd9e6c6d33b">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250950"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51756e88-4576-4d8c-b7ba-b1e77abbebec"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53746ade-171a-4e60-a775-5b8b5d8237b8"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aecd5d78-afeb-4f00-98ff-b1b21f0e0946"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5985e590-daed-497a-8774-dbad0e6276f3"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5333dbc6-0769-4e2d-8595-2397c92c01ab">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10bd68ea-2787-4ab4-833a-09610155f737"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <dc:provenance>Abstract</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f78800c-d43b-41db-b16c-e83a65615255"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/247df3f2-cfcc-40d1-b181-03df67ab4ece">
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66ea6f7d-c6ae-4edb-a930-dc6b90bb94dc"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ba4e8609-e442-4d48-9bde-be8479d0452e">
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30b64e4a-511d-4744-bb9b-3b5ac34ba52f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d44672bd-088c-4172-9cbb-b346057d947b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a82e15b9-da3a-451e-8e7a-10f60bb0359f">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/070bb99d-e14e-4cc4-8439-859663efc32d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f484622-05ef-4767-afda-b1625dd08563"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b49d8670-ab62-47b7-be27-9a63862cfe7d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/2-methylbutyrylglycinuria</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/599f5ef9-8eee-440d-a626-3ca5109c37c4"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0560e980-4c2c-4df8-a033-ef99b282279f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.newbornscreening.info/Parents/organicaciddisorders/2MBC.html#4</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Levocarnitine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/456e8026-f8b1-4d2f-bb4c-90fef79f00ca">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/121af46e-9161-4909-8cd3-9844e9c3c1c4"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/374efa15-8a3b-40d0-9e12-dc387bc9c00d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93860759-4365-4b8c-8cad-7935770cf612"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25b61c9d-d43c-4f41-839f-7fb990c0d7b1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09b6f9d2-a12a-498e-a948-942c63e910e1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e08a5a7c-92bc-4a8a-886d-075fd17bdd61"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c1e9004a-1e2e-41d9-b296-be2ae6ed3704">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/980b7b8e-5d1d-4653-ad82-66af60f832db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dd3c1f73-24e5-4b5f-9644-62c704b965ad">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5a1fbae-2d31-41b3-a22c-d3054cf36963">
        <rdfs:label>high intraneuronal GSL storage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc9609f1-0034-4d4f-abeb-01989939a276"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14630c9f-5f7f-486e-a5f8-2c0e19278225"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/24aa5f3e-8ca4-4c23-bc06-7aaeaf106bed">
        <rdfs:label>Symptomativc (C)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/884e8c1f-07d8-43d3-9ec4-fa3f4da482e7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb5f55d6-2692-4abd-8c36-2ef430492119">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/df89bc07-3337-4c5c-87e6-199a4755e8f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64081892-d1b7-4a97-8339-ad8ce2f3f11a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76478b78-05cf-4b93-bd98-ce743b5e377e">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
        <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
        <dc:identifier>HP:0030390*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c3a5250-bbd3-4422-848d-236d7de84e76">
        <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d341aab3-fc9d-4da3-9cc1-59de4105642d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb3234bb-f809-465a-9dfb-de517e7c0939"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe6a0265-afc3-49d9-a7e9-71d887e797cf"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a5bb99b-7f3f-4b73-b884-1ec0225f48d3">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf32beca-d2c8-4c9e-bbbd-4d96c4bd5a78"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5b8a826-db9a-44fa-a5e5-9bde849b80a0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48740ff4-d633-4b5b-a1da-4b7aa17d031d"/>
    <rdfs:label>Rosuvastatin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/531a0a37-3698-4941-9aed-bfc97068b99f">
    <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea120e83-cc95-4c2f-9664-01815df9a633">
    <dc:identifier>HP:0007015</dc:identifier>
    <rdfs:label>gross motor dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/495ec8af-f39f-425d-a4a9-956daa050fb3">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a9edbf5-ae71-451f-b4af-8287775ca9a6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb9a9680-e0eb-4f32-b0dc-ec10a50d8365">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5b3529d-4138-4b8a-b051-3358bb13e71a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45106cab-e51a-49cc-9474-8ba0f7addc5c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24bd65fe-983e-4747-a9c6-35bdc66e9d19">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:label>Osteopenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60312aa3-2b4c-4b3d-b918-4087031fd42f">
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:label>mitochondrial dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
    <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffdc05bb-7189-4c17-9975-2db9128b57d2"/>
    <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/866c408a-8a29-48e7-bd52-08ec234ba1bc">
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0cc3466a-ac8a-4cd0-aca7-3eaa1be80daf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4267174f-89ea-46f0-98f1-f90de341bd57"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fcb23ff-5bb1-4461-b9a7-26603eb4b4ba">
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>Abnormal kidney function</rdfs:label>
        <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8d942e4-f001-44ab-b06e-e6b451fe064b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14191467-d84d-47fc-bfb9-fff99a3cc5a4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/646d941a-ef7f-47e6-bfda-f681528c2938"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b7a3ddd-b229-4f50-8d5b-76a6eb783383"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34c17b22-8391-4bf4-a1b2-6ff15b7e9e58"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
    <rdfs:label>Chloral hydrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d117a9c0-c017-4972-8118-cca6549985f4">
    <dc:identifier>HP:0003455</dc:identifier>
    <rdfs:label>Elevated long chain fatty acids</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/980b7b8e-5d1d-4653-ad82-66af60f832db">
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09b6f9d2-a12a-498e-a948-942c63e910e1"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57188ad0-c322-4c4b-9583-da9f19b86ccb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d911676-b7a3-42f6-84b1-32e4f7d96e53"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3184996e-cf6e-4093-9d01-de56a7f004f7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0facd433-c7a8-4170-bcc9-19aac8a8e196">
        <dc:identifier>HP:0012654</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
        <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09720555-a62f-4ac4-bbd9-46108df38b19">
    <dc:identifier>HP:0001263</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>psychomotor retardation</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9886b31-b59c-4c0c-b34b-ccdd68f83490">
    <rdfs:label>Elevated transferrin saturation</rdfs:label>
    <dc:identifier>HP:0012463</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7ca6bd6-2e06-493e-bc7c-1bdbf84259a5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa05b873-44ce-421d-8275-f7e2dd14b375"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04532607-5391-4d7e-a56d-83700656db61">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11eade8f-8143-4dae-b105-86e584b41f72"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d7c4fbbe-5957-4130-8f46-fa76de448190">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1b5f28c-cc80-4633-a2a3-5fea055d52f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78e26c85-c139-48a2-be3c-26486b174ea2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5798c776-a417-4724-9624-d29ed4b62ab1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002069</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <dc:identifier>EC0:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/639f80b8-3e86-465d-acb6-bc84c12b8659"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/881e03a1-93f6-4330-9155-e263b5727b54">
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8763ac31-a33d-41aa-8ad2-c8078970a108">
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85f2bc9c-800a-4092-a663-2247a9a5901a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253601"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6080af56-bd4b-44ed-8d6c-ab507aabd2ee"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c32de93a-f838-4ada-87f3-a8e803d607d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdfb4e97-0f56-4c30-ac73-d6b2edfc200c">
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74966456-a48b-4b5a-843d-43a62b1cfdc9"/>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3f44e4a-4b40-47e2-9002-ae57a35247d2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/feb3e8ef-5525-42de-bbf2-efcf97c43f59">
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/5b44ec3f-b313-43b4-a30f-7c67b3b72143"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aea32e5d-a631-4f6b-ba3c-02d21a790cbb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d3ad8d1d-159f-43cd-acfb-bd0fa86ad991"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8e9100f-cb66-4033-bb95-414ee83a68d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21444d39-547c-460a-b80b-da404f40d13c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7aa741a-8591-4726-95a8-9ee0c280e6e6">
        <dc:identifier>HP:0012217</dc:identifier>
        <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b10441a0-4c69-43cf-afd0-f5de37834fb5">
    <dc:identifier>HP:0000488</dc:identifier>
    <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9a871785-1486-49dc-8e55-337c3afc3545">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/542dc410-c889-48ff-bffd-f9efa96a9a01">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Clonic contractions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/822fb095-f838-4657-86da-90cabf8679be">
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>R229W</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0446bca-e24e-4f85-b414-16cc8d68b0cb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
    <dc:identifier>HP:0040085</dc:identifier>
    <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c73a72b-7194-402e-8cb8-f07238b4b3b5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9eddd206-b19d-4fe4-b808-a6447cda5a7d">
        <dc:identifier>DB0084</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93e9f672-c5aa-4924-b241-cd79398aa977"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/488177c5-17ea-4258-9ef0-955ed06d524b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4b11dbc-7e9f-466b-9489-c51104cbc8e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69004284-a551-4d9e-8fa3-db067aa8638c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/451a2360-304a-48ac-8c03-91afbff518e6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
        <dc:identifier>HP:0011021</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35961a28-54c2-4e41-a531-dcd68a498bd6">
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bec19ade-e499-476b-b9e5-639eb59c5776">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
    <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
    <dc:identifier>HP:0003077*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c475a259-3673-4a45-b321-863082f92e97">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d85d0702-20cf-4fb7-b4f4-158ccbcd1135">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25a617c2-4ae5-448d-9105-7313e8b68322"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00f60324-4a8f-43f7-a610-1a4109d3f7b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98a1f593-0d3c-4379-bf05-762b2318b309"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/390bb0fc-2ebd-456b-a9bc-254998a1cdf0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000972</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
        <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92f7f465-f60c-4f25-bdf3-dbbb447b4190">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/89bb05a9-a10f-4d9f-84f9-16a465969446">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b37343e-852b-48cd-a965-bc7974401792"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd9a81c1-a8fb-49a4-afc6-b3f78d75ffc4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/37d5266c-ff88-4702-87e5-e5c2f2bc8bc6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/122ff360-717e-4b71-9dc4-4e1b21f679a0">
    <dc:identifier>HP:0000718</dc:identifier>
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <rdfs:label>Complex partial seizure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7cd753b8-b2f1-445e-9e61-b1716b317e66">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c96456f-8834-4b09-9934-1dca23bade97"/>
    <rdfs:label>HDAd-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f8f8bec-71eb-4a30-b35b-7e57b3b2dc44">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
    <rdfs:label>Cortisone</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/eba9cfbb-8df1-4ec6-92fb-713a79aafbfa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4757bf23-2422-44da-85bd-d92ea798aeeb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f839a777-c598-4263-8bf0-08566682a47a"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB14681</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/387c65dd-f279-42cc-a5c4-9dee01405618">
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>behavioral abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
    <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/93c6c1c1-a9d4-4b4e-a03b-1b09efc2c13d"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/abc7ed26-2e34-463d-a1e2-a2c2536df1c5"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dde180a-9045-4c92-8833-c9eb81c45025">
    <dc:identifier>HP:0012279</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
    <rdfs:label>Low plasma serine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/36070c3d-776e-4e93-8768-8ecb4ed589df"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f29b74c-86a7-4686-aee4-0f60ec2c62bb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
    <rdfs:label>Corneal Oedema</rdfs:label>
    <dc:identifier>HP:0012040</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/44215e3d-c499-4f24-af73-4f86f78e85ab">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eeff7b5d-7b79-47cd-b8ee-f59ac87bb395">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b086f8dd-0e25-4a4f-a69c-d4d8170457ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6298fc76-76da-40a0-b814-950b5f992c49">
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010979</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/177bdb6c-77b5-4221-bd9d-a0e3bd8402d5">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C  level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
    <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
    <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/61d578a2-e049-4440-a688-3a4b0aa8b6ad"/>
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d85c4628-950e-41fd-955d-85a35ee6e42d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
    <rdfs:label>Amphetamine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cf7c940e-d14b-4b58-bbcd-c7f32dd37f67">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3b69bcd-de1a-417a-914a-2bb82417bfee"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15c5b047-7d23-44e1-8664-946d7151a0d5"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00182</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/db7549bc-98c5-420e-964e-0633e0d50145">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2edde499-f76d-4c34-bb0f-f714cb66799e">
        <dc:identifier>HP:0012825</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
        <rdfs:label>Mild attack</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b3de35f-1965-4c89-92a3-7352b4f004ae"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2a11fc1-6d90-4e4c-9159-b0b2c3890ea9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44b75cb0-cb0a-4bd4-bd7b-49bf3c462ebb">
        <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0010472</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24584325-b7e9-4a80-9647-827d962cc6f6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>Congestive heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e60f5443-5a81-41db-a598-85c23766f399">
    <rdfs:label>mortality</rdfs:label>
    <dc:identifier>HP:0040006</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a171940-edd0-4065-864b-2d8832cf0a82">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cb9710a2-a5fe-4698-889c-025d607acf09">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43911890-8802-40c0-986f-926810553d3f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f306686c-5526-4a68-87c5-27376663e133"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3051d9e2-4115-46b1-a44d-33bfa5557f06"/>
    <dc:identifier>DB00641</dc:identifier>
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/346c490d-8861-4eb1-93dd-09c5dc0e26f7">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43911890-8802-40c0-986f-926810553d3f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42d6c3cd-e7e1-43de-bff6-12b60f82d0a2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
        <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
        <rdfs:comment>The drug has been reported to be unbeneficial in one patient .</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e22cfb00-8ad5-4d31-99dc-ec1082e10b1f"/>
        <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fc69a73-128a-4dcb-9eb7-0acce3c7d48d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9dec9c7-1584-4832-9022-13a5bfd310b3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebf581a1-56ea-405b-b23a-79055ff0a690">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d1c5a7e8-df42-4e3b-b7d5-08eefbbf6a99">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8baad37d-f8cf-468f-ae70-79bb96c07e75"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f306686c-5526-4a68-87c5-27376663e133"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7239f1d8-d6cd-46ac-a7cf-bc70b61d5e47"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV-cG6PGH</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a0cdfd55-710a-4995-803d-10b5f8fc6c43">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66ea6f7d-c6ae-4edb-a930-dc6b90bb94dc"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/85dc2815-0c06-48e1-a1dc-ed500d9ccb87">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea55395d-e2b0-4840-8f36-46c1f93ffcf7"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2751edd7-6c88-496c-96aa-05f25cc5bb24"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b8e7923-68f0-45ef-9a9d-0fc4aba83398"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7db42228-0fba-4688-8621-9011b77a7ee7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>pain</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30192e87-405c-428d-886a-b9e9a607de8f">
        <rdfs:label>abnormal mental status</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01798aaa-db2f-412e-b019-1e77b407fc49">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:label>hypertension</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/503909ed-df09-40b0-b984-875be1d24177">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01e73087-1b3e-43c0-99ba-c1bd3f569432">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3442e2c0-b8ab-47b2-b556-1372efbccbb8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c7628205-5d51-4be9-a5c1-565a6f99ce7b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5e51cda-f95c-4a18-8a1a-6cd69e03c5da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/324a4324-1d6e-4e47-bd64-01f9f3dddad6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/408fe1f1-b115-4d23-91f9-3d2b1ac6d688"/>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d3ad8d1d-159f-43cd-acfb-bd0fa86ad991"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e47f7ab-f1ef-4e49-bc7c-311fbbfabfd5">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/654a53a9-c726-452f-bfe1-0a4de87e5825">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f649a370-4122-4249-be2b-51ad88be2caf"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a6deae4-abbf-4095-8fdc-f691f8899f35"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Testosterone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8384844d-551b-4160-aff6-c516b1e273a4"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4466b75a-75ff-4385-b721-5d4d9e352ef4">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a6deae4-abbf-4095-8fdc-f691f8899f35"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a6a3637-a904-406d-bae1-88bbbc5978c2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58501ecf-379f-4fa7-b8e3-fdb1e09720e2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd44fc82-a3ad-4ceb-a3fe-3b973dc767d4"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00624</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/112c5de4-d717-499a-a014-6f75e9562439">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/086c278a-4348-4e73-b1fa-4ce1c79565e0">
        <rdfs:label>CoCarbs + HPro</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdac9fe2-22ec-432a-a39f-7352f474b078"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d95ef81f-e0ce-4caf-9d35-67979de35b7a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
    <dc:identifier>HP:0040181</dc:identifier>
    <rdfs:label>Perioral dermatitis</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05817cca-cbec-4036-865a-971ce900bfb2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e23e51bf-7562-4ec0-90c2-c065cf2a6bec">
        <dc:identifier>HP:0002156</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
        <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c63a4ba0-50a4-4346-9f1e-ad8033f54f75"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/68a2dd8d-8bb3-49d3-9d5d-e0a837fff48d">
    <rdfs:label>Mannitol</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1b08e997-d5fa-4f3a-a721-4b94e26e4f1a">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4bc76912-3b67-4d6c-be9f-7e654239f92f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3135813-1fd0-4ed5-a641-bdc064a4ae98"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00742</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6821fed-9c22-45e9-a196-111538a107b8">
    <dc:identifier>HP:0003287</dc:identifier>
    <rdfs:label>Excessive Reactive Oxidative System</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/99dcd964-7a31-4c8b-8a3d-f4bb1aa81676">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963c55dd-5b14-42fb-b9cd-c4204e8bc6c1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e799f0a4-7b38-431d-8d12-b44a55f32a99"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f202f51e-67a5-4eb3-9dab-077ad3edea58">
    <dc:identifier>HP:0005346</dc:identifier>
    <rdfs:label>Abnormal facial expression</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e6267574-c447-4b26-82a1-d04764a0f5da">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3142b106-25a8-49c8-a10c-ed602db74f49">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
        <dc:identifier>HP:0002155*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea7ce267-e12d-49ec-8a0b-8fd43c0ed7a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9086649-7776-4029-98dd-e341c7e3c4e1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d0005c3-40bc-43df-ac85-199798b98390">
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22153b12-64ad-4e7e-8f9c-af1ad9c0bfca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59099119-1dcc-4d8c-9094-62d6db9e716a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/289e35b5-4423-4813-9a2a-1b3c71bd7b66"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c18bcbf9-de38-4409-9d6d-bfe0356c6653">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a143d0c3-c299-458b-ae4e-093575eef873"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f1127fd-c8e1-4221-8bd1-1e634f8ebc62"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cacb5a96-26b1-4eb0-bd92-f5ae8d3021b6"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ed70b0e-224c-4241-82d8-ce49b6ff9aa6">
    <rdfs:label>Axial dystonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:identifier>HP:0002530</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/05eaf8c9-0c81-4ae3-8826-c80d996e86e2">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37d870c1-28ec-4111-bb98-52b914555a53">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <dc:identifier>HP:0007166</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5657ecd0-e178-4897-9050-3cc1eefb0b63">
        <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
        <dc:identifier>HP:0031884</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0859d187-e06c-45d4-839a-9c70cc169a1f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4df29142-cd8a-4e5f-a005-fd2dfb7a2ded"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14bb067d-1102-42f5-8347-80d943973c07">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:label>Abnormal motor function</rdfs:label>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb28adbf-94a6-4930-b653-024a835ad1b2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/838150d2-a5c6-4176-80c0-af0164d2d9be"/>
        <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
        <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a647e5cf-d3b5-4a0f-b4e0-0c8cd97f619f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a05a0e9-1ccd-4cc9-bdaa-8381ddfecc5a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d97a4b64-26fd-4f1c-bae3-7c47b2de7624">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
    <dc:identifier>DB00413</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7d97699-c575-4804-af6b-4b5a174f8b29"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2f6653b8-2469-47c7-9146-8dfa6681b362">
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4c7893b-5478-4fcd-b4f4-a6a9f1e9ef8c"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/90477b13-2a62-4d93-9daf-08e09dc5a897"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d09b011-c1b1-4f5e-80b4-c5ad189cb1bd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e871e13c-3365-438e-9847-03123e2e16bf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f84f01bb-37b1-49c6-8c1f-ec5513079034"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Pramipexole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ab342b2-165f-4e40-855c-b4f9f59d1601">
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd5fb2a6-2534-418c-90ef-411410a997c1">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3394cfb0-edb0-41f4-b4ea-bb44a230557f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b923d53-628e-46e3-931d-46eca245933c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6a73e9d-2614-40e0-a374-0dd4085e7542"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39910cb4-3da6-4bae-bf49-d8c578f93fc0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ced5be53-aea6-4fb7-8fc7-6733067c7780"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/353df1ca-4071-4a6d-9c08-8d799e95c995"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55ba0edd-7acc-4253-af5b-6ff0cde31a1c">
    <rdfs:label>Low height velocity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
    <dc:identifier>HP:0004322</dc:identifier>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7d28bcbc-f68b-4452-985f-42f31eb66c55">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/354a137c-966f-4f68-a7a0-0bd6dea0f0bd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e7d512b-5d7b-4064-b013-a6a01d3394d3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a0710b6-a667-4063-b365-1768a32a5edd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82844744-5f31-4226-bd3c-bdab0c127144"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1499025c-71c7-4787-bead-e33952e99a88">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e80a68-2850-43a1-a048-934ece7b8546"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a4944e4-addc-4c23-84df-1fdea209ebbd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0f0827f-0e6f-4bd0-b681-e56eab4aceef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3edd0b44-2b64-45c1-b285-b5abab705fda"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9ec6495-771c-4371-95a4-e50fdbf0592b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <rdfs:label>Sobetirome</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/95265078-45de-49c6-8241-ca7da31f40f4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e92f8625-1bfd-4e1d-abec-98245957025d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
        <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d117a9c0-c017-4972-8118-cca6549985f4"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB07425</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e3cbe17-1f57-470e-a944-1892453907c3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce7fed42-1750-4232-89f3-9d1a5eb2a771">
        <rdfs:label>Low life span (Mortality)*</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd43d6c0-f703-4d76-9f27-f0ede1c54d8f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06bac1e2-2b49-4339-b7ef-6aaec1d25577"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb54d37a-44ad-4c8d-ad0b-4993cf635945">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2839aa44-5e60-41a7-80fc-596376209b58"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68dd919d-9f04-47e5-b554-8301845b70e6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040129</dc:identifier>
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cee8b6-b735-49b7-b607-88be52f791ad"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cb475c0-272a-454f-ae7a-7f5e2df8894a"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbef9c63-b8d7-4964-aa38-de30f624a41a">
        <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6fe0e1b-96dd-4f63-b776-650a8280e0b1">
    <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
    <dc:identifier>HP:0003072*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/614dbcf7-f4c7-46f2-8479-783991e83cd1">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003452</dc:identifier>
    <rdfs:label>Increased serum iron</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be5255e2-edd8-4c1a-9bd1-40678c4e1a9f">
    <rdfs:label>High total homocysteine levels</rdfs:label>
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d131d37c-bc1f-4250-aac4-c208424aa584">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003107*</dc:identifier>
    <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac40f659-bd72-4398-b2e0-dd107b43688b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
    <dc:identifier>HP:0001987</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>High blood ammonia level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c319ebe-fb0d-47a3-aa30-48cff96d8239">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>synthesis of atypical bile acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a76361bb-e2d0-4ade-a592-df3db255106a">
    <dc:identifier>HP:0004325</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low weight,growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9348d7f1-16eb-463a-8920-f06b9270e299">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
    <rdfs:label>Increased urine output</rdfs:label>
    <dc:identifier>HP:0000103</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f349d51d-2014-44ac-a350-d266897eee14">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd3c1f73-24e5-4b5f-9644-62c704b965ad"/>
    <dc:identifier>DB11859</dc:identifier>
    <rdfs:label>Brexanolone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0190543b-548d-46db-8758-593e6f0baab5">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04c054eb-f972-4185-a472-b2f5b6e33d04"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d74ba1d0-f444-4a4e-ad3e-608c307e3a4e">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99524373-97e0-4243-b4ba-71f95babf9b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c456a17-c5e2-4c54-a8a8-d670a7b1ba96"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f570193c-9a71-4c6e-8c33-e868b1e27371"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90921a76-8314-46d5-8f1d-e9c1c944b43a"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0762c8c-b57d-4e8e-83d1-cde2a891bb3d">
    <rdfs:label>Diazoxide</rdfs:label>
    <dc:identifier>DB01119</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6a03ff07-3590-4a98-8eb3-875c8cae8331"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44094529-1cbc-49b6-a57a-d2e97ec10bae"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/68e364f3-d080-4dbe-b5fa-b0fab83f1352">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0003304>E1506K</obo:RO_0003304>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <obo:RO_0003304>R1353H</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0e1a637-b15c-41f6-a6a4-89ca3bcaf0ea"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9ed668c-fc3a-46bd-9493-e4f9f33915f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <obo:RO_0003304>delSer1387</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ffaae4aa-c172-479d-9872-c3e356a73e74">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d18f76a-47c6-4ba0-9484-d274280c8db6">
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60127211-e36d-4e62-a235-db20dcf6497c">
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012113</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eda256d9-b92e-4b1f-b926-3498d4630eb2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low brain creatine phosphate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/387c65dd-f279-42cc-a5c4-9dee01405618"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c163a5b3-11fe-4230-8292-fdea583c2f18"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3643d991-bcf2-4187-bc06-bb267ae9eee1"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d46b65b0-9059-461c-8369-40f8005110b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0a7c605-661c-4fea-9447-b771bc2ef76f">
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4dfbc52b-5542-47ff-a0bd-113073c262a3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025051</dc:identifier>
        <rdfs:label>low cerebral creatine</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb55ad6c-74cf-4630-8735-f5e6692876fc">
        <rdfs:label>abnormal coordination of movements</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
        <dc:identifier>HP:0011443</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5b3529d-4138-4b8a-b051-3358bb13e71a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/495ec8af-f39f-425d-a4a9-956daa050fb3"/>
    <rdfs:label>Albiglutide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <dc:identifier>DB09043</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/83d2b7a8-3db2-47d1-a768-b99a0e2a3e72">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bc42850-1f13-4423-8e18-61d7ff6e0c8c">
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/046a33a9-3d81-4a38-b213-f1dec707aa21"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/509e2d37-311c-43db-9995-65a784ecfef4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Focal seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
        <dc:identifier>HP:0007359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5395dbc6-0135-4d2a-b9e8-b0932c5d87a2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609f1ba-a5f6-4232-9455-600acc5fb9ee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e45998c-9f4f-4872-ab6e-4ee29b83a0d1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6298bf2a-b40e-43eb-a5c7-6ee514e033c6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c3e5862-4e47-4375-9635-40a80fd8ab19">
    <rdfs:label>Ciclosporin</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ff16f453-b514-4716-85f4-067dbd6d4490">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/146e9834-8a59-4c8a-9f99-334bf5830daf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/139edfc9-2e1f-4d9f-9ad0-2db15102dc9f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6244b024-f848-4966-81bf-096a8626c990"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10d95793-3e2d-4e49-8563-bbfd5feba260"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/efb72111-63e3-4fca-9892-2d985193a32b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/139edfc9-2e1f-4d9f-9ad0-2db15102dc9f"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24bd65fe-983e-4747-a9c6-35bdc66e9d19"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00091</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1868fe00-ed6f-47f7-ab13-3bf26ea8e8f1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3e6c036-539f-4ef0-a1d8-477d43479b41">
        <dc:identifier>HP:0000982</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
        <rdfs:label>Keratoderma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b22af8e3-6f33-4592-be35-244dc6161c6a">
        <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
        <dc:identifier>HP:0000166</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e20e8608-956b-4165-9750-e57c4bbda863"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdfb135f-f044-4d16-a803-87f7cf3cd8e2">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Corneal scar</rdfs:label>
    <dc:identifier>HP:0000559</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b179d799-45b5-422c-a069-ed33598ea07a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd13ed4f-ea28-4615-958e-acdf624a73a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/464c5d39-7ce8-4a1f-8500-012e10d4aabe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8e554fc-81e2-4bf9-ade4-1c8b8e0081b2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31a28101-243b-4aff-9e9c-cb84c426c9ec"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47114980-fca1-4ead-8284-307b5f069108"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51675609-660b-41a9-9007-077d5cbcae8a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/277d7b7f-2f80-4836-b8c5-a2b2a5da17bc">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c362fa10-c157-4ecc-884c-99579225ebf3">
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7bd5425-9430-405b-8992-8433c2bd1f42"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6fb37306-a211-4d4c-ad00-c929164a4cfc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/45d8a7e5-1dcc-45a8-aeb4-2b3d670203ce">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2423d547-a4d6-459b-85b5-48ae78a24de0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65d124d9-35bd-443e-a928-93c42eb0ee29"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/c623d139-2451-4db7-827e-9203a2ba809d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608099"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85d92e39-45b9-43f1-9859-cde450437a99">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f5e3fee8-9af7-4940-b230-6ebbfa0c486b"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14e0f441-4aec-4639-9171-77644daed2cf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ae050b2-d9a0-4d69-baba-5e8c4d2e6523"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3df60449-b57c-4651-9b9d-2e24b1d6e920">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/408053b1-e1da-4136-846f-4969b319c113"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33b6d078-aeb5-4e46-aae5-784baac027d3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Kinetic tremor</rdfs:label>
        <dc:identifier>HP:0030186</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27fd721f-8919-4b8a-91f3-dd03b4ae5151"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b036d0cd-5fa8-40d7-865c-3da16d40dddc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <rdfs:label>Postural tremor</rdfs:label>
        <dc:identifier>HP:0002174</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022510X16303495</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/faca736a-6e93-4d0c-beba-bcd1af0ae2a8"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c9ecd54-693d-4361-8b7d-673b372bb688">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
    <dc:identifier>(DB00440</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a7bb9f30-bb06-49b0-8750-5046a92dde50">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e441fa8c-a6b1-4dda-90cc-3bb1c312b38d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4289a87-1c6d-4bf8-a302-48ce7f4e42a7"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90e68388-d963-4812-8d5b-bd3deaaf76ef"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0cef4e36-4ac4-41dc-9672-6722e79cea01"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52b7b915-02fd-4ae9-bc72-3494ac88d60a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/481dd176-520a-4c5e-b493-2a0881573d15">
    <dc:identifier>DB04075</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bec3c482-aa6a-4b34-ba40-07c063672017"/>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5994609d-5b8f-4d35-8f02-6815ebb7e1cc">
    <dc:identifier>DB00129</dc:identifier>
    <rdfs:label>Ornithine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98737d93-4ff1-42d3-9dc5-d9fa0c3d5dd2">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c8c8d48-4aea-4a4c-b41e-3a572b5792d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebddca3f-c0c5-4f02-8707-2078ba1bdc4f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de389633-e330-4dbb-a636-2dd8c33e23fb"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80db5ce0-48c1-4ad2-9dce-f8577ed73b45"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76715966-07eb-4eac-ab88-cfd2ac6265d7">
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b464ce07-d9a6-4cea-8cfe-f579d3c78b29"/>
        <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
        <rdfs:label>GRACILE SYNDROME</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3af88b5d-64c3-4b37-a4f2-45bd8291b744">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:label>lactic acidosis</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0206d427-84af-405f-b548-b676f81c6d34">
    <dc:identifier>DB00480</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <rdfs:label>Lenalidomide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19042206-17a1-4a91-a094-ea7fc597e1f2"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fabe27ec-3344-43b7-a872-8735db76e747">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85c542c8-6c1c-4c27-80c8-8429b22bedd7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27162232-0098-4d9b-b573-ddc220097842">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
        <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0003193</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12fdfa7c-5a22-46fc-8aaf-a893a3c7067e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8dcf353-0f0b-4588-b58f-d1b45d937da7">
        <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0011598</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c6f8ddd-6e1c-4c61-806f-85535a2c3952">
        <rdfs:label>low HDL level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50d5e02b-7b5e-40f5-988e-a95f4e89886f">
        <rdfs:label>low APO A level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025201*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6bd87ae-81b9-4ab5-979f-3950bbaba870">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>low HDL-C level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9931cc2b-1020-4fc3-83ba-029337a45022">
        <rdfs:label>proteinuria</rdfs:label>
        <dc:identifier>HP:0000093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9bffb4d-1b08-48e6-b1e4-310c55c5ed78">
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:label>Low Apo B protein level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/978c25bc-a4fd-46c7-81fd-b38b89cd5952">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8395c262-057b-446f-a115-d8fbaf80b995"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7263897-6af2-4147-8839-7093f16ca467"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/14df4d81-e4b8-47df-b389-3ae6a942d9d3">
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/773f5849-91ef-4a20-87c2-a579196dcd00"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4af5bd5d-26b3-4ad1-8e8b-e62e46bc796e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <rdfs:subClassOf>
      <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/525e6dee-9886-4d21-bb9d-60c7987f1c7e">
        <rdfs:label>Functional intearction ( Mechanistic B)</rdfs:label>
      </ddiem:TheraputicProcedureType>
    </rdfs:subClassOf>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/049e2718-6497-4b73-9edc-089febd6256f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7bdfe97-96b3-4e4a-b0a6-c50feb976ed0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c488cae6-1f81-4ab9-8877-344098c98be1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df07ad80-d7c3-49fc-bbf7-20a21cb3a40d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c05f998-3f56-452d-912f-5600ac0e29e3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb618899-676a-4500-89a0-e46fd7b5f6b6"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c35b774e-7c86-4b4d-9fb5-b62f3a3920f0"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9927e504-f5f6-4b12-9be8-2ed6e976d05b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3092f08f-72a3-41b7-bc3d-8f11497ac30b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09dd32d5-6775-4944-b191-9a0757e4018e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7235a637-7fd8-41ef-94bb-3ceb1e152153"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f17d3168-31e3-4d37-a223-ff2591a58549"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
    <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f5df2783-ff62-446d-a814-be939e5a6d4e"/>
  </ddiem:Disease>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/79a18315-a9a4-426b-a6df-10c1501cd7bd">
    <rdfs:label>Direct interaction ( Mechanistic  A)</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
    <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
    <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a53de917-f4d9-4891-88bb-1d65041d7908"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14fc0a27-1380-4aba-b3fc-f52aa79739d7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6f0fc37-28c2-4b25-9c04-aeb46105931f">
        <dc:identifier>DB00855</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b2c87a0-b996-4b8a-ae1f-d2f975ce1149"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
        <rdfs:label>Aminolevulinic acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d29f1d8-570e-481b-b2b0-1e7f64b639ff">
    <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
    <dc:identifier>HP:0010876*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/469117ce-9a23-4add-9f52-bf85d314b3f2">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0470a48-23b7-4987-8392-91d07602e762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/433b8047-047a-4861-8fa3-d91d97d60a2e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/952d2c6e-b8ce-4ef4-94cf-574d1286695e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82f7ea61-5a63-4e55-80e3-b05dad441491">
        <rdfs:label>cystoid macular edema</rdfs:label>
        <dc:identifier>HP:0011505</dc:identifier>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5d804cc-09d5-44a3-b667-3ceeda2fef26">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <rdfs:label>Desipramine</rdfs:label>
    <dc:identifier>DB01151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb76efb9-1a5b-46af-87f6-6659e2aae056"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f82deb23-fa3e-4d09-a92e-8addbb8ffa61">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/269920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1d4def10-e870-4340-8e2b-ae37f5912084"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/321c1804-142c-41a3-b530-00e5385cf0c0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
    <dc:identifier>HP:0009020</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/73239df3-03ae-4537-a05f-7083844ea368">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/046a33a9-3d81-4a38-b213-f1dec707aa21"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fb4eeac6-d6b7-44d9-a9cf-cf627eea0a54">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6cbcde1b-cc16-4021-aabc-9c0d0c515c23"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c57809ab-a984-452f-9721-602647210ad1">
        <rdfs:label>Trial is no longer available</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/07516c03-8136-4452-8376-dd6ac044a6ad">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd28b2b3-fa6d-41ca-8d66-64b8ee7ba451"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3536671-695a-432d-b887-9329e696fb66">
        <dc:identifier>HP:0001892</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bleeding tendency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79465ef0-e5da-4300-aa51-83de6b0cbaee"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e610ea95-e759-46a6-9447-f0b141540a51">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c2a3dce-bd28-486f-a6d5-0ded3cffd79b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f77a7030-e7e8-4ec2-8869-024a0115d8bb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300818"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cf7fd42-9e16-4ca5-b589-87cfa18f7d0c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
        <dc:identifier>HP:0004818</dc:identifier>
        <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8801a43-b830-49a6-9500-e111b5d0e6d0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609f1ba-a5f6-4232-9455-600acc5fb9ee"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51ac32c1-b15f-407e-85ed-3aea4c6e755a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/313c4e71-db87-4926-b9ce-ce7515525bc9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7b79e46-ce5e-408d-9297-9aae947e0e1a">
    <dc:identifier>HP:0001369</dc:identifier>
    <rdfs:label>Joint inflammation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76c565cb-1a60-406a-85db-a71b378dd3d6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb6d8fd9-056c-48c8-9bc8-71ae98576b7c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001369</dc:identifier>
        <rdfs:label>acute arthritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f22ed985-dc1d-4dd5-91b6-8387afbcb033"/>
        <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cacb5a96-26b1-4eb0-bd92-f5ae8d3021b6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b47f764b-a317-4b3f-9d48-959ccaab26e6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6bc9f375-a10d-48c1-9170-40c45276aaf6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a87be9a-8f29-46b4-99fc-033dcf3efe94"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b88225d-86a4-4261-a220-59604248bc73">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a913b222-c016-49cf-bb52-cc648f97cd49">
        <dc:identifier>HP:0100529</dc:identifier>
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/109101dd-657e-4945-a064-6ee9d5105007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/efed1505-2912-4a47-9205-7a3c5a26b5bf">
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <dc:identifier>DB14751</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e18f31bd-f843-4f65-91cc-f03ee3dcaf68"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/8a5c5203-9f9e-4654-9e6c-6c5d565397b6">
    <rdfs:label>functional complementation of a defective protein by inhibition</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/87b9df61-8c8d-460c-a5e9-e9b7b8c2b359">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/532cbffe-cd10-493f-beea-3078a668633d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0566178b-1c21-46ed-94f4-261aaf2c9670">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5d95ca9-c3f1-40d3-9b0e-dc07b842d76a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b656966-60c6-4a94-92ad-422c10eb7ff1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f219a649-5d9d-43ce-9abc-b7b7619a6a84"/>
    <rdfs:label>Phosphocreatine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a93dc0d5-b127-448d-a3c9-58fe78d1f0be">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4f9ae31-52fa-4a80-8261-43bc4a85889a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4d0fc44-d98e-442c-83b8-f46340e1f78c"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB13191</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9877164-2692-40b1-8d42-6fc1b2d88e26">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/956e4780-6600-43ea-a8e5-035870eea054">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ce76469-459a-4173-a26e-75190e01f3ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82b76ce9-e67a-40f3-a0bc-390fbc8c9e91"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35961a28-54c2-4e41-a531-dcd68a498bd6"/>
    <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/477f6527-9c5d-4711-8404-68cf3dd9692a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e775c603-f222-4d76-a9c0-db8e8d8f13fc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51af49fe-d133-4b04-a96e-0ffa8d2d9f28"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d59c6d17-81dd-4e36-941d-3f78f927c140"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/832655f7-ac80-422b-89f4-ed9fb9d0a553"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/167b9c89-18f6-441f-ad65-35ec7473d9c1">
        <rdfs:label>hepatomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/296021bd-26c9-485c-9801-eb923b9e5873">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b22e24a3-5b2a-4d60-9b57-78437ec71d7a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/353df1ca-4071-4a6d-9c08-8d799e95c995"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa6c9cc-6bcc-44e8-83ee-31ea74516af6"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb065332-2430-4a70-adaa-233b51cb020e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9428dfe1-55ca-40a3-9ae3-f330f35d6f33"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4765302d-b1b7-4642-8795-3e8be44d3af6"/>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6aabb12b-72af-4844-afbc-af671c122b88">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbab6631-b562-422c-91fc-c317f7663892"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32e4844a-4f74-4ecb-951c-4c330292931b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
    <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
    <dc:identifier>HP:0002446</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a24c5361-66ed-4cff-87b7-af0df95598fe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fcb23ff-5bb1-4461-b9a7-26603eb4b4ba"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0cc3466a-ac8a-4cd0-aca7-3eaa1be80daf"/>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/947e042b-f0fd-44c4-a005-a55a90b1f7ba">
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db7549bc-98c5-420e-964e-0633e0d50145"/>
    <dc:identifier>DB09341</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d826681e-af56-4f2b-9240-4efafa66a272">
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <dc:provenance>Abstract</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b3de35f-1965-4c89-92a3-7352b4f004ae"/>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbf65af9-c41b-4ef4-96d5-989ffe173b84"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12a205b0-56c9-414c-9d41-9578c008035f">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d9d26983-684b-4213-9934-edf3dcc54996">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/121270"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/027ad5c0-aef4-4e0d-b593-b21edd0d07c1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e832eda-8e71-4516-9666-e111a07e5a59"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <dc:identifier>DB09130</dc:identifier>
    <rdfs:label>Copper</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77a19662-1918-4ac9-b919-57bcd5514086">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f69e89dd-0990-496c-b280-53906427d65a">
        <rdfs:label>Uridine triacetate</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
        <dc:identifier>DB09144</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08644f9b-8cbf-4e3d-a719-a6bc477d7cc5"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d408236-27d5-41d4-a14c-bc4be7b6218e">
    <dc:identifier>DB12536</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e9c89257-232d-4ed3-8be3-2f0ec1784e1f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac5c34d8-6059-4fa6-b8f1-2d64e96e3686"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/adb3a65e-6547-4739-a3a3-64ddcbd62b35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd7e9bf7-cd3e-41fa-88bd-4a6a86735801"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cd01c540-40a3-475d-8e73-c5ac9695e229"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8bb9125-5908-414e-86a6-7abb5e4a3a91"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>N-acetylmannosamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69b3fc66-250a-4ae3-b010-dd67186394ad">
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ce02324b-441d-40e9-9feb-4e5e7cea54d2"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ff7e7f98-6e16-40e8-9d37-e7c9c5aaec9b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <rdfs:label>Tocopherol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb627306-bef0-42b9-bece-fa5804bb0ff1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75d10995-db10-42f1-9a88-e44a9946d0c7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89582e11-27f3-43b5-ba67-e94f3ec232b5"/>
    <dc:identifier>DB11251</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8a0a4de3-c0d5-4ce9-a1d7-41d90a5e23ea">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01954d0d-991b-40cf-b856-b488e742df3c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8af93fe8-05ff-4d50-b7b3-36fc36855696"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78862af1-6be0-477e-81ce-26a6d5704100">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurologic deficits</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc1147dc-38d4-4306-ac78-ba67a5c6d0e6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8fe1629-0a9e-4663-bcaa-3f95868aa964">
        <rdfs:label>loss of ambulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002540</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2df8b7d1-9fd0-4f7e-a4e3-3f1c1e14d806">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>cognitive dysfunction</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/97cfc003-6817-42bb-8370-d3aebc6c2d75">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22d439ec-73d4-406e-9c25-d68aae7b84a4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8908823b-f4f0-4936-b975-4dff6afd08f3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/614921"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04a439b8-9ff8-472b-ba73-f9330c40a368">
        <rdfs:label>abnormal nucleotide sugars</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3423853-029e-4284-a233-6abc60221ae0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3019a8a-a298-4ff4-aee4-7ed7fcebd3bb">
        <dc:identifier>HP:0001976</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fd4a349-1ef0-4927-9838-71b3cd67960f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a647e5cf-d3b5-4a0f-b4e0-0c8cd97f619f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec783b03-5e78-4295-9b56-fd273269b498">
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2466699-b961-45e6-a222-60362d3c7be0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1698e7a7-7d73-4193-9cc9-c3739e45ece3">
        <dc:identifier>HP:0003645</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal aPTT level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e4867686-4e2b-42a8-8a0e-bdc1c476527b">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15ea5a1d-a9a0-4bab-8356-18ff9935bb27">
        <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a29eecef-f1e7-4867-9749-72ded5b72cf3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/050bf255-d3c2-408d-8671-93c72c4b5f1a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100512*</dc:identifier>
    <rdfs:label>concommitant low vit D level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22955ed7-d2b6-49eb-be60-4ca76b4ae6e9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
    <dc:identifier>HP:0009124*</dc:identifier>
    <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d93e631e-a9c2-4d2c-88b7-2d0f050c4418">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>Low HDL-cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08fe3809-6032-4a9c-a999-27242ca644db">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee68e44b-6e60-46ac-903f-f98d06c7ed7b"/>
    <dc:identifier>DB00136</dc:identifier>
    <rdfs:label>Calcitriol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f87bcf1d-0829-4065-9181-e4eb49881013">
    <rdfs:label>low insulin senstivity</rdfs:label>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <dc:identifier>HP:0008189</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be3487a0-2580-4f2c-87cf-456bb19436e7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/343be2f8-cba0-4661-ab96-13ae2487d62c"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdec12c4-0d23-4912-a433-59f8f06c6096"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e2f30233-edb8-4c11-a48b-be64b9dcc842">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20b9a11f-67fd-4e21-bebb-43b62fb8b81e"/>
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a1592e3-072b-473e-8866-4934f6ced619">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low cell autofluorescence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81c4f246-1e97-44bf-a58c-a434f68c6f27">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffa9df37-3549-44e4-bfb0-31446bdebb68"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f338cf96-d17b-4bd2-8cf9-728b0bb3c2db">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a579d139-865f-4977-8d64-eeeede9d8670">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>membrane fluidity alterations</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f096527-b7fa-471b-80b4-bb4d7b43b2e5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3759705b-3518-404a-b35a-75cd3f73a69c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e60a2eb1-b2c4-4062-9d1f-33223f5d3f2a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
        <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
        <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1ecf7328-81cc-46c8-91d4-8d4c9d716ea9"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85dc1265-e4f2-4524-85eb-4c8c1e2b8f4e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6452738-c9a9-416d-97f5-d13b34325407"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ab4308a-385a-4f0c-8d80-3fdddb85d88a"/>
    <dc:identifier>DB11094</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6d29099b-9b3a-463b-9750-2fb231715d08">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/050bf255-d3c2-408d-8671-93c72c4b5f1a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4cffaaf-9556-41d9-bbe3-897a4f08ad0e">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93a5a562-ddc9-4312-abe9-7250f8b8549b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8bf97396-107f-402d-afad-de14f26db20b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044915</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfaf29cf-df43-4ef8-879b-523ec10e0573"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Vitamin D</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ea3afc01-b400-4c27-b6d5-1ee7b775bff6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5eb5be86-f484-4774-a0b6-0635b18f4c49"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9de9be1e-6147-4a9c-9aa6-1f0e59fe8893"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/316de402-f21d-477b-b6b4-1bf30fb95ef4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
    <rdfs:label>Hypoxanthine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ce37eb27-be26-4b8d-8049-6bfd2c21b9d8"/>
    <dc:identifier>DB04076</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efa4a16d-4152-4ca3-8310-11d4c111ffa7">
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
    <dc:identifier>HP:0000718</dc:identifier>
    <rdfs:label>Generalized convulsion</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4b1675a-8e5f-46eb-9e6b-4fa18fe739b7">
    <dc:identifier>DB03147</dc:identifier>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f78800c-d43b-41db-b16c-e83a65615255"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ca88d72-2401-4ca6-8b46-26dd406e875e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55e944c8-8d4e-4ec5-b1be-39d8cd32be44">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/09386019-b422-4358-9752-7950d0081c86"/>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Serine</rdfs:label>
    <dc:identifier>DB00133</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaee9be4-10ac-4cb2-a9c8-b15691441ba0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
    <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0045010</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b5d3a2e7-2e62-4699-b909-a5722c10e9fd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbf65af9-c41b-4ef4-96d5-989ffe173b84">
        <rdfs:label>Ketosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <dc:identifier>HP:0001946</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1f1d449-5c26-4f50-8b12-f8ebb0c75e2d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
        <dc:identifier>HP:0012051</dc:identifier>
        <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
        <rdfs:comment>Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3688323b-2302-4fd5-a5c0-916b52d72e39">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59c7bb09-2f0a-4579-a7d4-86c077d4a9c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <rdfs:label>Deferoxamine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1871e580-19e3-4f37-bba7-c996c25c1d0e">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d04d45c5-b938-4efa-9eff-64d6e382ed75"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs12185-017-2365-3</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c35c02e-ead2-49a1-9eb2-b2f7d902f6ac"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b4e734cd-eb8c-4a65-9b01-8aca1c15129a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf1037b2-581a-4b10-ade0-048fac37bcea"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c35c02e-ead2-49a1-9eb2-b2f7d902f6ac"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00746</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0d10af08-038a-4e44-8d10-5b78a0f2f378">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d04d45c5-b938-4efa-9eff-64d6e382ed75"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c35c02e-ead2-49a1-9eb2-b2f7d902f6ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0915bf85-93fe-4e88-8933-9c2e68dfa7fb">
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f48f38f-9d65-4131-9af9-02aa42eaea3d">
    <rdfs:label>Warfarin</rdfs:label>
    <dc:identifier>DB00682</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7121adc0-0c5b-4337-9dd5-5ffb17c69555">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/772de7dc-8a04-45b3-a78f-bb5076a5bc60"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71bc546c-0511-4167-b37b-f33dd847981e"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/061dbf67-4c7d-4138-b413-88166070fe0f">
    <rdfs:label>L-Arginine</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c96c0262-d229-4c22-ab25-70f50bc0d65f">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a1fa805-bb7d-4f47-87dd-e9561f941c9c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24584325-b7e9-4a80-9647-827d962cc6f6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e7d512b-5d7b-4064-b013-a6a01d3394d3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc736ec5-cec4-485b-bc6d-06ddfe17d4c5"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc2ebf01-5452-42f2-a1ea-3872af84f312"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93860759-4365-4b8c-8cad-7935770cf612"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d28bcbc-f68b-4452-985f-42f31eb66c55"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f2410792-5eb3-4b01-9ff7-fa57c88ef327"/>
    <dc:identifier>DB00125</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/373cb716-974c-4138-9f74-e8feb7074aa1">
    <dc:identifier>DB11135</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a46fc5b0-3793-4d9a-a4d1-faa388af07b9">
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12f4d3d0-8efc-47a9-93bd-e5ce56f91a41"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e274456-2d99-403e-ae40-c40c4d724656"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Selenium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02d7020e-b832-4f60-b2e8-a7d8453fcc41">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/7a5e49ad-6240-4a96-8f74-2433839c257d">
    <rdfs:label>Direct Interaction</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4876ab9f-3f3d-4066-855b-af9c62c4e15f">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c557636-8ab4-46d6-98de-38fc2c0e9e14"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4e155640-cf7e-4d31-8560-0035f4b39fda"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29964d9a-3f90-4743-8f14-17b42483acb5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34bb4c4c-49ed-48fc-888c-64504e0ec6c2">
    <dc:identifier>HP:0006670*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1244cd74-f338-46c1-b380-e40c3aa3c7b5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5fd7149-21e8-47ad-9c5d-1ba7854c7042"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-016-9963-8</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54da1121-fea9-4695-9d22-671075b458f7"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4d39c5f4-30d2-41c9-82d4-bdd774ce1a48">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eb367fc-a122-4164-92c2-e0c762b4ad8a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efa4a16d-4152-4ca3-8310-11d4c111ffa7"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eea20ccb-b323-4c4f-8f0f-d9770d5f9238">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ebad508-405c-4177-8a52-fc35df828867"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/122ff360-717e-4b71-9dc4-4e1b21f679a0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f29b237-c1ef-4b28-bcfd-c2e930794f51"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/418326ba-9369-4716-b5ad-8070076c974a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5fd6fc9-d5e2-4002-a0c6-703d80431bf6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low muscle mass</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0345858f-4ab0-4500-9cee-4a3722666126">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c04293c-cf06-40ac-baaf-a217dc0cb0e0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Malnutrition</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
        <dc:identifier>HP:0004395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8752ea67-43df-468f-ab8e-0a9536f2c8f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ed4d068-92cb-4d09-a126-c858a882a78d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2b4d3833-37da-4a92-b3f9-49557ed64eee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15a1b823-0a78-40fd-a3de-1532ce6c7e92"/>
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e539ccd4-c39c-4039-9dfa-5fd9a28bb0b5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52a7f49b-08c1-4d12-b85c-3f8319e315cb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4c7893b-5478-4fcd-b4f4-a6a9f1e9ef8c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Movement Disability</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3f53824b-53b5-41ba-b6ab-836e784cabc2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c6ddac3-7844-490e-9405-fcb762af7c9e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2be06e7c-475a-42f5-affb-d17225d4ca6e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e7fb6b-d32d-4c26-a959-1bb81081eead"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f4e2e0e-7fc8-4baf-ad28-757e08ef3b87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7327bec6-617e-41ad-b987-b3d809522bf9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e95cfa73-9357-4980-8557-d51defae0fc5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42f599dc-d8e5-46a6-a60c-a1a68a891e8a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7f47eeb-403d-4d6a-82c5-db265741d4f8"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19dde51f-fcb7-4296-93d8-9b06645c22ee">
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73250044-d44b-40e1-bb37-c725dd4cf8d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/402810bb-141f-4a01-9aba-bcf97ad04251"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/273f367d-37dd-47f5-81ce-b7daacb8e380">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurologic abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d35d5143-5ed3-4c23-87af-3ec136203246"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/466f7bee-d490-465c-9e62-32ef3af4a847">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ecc40647-4fbf-4000-a933-118dc522cb11"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66e87d8f-9fb6-4352-bc32-8d0d5ccf2c2f">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69f25729-deca-4317-b9b2-7a9fa898d1fe"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
        <dc:identifier>(DB00328</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97ea3b78-83a1-4d19-a3f8-1d35cdeb5276">
        <dc:identifier>DB00700)</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69f25729-deca-4317-b9b2-7a9fa898d1fe"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b46d19aa-7e3b-479b-9c89-3cabd9a2b188">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/995b5b0d-dec1-42f7-aa81-41948904efc6">
        <dc:identifier>HP:0008344</dc:identifier>
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b074a1af-cc87-4691-be36-9e2b14cc7f9a">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9ca0d15-be56-4788-8ab9-e04d223a2787">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6c1c202-5fc3-41db-be5c-342b4a2356b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/377a7b12-6c8c-452b-b9b8-40893a15d10e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c8b74bf0-9f5f-4997-a3e5-38b3767c29df">
    <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
        <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
        <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/006ca4fe-c40c-408e-ad4c-80a81f30ffc9"/>
        <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dd14861-aae1-4063-98bf-e6bfd1ad1146">
        <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32312dee-8af4-4fef-9fba-3109a858775c"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/51caf982-8a10-400d-963c-ef1fa6a62d4e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeeecfdc-47d9-488f-9721-bd09b1c134ad">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Polyurea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e47a6d0b-dc3d-444c-8ab5-45c2323ed0ef"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5c5512f-757f-4eed-b3f8-6c3aa7a42109">
    <rdfs:label>Hepatic steatosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <dc:identifier>HP:0001397</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/118e7baf-0387-424f-9738-d140462ce689">
    <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9fd4e498-6846-4e9e-b475-7193a553e8d0">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d55ef447-a0ae-4ba2-8aa6-3011c68d53c6">
        <dc:identifier>HP:0100716</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <rdfs:label>Self-injurious Behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e10b1e9-13e1-4a0f-b882-914644846d15">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4844f66-bb53-4b4f-9e2d-1c01f8fc01e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d698586-1ab1-4516-b9e2-a1758221d2c6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13b78dea-d041-458b-b6cf-1859ce85c708"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd50cea7-a6c4-4b37-88e5-0ece4987125f">
    <dc:identifier>HP:0003688</dc:identifier>
    <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c50a93c8-7c7d-4379-9ffb-2e0b90d2cd83">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:label>Reduced pulmonary function</rdfs:label>
    <dc:identifier>HP:0005952</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26b71192-2540-4244-8fcd-48f96f8a26af">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
    <dc:identifier>HP:0010472</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b2390357-0423-4ef7-9118-f2d74ae711bc">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ab87e7-eb03-4f32-b467-3522f48ffe7d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca10eb2c-a29e-45da-895d-eb006a3e436e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51c99e81-0dd9-48b8-b5f4-e75a849f270e">
    <dc:identifier>HP:0003107*</dc:identifier>
    <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e50735d-3d4d-47d4-a18c-e6262b051b8a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79ac7c23-8042-47d6-b140-50f95156d001"/>
    <rdfs:label>Copper Histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7fc06979-e87c-4073-9de8-3984a972c6af">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5cbe6e73-6477-49ca-984d-dbee55537552"/>
    <rdfs:label>Vasopressin</rdfs:label>
    <dc:identifier>DB00067</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0fc5149-ec28-49e0-9bd0-a60b517c4616">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>High serum amyloid A protein</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48975f8b-a3de-4ac7-b193-b8b69839588d">
    <dc:identifier>DB00697</dc:identifier>
    <rdfs:label>Tizanidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf7c940e-d14b-4b58-bbcd-c7f32dd37f67"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/826cb97f-9624-4af0-95ed-20999a4456e1">
    <rdfs:label>L-Glutamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
    <dc:identifier>DB00130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4f6afc3-704c-43c9-9e33-b64f85822eff"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b35dd9f8-bbf1-4d73-956c-14e21fda535a"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8b94c815-c838-4767-b66e-248ee8733d9c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57c76db7-6a7a-4203-8e5f-41c74834d1d4"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e484d02-6c95-4731-988f-9af5cbaa6a47">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/126e3917-7cfb-4528-98a4-c39cf8501207"/>
    <dc:identifier>DB01345</dc:identifier>
    <rdfs:label>Potassium cation</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
    <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
    <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e596c94f-82fe-4d6f-928b-def952eb29ff"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29193417-bcd8-4e56-a538-305bcf3b28ab">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Insulin resistance</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
    <dc:identifier>HP:0000855</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0458c25d-b4d5-4c1c-aa25-5e4ac01d65b9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7913b413-2874-4208-95f3-444855c84fcc">
        <dc:identifier>DB00282</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0540173e-391b-4716-84a9-c821c553e625"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
        <rdfs:label>Pamidronic acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b84579f-6061-444f-95b6-9e718f83dab4">
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6c30cfa6-ddae-48c7-8027-9bd4bcc3e962">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ecd5bbfb-eaed-4a07-8504-003ac38b7f9b"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc1147dc-38d4-4306-ac78-ba67a5c6d0e6"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e274456-2d99-403e-ae40-c40c4d724656">
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>oxidative stress</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/67e1fd9d-50fe-41dc-b699-37d5480c5e20">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22ac73bb-8fe2-4869-af90-d11e3ec6e00e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased life expectancy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d23f5766-a1a0-4c5c-8b1f-9370e30fed2e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Growth retardation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc464821-d0ef-4b5f-93a9-be77bb50f3e8"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27ca0b78-6e0d-4b50-a164-899c831b85d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9d6fe536-b883-4888-9079-d3f193da2777"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34279e2f-a0a7-4493-bb45-4609affac1ec">
        <rdfs:label>Deleterious prognosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/776bbf79-d17c-4fa7-a796-e5fec008c0ab">
    <dc:identifier>DB00098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff16f453-b514-4716-85f4-067dbd6d4490"/>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc55fe2b-e57e-401f-813f-15bb16aa6f09">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6c678d8-b780-4021-92ec-f3e7019be13e"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0750207d-b1d4-4db1-8490-ffed29a9c257">
        <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
        <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
        <dc:identifier>HP:0010832*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/80201cf8-8d0f-4202-83e8-ec17b871668f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/535204ef-5d71-440f-a75c-2090edce5763"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b673975f-91ae-4faf-96e2-f306f8e3faaa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/54dba8c1-8401-4c81-9840-fe014e94f394"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6821fed-9c22-45e9-a196-111538a107b8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66987ed2-170b-4720-b974-d66f639c9dc0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a50902b9-56d1-4079-b55e-eaa9696d12e0"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/81b27e5c-213a-40c5-9008-7916c26bcb94">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3da77210-3cad-4832-a942-a195f08c36da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80f24d09-638b-4464-8268-110fbb2ba454"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8b12b36-695e-4b50-b5d1-bbcad4b4dbb5"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f83aa633-4a41-4eb5-9d40-4d39678e993b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e79a5b88-23f9-40ff-aca5-d497911612c1">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa37fb2c-3585-459a-ba63-7296d07e767b"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5fb66a92-4889-431f-bae2-d5786ffa6ea6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a961da86-b699-4af2-be94-7099a8cd8b58"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74d556b1-7165-4d27-9c4d-67dadc342800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbec6364-2abf-4001-a533-538d2644494c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f79fb67c-2a5e-4047-b1e2-bfb6dfa7901b"/>
    <rdfs:label>Duloxetine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
    <dc:identifier>DB00476</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3b42e89-8be3-4aa0-8a47-e9d47c12857e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d262e9e-25dd-4fac-9777-88aec7b6212d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f1f63da6-13ba-435a-907a-61394dd01b09"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e08a5a7c-92bc-4a8a-886d-075fd17bdd61"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
        <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bedd25a3-3460-47e1-8e5e-b9bd1ef05f6b"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
        <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/512a29ba-a38d-4b21-922a-349a5919c908">
    <rdfs:label>Bortezomib</rdfs:label>
    <dc:identifier>DB00188</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a80659fd-bd05-400b-b52c-343a30526d04">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f422ec6-a146-4c09-823e-17d0a33fb54c"/>
        <obo:RO_0003304>I278T</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f51a5bb-b5c5-4c38-94b3-bf7843d80547"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21dd77ff-a98d-425d-a8ff-28486f1b497a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fe98491-d858-4ee2-97fd-9ef4c93e8390">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72e82757-9232-4ee1-9c13-20642fb649a4"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33954865-2154-4e37-9ebd-b3ca46cca775">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3bcb67bc-452e-4ab1-b3b0-e7d0dd7e4946">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98cc2993-e59d-49a1-8616-282abf1974b0"/>
        <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/57c3be7d-57d3-4e49-942d-54d3218fe45c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69ac4372-df3f-4767-ba29-6bf75542c25b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cb0f7df-5652-4f36-badb-4b3655b7f7b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a961da86-b699-4af2-be94-7099a8cd8b58">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <dc:identifier>DB14555</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e79a5b88-23f9-40ff-aca5-d497911612c1"/>
    <rdfs:label>Ursadiol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f60bc44-3f39-4d9b-ae11-ab2cab40e54f">
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <dc:identifier>HP:0004387</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
    <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93a5a562-ddc9-4312-abe9-7250f8b8549b">
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8584c4dd-f6fb-45ce-b86c-804434116186">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea3c0e8a-9e2a-490e-bbf7-c8d1a8656f2e">
        <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
        <dc:identifier>DB06756</dc:identifier>
        <rdfs:label>Glycine betaine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5142b556-249b-4325-bbe5-ead33a7d59d2"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2629574-0cdb-41cd-8871-606550ed4a19"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/329502f8-8ac9-40c8-b940-d5c971dfdcec">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a871785-1486-49dc-8e55-337c3afc3545"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f60bce6a-ccd3-45a0-b6a0-75ce3f721d75"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/729b1aeb-8b48-4222-b31f-a0098b3c4164"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d1f9824-7ff7-4bb6-bb8e-4cf5f5ddf7cf"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13063f05-ac3e-4cd5-b2de-d1e587b542f0"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/228cfcca-c8c9-4705-afa6-2cbf2b2623dd"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a6e84942-30ba-4c08-a6fd-b2a75bcec64b"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c7d7739-463d-4019-9ade-b6b621b2ad60"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5142b556-249b-4325-bbe5-ead33a7d59d2"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99c2b991-e3d4-4eba-9e3f-fd38c42628cc"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cbb251b8-3de9-4eca-925a-619b0b025480"/>
        <rdfs:label>Pyridoxine</rdfs:label>
        <dc:identifier>DB00165</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5c831d0-461b-421c-9717-f9abf0429d4c">
    <dc:identifier>DB00159</dc:identifier>
    <rdfs:label>Icosapent</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90a9070b-70e0-45b7-a62a-39d80d26ca39">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fb756ab-76fe-40ec-8c2d-93ec4e05047a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57623eca-04db-40bc-bcdc-c59c4ee20b1b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3bd5b06b-6326-42ca-8b50-43768936c1cb"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a070f37-d377-4c9f-91ad-469457bedeb4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d3830de-3b2c-4052-86ee-9fc75f408ae4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb896c84-72d3-43d1-a70a-1dad6f339d08">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79b20a54-351d-475d-ad62-83d63d9584e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f648c71b-7b74-4e57-ac72-862d9249571c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ee224a8-477b-4b5e-a89a-3b7239e6a9cd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96969229-02b7-4073-9c2a-94812ed67786"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9ed668c-fc3a-46bd-9493-e4f9f33915f2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d0f885d-1dd3-4ae8-95e9-6ddf596813c6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b0da6e0-aa47-40f9-aa56-bdd7e3577bba">
        <rdfs:label>obesity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <dc:identifier>HP:0001513</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96879685-e4a7-4172-8721-2f6695c3ee67"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c36f473b-635a-4fe3-a625-f7ee62064bcf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased ROS formation</rdfs:label>
    <dc:identifier>HP:0025464</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b197a78c-4448-4f9f-806d-a86d2f1bf40e">
    <dc:identifier>HP:0000821</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>subclinical hypothyroidism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1891ab00-07b4-4e19-81bc-8a865c19d546">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b857151c-5fd0-4f01-8fa4-c9b036f8ec07">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a6d9689-dcca-42a5-afe8-384e2c235682"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12218263-6874-4330-a0ce-f2ab5172a4f1">
        <dc:identifier>HP:0002718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <rdfs:label>Recurrent bacterial infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6298bf2a-b40e-43eb-a5c7-6ee514e033c6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0ba06c7-bbaf-41f0-8460-98d9b977443d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e1206f7-7297-4cee-95f0-315c34db4dbd">
    <rdfs:label>Renal tubular acidosis</rdfs:label>
    <dc:identifier>HP:0001947</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
    <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/85d545c4-5921-4ce3-b09e-1770e50ca8e4"/>
    <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9d95af2-603d-4e4a-9f76-38c0b980bf7b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8d0321ce-c28d-42d1-a1b9-345cc13f3d96">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81987d81-f7dd-4137-9a53-11aa77836bfc"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0cda1e65-c140-4627-950e-6bc7d2878e58">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81987d81-f7dd-4137-9a53-11aa77836bfc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <rdfs:label>D-glucose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a2bf7c0-6494-42f5-8c0c-4071531eaa5e"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/100e35ce-92c9-4077-bee3-6eda67e9e170">
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81987d81-f7dd-4137-9a53-11aa77836bfc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe055639-7db7-405e-aa21-22b21e015ce9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5050dc4a-0370-4f33-abf3-338d612f7bf2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB01914</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f3bfe5d0-7bb2-44ac-8097-bfa0ac220210">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609f1ba-a5f6-4232-9455-600acc5fb9ee"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/51ac32c1-b15f-407e-85ed-3aea4c6e755a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/964cd8c1-907e-41dd-a1d5-353f30369d08">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417300086</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e2ac81a-a13d-4381-ae68-de11fa0a169e">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavioural disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28165ec0-f618-4900-839b-b83e5c4b93a3"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cf21c0d0-051f-4746-ba29-9aa6d7a3ccc9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17dbf8f9-0494-48e8-b7a8-0cb0db89a2f5">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cd5a39aa-fca0-4966-992f-03de0a5079e2">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/579689fb-73af-48dc-91b0-4ec40234666f"/>
        <rdfs:comment>Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a74a69d-30e6-4262-91ac-ce995ad371df"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <dc:identifier>DB00083</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6d47338f-4153-4eac-964f-690714e5f82b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3556e1fb-891a-4bcf-a118-01770c5308cc"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/90ad1b2a-2cef-49dd-bf5a-2f4710a86bc6">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a29eecef-f1e7-4867-9749-72ded5b72cf3"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01c7bfad-0f1d-4f0d-82b4-18f2ceacb441"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6244b024-f848-4966-81bf-096a8626c990">
    <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
    <dc:identifier>HP:0012410</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25a617c2-4ae5-448d-9105-7313e8b68322">
    <rdfs:label>Salicylic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c475a259-3673-4a45-b321-863082f92e97"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <dc:identifier>DB00936</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55560033-36de-4fbb-a0a0-58cdf052d742">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <rdfs:label>Erythropoietin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c64de613-b0db-445a-91bc-c9b2f94793b6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/daca2d57-268c-43d9-ad4b-0677deaa894c"/>
    <dc:identifier>DB00016</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/97e0d4e5-b8d1-4906-927c-955b4bcd08c9">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/261cd740-b486-4d44-bec7-a5278245b8c2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf0a38aa-ad96-4039-994b-4bd92389762e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06dc37f6-b41d-4b68-aedb-17385ef6225e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db9693f1-d03b-402e-80c7-8324436c63d7">
    <dc:identifier>DB06667</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb4eeac6-d6b7-44d9-a9cf-cf627eea0a54"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28eae774-f6cc-4e07-961f-e9e064f2ec75"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/34d24568-c534-428c-956c-b43877f3e7da">
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa5172b8-585d-4049-b0c5-36c99dd7ec12"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a879e4ac-b5c0-4036-a5f9-86ed93d9d9d0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <rdfs:label>Abnormal serum folate</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <dc:identifier>HP:0040087</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfc5ea67-787d-42d1-88a9-c507f821584e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
    <dc:identifier>HP:0100709</dc:identifier>
    <rdfs:label>Oligodendrocyte loss</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/740b80c6-21c0-46ae-bfd4-9c87a889bb28">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:label>renal salt wasting</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84b82f1d-4cf5-4860-9dd1-064a11c811fd">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
    <dc:identifier>HP:0003165</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3b25be1a-0755-4c9d-89e7-31306bf1ec1b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17bd0447-b6fe-4185-bd8e-90da12acb8d5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba8e0032-b302-4d44-80fa-3fa032947cb2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0473cc96-6147-44bd-917e-fccda698913f">
        <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
        <dc:identifier>HP:0011167*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a41c8a7f-b60a-49a7-a468-7d4e40f14a33"/>
    <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/330905d0-5495-4e4e-9af5-90cfbc2da88e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/206e66a9-afcc-49e4-94e2-7429eb17cf55"/>
    <rdfs:label>Ethosuximide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <dc:identifier>DB00593</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d4cdcb9e-4c0d-4506-91b1-7c541c873e56">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5c5512f-757f-4eed-b3f8-6c3aa7a42109"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9203fbab-f99f-42b9-b0bc-35b2a483044c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e30b04db-32aa-41e8-af7f-da6e6f9802ac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/000ede91-ccdc-4107-b6ce-cd3608ea117a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/efbacaef-e06c-447c-803b-5fd7b095c4c7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1a2223f-609b-4955-b11c-230219435ab2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e2d0803-eee9-4228-84d0-29eacea91874"/>
    <rdfs:label>Clofibrate</rdfs:label>
    <dc:identifier>DB00636</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76a313cd-ae36-4508-a7b7-6858301c496f">
    <dc:identifier>DB11098</dc:identifier>
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28c66d2a-9127-4995-8372-0d149fbf91f7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a8b0adc4-3309-4fca-a982-c70650c73739">
    <rdfs:label>Perampanel</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a88b218-e141-415a-be6a-59fa2672f0a4"/>
    <dc:identifier>DB08883</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc4717f1-b41c-499f-9ea8-89dd6b1b2628">
    <rdfs:label>High serum triglyceride</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <dc:identifier>HP:0002155</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f65b22e4-3b3c-4134-af08-99cb802c01bb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fcf53bc-2355-4bbe-8f08-73289dd5c1ef"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/29e4ff9f-0362-4ea8-b216-b3a20c946080">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <dc:identifier>A11EA</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/de33d46a-52dd-41d0-81c9-153b3e839bea">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dc84b5c-77e5-4cf3-bdd6-78a7076ce481"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81b24822-fa11-48aa-aa51-c98a76dc3599"/>
        <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/8c928675-538d-4f59-8ac6-14799ea79a75"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5e3e815-a25f-4e83-a3a7-90bdf0e4113a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ad9300f4-186e-4677-bb9a-074e5d709c04"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/496616db-696e-4d45-8d4e-dfecdb582f7b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1da774db-e307-40c7-8d8b-8bc7932f2119"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13fb3185-4fb7-4660-939b-0745c656a1a9">
    <dc:identifier>DB00993</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24c4b84e-0c17-4c76-ae40-95a9c1a0ed26"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/916a4420-7eca-4fa0-b44f-9942f06ad342"/>
    <rdfs:label>Azathioprine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8af93fe8-05ff-4d50-b7b3-36fc36855696">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a0a4de3-c0d5-4ce9-a1d7-41d90a5e23ea"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
    <dc:identifier>DB13173</dc:identifier>
    <rdfs:label>Cerliponase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ef875fee-56ea-4886-b518-da2f99409ea3">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eee5c2d6-73b0-46c5-ae55-a0f5ea0f32d9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d562a22c-4181-401c-a12d-3cb15d59d0c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5d79670-1c3b-4914-8367-68ab27cfd1fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e4d9247-1469-4336-8bde-9b003e6afad8">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2ace6935-bcc4-44c4-b040-a3471208cac5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e08a5a7c-92bc-4a8a-886d-075fd17bdd61"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41cab147-8711-498b-ba41-3edb6d2f325b"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/02fa091e-25d0-4401-82d1-0ff258308555">
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bef804ad-0b71-40ef-85c4-c53b9dd5b781">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0e6f39e-44d5-4894-9682-f392101f31af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d8ab7738-9528-4a59-bb2e-aa1f2ce0c84a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d870f003-aa60-4f2b-9161-1e19f9858531">
        <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bfeb1a4-bff5-464c-abb1-7abe6543e15a"/>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/835ede20-bbe2-4456-84a0-aeb18c8cef24">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/046a33a9-3d81-4a38-b213-f1dec707aa21"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/456b9256-d6d4-4de7-98a3-78e265e5ddbd">
        <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43ca6394-adec-468d-bf8c-62561e8c706a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7f395ca-836c-42c3-9698-d0c6cee44553"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9fe1a1d-69f5-42b3-82be-47abf40260f0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68d3c201-cab2-438d-bce7-29b6b809455c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdabe39e-ae54-483a-848c-c6fe7f61ba36"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e30d7a33-1520-478e-b6d2-9bb16d0c8dcb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
        <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0000491</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdfb135f-f044-4d16-a803-87f7cf3cd8e2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98df723d-a510-4756-b284-3b3ee443c4cc"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/77b6d458-f726-495c-b4c0-915be36b2d06">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f6b395-a3da-4f7f-ad5e-cb4ed9585768"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/995c2dee-3880-4558-a368-12d6a01aff2d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f1c9017-61d6-46a5-b400-3b9e4d996570">
    <dc:identifier>DB00679</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14191467-d84d-47fc-bfb9-fff99a3cc5a4"/>
    <rdfs:label>Thioridazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b317018-ba6d-4657-a544-dcdbd3691f98">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49e72aff-85c2-48e7-b5d6-e9d8119f85db"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f65b22e4-3b3c-4134-af08-99cb802c01bb"/>
    <rdfs:label>Topiramate</rdfs:label>
    <dc:identifier>DB00273</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e1236387-1aa9-4b7a-95ee-f76fc887fd74">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fcf53bc-2355-4bbe-8f08-73289dd5c1ef"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/daad40fd-d737-448d-84a2-7d8f29d9633a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1841706e-5473-4478-9346-011942fdee74"/>
    <dc:identifier>DB00030</dc:identifier>
    <rdfs:label>Insulin Human</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/77b6d458-f726-495c-b4c0-915be36b2d06"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6eac31b3-83be-4518-9bc1-3ea45623f69b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bd2923e-6294-4762-8fce-da5b90a7198f"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/78f6b395-a3da-4f7f-ad5e-cb4ed9585768"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/397e182e-b112-49e6-9bc4-fbb13750de63">
    <dc:identifier>DB04540</dc:identifier>
    <rdfs:label>Cholesterol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1a078f3-9356-4faf-99f4-e67df531dd52"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6e16ca55-7d12-4c5c-ac0c-3d858093c12f">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0088ace4-13a7-47d0-bbfe-f1f804124448"/>
        <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d131d37c-bc1f-4250-aac4-c208424aa584"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4b517aa2-c512-4206-9e0a-12c2bffc2766">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0088ace4-13a7-47d0-bbfe-f1f804124448"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eadfc0ae-57fa-40f7-a063-ccc67049dcc8"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51d40475-1ee1-4304-8c93-85450c318efc"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c05c42d-372f-481f-b684-0ead2e134586">
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98bbacc8-4f7a-4c2a-9980-95f43b63e396"/>
    <dc:identifier>DB6756</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13be5ea3-60d0-4cfa-9b28-42580a3b926d">
    <rdfs:label>AT342</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a843810a-ff72-4106-ac8e-fd1beec5e2d2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3fba4b92-a84f-4f69-b1f5-b8a5fab4c990"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/095b0197-65d9-4646-a4e6-9b949fb835cf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75fcabf9-7683-4f2f-9654-b4927cd29eba">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
    <dc:identifier>HP:0002123</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5d44a716-6ee8-4da3-8fcf-16249bf8aad5">
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a4ce962-a24f-4213-96f4-ff8c179f8f76">
        <rdfs:label>Hyperuricemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <dc:identifier>done</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f306686c-5526-4a68-87c5-27376663e133">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:label>Hyperlipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4bc978c-88e6-4326-be2f-af2de76c3fae">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9790331c-24f6-4ac2-8060-9fc132fa1ceb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe10c9e-72ce-46c2-8b33-51f97f2051e2"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d23f5766-a1a0-4c5c-8b1f-9370e30fed2e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/533d5a8a-62cb-42a0-8df4-445ce2759e2b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92d9b1d0-d758-4ccf-9a9c-2a1630aa4578">
    <dc:identifier>HP:0011009</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b64511f3-3a79-4abe-a239-10ac8cf906ef">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8195757-613f-4a3b-a991-3f9e39220a48">
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:label>Abnormality of immune system physiology</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d03f058d-9242-4f4f-be65-23db5390eadc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86843d78-6162-4be6-a1c0-b889a80e75e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f60920e2-493d-4153-b582-ae0f60c65f11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50a4aec2-1dd3-47c7-bb1b-9fc4a296213c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6cbfbee-7994-4308-81e4-3ade1abff890">
        <dc:identifier>HP:0001954</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <rdfs:label>periodic fever</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf5c46e3-36c3-4d7b-be3b-4fd2f8227189">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Protein oxidation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e22cfb00-8ad5-4d31-99dc-ec1082e10b1f">
    <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <dc:identifier>HP:0012759</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f2b4851-a363-497d-b374-54e603d0a0c4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb5a5e4d-a274-4dc8-99ca-a85595dbb4f8">
    <dc:identifier>CHEBI_32362</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad331ebf-11ef-4eac-8108-c71f19081b83"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
    <rdfs:label>enanthate</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ebbae2d0-b094-4013-a7f8-18d02e3f7b57">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f39f58c-bb3e-4859-a250-384c1b445936">
        <dc:identifier>HP:0007103</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
        <rdfs:label>White matter changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46062f4d-0712-48aa-bea1-37906af3ca99">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/556a7eeb-7b5b-437c-b905-c8313b67c509"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7aefa3e-fe52-4d3f-acc1-264e5a38e4bc">
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4d0fc44-d98e-442c-83b8-f46340e1f78c">
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4df29142-cd8a-4e5f-a005-fd2dfb7a2ded">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05eaf8c9-0c81-4ae3-8826-c80d996e86e2"/>
    <rdfs:label>AAV-GLUT1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f03bf0fa-abb9-413e-9137-402b9ee84fe5">
    <dc:identifier>DB03485</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abfcf26a-961d-4ccf-bd30-a6d9c52e62dc"/>
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91e6196d-0ad5-4fad-8195-c1b1e29c683b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6273daab-e42f-4493-bf1a-c6a1cfa92ab6"/>
    <rdfs:label>Selegiline</rdfs:label>
    <dc:identifier>DB01037</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98d409d4-e94b-464e-ac88-986824923f18">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7bb9f30-bb06-49b0-8750-5046a92dde50"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <dc:identifier>DB01015)</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08d1d270-e4f1-4e25-89b1-5964efce5ed3">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d3ad8d1d-159f-43cd-acfb-bd0fa86ad991"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/979ffb2a-feb4-4afe-be08-55276b2baede">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <dc:identifier>HP:0012217</dc:identifier>
        <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92d9b1d0-d758-4ccf-9a9c-2a1630aa4578"/>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/135e64e3-9af5-4d4e-a748-8b2132cf093c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/121ff57d-6fba-452f-9099-c9d01ef81b2a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ab541d9-6c24-497c-8d9f-933f09394b2d">
    <rdfs:label>Lovastatin</rdfs:label>
    <dc:identifier>DB00227</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c32de93a-f838-4ada-87f3-a8e803d607d8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c2a1c51-d334-46b2-8752-7c94604df545"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1179e7a-9ffe-450e-9abd-8d084873d6ba"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a34a0d4-0b62-434d-9917-e5aafea146e3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b875dd55-c5bd-4023-8dce-807253be6a8c">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1eaf6f06-5e50-4d02-9be0-2329c80252a4"/>
        <dc:identifier>DB01001</dc:identifier>
        <rdfs:label>Salbutamol</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b26e7667-122a-46ed-bcb2-a59dc3a10b23">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
    <dc:identifier>HP:0003117</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/408053b1-e1da-4136-846f-4969b319c113">
    <dc:identifier>DB05271</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14e0f441-4aec-4639-9171-77644daed2cf"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/91ceb6cc-39cf-4248-afb0-2abb9c55cc6b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b22e24a3-5b2a-4d60-9b57-78437ec71d7a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9428dfe1-55ca-40a3-9ae3-f330f35d6f33"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fe5dcb1-e882-48da-a055-c2f1a8f76911"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/353df1ca-4071-4a6d-9c08-8d799e95c995"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3df60449-b57c-4651-9b9d-2e24b1d6e920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baa6c9cc-6bcc-44e8-83ee-31ea74516af6"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
    <rdfs:label>Rotigotine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d2902bc-4c3d-4553-adba-963c5f1146f0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46d64f6f-c14f-46d6-b02d-4064f3eb7e41"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6602a827-3d5b-4a24-a72e-45450a5c2e87"/>
    <rdfs:label>Carglumic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <dc:identifier>DB06775</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da591ac0-6dee-454f-a99f-06547750785b">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002097</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
    <rdfs:label>Progressive emphysema</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ec3ad731-7e16-4b27-8f05-0ed692af28ca">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b358d901-8d89-4053-9ab5-e901f75027df">
        <rdfs:label>High desmosterol,cholesterol ratio (Abnormality of cholesterol metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a29eecef-f1e7-4867-9749-72ded5b72cf3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e06054b-877e-49ba-b833-05027d3ea8da">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <dc:identifier>DB01115</dc:identifier>
    <rdfs:label>Nifedipine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ab27fd3-6a46-4fcf-b989-465f6bcc3d4f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e0c5f3d0-1e16-4efc-bc39-37a0b5a6e8de">
    <dc:identifier>CHEBI_17012</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e5ba0b12-07e1-406f-93fb-ee32d8e3ab3e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7aa17f6f-19b8-462f-84f8-755ef3ed7466"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/67bbb41d-6282-4609-be32-d0aca9bbe8b1"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f00ab340-0d18-4179-9b54-48ef837ddffc"/>
    <rdfs:label>NeuAc</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/6b2c87a0-b996-4b8a-ae1f-d2f975ce1149">
    <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14fc0a27-1380-4aba-b3fc-f52aa79739d7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f422ec6-a146-4c09-823e-17d0a33fb54c">
        <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379*</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3cc0dc31-27e4-4564-90b8-e241db240ec1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0003304>R266K</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0003304>R125Q</obo:RO_0003304>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b01f172-8fd3-471d-8080-80043d50b80b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
    <dc:identifier>HP:0003800</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76ee6454-00a4-40a2-aa9e-099431fb5492">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c64de613-b0db-445a-91bc-c9b2f94793b6"/>
    <dc:identifier>DB00158</dc:identifier>
    <rdfs:label>Folic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3020a77e-b6b3-4f3e-a9f8-f41b0f3a776e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1ccb4c8e-66f0-49cb-9dbd-a3c00269aa36"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea0687f6-39f1-4ffd-b8e6-0628c2b6ef59">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4037b5b-1473-4bc9-8983-d1e4059db5e1"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bd49b68c-612a-45f5-8436-d3c6c0aa4b55">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e1206f7-7297-4cee-95f0-315c34db4dbd"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bb4fe85f-ec95-4958-ab2b-536e818596d9">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f83aa633-4a41-4eb5-9d40-4d39678e993b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9348d7f1-16eb-463a-8920-f06b9270e299"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3da77210-3cad-4832-a942-a195f08c36da"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5147c19-505c-4a7a-abd0-8e955eda9330">
    <dc:identifier>HP:0045082</dc:identifier>
    <rdfs:label>Low lean body mass</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5bc4f5e-96a6-40c3-a494-d5d1b305427a">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/19484f31-d719-42a7-a572-8b7f4a498fd7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0dbe249-995f-441e-ab7e-850eeb8d78ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299fa19e-a777-47da-8d96-4a9ab16b0067"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9428dfe1-55ca-40a3-9ae3-f330f35d6f33"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20fdd993-9dc9-4930-a2fd-88a2813459ac"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/75c75e7d-9364-4618-87a1-e13dfdcd270f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c465c716-5091-4cf9-82a5-d8d9a5b49edf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a697a15-d53a-4e6c-a50e-26e67e17838d">
    <rdfs:label>Leucovorin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a83b0729-6a3d-45ba-ac13-0b8aef1ce841"/>
    <dc:identifier>DB00650</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05252866-f210-488b-b910-c8828fb09262"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ef1564c-781a-4c09-a4fa-986b8ee5db37"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0190543b-548d-46db-8758-593e6f0baab5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7586e4b3-2fe6-411a-a5b7-fdd73dc5f12e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e5ebfef-7e60-4652-9098-8ebe5e65c45e">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0605303d-6518-4fbe-8c1d-96e669480319">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f3c0986-d758-4eaf-8030-1814f0afc5ce"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/123b7d36-c3a3-482e-ad1c-5edc4c7850f3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ba0a24d-30ff-40b4-bee2-f092c6e67398"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
    <rdfs:label>Taurine</rdfs:label>
    <dc:identifier>DB01956</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f876ed4c-1628-4238-aa99-f386bb0ab3bc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bcc235f8-9490-46f8-a40a-df0e232aa287"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0003304>Spa</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26cee8d3-cf09-4b26-8de6-3d06dfea7709">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
        <dc:identifier>HP:0003808</dc:identifier>
        <rdfs:label>Abnormal muscle tone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a6be55c-d881-4c6e-91bf-9d0d36ae24e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/11bbd3c2-f41d-4952-bb32-8bfd7a20a371">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdd0c69b-3f02-4585-8393-bc9e71a0b42c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3eaa191-abf4-4845-befa-6bc6c2360e5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c89483e-4b44-4197-9641-49009a371fd9">
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <rdfs:label>disability(Functional motor problems)*</rdfs:label>
        <dc:identifier>HP:0004302*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2fe52cc-fb97-479e-b02e-9fbc5082bbc0">
        <dc:identifier>HP:0009020</dc:identifier>
        <rdfs:label>Abnormal exercise physiology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3eaa191-abf4-4845-befa-6bc6c2360e5d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
    <dc:identifier>DB00178</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11bbd3c2-f41d-4952-bb32-8bfd7a20a371"/>
    <rdfs:label>Ramipril</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fc84decd-afdc-47fe-8945-3d33b9b718dd">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01798aaa-db2f-412e-b019-1e77b407fc49"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f55f2a7-1db1-4490-8cd4-5ba962bf2d26"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9950cec5-ef59-4e6c-bf5e-c411c1c88246">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6b6938c-4f56-4f3e-8d47-9bf13e3182a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1407c6d3-c7f6-4558-b4d8-0a385a036c51">
        <rdfs:label>Cardiac hypertrophy</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b3e04b6-d5c1-4f9d-9351-5df31b16cf22">
        <rdfs:label>endothelial dysfunction</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99f1a093-a4c3-47fd-abc5-8d3503bcb7d0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c668746-e624-48a9-b69d-eab376f489da">
    <rdfs:label>production of toxic intermediates</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cee156a3-5c2e-4e44-8fee-32e7c906fdce">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b10441a0-4c69-43cf-afd0-f5de37834fb5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fac80c6d-74bf-4176-8375-8228bcd7e74a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25224dc6-67c5-41a1-bc4e-ec48e3441852"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88ab08b5-7f2b-4891-90ef-4edcd632d628">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1adc5155-9e48-4461-9ef7-8d3bd32bd808">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
    <dc:identifier>HP:0001954</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aea21e72-62c3-4131-8661-77d3520edac3">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
    <dc:identifier>HP:0040215</dc:identifier>
    <rdfs:label>Abnormal circulating insulin level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/363920b5-1ac5-40f5-afd6-c7426cb54166">
    <rdfs:label>Hypsarrhythmia</rdfs:label>
    <dc:identifier>HP:0002521</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f42b990b-a1e2-4b59-9e09-c3eb7110c4e8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5cfd7ba1-7903-4f75-816c-f9f1f23d55ed"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49f2df6c-f602-4f7e-b720-9cb93cfef979">
    <rdfs:label>Starch, corn</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1787471c-d7e9-4447-8cbe-dfd09b8a2267"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9084f5f2-4a23-4d98-adaf-523842b3d533">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4922f887-5b05-4402-a07c-8d3dcd4084b1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41cab147-8711-498b-ba41-3edb6d2f325b"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5d3a2e7-2e62-4699-b909-a5722c10e9fd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10635361-7ccc-4424-997c-4a5d56cf43fe"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b373dff-dbfd-4c4a-8f40-888e6343404c"/>
    <dc:identifier>DB11599</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc38db20-873b-4db0-8f03-93986a5ecb72">
    <dc:identifier>HP:0002907</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Microhematuria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/523148ec-c6d8-4679-b490-b2d230c2ee71">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/18819fd2-1df9-4e03-9790-1659af494040">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ce761d4-3c71-4928-ac6b-9c2e54903cb6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bea3a6b7-9915-4873-b4af-b88e5f793c76">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>intolerance to sunlight</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a626da0-16e3-43af-bee2-622610136d53">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
        <dc:identifier>HP:0025280*</dc:identifier>
        <rdfs:label>Pain in the skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6fe2afd-5ded-49a1-a5b5-7c3e760428a5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec5f5b4b-4c6f-4c0a-8265-ea0fbc2f4517">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e55f8a1b-b285-44a2-8872-d42302f79497"/>
        <rdfs:label>Interferon beta-1a</rdfs:label>
        <dc:identifier>DB00060</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f63e2834-594c-4b0c-b2f3-b3831630f13e">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2be704aa-a220-4d2d-a44b-2b0c769bd8a6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22a67bac-9f32-4c77-84c4-db5d52959301"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/531a0a37-3698-4941-9aed-bfc97068b99f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10e4d739-7dfd-42a4-85af-167bc2b1fdd9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92b029ee-d2e4-4a2c-af0d-b7543c435209"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e18b64ea-2d94-469d-a228-245586df52b0">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1fc8e117-fd69-43ab-ad82-95b900e918c7"/>
        <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
        <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0470a48-23b7-4987-8392-91d07602e762"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/369e6aef-10ab-4a4f-8304-32d9cd595b06">
        <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002066*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dad64159-30f0-4bff-978a-49f7fce6ad6f">
    <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0000144</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dcbb07d8-b571-4eb3-96df-2cbb8e4520f6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e99cfac-9771-425e-9945-84fd0bf3a70a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a869a2dc-4e37-4eda-b907-71be8d3fa36a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b01f172-8fd3-471d-8080-80043d50b80b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f34dba20-412c-4db4-980f-40fe7227106a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
    <dc:identifier>HP:0030878*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Low FVC%</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1d492f99-3fdf-4905-a661-f9419ff76dba"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/901a24b4-09ed-4d85-a836-aea7015717a6">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1fc8bfd-42a8-4147-bb08-79efb7c0e057">
        <rdfs:label>Hypertension</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <dc:identifier>HP:0000822</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3daaa37e-dc5d-43f1-a4bb-c077ad69f5ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f08fa5f1-28af-4496-8ce9-304fd52d54d9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>Abnormality of metabolism</rdfs:label>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56c5d4b5-5ae1-49dc-af58-45e52d2d4036">
    <rdfs:label>Potassium chloride</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e57f8965-1e3c-4a2c-852d-82d3d91263cb"/>
    <dc:identifier>DB00761</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f59d1c3b-eaed-475d-99b5-8e62278f3e83"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdabe39e-ae54-483a-848c-c6fe7f61ba36">
    <rdfs:label>Infliximab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
    <dc:identifier>DB00065</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9fe1a1d-69f5-42b3-82be-47abf40260f0"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/c7817e8d-7dad-4faf-bd73-b72916ed1ded">
    <rdfs:label>Direct interaction (Mechanistic A)&gt;&gt;Functional interaction( Functional complementation or a defective protein by stimulation)</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea6eaf7c-8af7-4171-a769-0877720e6ced">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:label>epilepsy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54e97738-0584-4a1a-9a0c-30c8af99780f">
    <dc:identifier>HP:0002630</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4da3e29-ff5c-47c4-9621-3e824a396182">
    <rdfs:label>Amino acids</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b35dd9f8-bbf1-4d73-956c-14e21fda535a"/>
    <dc:identifier>DB09393</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee6ad6a6-ff1c-4922-921e-0d5c80df982f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42bbbf16-6b92-483c-84fd-e12e4fbb88f6">
        <rdfs:label>Torcetrapib</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08fcd069-d2bb-48cc-942e-829e2295729b"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
        <dc:identifier>DB06281</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c456a17-c5e2-4c54-a8a8-d670a7b1ba96">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d74ba1d0-f444-4a4e-ad3e-608c307e3a4e"/>
    <dc:identifier>DB00472</dc:identifier>
    <rdfs:label>Fluoxetine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/602c86e0-72e3-4f47-a238-3fa293d0595a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
    <dc:identifier>HP:0040144</dc:identifier>
    <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94bff458-9f1d-4d40-b547-5ff501cfa3a9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001392</dc:identifier>
    <rdfs:label>Liver injury</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccbfb2ab-610e-4fe6-98b0-7ff32162853a">
    <rdfs:label>Granulocytopenia</rdfs:label>
    <dc:identifier>HP:0001913</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f462f60-0616-4ad8-bf17-0705b970600a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/973ef49f-ba9d-4d5e-85db-b4c6e4c4cb68">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/7a5e49ad-6240-4a96-8f74-2433839c257d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0003304>W610X</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5468b765-2565-4f22-a43e-ad65fd5fd57e"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0b21503d-017e-4de7-ba78-205c72e03bb3"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB04263</dc:identifier>
    <rdfs:label>Geneticin</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/27c58f43-c5e3-473e-896b-34443448bcb1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94c90bce-fac6-4928-9dd4-ebfd27333661">
        <rdfs:label>psychotic  disorder</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
        <dc:identifier>HP:0000725</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e836bd56-f0d2-48a4-b567-1a2ffbfee872"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417300086</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/151e16b5-507e-48f9-86ab-c017e55b2dca">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
    <rdfs:label>elevated liver iron concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040134</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d2629574-0cdb-41cd-8871-606550ed4a19">
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fedab3f4-44a9-4acc-94d8-3f93ecdcca1a">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Misfolded AGA</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed87357e-da0d-4a6e-8f60-5ac491c58193"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22153b12-64ad-4e7e-8f9c-af1ad9c0bfca"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfd503d0-f137-46e0-bbf6-9d8a60d3b93d">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Unstable AGA enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da6ac73e-a8ba-402d-94af-4e4b96e9b0fd"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0003304>T122K</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10a3261d-4597-44f8-bef2-3ae7314426f0">
    <dc:identifier>HP:0100753</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>impairment of reference</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dca82d92-e7a5-4ea6-96a8-99e4c2e6eee0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:label>speech impairment</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e20303ff-75bf-445e-b589-6d783e8be9ee">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/460503c0-3725-420f-825c-22044f7b2d24"/>
    <rdfs:label>Inositol</rdfs:label>
    <dc:identifier>DB13178</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2245d406-03ae-4c4e-916e-fd85bb47b605">
    <dc:identifier>DB00620</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d83fbf30-e45c-4cfa-acaa-bba9e2566867"/>
    <rdfs:label>Triamcinolone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/980c4f7f-cc7b-48e1-80c5-73b4cd54c5b7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9386c14-7a55-4c1b-a420-d516ca739f6e">
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5699fc71-07d0-435c-a7c6-d0b33f16f39a">
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <rdfs:label>Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9def095b-edc1-4ad6-8180-4d530dfc4688"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2c13d52-6338-433f-b6e3-3e1758053001"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d95ef81f-e0ce-4caf-9d35-67979de35b7a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc17910f-b30c-4abb-aa17-d852cf073c87">
    <rdfs:label>Rifampicin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2f8faf6-aaec-4456-889c-2f08dc8de8f6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
    <dc:identifier>DB01045</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed3d3c84-d84b-4f75-891e-51b5b6a47c52">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010783</dc:identifier>
    <rdfs:label>erythema</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/52b7b915-02fd-4ae9-bc72-3494ac88d60a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c9ecd54-693d-4361-8b7d-673b372bb688"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c493cad9-b0f9-4fac-b42a-3b60068dd240">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e60a2eb1-b2c4-4062-9d1f-33223f5d3f2a"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7450109f-4adc-4f6a-8605-1e1f449b3224"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7db2426-f749-4410-836b-d13fbb45be8a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25784a00-cd9b-48ad-8cc0-2cd8603f3048">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf0cd83f-c09e-4c1b-9e75-c70d02e2e141"/>
    <rdfs:label>Glycosade</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/29ff9efa-3945-4a64-bea8-24b568cf4e64">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
    <dc:identifier>DB00951</dc:identifier>
    <rdfs:label>Isoniazid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f949960-9885-47a2-9fba-bfed230b826a"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c3781076-0125-4114-97e8-d80232eb3237">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-013-9660-9</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42d8e632-db98-4fdb-9405-a24b19e41dad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d6d98da-a23a-46b1-87d1-64e47235baf9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/077ec389-5967-456c-916e-85f38ed1de3f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20cbe9f8-5f94-4a06-956c-ac3a2fdd6771"/>
    <dc:identifier>DB00119</dc:identifier>
    <rdfs:label>Pyruvic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/790a4a29-ee5b-43f0-96e9-384ffce727cf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f63e2834-594c-4b0c-b2f3-b3831630f13e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c537ed0d-a654-4110-8fe8-0940a8f1f212">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <rdfs:label>delayed growth(stature)</rdfs:label>
    <dc:identifier>HP:0000002</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f1959e6-e820-449f-985d-dbd12d7fabd4">
    <rdfs:label>Carbidopa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c046c97-4480-4352-85f2-dbfde55f1cf3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/74a76c20-7719-4cff-9b26-8d87fa1f715d">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/963c55dd-5b14-42fb-b9cd-c4204e8bc6c1"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a4944e4-addc-4c23-84df-1fdea209ebbd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99dcd964-7a31-4c8b-8a3d-f4bb1aa81676"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b4111aa2-0200-4307-8333-65713d816308"/>
    <dc:identifier>DB00190</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ba16de3-db71-4b22-9ea2-503aa1a28c6a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:label>Increased serum ferritin</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfcc74f7-d0b8-455c-91fe-d730deb4cee9">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011999*</dc:identifier>
    <rdfs:label>hallucinatory-paranoid state</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/324ae299-4415-4320-b3ad-5b0c55a0533f">
    <dc:identifier>HP:0001653</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mitral incomptence</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2278f86e-ab78-4bf6-b698-7803f3c576e2">
    <dc:identifier>HP:0012647</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal inflammatory response</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/599f5ef9-8eee-440d-a626-3ca5109c37c4">
    <dc:identifier>HP:0011804</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>Abnormality of muscle physiology</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea86426b-5633-4a56-bb8a-d1660112cd2b">
    <rdfs:label>hyperproteinemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0002152</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/996c7f05-f892-419c-956c-d3cfd23f7591">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>growth impairment</rdfs:label>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <dc:identifier>HP:0001510</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dde37bac-58d7-4e34-9540-d72e1ef5e417">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:label>Scaling</rdfs:label>
    <dc:identifier>HP:0040189</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dc84b5c-77e5-4cf3-bdd6-78a7076ce481">
    <dc:identifier>HP:0007340</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <rdfs:label>Lower extremity weakness</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/685c6525-44a0-49fa-9d07-fde3632d6a72">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92940f3f-a9dd-41f4-8a8d-994ce824b07c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0e861ea-f1ea-49ba-9449-9113a6b745f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9428dfe1-55ca-40a3-9ae3-f330f35d6f33"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de75fab7-ae6e-47db-b31f-4e06af29808c">
    <dc:identifier>HP:0012405</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
    <rdfs:label>Hypocitraturia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5877a283-483f-4cc0-b617-acae37101dd4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
    <rdfs:label>Microgliosis</rdfs:label>
    <dc:identifier>HP:0100708</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/91932193-d3a0-41d4-8857-ec4afa085a8a">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7882ce89-9643-477e-9dc2-90874b7468c7"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db71b42c-4c3d-4adc-a755-c1007d3a42d5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c78550e6-4d6b-46c0-a73f-03805e2139ea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdac9d66-513f-4e1e-bc73-4a07ca5d0a40">
    <dc:identifier>HP:0010438*</dc:identifier>
    <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/729b1aeb-8b48-4222-b31f-a0098b3c4164">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bc66e37-e42b-4bf7-b3b7-c5996831b52c">
        <dc:identifier>HP:0001337</dc:identifier>
        <rdfs:label>Tremor</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fe96f09-ab72-442d-9b28-d6b1ac41b165"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95488751-564d-4c0a-88f4-89fffc9c2137">
        <rdfs:label>Impaired fine motor skillls</rdfs:label>
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <dc:identifier>HP:0007010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bfeb1a4-bff5-464c-abb1-7abe6543e15a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea6d7efd-5393-422e-a92c-0541449d5c86">
        <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
        <dc:identifier>HP:0003153</dc:identifier>
        <rdfs:label>Cystathioninuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69004284-a551-4d9e-8fa3-db067aa8638c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/488177c5-17ea-4258-9ef0-955ed06d524b"/>
    <rdfs:label>Nimodipine</rdfs:label>
    <dc:identifier>DB00393</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1cea9fbf-6289-48dc-9ff7-1debe270aff5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/207ea0ac-efdc-4736-b589-b50ea291215f"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/277c7006-059c-45f3-a9fe-44e59bb6a1af"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42cc7367-6ef6-44db-b247-e21431fa9aff"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0c92e37-da62-4859-8618-8526879e41c7">
    <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
    <dc:identifier>HP:0011042</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8cbae0b4-5167-4b99-ae08-907fb78ed175">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2696ae7f-8a38-44c0-b59f-33290768b2c9"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7660f182-f222-4b4d-bc9c-30bfed86a87f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/996c7f05-f892-419c-956c-d3cfd23f7591"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9de9be1e-6147-4a9c-9aa6-1f0e59fe8893"/>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc47a960-729b-4a63-bfd2-b1befb5448d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0af6151b-5ad7-44d9-aaa3-9a6624ace52e"/>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f853bb4b-c293-4766-ab10-61b4dc43af7e">
    <dc:identifier>DB01586</dc:identifier>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16bc5c22-d054-466a-a8f5-7c103dc15d97"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/241a8fb6-80ed-4b3c-8952-dea58c13f92e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a004e260-3c8b-4c08-9db8-fd773522913c">
    <dc:identifier>HP:0003127</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
    <rdfs:label>low calcium urine excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa14e9d5-0456-4625-b481-245a5d090c79">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cirrhosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
    <dc:identifier>HP:0001394</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a6d9689-dcca-42a5-afe8-384e2c235682">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1891ab00-07b4-4e19-81bc-8a865c19d546"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <rdfs:label>Filgrastim</rdfs:label>
    <dc:identifier>DB00099</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddaeadcc-6db7-4de4-95ec-57370b299c37">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0004144</dc:identifier>
    <rdfs:label>Drawing inabiliity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ddecda0-9bd9-4260-8684-4c8dfa6f2f78">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ff96702c-10fd-46de-99ba-ac28e8c6404a">
        <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe5b0411-e211-4513-96f8-2ea32f5be209"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6edfa81-646b-4258-ab5c-15290cf294cc">
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:label>Elevated Phe level in blood</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/8846f8b5-a298-49a9-b755-9bbc85e9b9de">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aabee547-5268-40c9-9e58-a5050256fed9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/840fc8e7-6670-4aa3-8591-da9fe6daa619"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/151e16b5-507e-48f9-86ab-c017e55b2dca"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/24ca6d23-9428-44f2-a96c-58cfc7d5d2f3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19bb7150-d4a5-47e3-95f8-b94cca9b8af3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001332</dc:identifier>
        <rdfs:label>Cerebellar dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdac9d66-513f-4e1e-bc73-4a07ca5d0a40"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e60a2eb1-b2c4-4062-9d1f-33223f5d3f2a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef9ea9ee-2331-41fd-9ad9-1269e32cf96d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea8a8f70-6a58-4642-8626-65b714a0e6f2">
        <rdfs:label>Nystagmus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000639</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7293dcd0-5a7b-4404-aaa0-66df34a4e27a">
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d6d8144-5e58-45a1-8d27-6225d152f232"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dec372ed-1e68-4717-9d4b-c2bf0bf2a6ad">
        <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001712*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfe41049-68df-494c-b465-f45ff345a6cc">
        <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
        <dc:identifier>HP:0000570</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af134d3b-16cb-40c6-bfff-785eafd5f256">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
    <dc:identifier>HP:0032367</dc:identifier>
    <rdfs:label>Abnormal circulating GH level</rdfs:label>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c92ca07-40d9-4a0d-9b23-f54808f38c57">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4243aa2a-8d9d-478f-b584-6abb0dab110d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c36f473b-635a-4fe3-a625-f7ee62064bcf"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/55f40082-fadd-43a3-bf93-62464c0824e3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c17e35e5-6872-4412-afa3-68fb9cdf4c7a">
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <rdfs:label>High plasma uric acid levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7bdfe97-96b3-4e4a-b0a6-c50feb976ed0"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c6d1e34-5ded-4927-b4d1-882e0ddf577e">
    <rdfs:label>Amenorrhea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000141</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61ad94bd-0a5e-404c-9e79-ccad93904f4d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
    <dc:identifier>HP:0012647*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/102ce6ff-adbe-46fd-a6e3-6e3bb64fb142">
    <rdfs:label>Propanoic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c5f87ba-3633-4b35-b5d2-007b3b87409d"/>
    <dc:identifier>DB03766</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24b36b18-ffb7-496c-97be-ce3e6371b712">
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>Neuropathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b68378c7-a40a-4a5f-86fb-99559d223fe5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0152dbec-65bd-4088-9833-ba373eefe7a0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb419f1b-bc8d-489e-ac89-ae4e6086174f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d93e631e-a9c2-4d2c-88b7-2d0f050c4418"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7041d57-f48d-494f-920f-9ec8176b4a68"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98cdae13-37ee-4da2-ba3a-77f3cf878803"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/08644f9b-8cbf-4e3d-a719-a6bc477d7cc5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e60f5443-5a81-41db-a598-85c23766f399"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1002dc5-68e8-40ec-87f9-3876818808df"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77a19662-1918-4ac9-b919-57bcd5514086"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88135ffc-d0d5-4138-b2fa-56279164454d">
    <dc:identifier>DB01219</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
    <rdfs:label>Dantrolene</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf7c940e-d14b-4b58-bbcd-c7f32dd37f67"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d625efb6-815c-4ad8-bae9-7dc5d8a11cbc">
    <rdfs:label>High urinary malonic acid</rdfs:label>
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d618f96a-a2bd-4a1b-82a5-065aec810882">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
    <dc:identifier>HP:0000964*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1f64353-95fb-427d-9a51-1a78c014171b">
    <dc:identifier>HP:0012465</dc:identifier>
    <rdfs:label>Increased liver iron level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0540173e-391b-4716-84a9-c821c553e625">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/500e46a0-e4c4-4e02-af81-5b441245662f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36406894-44fa-491f-b6be-e55236eb6c55">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypophosphatasia</rdfs:label>
        <dc:identifier>HP:0002148</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0458c25d-b4d5-4c1c-aa25-5e4ac01d65b9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc47a960-729b-4a63-bfd2-b1befb5448d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0960c2e-2c66-48f7-850d-fed3d011d866">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0009051</dc:identifier>
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34130dd3-165f-4128-a6a8-963cf049f2ef">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
    <dc:identifier>HP:0001396</dc:identifier>
    <rdfs:label>Defected bile flow</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9d6fe536-b883-4888-9079-d3f193da2777">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67e1fd9d-50fe-41dc-b699-37d5480c5e20"/>
    <dc:identifier>C03D</dc:identifier>
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9798132-b289-4207-b7e7-d7568cbd0909">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
    <dc:identifier>DB14573</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1244cd74-f338-46c1-b380-e40c3aa3c7b5"/>
    <rdfs:label>Phosphate ion P-32</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5c7d7739-463d-4019-9ade-b6b621b2ad60">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2a4bba5-3a02-4c96-9a65-533bfa58d6a4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0811275c-2c98-4256-9e56-16a9e8fe96ca">
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
    <rdfs:label>Decreased body mass index</rdfs:label>
    <dc:identifier>HP:0045082</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/593c0d7f-04fd-41b0-8670-7eae26e4cc11">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/921d429a-03b3-4f41-87b6-719039ded30e">
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <dc:identifier>HP:0004910*</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d562a22c-4181-401c-a12d-3cb15d59d0c9"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4923d94d-61f9-4863-986b-0aa7b2584b2b">
    <rdfs:label>Methylene blue</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab014fcf-6d3c-4c09-baea-0e5b49c90ac1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
    <dc:identifier>DB09241</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/4195678e-66d5-4bb7-8a26-0ebc2a3a1dce">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd69bfb6-e129-45f5-a0ef-75aabb646d55">
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc9609f1-0034-4d4f-abeb-01989939a276"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29d91ac6-d2b5-4cff-aaf4-783214523344">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:label>Poor swallowing</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a031511-a66e-4880-840c-6e4235934b8d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fine motor impairment</rdfs:label>
        <dc:identifier>HP:0007010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c31794d-825a-4242-b049-686f7edd3f08"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/462b21b9-6bae-4da9-aee6-14ac996b433e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a7d4f7e-f6e0-45ba-b7a2-603121cfa76b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51c99e81-0dd9-48b8-b5f4-e75a849f270e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52ee7e19-a7a7-48e5-ac1a-25655124ffae"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94bff458-9f1d-4d40-b547-5ff501cfa3a9"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11eade8f-8143-4dae-b105-86e584b41f72">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7ca6bd6-2e06-493e-bc7c-1bdbf84259a5"/>
    <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/15d8382c-f6d9-4ff2-87c7-2c8705caa444">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/62d68ab3-3930-4826-a98b-7cde7b8e0a44">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aae68cef-b1de-48d0-8797-285fc58b7fe9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a18d2dd9-a388-4dec-930f-c9257b604dae">
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f283b368-42a2-4a5f-9dfc-da537ffc33ef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/330d0bb4-ef66-4e70-abcd-c8bf5d1cc986"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/608013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/022a79fc-6891-4601-bd01-cb93db9eb748"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6981324-45eb-43e5-b90f-0d5e898c6e64"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8e554fc-81e2-4bf9-ade4-1c8b8e0081b2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2665b99-1372-415b-8104-889af46c02b7"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da5f29a6-be0d-4697-af50-a408bfd659c5">
    <dc:identifier>HP:0000707*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9842c6d6-1971-457b-9cd9-bbc077e54e4a">
    <rdfs:label>Intellectual disability</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <dc:identifier>HP:0001249</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52ac3698-bd54-429a-b20b-c7d4796236b0">
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6a73e9d-2614-40e0-a374-0dd4085e7542">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
    <dc:identifier>HP:0012450</dc:identifier>
    <rdfs:label>Chronic constipation</rdfs:label>
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34409f2d-aab8-4df2-a688-415c4cd516b1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4867686-4e2b-42a8-8a0e-bdc1c476527b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90ad1b2a-2cef-49dd-bf5a-2f4710a86bc6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <rdfs:label>Nicotinamide</rdfs:label>
    <dc:identifier>DB02701</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50c482d9-9865-4742-bd18-e7348b084a31"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec3ad731-7e16-4b27-8f05-0ed692af28ca"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5d79670-1c3b-4914-8367-68ab27cfd1fb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef875fee-56ea-4886-b518-da2f99409ea3"/>
    <rdfs:label>Polythiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/593c0d7f-04fd-41b0-8670-7eae26e4cc11"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
    <dc:identifier>DB01324</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44d554cf-34af-4207-98bf-ff167d3b7cc1">
    <dc:identifier>HP:0004356*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3135813-1fd0-4ed5-a641-bdc064a4ae98">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
    <rdfs:label>Brain oedema</rdfs:label>
    <dc:identifier>HP:0002181</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/788b079a-7dc0-4a66-a88b-af07729e657d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
    <rdfs:label>Pyramidal neuron loss</rdfs:label>
    <dc:identifier>HP:0002062*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a1fdfcb7-7e73-413f-a71e-25a0f8a43f20">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ccfbb051-ce1f-4627-82b1-5b9622b5fe64"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c426af25-d062-4763-a163-442d14f7525e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ae692bf-5648-441f-afd0-646aa53889e3">
        <rdfs:label>Thrombosis</rdfs:label>
        <dc:identifier>HP:0001977</dc:identifier>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1ec7ada9-ea03-420f-9c8e-ac30c6538036">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/32312dee-8af4-4fef-9fba-3109a858775c"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f1cd443-ff58-43fe-a06d-cd80c068cf3c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:label>abnormal fat metabolism</rdfs:label>
        <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
        <dc:identifier>HP:0004359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04867fff-a7a3-43b0-b97b-017dca6f339b"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3ce173f-8a70-4a99-82fa-985351dc601c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc2b78f9-d903-4464-9e46-66cd25a5df3c">
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/efa0430b-a387-49d0-977a-3c27bc7aa7b6"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
    <dc:identifier>S01EC</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8bb9125-5908-414e-86a6-7abb5e4a3a91">
    <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
    <dc:identifier>HP:0012363</dc:identifier>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cdac9fe2-22ec-432a-a39f-7352f474b078">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/112c5de4-d717-499a-a014-6f75e9562439"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e08a5a7c-92bc-4a8a-886d-075fd17bdd61"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a5c66e2-9f85-4762-8305-5afee1894571"/>
    <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/76fdf908-536b-4eec-9c9b-0fd339b6175b">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae5ada81-2065-4dec-be8d-cf0a4e8fd829">
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c3d49f1-546a-4092-aebe-b6e44324c5eb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14630c9f-5f7f-486e-a5f8-2c0e19278225"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74aba25f-0b62-4f1c-b85f-30bb1c15b101">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8439b81a-48a2-44e8-b4e3-fe26b1fdb2c1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8e554fc-81e2-4bf9-ade4-1c8b8e0081b2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a30e5a48-b6aa-4682-94c1-38a50b0bc0b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a09f61e-c67c-4548-bbbd-d8545623a5a0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29993c1f-2824-4c77-8ad5-4f1592755fd0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:label>Motor function impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8b86f04-0aa2-48bf-afff-2357242f95e7">
    <dc:identifier>HP:0007166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <rdfs:label>Paroxysmal movements</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77d73f13-24e7-4254-8e47-39765d3b2b27">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c591a1ca-a039-4148-9670-7f3cb547d675"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96842997-0ce4-4292-b551-25413e5ed32c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dbc3e60-44b7-4b22-94ab-f44be1688fa8"/>
    <dc:identifier>DB01200</dc:identifier>
    <rdfs:label>Bromocriptine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1dea9928-68d3-4a73-b9f3-c61d5dc348ed">
    <dc:identifier>C03</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1485288c-df23-48b0-8573-2143c0659909"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe384f4e-cd79-4c52-9cbb-6c53bee42d92"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5a3c06a5-6a17-4080-92f1-33c51c71ceb4">
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9939c19-938f-474c-abc4-cc7fc7e79423"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a730beca-8d1a-4274-8029-e55d962ede63"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>DIURETICS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08690382-a5d7-4815-8df6-79aba3bb368d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/085e63bb-5a70-49d1-bb9c-a6322bdd1941"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <rdfs:label>Vitamin A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cee156a3-5c2e-4e44-8fee-32e7c906fdce"/>
    <dc:identifier>DB00162</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af0fdf7d-623f-43a1-86c9-3426a5ac7500">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83d2b7a8-3db2-47d1-a768-b99a0e2a3e72"/>
    <rdfs:label>Vigabatrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8ab7738-9528-4a59-bb2e-aa1f2ce0c84a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/73239df3-03ae-4537-a05f-7083844ea368"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/489e243f-5dd2-425d-9bd6-a5a6a16a5f1b"/>
    <dc:identifier>DB01080</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0a8f44bb-f9d6-4ab3-8b7e-fc15a220f95c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc526bee-b3fd-4321-abbf-6e62bad9be3e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c756a390-5d6f-47dc-9597-5df8fa4686d4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b857151c-5fd0-4f01-8fa4-c9b036f8ec07"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b7c4031-f88c-41b2-8792-739c557047b3">
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
        <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
        <rdfs:label>Neutropenia with IBD</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cdabeccd-d97f-443f-8f4b-aa5310922145">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2a935b1a-69bb-4ad8-bdea-3d4d56f508b6">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/354a137c-966f-4f68-a7a0-0bd6dea0f0bd"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d65afd4f-54f4-4a8b-8646-b8f28827b08a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35e5693c-9ab5-461c-a76b-2359be9c95b3"/>
        <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da5f29a6-be0d-4697-af50-a408bfd659c5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b2fe6c7-848f-4dee-865a-d1d3b4410fe0">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/93e9f672-c5aa-4924-b241-cd79398aa977">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aafcdd03-8bd0-4cb3-ae00-db6447574150"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3a7c3026-bec1-4392-887f-49f34bc08aed"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a937e11-acdf-4a69-a2cb-6e8157e2a360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/576dca4e-9579-4b7f-becd-4975dbcf216b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4c73a72b-7194-402e-8cb8-f07238b4b3b5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Milrinone</rdfs:label>
    <dc:identifier>DB00235</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7681a435-5661-4b73-82a6-2ee72588ab73">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46018fa7-f853-4fc1-a16a-7c89ad27f155"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f27b94a-2fce-408d-810e-b4f35c0e86c0">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31a9561c-3aca-4757-bc75-2fb63a9e7681">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24481fb0-916a-41d6-8e86-d05e711354a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cfdb173-93de-4861-a7a3-a683685a5433">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Sulfide toxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/feecd88f-d311-4f86-bb36-e5c3bdfd2af8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ccd27b8-2974-40a1-a513-4ddf6530b10e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84b648b7-2148-42a3-9292-f18c4d89e645"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51109cc8-01d1-4670-bb39-fc54c452c8b5"/>
    <dc:identifier>DB00776</dc:identifier>
    <rdfs:label>Oxcarbazepine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b1599a0-d914-4a09-b7a7-7844e9a0a44b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0030872</dc:identifier>
    <rdfs:label>Left ventricle dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70a5a4e6-6aed-451e-809c-60e303f0874b">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9f8e2473-0aec-497a-822a-a51cc42d0481">
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d146e83b-11b7-409f-bacd-856e8a680cfb"/>
        <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
        <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de072562-44cd-4b45-88c1-6e580ab63497"/>
        <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/bb049934-2a56-4f4a-b027-751bf2fb6e43"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <dc:identifier>CHEBI_15724</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
    <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/86f2ca53-c740-4927-b082-4564a5d3b319"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9685f75-45e7-4e90-8d5f-b69bd014daa3">
    <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0ae98760-4682-4f00-9472-eba57ede5ba4">
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6b6f7363-3b12-4cad-8635-772b7aa86a02"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15171229-5762-4d2d-9930-6417df56cbf8">
        <rdfs:label>spastic bladder</rdfs:label>
        <dc:identifier>HP:0005340</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7590432-ece5-4760-9522-f31bfac92902">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f283b368-42a2-4a5f-9dfc-da537ffc33ef"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e688e7be-3e87-416a-aaba-a23f8a7c676b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a643c76-7a31-495c-be03-115fdd2388ab"/>
    <dc:identifier>DB09039</dc:identifier>
    <rdfs:label>Eliglustat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7e63bb9f-28ef-42b8-b4b8-03c894c7f575">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eda8237e-e10d-4b30-b2d8-5b4b63158a90">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d0c6919b-8023-4334-b3d9-74d4f7ba1609"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2a55d33-d0bb-4757-9803-d987d98a6119"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c19163f-bf66-4599-b334-2303cd2dafd1">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5f39291-0137-46eb-bc13-7bbc58d9fb4a"/>
    <dc:identifier>C09</dc:identifier>
    <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0e6f39e-44d5-4894-9682-f392101f31af">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02fa091e-25d0-4401-82d1-0ff258308555"/>
    <dc:identifier>DB13961</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
    <rdfs:label>Fish oil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee8fdde1-9581-4b6b-b1e7-29df5d604a6b">
    <dc:identifier>DB06720</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7d582c7-9fff-4220-b5ed-98dad4c96026"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93cc75f7-0a85-4d4d-9f9b-2d6c7a56f8ab"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ce761d4-3c71-4928-ac6b-9c2e54903cb6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <rdfs:label>Beta carotene</rdfs:label>
    <dc:identifier>DB06755</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/523148ec-c6d8-4679-b490-b2d230c2ee71"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6b2ff11-35a7-4108-9ca1-6d51ce8bdb47"/>
    <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cb0f7df-5652-4f36-badb-4b3655b7f7b5">
    <dc:identifier>DB01323</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57c3be7d-57d3-4e49-942d-54d3218fe45c"/>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/087bb3e9-2138-44cd-b5c3-b88f885e3514">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0001873</dc:identifier>
    <rdfs:label>Thrombocytpenia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b643351b-f9f6-432c-9167-b3e57280f5d7">
    <dc:identifier>HP:0012120</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33132c69-823d-41b7-89fc-78e3ba48f16e">
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
    <rdfs:label>High plasma branched chain keto acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fed4429-ded2-4283-afcc-6c6bfffdc775">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58c4e1bc-60ab-4bac-a543-31e94d348bf5"/>
    <dc:identifier>DB00034</dc:identifier>
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1f3e960b-2466-4930-8870-c8776f83a1e8">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a06a2905-176e-49b7-a6e3-1d2e86a2db05"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cf178bb-acb0-4b1b-a318-b7f3d58cf178"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4f8690f-53c6-4474-9bb4-561420bda81a">
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
    <dc:identifier>HP:0002020</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
    <rdfs:label>Acid regurgitation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10e1e1b9-661e-4254-b531-ae057e794a5a">
    <dc:identifier>DB11635</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/dddb0afa-63d7-4c1e-a124-54e048c7a9d9">
        <dc:provenance>https://www.nature.com/articles/nrrheum.2010.182</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3e1838be-e028-4dfe-a6df-4fdd95532049"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e50bd42c-4b41-43a5-9fda-1efab94512aa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Tocofersolan</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c48e0dec-9a54-45c6-8b08-2051b7a7dcdc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <dc:identifier>DB06372</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bae5631-7169-444b-a8ab-b41f6b291ef2"/>
    <rdfs:label>Rilonacept</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ff596dc9-6f15-496f-bdc9-a88bbfe3ccfa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4876ab9f-3f3d-4066-855b-af9c62c4e15f"/>
    <dc:identifier>DB01241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/894938bf-035f-44ab-aab6-78b4cb7898c7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a83cf8c-65f8-4f68-b2ee-ff23b3041844"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09f6b97c-e01f-4c00-b446-1039f2f3b004"/>
    <rdfs:label>Gemfibrozil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/848274c8-1485-4963-b5d5-381415f5586d">
    <dc:identifier>HP:0008064</dc:identifier>
    <rdfs:label>Ichthyosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/423ec7fa-fbbe-4dd8-8ea4-c50addb53c45">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/f7789087-c411-4b31-9b3a-4175b95a47f0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d3879dd-f797-4c3e-b5cd-3f0e51a49f3c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b6c6276-6ea3-49ee-919d-ab6c360916f9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/323874bb-1934-4dbd-8379-778795e0ecc7">
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f59d809f-3468-4c17-a5e2-9fcc0c98db62">
    <rdfs:label>somnolence</rdfs:label>
    <dc:identifier>HP:0002360</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cbb251b8-3de9-4eca-925a-619b0b025480">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/402d8f9b-9785-477b-b3c3-6fbeee4e973a"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10545-013-9660-9</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07baa9a5-c0d7-4223-aa29-9a5740bd2b66">
    <rdfs:label>Green tea leaf</rdfs:label>
    <dc:identifier>DB14307</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a081e2f9-0bb8-416e-91a9-b813eea7103c">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S075333221630645X</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8122435f-d7cf-4378-bef3-e86babcdb739"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/352066f7-389d-44d2-8a44-de2d8a47e831"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e7767b5-663f-4532-ad76-de0073766c5f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
    <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
    <dc:identifier>HP:0001251*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d7acae8-1de6-4080-9e24-e9c699c07c82">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a3812ab-709a-4444-907f-51086eafc2f8">
        <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e53b4542-a9ae-49a2-810e-5f078029c56f"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66a4fd58-ad13-4644-a54f-e587af572f5f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a75347cc-d2fe-4ebd-9fb3-85236b741a69"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5acb33e-fdf1-4c67-a874-89597236a600">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e053dac-a343-4bf1-9e74-cb3a9a3850e5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1141e494-12c6-4f08-b2e2-9a92364606da"/>
    <rdfs:label>Acitretin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
    <dc:identifier>DB00459</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c7817c8-d367-4c81-b325-94d9b38c5076"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/0b4f6400-2ead-4daf-9290-07c4abcdbdb8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d913833-0412-47cf-a6b7-9bf0c939eab6"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d34b63b-f7dc-41f9-b345-d12298f2d1dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cc49d7fc-e4a2-4178-84bd-075571609463"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/630bcce4-8efb-4ae3-8cf6-5b5421b0318f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ea5e0423-17c1-4d99-8c77-c2dfeb053151"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
    <dc:identifier>DB00458</dc:identifier>
    <rdfs:label>Imipramine</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/621be890-7699-4a98-a935-f0a4ab1954c1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7c022db-99b2-4e41-af65-a1334b1edbfb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcab8520-40fc-4e10-96dd-af0e2a9fd18a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2278f86e-ab78-4bf6-b698-7803f3c576e2"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9c0c59b-797a-4243-a794-39eadadb5d5a">
    <dc:identifier>HP:0000114</dc:identifier>
    <rdfs:label>Proximal tubular dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b51962c-bb68-42a4-92ec-a908daa5c67e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
    <dc:identifier>HP:0008222</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Female infertility</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29da9905-3272-4440-b301-72b3f5c902f3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4327008-697f-4896-a8fb-90d6032e96bd">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
        <dc:identifier>DB01329</dc:identifier>
        <rdfs:label>Cefoperazone</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d61c55e7-8a48-4037-9e21-beed21080e05"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f7d4dba-d667-4d07-9d69-5b21c0b6ea95">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd511d1d-32a8-4c73-95d7-5de83256bd0d">
        <rdfs:label>Canakinumab</rdfs:label>
        <dc:identifier>DB06168</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/431613db-71de-4ca0-a78f-0a2311e754fc"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29d052f8-dd0b-4804-9a95-389276d2ac04"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/501d7208-c4ea-4ff3-98df-93924ac3f99c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78557d5a-2904-426c-977f-47c3b2259b55"/>
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa507351-0e08-4847-aed6-b4c39d49c7f1">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/978524f0-1395-4e35-ab67-7881074be020"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29f620f8-8b54-4f0d-9141-28f14fe77166"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e5c31b49-3480-4147-9dbf-d9a4fb8b4f59"/>
    <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
    <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a9016c5d-ce2d-4b77-a81f-5dee32438783">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfcc74f7-d0b8-455c-91fe-d730deb4cee9"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd161d15-b039-4473-b2a8-02e5712ff6c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b969eec8-02d5-48d7-aeb0-40962876eca3"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b1662f9-e328-4078-86d0-c86adfb0c79e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e775c603-f222-4d76-a9c0-db8e8d8f13fc"/>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e807a5b-dfa0-42c7-8cbd-1dcf41090250"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08c519ff-9a40-4618-ba5f-233b821783d2"/>
    <dc:identifier>DB06777</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b702a324-f5ec-4cd5-b6a2-a12454ed5ac4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4844f66-bb53-4b4f-9e2d-1c01f8fc01e0">
    <dc:identifier>DB12273</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9fd4e498-6846-4e9e-b475-7193a553e8d0"/>
    <rdfs:label>Ecopipam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aae68cef-b1de-48d0-8797-285fc58b7fe9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15d8382c-f6d9-4ff2-87c7-2c8705caa444"/>
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <dc:identifier>DB08909</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1676cce2-8fc2-47b6-b2b2-8f93c283b386">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/9a632f47-e14d-40fc-ba37-f5d8694805ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93cf5086-ff00-4e82-a141-49eef9a3f28c">
    <dc:identifier>DB14098</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <rdfs:label>Cobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd150e9c-8605-4f59-92b2-d48b54ceb3d9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/840fc8e7-6670-4aa3-8591-da9fe6daa619">
    <rdfs:label>Deferiprone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8846f8b5-a298-49a9-b755-9bbc85e9b9de"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
    <dc:identifier>DB08826</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f9ca388d-0c81-423e-9a2e-20aa82172bfc">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02e04429-9438-4fc7-ae56-358e4f63c91a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aabee547-5268-40c9-9e58-a5050256fed9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfcc01dc-8b49-4989-9b81-67c21050fcca">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae63e0ef-43a9-4de7-a9b6-7f980f2a1268"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8817c366-2167-4eee-8280-f4e491c4d73d">
    <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007479*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/214b58aa-ffd2-4c80-af40-e775830c1db9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
    <dc:identifier>HP:0004918</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bd7aa9a-73d7-4ff4-b9c7-622458fe4373">
    <rdfs:label>working spatial memory impairment*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002354</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f9e53b9-ac04-42cd-bbf4-f43795d642b9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49bbe408-6d1f-4483-adf4-26db8dc844c4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89d643f3-d1e6-49ec-a4f3-86bc75f23e79">
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7a3cd9e-b218-435f-a63b-375a34f4bed0"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed53b89a-1a66-4896-9247-2a8fd4b34c99">
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1b90f11-338e-4b06-a9a7-efa8169681e0">
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78e729df-5b9d-460f-ac6c-6327913d04d2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a808b18-4ffd-434f-bbaf-a0b35628b6ea">
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c50a93c8-7c7d-4379-9ffb-2e0b90d2cd83"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/393c24d7-7cb0-48d9-8610-c0e029601e94">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d16e277d-24dc-4959-9d95-57f2a3a21cc6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f34dba20-412c-4db4-980f-40fe7227106a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5bc4f5e-96a6-40c3-a494-d5d1b305427a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae051364-1e33-43b0-97b3-968607a7e865">
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eeb2a093-19c2-4f16-a542-07dea3d7d313"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5130d21c-7378-475e-8314-afa93ba0e1d1">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23422fff-3c5d-4ce4-bc69-f37b2dc7ce7d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b0d95ef3-ea43-4b5d-8bb4-f07d8460ff94"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/228cfcca-c8c9-4705-afa6-2cbf2b2623dd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f59d809f-3468-4c17-a5e2-9fcc0c98db62"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/9aa40bb4-406e-4ab0-8bde-b28892352ae0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0b2039c-9542-420f-9c88-d3f94fff83f3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d46b65b0-9059-461c-8369-40f8005110b1"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c206308e-19ca-401d-bc25-f18f93f7aa55">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8fd1947-c929-47c5-9bc9-61a683f82522"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/289e35b5-4423-4813-9a2a-1b3c71bd7b66">
    <rdfs:label>Amlexanox</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d0005c3-40bc-43df-ac85-199798b98390"/>
    <dc:identifier>DB01025</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32e98999-6217-41a9-9c83-6569f5d1f9dc">
    <rdfs:label>Lucerastat</rdfs:label>
    <dc:identifier>DB14872</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/47e2f0d0-967a-4566-8118-5fa56fbfcc8f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/934a3af2-f6f5-45e4-9f0c-e6e92fa8aff9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f51e618-8e40-4863-b96a-76f2af1d8761"/>
    <rdfs:label>Sargramostim</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5395dbc6-0135-4d2a-b9e8-b0932c5d87a2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <dc:identifier>DB00020</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb620330-1da2-4464-9b93-762b460f6039">
    <dc:identifier>DB00477</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
    <rdfs:label>Chlorpromazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7f6c646d-e508-4185-b580-ba0e1d56ec5f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3442e2c0-b8ab-47b2-b556-1372efbccbb8">
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/503909ed-df09-40b0-b984-875be1d24177"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a34c7f25-f0da-4040-9657-69a60e14e025">
    <rdfs:label>Cardiac dysfunction</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab403396-5654-410d-827f-d0e2a5032e25">
    <rdfs:label>Bevacizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6d4568b1-88c3-4970-b86d-7b4e84db2912"/>
    <dc:identifier>DB00112</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ea5b264-d8b2-4789-b115-c79199e24555">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4195678e-66d5-4bb7-8a26-0ebc2a3a1dce"/>
    <rdfs:label>Adrabetadex</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd3c1f73-24e5-4b5f-9644-62c704b965ad"/>
    <dc:identifier>DB15146</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e79df711-0b81-41ce-b776-16b072f2d7f5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58d6b6a0-d77d-4f19-811e-5471b0864342">
    <dc:identifier>HP:0008972*</dc:identifier>
    <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/697df3ab-4542-4497-bbf4-a48cbbb18b2a">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
    <dc:identifier>HP:0000114</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/be2db80c-9aba-4e0d-85ee-724caa906f2e">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b72b831-6707-4a3c-b653-e34b402505d1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f7beb367-138e-4a45-bfbb-96ffb8eb0136">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f12ad9ff-2aef-494a-8d12-8f5d46732a8d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbf59a84-80e9-4a2e-91eb-182d5b5daba8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/d61c55e7-8a48-4037-9e21-beed21080e05">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29da9905-3272-4440-b301-72b3f5c902f3"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2278f86e-ab78-4bf6-b698-7803f3c576e2"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee09b8f6-85e1-4c81-9480-d83b14d724b5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad8c1865-972b-4c68-bdfc-3db67ca11ab0"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/441a3644-6e1f-4ebb-a6fe-637f06c71706">
    <dc:identifier>HP:0001298*</dc:identifier>
    <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f712d70c-64e9-4c84-bacc-43ccf4cc1559">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011804</dc:identifier>
    <rdfs:label>abnormal muscle function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4e1b9eb-6d0f-414f-aa4a-dbad6035b200">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3c6ee90e-817d-41b0-b915-fc4591a47c50">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed784bb3-af70-4a73-a38f-7ad5992641ab"/>
        <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0321408e-e2be-4045-8834-eb8ac8d23c46"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Carbamazepine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45be5923-2f46-42d6-bb80-b9128990de54"/>
    <dc:identifier>DB00564</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3cf40053-f69a-40b9-afae-238f96cbb931">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b673975f-91ae-4faf-96e2-f306f8e3faaa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e274456-2d99-403e-ae40-c40c4d724656"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cee8b6-b735-49b7-b607-88be52f791ad"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b137d29-2b98-48e0-a157-c34b277aed18"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2bbb32e2-ac70-443e-90d5-9b565abcceb4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ecfda120-8e45-4a6c-a83b-247569ed0f0b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61ad94bd-0a5e-404c-9e79-ccad93904f4d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78d19c21-24dd-48b6-b625-6a2b9e0a9d43">
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:label>Abnormal spleen size</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7b79e46-ce5e-408d-9297-9aae947e0e1a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7013e6e6-1b28-4f01-a82b-f0bf46fde4c4"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2da3a66-b43d-4d8d-a128-4097e858088d">
        <rdfs:label>High cermaide level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <dc:identifier>MP:0020582</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/47c90eb3-d80f-457f-bc68-7a496548b90d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0c14dad-66f9-4ae6-9e31-81a3227eaf7e">
        <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26662545-8afc-468b-9aad-6d9b7476c525">
        <rdfs:label>High intracellular cermaid level</rdfs:label>
        <dc:identifier>MP:0020582*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cbd89f5-8111-468e-87a1-501f7e5b5d14">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b541052-c1b1-43b1-bdb8-36b6e4d7c6c9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dedfdf4-02c8-4898-9d2e-983d7cb238e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e048d0d1-f0e2-45f3-aaec-b19fd1a06a5c">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d131d37c-bc1f-4250-aac4-c208424aa584"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7c347570-0aeb-4967-bae9-01fd20638cc2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
    <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/70aefa26-4d7e-4c6c-bd22-b4c822bf63fd"/>
    <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
    <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
    <rdfs:label>SALLA DISEASE; SD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d5ca22bf-7617-4c2b-83d4-f6f192dfba52"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b086f8dd-0e25-4a4f-a69c-d4d8170457ae">
    <rdfs:label>r LCAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44215e3d-c499-4f24-af73-4f86f78e85ab"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c490b291-e9cd-4600-98c0-0f924bf0a347">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cacb5a96-26b1-4eb0-bd92-f5ae8d3021b6"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b634e75c-5211-4e52-85b9-3865727fe00f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0acb0814-23dc-4337-924f-4219e8e559b4">
    <rdfs:label>Astrocytosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0003354</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7643bd4-3684-454b-b878-c8132c93ee1e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7199489f-c6b3-49a4-950b-ccdae4b5fc20"/>
    <rdfs:label>Elapegademase</rdfs:label>
    <dc:identifier>DB14712</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9f37edb-ad99-4a42-a257-5e90111d6be0">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
    <rdfs:label>Erythroderma</rdfs:label>
    <dc:identifier>HP:0001019</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/685fe4a1-b93f-4c9a-93c5-9d7bacada1d3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
    <rdfs:label>low renal glomerular filtration rate</rdfs:label>
    <dc:identifier>HP:0012213</dc:identifier>
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/98cc2993-e59d-49a1-8616-282abf1974b0">
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48e35668-ff0e-44fb-b5ab-22c2470acd5a"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33954865-2154-4e37-9ebd-b3ca46cca775"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9aa8579d-c385-44cf-a6ef-619a52bf6ac0"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed0ef6ae-29ff-4641-b538-521ad4710bde"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64081892-d1b7-4a97-8339-ad8ce2f3f11a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb5f55d6-2692-4abd-8c36-2ef430492119"/>
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
    <dc:identifier>DB14002</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64f76951-e7c6-4d97-9dec-63a7f7f81fb5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ef773f1-59f7-49f8-879c-1e31889f64f4"/>
    <dc:identifier>DB00145</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/894527d4-b53a-4ec9-95b3-03587e59c6a8"/>
    <rdfs:label>Glycine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3edd0b44-2b64-45c1-b285-b5abab705fda">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1499025c-71c7-4787-bead-e33952e99a88"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
    <rdfs:label>Trihexyphenidyl</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf7c940e-d14b-4b58-bbcd-c7f32dd37f67"/>
    <dc:identifier>DB00376</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d0c6919b-8023-4334-b3d9-74d4f7ba1609">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e63bb9f-28ef-42b8-b4b8-03c894c7f575"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
    <rdfs:label>Isocarboxazid</rdfs:label>
    <dc:identifier>DB01247</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/723b751e-d7af-41ea-bae8-45d0d91c067c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <dc:identifier>HP:0001336*</dc:identifier>
    <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f90c82ee-8cd8-4916-a538-0e939f6c417e">
    <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
    <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6d96d53-6c35-42d0-87de-3dfe0facb8e5"/>
    <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
    <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9ecbf807-f5de-452d-aab0-836f939b6049"/>
    <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/17537855-dd81-4a85-b678-4a5d6ea31981">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f671312d-cdd1-4a8e-84fc-b510355986ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14dd3b26-9b96-455b-8623-52b46a610180"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f649a370-4122-4249-be2b-51ad88be2caf"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c6d1e34-5ded-4927-b4d1-882e0ddf577e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7f9bb6d0-60ea-4908-866c-aae3eb1035c5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ea407c5-0927-4972-98d5-58730f7f8788"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
    <rdfs:label>Tanespimycin</rdfs:label>
    <dc:identifier>DB05134</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8baad37d-f8cf-468f-ae70-79bb96c07e75">
    <rdfs:label>Growth Failure</rdfs:label>
    <dc:identifier>HP:0002240</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/039126b8-28aa-4975-9dc3-5f3415dbacbe">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ddade836-8e67-4033-b848-0530bfcb6f47"/>
    <dc:identifier>DB00111</dc:identifier>
    <rdfs:label>Daclizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50499ba6-a2eb-48e4-b212-45458a46e3f2">
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7b7a150f-8089-4f53-a03b-f4b44815fa64">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8659635-b7c9-4cf4-bd7b-8745abf9a8df"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44d554cf-34af-4207-98bf-ff167d3b7cc1"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b99992cc-244a-4136-a2df-4aecabda1c5c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f60920e2-493d-4153-b582-ae0f60c65f11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f60bc44-3f39-4d9b-ae11-ab2cab40e54f"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/146e9834-8a59-4c8a-9f99-334bf5830daf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/776bbf79-d17c-4fa7-a796-e5fec008c0ab"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/402810bb-141f-4a01-9aba-bcf97ad04251">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19dde51f-fcb7-4296-93d8-9b06645c22ee"/>
    <rdfs:label>5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/beb77d71-e65c-4b51-8fc7-8fc8a43c635f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3fb96d82-ebfc-4421-bfee-ec887313d56d"/>
    <rdfs:label>AAV9-TAZ</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbab6631-b562-422c-91fc-c317f7663892">
    <rdfs:label>Dihydrexidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/296021bd-26c9-485c-9801-eb923b9e5873"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
    <dc:identifier>DB12890</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dcda867-8d16-48d5-88e6-dd56c01c1f63">
    <rdfs:label>sleep cycle disturbance</rdfs:label>
    <dc:identifier>HP:0002360</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/c623d139-2451-4db7-827e-9203a2ba809d">
    <rdfs:label>Direct interaction(Mechanistic A)</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4ddd9f2-3b17-4638-8de2-e334e3d7d482">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Abnormal neurololgical function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1bda507a-9188-49d6-b428-632ae584597a">
    <dc:identifier>DB00115</dc:identifier>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4bbdcbf-93c4-48c4-817b-14e57d326ca6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/227759d8-f192-4672-a22b-42f3db108207"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33bf4320-b6e8-44ae-89b9-a6290129f89f">
    <dc:identifier>HP:0000709</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
    <rdfs:label>psychosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/391c9b3e-f64b-498b-8f64-cb9e86ce9f60">
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/510455a0-0c91-4640-b2b2-46aa154c35ff"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da6b009e-6c6c-40c1-ae16-e51c84ff3bb9"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a2e14373-0081-4c10-bed6-a2b1d1cd9bde">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cc46f35-cac2-4b9f-be5d-3a99f4aac189">
        <dc:identifier>HP:0001877</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low RBC count</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6794a391-4559-4cf9-b9df-daba46df266a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74a5dde6-1130-4aa1-906b-e6aed239954b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd7b50ae-d87f-4b61-b45f-5557301166b5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34d24568-c534-428c-956c-b43877f3e7da"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/01fec205-f9d5-4a54-ba1e-ac639d623bd1">
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6640b7d-b0f2-4252-a32b-07b499961aeb"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e468dbc-1b16-40ff-a20c-dc4637342a07"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cedc80c-fb5e-414d-943c-f214c78242d3"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/1dd04830-d45d-4120-b464-8dbcbe482d4f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa5172b8-585d-4049-b0c5-36c99dd7ec12"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB03256</dc:identifier>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e15f8b35-f4f5-4c7c-ad1b-677ebbfc8eb8">
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74966456-a48b-4b5a-843d-43a62b1cfdc9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe520161-0116-4d4c-99a8-305c0caee9d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d116c253-8b69-40ab-9a8d-890772e35349">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b1a15b3-a9b8-4edf-97fa-8ebe04d1d2fb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0088ace4-13a7-47d0-bbfe-f1f804124448"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cc49d7fc-e4a2-4178-84bd-075571609463">
    <dc:identifier>DB00151</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b4f6400-2ead-4daf-9290-07c4abcdbdb8"/>
    <rdfs:label>L-Cysteine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba8e0032-b302-4d44-80fa-3fa032947cb2">
    <dc:identifier>CHEBI_32030</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
    <rdfs:label>Kaliumbromid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b25be1a-0755-4c9d-89e7-31306bf1ec1b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/952d2c6e-b8ce-4ef4-94cf-574d1286695e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/469117ce-9a23-4add-9f52-bf85d314b3f2"/>
    <dc:identifier>DB00869</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
    <rdfs:label>Dorzolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71bc546c-0511-4167-b37b-f33dd847981e">
    <rdfs:label>Deep venous thrombosis</rdfs:label>
    <dc:identifier>HP:0002625</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18ae7761-29b1-4ba8-b68e-c786f60c5277">
    <rdfs:label>Clioquinol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/65fe98a9-966b-4299-90cc-56270af79338"/>
    <dc:identifier>DB04815</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f2573846-8a7d-4b41-811e-fa30f9f8b3e6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e7fb6b-d32d-4c26-a959-1bb81081eead"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220120"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68875907-2da3-4157-a9c2-4aeaacf5830b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
    <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87d40994-ba51-4a73-b82e-8b61dcef1dc4">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
    <dc:identifier>HP:0004356</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/952ff5b0-c842-4b7e-8a44-438cb7e1a49e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b69fa687-f621-471b-89ca-af01d1e70a68"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05817cca-cbec-4036-865a-971ce900bfb2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0b072cb-5662-4120-981f-2a7aa977b41d"/>
    <rdfs:label>Ademetionine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4662a688-ddbd-41fb-bdce-37b5a7824011"/>
    <dc:identifier>DB00118</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/759b8704-2b48-4dbb-b91e-58f1e93dcde4">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19a0637e-950b-4d7d-9a0d-a94a2eac41bb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002748</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:label>rickets</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
    <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
    <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d5ca22bf-7617-4c2b-83d4-f6f192dfba52"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eeea444f-7060-436c-8fbf-0802db073f25">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de946b65-07f1-460e-8dd9-123092c279ec"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/069c855b-cc7e-47cd-9c22-f6de64f8820f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005242"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39520fae-38ab-49d1-87e0-4fa90140b5d0">
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0003676*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e8f672c-1a9b-4a85-a6d3-8fdb05cbe8d4"/>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d0e21e9-0b1d-4a36-b4f0-bf3e65f64842"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e3999c4-70d9-4df8-b0e7-2f4ef8b471d7">
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>Abnormal renal function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8630acb-bbc6-4393-bfb1-a5b93fb73be3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d18d681f-8fef-4bd9-be25-5fdefafa8b06"/>
    <rdfs:label>rAAV-PPCR</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1590f4ea-9706-4f46-a7ea-6379d576a96e">
    <dc:identifier>HP:0001270</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <rdfs:label>abnormal motor development</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3b0394f-e730-47df-bc70-1d13e0f75206">
    <rdfs:label>High total plasma cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7c1ac058-e1a0-486d-be2f-2a0f2d2f30c4">
    <rdfs:label>Ethoxzolamide</rdfs:label>
    <dc:identifier>DB00311</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e670f12-df84-4e37-a5b3-d9311eecfcf6"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/78dc59cc-018a-416a-941f-cd5ed9b9ce6f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/df4cd603-43e6-4826-8685-2c762ff2b1ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08f74470-1872-40c2-ba02-8f9a1426e041"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f91f11d1-2cd0-4503-a1ab-149366482269">
        <dc:identifier>done</dc:identifier>
        <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/431613db-71de-4ca0-a78f-0a2311e754fc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f7d4dba-d667-4d07-9d69-5b21c0b6ea95"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/962ede59-d46b-4942-87a1-1fb3f6545627"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0fc5149-ec28-49e0-9bd0-a60b517c4616"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8bd1863-97f4-400e-8846-42b1feff1b02"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06bc49d3-2f90-47bb-8fcd-3d578ef6be21">
    <dc:identifier>HP:0003737</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Mitochondrial myopathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/bf2bddd6-36c2-4d7a-9f30-f2989afd5f99">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af713ea8-9ac8-4476-9273-9c521d88629a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9183ed94-736b-4214-9a5b-3971e9293c38"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa05b873-44ce-421d-8275-f7e2dd14b375"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6fbb43c7-c4be-4630-a962-ab8c36fb21ec">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80634b18-afdc-43e5-b7a2-d60c4eb9ae2c"/>
    <dc:identifier>DB06285</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <rdfs:label>Teriparatide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fbdec5c-afab-4b60-8a75-0d3ab482109d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7bf822b4-bb96-4430-b2d9-017cd9ba58c1"/>
    <rdfs:label>Vandetanib</rdfs:label>
    <dc:identifier>DB05294</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/51d40475-1ee1-4304-8c93-85450c318efc"/>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e53b4542-a9ae-49a2-810e-5f078029c56f">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f60cd25-83e3-4d45-a063-1e1d83ce1d97">
        <dc:identifier>HP:0030098</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f931419a-b78e-4680-a83d-a22f4830b1d2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pathogenic exon trapping</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d7acae8-1de6-4080-9e24-e9c699c07c82"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34998226-9f15-4b80-a009-d8252ca8fe14">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/63be63ad-a56b-424b-9489-cad02b98fdaf"/>
    <dc:identifier>DB01083</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be3487a0-2580-4f2c-87cf-456bb19436e7"/>
    <rdfs:label>Orlistat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7498a683-41f5-40c7-8fbd-f0ae5bc664dc">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/7966b75e-3850-4f24-ab8c-270250e84d74">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88106314-b868-4b45-b719-46b29bae0b12"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b85cf90-0aaf-4212-8b20-f2b253ceddd0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <rdfs:label>Calcium</rdfs:label>
    <dc:identifier>DB01373</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/5142b556-249b-4325-bbe5-ead33a7d59d2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9685f75-45e7-4e90-8d5f-b69bd014daa3"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6613edd6-f720-47b4-9053-edf4b6daf3a3">
        <rdfs:label>High total cysteine levels</rdfs:label>
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0010918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dde180a-9045-4c92-8833-c9eb81c45025"/>
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8584c4dd-f6fb-45ce-b86c-804434116186"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be5255e2-edd8-4c1a-9bd1-40678c4e1a9f"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3031f12-62c5-4633-bc6a-6e36ff11a250">
    <rdfs:label>Ad-hBUGT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbe6d1fe-4a16-4529-8a28-363c77bd6958"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/66787e11-fc25-4ff5-82fb-a18faf7034be">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f91289d-fdf0-40bd-8a8f-7a99f68660f7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2fa9c2c4-0bba-45da-b2c2-96aeb3799436"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29193417-bcd8-4e56-a538-305bcf3b28ab"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1fc8bfd-42a8-4147-bb08-79efb7c0e057"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9939c19-938f-474c-abc4-cc7fc7e79423">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a23a6ee-9608-49ea-842d-bcbe5aea5949"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf85adf4-bb34-46da-8503-8f4209332a14"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81b693a5-9602-4002-a5d5-1f98b8fd9c75"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1dea9928-68d3-4a73-b9f3-c61d5dc348ed"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fd2b683f-6f4a-4107-83a4-dc5fe94df2f4">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/a8be9f61-f918-4ab0-9d46-5677862d0154">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/af7d7cb6-8d54-47de-8b80-d9674b40092b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42025b89-40da-4eb8-9f07-669b93fcee17"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00996</dc:identifier>
    <rdfs:label>Gabapentin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b4319f33-602e-4b19-b320-9b3ec5de8bea">
    <rdfs:label>high protein diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d45ea0f0-ae06-4916-91a8-a10c200f68de"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21444d39-547c-460a-b80b-da404f40d13c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aea32e5d-a631-4f6b-ba3c-02d21a790cbb"/>
    <rdfs:label>rhPBGD</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a3ba450-d153-4d97-ae82-2f9695df8e44">
    <rdfs:label>Metronidazole</rdfs:label>
    <dc:identifier>DB00916</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19484f31-d719-42a7-a572-8b7f4a498fd7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df254261-b0fc-4771-8230-837a19ec4dbb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e94bf477-2a7d-4c1f-94d4-72027f460a61"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d69186d1-975c-4e97-afcb-a501da431a3a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c92ca07-40d9-4a0d-9b23-f54808f38c57"/>
    <dc:identifier>DB01593</dc:identifier>
    <rdfs:label>Zinc</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9be0b219-7698-4c5f-9cbc-13ef2923a7f7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4778de72-28ea-49dd-b03d-93d04bfead20">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dff98d2-8a58-4f46-a231-33ca90693d52"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
        <dc:identifier>DB04789</dc:identifier>
        <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b969eec8-02d5-48d7-aeb0-40962876eca3">
    <dc:identifier>DB00502</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
    <rdfs:label>Haloperidol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9016c5d-ce2d-4b77-a81f-5dee32438783"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d186861b-849f-4750-b51c-f889404fe366">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3d489b84-d3f9-45d1-8fc7-c05539939901"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/99c2b991-e3d4-4eba-9e3f-fd38c42628cc">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/a0ff1da0-d2cf-46ab-aaa7-a55561b0617c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5384e76f-00ce-475d-9b64-3ec063f4d375"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e50bd42c-4b41-43a5-9fda-1efab94512aa">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No Studies were done on this drug.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3fd2d7b-37e5-4493-b413-de4c28df9423">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
    <rdfs:label>Epigastric pain</rdfs:label>
    <dc:identifier>HP:0410019</dc:identifier>
    <rdfs:comment>The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee047e33-5c09-4472-b3ee-562717af981f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
    <rdfs:label>Neomycin</rdfs:label>
    <dc:identifier>DB00994</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7dbd10d-9aa9-4b3e-ab4e-80128290c8ff"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08f74470-1872-40c2-ba02-8f9a1426e041">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78dc59cc-018a-416a-941f-cd5ed9b9ce6f"/>
    <rdfs:label>DTX401</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c99a1bb3-b00d-4b28-8d7c-2309429da57e">
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c513f23-ffae-4955-bbd4-0cf4cddce6dd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
    <rdfs:label>Methyclothiazide</rdfs:label>
    <dc:identifier>DB00232</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93e9f672-c5aa-4924-b241-cd79398aa977"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/098b00b8-16f5-4bcf-88d9-7ad835e4c088">
    <rdfs:label>Tetrabenazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
    <dc:identifier>DB04844</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e886ce0f-0aef-46ff-8b58-4ee481bd3701"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10bd68ea-2787-4ab4-833a-09610155f737">
    <dc:identifier>HP:0001992</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
    <rdfs:label>Organic aciduria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31fcf179-bf75-47a8-a7e4-67cda339b0d0">
    <rdfs:label>Low ejection fraction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
    <dc:identifier>HP:0012664</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/121ff57d-6fba-452f-9099-c9d01ef81b2a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08d1d270-e4f1-4e25-89b1-5964efce5ed3"/>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/374efa15-8a3b-40d0-9e12-dc387bc9c00d">
    <dc:identifier>HP:0200125</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6c1c202-5fc3-41db-be5c-342b4a2356b7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <rdfs:label>Ketoconazole</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b074a1af-cc87-4691-be36-9e2b14cc7f9a"/>
    <dc:identifier>DB01026</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf1037b2-581a-4b10-ade0-048fac37bcea">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>high plasma ferritin</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f12ad9ff-2aef-494a-8d12-8f5d46732a8d">
    <dc:identifier>CHEBI_2786</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be2db80c-9aba-4e0d-85ee-724caa906f2e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a380b03-fae6-41c4-9560-2326f34f1a10">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/43ecb561-6e40-4062-b1e8-4a4335626885">
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73aa3845-2372-48ea-b71a-3b18cf4366d9"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/249900"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebddca3f-c0c5-4f02-8707-2078ba1bdc4f">
    <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002353*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41b31e9b-b999-428b-a2e9-5a0ad65ca5de">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d21f7a8e-885f-4b7a-8c96-0bd3be1ad93d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a730fd9-ddbc-431a-86b8-60620a2da25c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003165</dc:identifier>
    <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e98c9bdc-a6eb-43d4-9f86-3be7cd317aa4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a583724e-d071-4175-aacb-0f096036f1d3"/>
    <dc:identifier>DB01609</dc:identifier>
    <rdfs:label>Deferasirox</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/caa16fc0-dcad-4c35-8515-b81a56d3817a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ffaae4aa-c172-479d-9872-c3e356a73e74"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/feadf5cd-8857-4585-9898-f0aedcf952c4"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/704c0719-af8b-435e-8ce9-9ed2b8ca78cc">
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d46b65b0-9059-461c-8369-40f8005110b1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82844744-5f31-4226-bd3c-bdab0c127144"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <dc:identifier>DB03793</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9aa40bb4-406e-4ab0-8bde-b28892352ae0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fd6273a-1e4d-4712-be8c-672f3912b847">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
    <dc:identifier>DB09278</dc:identifier>
    <rdfs:label>Activated charcoal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30f1a5d2-8bd3-4c75-9e89-3d46babb1a38"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8b37a7d-133e-447d-a81a-d54045205450">
    <rdfs:label>Siagoside</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
    <dc:identifier>DB12351</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/934e9240-8165-4685-8b03-9a9658682dbb"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/106a2d9c-37d5-4f7b-b335-4e897cfea926">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/329799e3-bd36-45c5-9cbd-8e20ff417470"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d8a627b-fcd7-45e2-89ca-4ba5769c5056">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Atypical bile acid synthesis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb11f77f-9633-46ad-b2d3-d6dac8a60167">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
    <dc:identifier>HP:0008166</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30b64e4a-511d-4744-bb9b-3b5ac34ba52f">
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/439bda36-94a2-4b89-9d75-60617032cf70">
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/2e2a1263-2772-4657-9d31-82eafa179d7d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/135a6093-cfc7-4a37-a07c-ee851e0b7e8f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d35e16a3-42ef-43c4-a7c2-14760e27fe8a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c1022c11-fd20-43cd-ade9-f04b09b57d4a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a65f183e-325b-4cd8-a18d-923516d9ba17"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <dc:identifier>DB00783</dc:identifier>
    <rdfs:label>Estradiol</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ad83533b-1a86-4c62-8142-81b66a43810a">
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/325e3bf2-db3a-4012-9433-b3585969591a"/>
        <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002606>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/77251e75-9c85-4d5f-9a5d-8f39d668f8cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5fd6fc9-d5e2-4002-a0c6-703d80431bf6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c15e163-dc6b-4d27-9399-9b25ef7c1486">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/499934ad-7279-4771-b124-0cce87238dd2"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebb6c679-506d-48cb-a0e1-5b8f7fd233ee">
    <dc:identifier>DB01032</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <rdfs:label>Probenecid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57be792f-37c7-4b9f-ba3c-7a382f05676a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8baf6428-97c3-4cf4-85a4-4d24d27b4f3e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2f44f29-0377-423d-94aa-4d748859eeff">
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>Increased inflammatory response</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
    <dc:identifier>HP:0012649</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ef87dd1-294c-47ad-bdde-05696327cfa9">
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/861d9089-6a42-4734-9858-8bd5e943ac8b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/14dd3b26-9b96-455b-8623-52b46a610180">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17537855-dd81-4a85-b678-4a5d6ea31981"/>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <dc:identifier>DB00603</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1affcac7-c941-430a-8d09-06b0bf25c785">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/312343fa-1c9d-4522-ba86-e14ce6b86d9b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/731ddcf1-4218-4888-a0aa-eb0c72a2cd52"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/550ab83f-2dca-46fa-9224-2d0e77ece088"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <dc:identifier>DB00734</dc:identifier>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c5f77412-4016-4d6a-8d91-4c8b499c1b79">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/731ddcf1-4218-4888-a0aa-eb0c72a2cd52"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4abcc58-1cd5-4640-a31e-327b250ff5f6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <rdfs:label>Risperidone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cae401f-bee7-4dd1-83bb-897de04a536e">
    <dc:identifier>DB01432</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1690c457-7b44-45ab-b27b-c35a86ab27aa"/>
    <rdfs:label>Cholestyramine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8b3662f-f74c-4877-8d44-b1e8216f356e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fa9c2c4-0bba-45da-b2c2-96aeb3799436">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66787e11-fc25-4ff5-82fb-a18faf7034be"/>
    <dc:identifier>DB01132</dc:identifier>
    <rdfs:label>Pioglitazone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d852b5f-ab1a-40d3-85d1-99825a64164a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
    <dc:identifier>DB08860</dc:identifier>
    <rdfs:label>Pitavastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe6a0265-afc3-49d9-a7e9-71d887e797cf"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3939180-0c9a-458f-b238-c014cc3418b4">
    <dc:identifier>HP:0002630*</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66341a89-6357-42ce-8a72-9c903b635d32">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f1959e6-e820-449f-985d-dbd12d7fabd4"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b357b7cb-8e4a-463a-aae5-a1c6d9c11bec"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de7191ab-978f-4202-8a8a-8644c37044db">
    <dc:identifier>DB00152</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2e691c81-488a-4577-b584-7b382080f028"/>
    <rdfs:label>Thiamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b94c815-c838-4767-b66e-248ee8733d9c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0cdfd55-710a-4995-803d-10b5f8fc6c43"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e657eaf4-99b8-47c7-8247-b7501d4f1c28"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b46d19aa-7e3b-479b-9c89-3cabd9a2b188"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e871e13c-3365-438e-9847-03123e2e16bf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
    <rdfs:label>High prolactin level</rdfs:label>
    <dc:identifier>HP:0000870</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3d9eb274-1305-460d-affe-abe0c759d722">
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f6f2555-48d5-466b-8d74-ec320f76f461"/>
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b49f131d-d6a9-49a1-9846-e54af9577862"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a937e11-acdf-4a69-a2cb-6e8157e2a360">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22b9d1eb-bacf-4942-9a53-b0578d85db7c">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93e9f672-c5aa-4924-b241-cd79398aa977"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
        <dc:identifier>DB00988</dc:identifier>
        <rdfs:label>Dopamine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47c60a56-041c-45fc-94bf-07887e8c2748">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e52f5d92-ba6d-4448-8565-b95f1ceb5fbc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34b4a50a-0d05-4d24-bb33-cb63dd2d6d36"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad9300f4-186e-4677-bb9a-074e5d709c04">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29e4ff9f-0362-4ea8-b216-b3a20c946080"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2af90029-2556-4e47-8dfc-f8b708e26378">
    <rdfs:label>Insulin Aspart</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00f95c0f-f868-4c73-81d0-bd97a1a4237a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <dc:identifier>DB01306</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0560e980-4c2c-4df8-a033-ef99b282279f">
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5da39d12-0dc5-465b-bcdf-75d3a94d8053">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a82483a0-3807-481b-bed9-2ed76278daa1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
    <rdfs:label>Eltrombopag</rdfs:label>
    <dc:identifier>DB06210</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0fded85d-241e-4b0e-93ea-3bda1b0e2492">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/901a24b4-09ed-4d85-a836-aea7015717a6"/>
    <dc:identifier>DB01197</dc:identifier>
    <rdfs:label>Captopril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/062b87aa-358e-4cf5-af79-5576af48a9dc"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ed6e829b-d0a5-4a10-be43-4f3727543fb0">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54726add-905d-41d7-adda-79aaabda3f26"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/058aa419-2107-4fbb-8aa8-04ffe7e32a26">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1b3d351-bfe5-4224-9467-75a2edd9f55e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/119c7fc1-44b2-41ce-9976-1fceb31c8a33">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc1205ff-f3bc-49f1-8e1b-4c8d2636f94e"/>
    <dc:identifier>DB00213</dc:identifier>
    <rdfs:label>Pantoprazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd44fc82-a3ad-4ceb-a3fe-3b973dc767d4">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>decrease muscle strenght</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/501a7047-52eb-4724-926e-5e120fa75cc1">
    <dc:identifier>DB00053</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
    <rdfs:label>Imiglucerase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c00fd328-c3fb-4423-b4c3-5f92737031f0"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3e1838be-e028-4dfe-a6df-4fdd95532049">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10e1e1b9-661e-4254-b531-ae057e794a5a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f79679b-666f-480e-bbfc-abe08b834162">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
    <rdfs:label>Pegvaliase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2d295c3-3721-477b-83b2-63d1732805fe"/>
    <dc:identifier>DB12839</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61b5fbce-d459-4407-a7f4-8e06bd04e4eb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e208b472-b35e-48a1-b851-5b51150cc7e6"/>
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86843d78-6162-4be6-a1c0-b889a80e75e8">
    <rdfs:label>Etanercept</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b64511f3-3a79-4abe-a239-10ac8cf906ef"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
    <dc:identifier>DB00005</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b6ae360-40b1-434d-b8a5-cbefadb59bda">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebc319b7-e7e0-45d6-8da2-03c328a7eaf2"/>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <dc:identifier>DB11133</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/347f6143-e22b-46b0-8a3a-9e7b09f20939">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83fa51dc-4552-4aa6-9628-34b39f1c264e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fb756ab-76fe-40ec-8c2d-93ec4e05047a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/aa6216b3-f6e0-48ed-a7ad-6b16737ae4d5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50450c1d-626b-4d96-9f5b-f33260916415">
        <rdfs:label>Anemia</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c2a3dce-bd28-486f-a6d5-0ded3cffd79b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc38db20-873b-4db0-8f03-93986a5ecb72"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/642e769a-6ed1-4b50-853a-afb6bef87b6f">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
        <dc:identifier>HP:0012594</dc:identifier>
        <rdfs:label>Microalbuminura</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2665b99-1372-415b-8104-889af46c02b7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ff79a1d-ebad-49de-b0c3-a326b57fd21c">
        <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <rdfs:label>Thrombotic microangiopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/91b6d65b-c014-4580-a938-64fc384be047">
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a789c1d6-efb1-4d28-87ce-eaed1cf78c77"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1676cce2-8fc2-47b6-b2b2-8f93c283b386"/>
    <rdfs:label>Riboflavin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95f9aca1-ca64-4725-bea3-2061fe27c7a6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85dcd7fb-2d2b-4cd5-965b-368f26d47655"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e048d0d1-f0e2-45f3-aaec-b19fd1a06a5c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f97109b6-cdb2-4c38-9b16-f5cee826d62a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9de2cde7-5b3b-4e79-85c6-fb67e0d28e5d">
    <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0577dd89-fdf3-48c7-aa49-dff1172a01b2">
    <rdfs:label>hepatomegly</rdfs:label>
    <dc:identifier>HP:0002240</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5528b298-c81b-4b5b-bb30-cf8dc0f5a493">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b94e3f6-cab1-409f-a1c0-7a9e596106d9"/>
    <rdfs:label>Sucrose</rdfs:label>
    <dc:identifier>DB02772</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a869a2dc-4e37-4eda-b907-71be8d3fa36a">
    <dc:identifier>DB03227</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcbb07d8-b571-4eb3-96df-2cbb8e4520f6"/>
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f81cbd7-2ced-4134-8a44-0e71ed2d111f">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>High chitotriosidase level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecaa35e6-895c-4ca5-9a00-9ad5d95dd6cd">
    <dc:identifier>MP:0000880</dc:identifier>
    <rdfs:label>Purkinji cells apoptosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bd2923e-6294-4762-8fce-da5b90a7198f">
    <rdfs:label>Diabetes</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <dc:identifier>HP:0000819</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/431a931c-3513-4f7a-9cee-17ab0095f273">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfcb3652-3b21-4c5d-821f-9101ad5af387"/>
    <dc:identifier>DB00090</dc:identifier>
    <rdfs:label>Laronidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd1ed8c3-6416-4a61-9a19-6cb466510f27"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df13bbc7-cea2-44e3-8aaa-5d65cbe57253">
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <dc:identifier>HP:0002160</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
    <rdfs:label>Elevated blood homocystine</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dee52ca0-7b59-4acc-b9c0-438c6ec5696b">
    <rdfs:label>Febuxostat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
    <dc:identifier>DB04854</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3878b3e7-f8f8-4051-9220-8822decb7f94"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9790331c-24f6-4ac2-8060-9fc132fa1ceb">
    <rdfs:label>Ad-mG6Pase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d44a716-6ee8-4da3-8fcf-16249bf8aad5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06bac1e2-2b49-4339-b7ef-6aaec1d25577">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e3cbe17-1f57-470e-a944-1892453907c3"/>
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
    <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f4a23f2-63fc-4b93-9268-0e1a763f1547"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/324a4324-1d6e-4e47-bd64-01f9f3dddad6">
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7628205-5d51-4be9-a5c1-565a6f99ce7b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c669b255-a1e8-4230-b166-2a037aba4088">
    <dc:identifier>HP:0008993</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased intraabdominal fat</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d298291f-4703-41d0-aa17-997fac25921b">
    <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0025460</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/476a68f4-59e4-49df-900c-02ffab8c2364">
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b38da6a8-4b16-4c98-ac7a-90d6882be8f8"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4cfddb2-e1d9-4fa1-b0aa-8213a16f3454">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f64e7e1-d3e4-4197-8583-960ed881b4f9"/>
    <rdfs:label>Hemin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85dc2815-0c06-48e1-a1dc-ed500d9ccb87"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <dc:identifier>DB03404</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/522f15d0-758a-419c-ace3-3920c1471692"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/e89ed383-88ca-4862-8f6f-d35958903903">
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/4b70c7ab-5d02-4caf-8a61-2e316d7ec3a7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/013f6b6b-1492-4274-a378-75bc3fee77b1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7db42228-0fba-4688-8621-9011b77a7ee7"/>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4267174f-89ea-46f0-98f1-f90de341bd57"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/685fe4a1-b93f-4c9a-93c5-9d7bacada1d3"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/962378fc-b62a-4346-93d7-374c285f0ad0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7129746b-94a7-4701-b363-c2a635fce432"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f489ca49-628b-4bab-b13a-535333ccad13">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <dc:identifier>DB14778</dc:identifier>
    <rdfs:label>Setrusumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d12ebba3-0757-4a67-bbcc-c5d2285a2f25"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afaca43b-f6ac-4bfa-be79-27e7a86c4994">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8dd343c1-064a-4a20-abd8-cf6d3a2a4e26">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8209a33a-1724-4913-ade1-e080cfcceedf"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/741cf7da-bb9f-4b51-83c4-f743ec5e59ed">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ae98760-4682-4f00-9472-eba57ede5ba4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9d33144-9d01-4862-8174-0bcaeee32c3f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd3cc103-b00a-4489-afa4-19f4d6118048"/>
    <rdfs:label>Amcinonide</rdfs:label>
    <dc:identifier>DB00288</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ce22cc0-d1e7-409d-bfd3-aeaf207977f3"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/bb049934-2a56-4f4a-b027-751bf2fb6e43">
    <rdfs:label>Direct interaction( Mechanistic A)</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0f6749e-d14c-41fe-b70a-494de89ac665">
    <dc:identifier>DB00915</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95255f1f-79b8-4357-9a30-fa185c19fd59"/>
    <rdfs:label>Amantadine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e64c081c-0428-468c-a4cd-ca6da36fa15f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e3afd75-ea2a-4af6-b5c0-921533356eee">
    <rdfs:label>Nitisinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59679ca1-a103-4fe8-b759-4891b72638a8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab78e219-f998-4c6e-8b6b-88812750c900"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
    <dc:identifier>DB00348</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99fdb40e-5044-4068-ae9a-36b520f71f61">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66a8589e-9aab-4d27-af71-23ab4a6b7536"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69d3cb4b-33ce-4ee9-bee6-387aeb1b5f41">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bce223f8-4234-42f8-911d-99f64d3477a4"/>
    <rdfs:label>Piracetam</rdfs:label>
    <dc:identifier>DB09210</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/550ab83f-2dca-46fa-9224-2d0e77ece088">
    <dc:identifier>HP:0000742</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Self-mutilation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1734853-727a-4f5b-9a27-0e360ea3aaa5">
    <rdfs:label>Atypical bile acids</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10aedd86-0ec3-4441-87d1-ae489a1d43d2">
    <dc:identifier>HP:0001250</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <rdfs:label>Decreased niacinamide level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/09b151e0-43ca-4f89-a7bf-012f96c637c7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f5b5ac63-3cb4-4407-abc4-1bae4a51acc1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/162dbb94-56e4-498a-82f4-447c32defb08"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a05a0e9-1ccd-4cc9-bdaa-8381ddfecc5a">
    <rdfs:label>Galactose</rdfs:label>
    <dc:identifier>DB11735</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97cfc003-6817-42bb-8370-d3aebc6c2d75"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb28adbf-94a6-4930-b653-024a835ad1b2"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
    <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a2d3d9ab-35a5-4a45-85c3-9a238c98aa62"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
    <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc497e80-de01-484b-b4c3-67c0442a91b2">
    <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012535</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e36c9e4-c1cd-4665-9939-9fd1a1f29963">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1af2ffc4-a737-455b-b175-6694f2277323"/>
    <rdfs:label>Norleucine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/556a7eeb-7b5b-437c-b905-c8313b67c509">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebbae2d0-b094-4013-a7f8-18d02e3f7b57"/>
    <rdfs:label>leucine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d6d98da-a23a-46b1-87d1-64e47235baf9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3781076-0125-4114-97e8-d80232eb3237"/>
    <dc:identifier>DB02209</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9086649-7776-4029-98dd-e341c7e3c4e1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6267574-c447-4b26-82a1-d04764a0f5da"/>
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e769d3d9-42ba-4c0a-8ca8-7ac06e25ceec">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4834e83f-b302-4c11-a414-2e3ce5de3a21"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf572e57-ce0d-4622-9485-6d1917100ba4"/>
    <dc:identifier>DB14513</dc:identifier>
    <rdfs:label>Magnesium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09b151e0-43ca-4f89-a7bf-012f96c637c7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46f6c146-38e1-4f60-a6df-b73e0842cd1e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b3d85a4-c82d-410f-a092-cea8694f322b">
    <rdfs:label>decreased appetite</rdfs:label>
    <dc:identifier>HP:0004396</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/30dc15e4-6b1b-4ef8-9fd9-f63153fd8174">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c670b535-9706-4d71-b881-dc488ca75711"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8fd1947-c929-47c5-9bc9-61a683f82522"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f77a7030-e7e8-4ec2-8869-024a0115d8bb">
    <dc:identifier>DB01257</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e610ea95-e759-46a6-9447-f0b141540a51"/>
    <rdfs:label>Eculizumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa6216b3-f6e0-48ed-a7ad-6b16737ae4d5"/>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/13063f05-ac3e-4cd5-b2de-d1e587b542f0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
    <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f422ec6-a146-4c09-823e-17d0a33fb54c"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/e1a80218-5bbc-416a-9d28-94805d9273fb"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a398b94-c171-4e9a-84d2-682d7b5fd080">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/667a2cf2-ae5a-48e1-968a-ccaec21094c1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7042efc5-07ca-438a-b824-4dca85d7b6d7"/>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/f8684ddd-f1fe-4e20-9c83-cb223fa2fa39">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9c0c59b-797a-4243-a794-39eadadb5d5a"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5686c981-01a2-405c-af90-f51116b60ab5"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd49b68c-612a-45f5-8436-d3c6c0aa4b55"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76715966-07eb-4eac-ab88-cfd2ac6265d7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f2573846-8a7d-4b41-811e-fa30f9f8b3e6"/>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <dc:identifier>DB01390</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63b255b0-ffc7-4837-b5e2-5a6fb276c735">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>neurotoxicity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04875cf6-9f7a-4d36-bbe0-fe0f671fcb33">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de072562-44cd-4b45-88c1-6e580ab63497">
    <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/496f2ed3-605d-4326-a768-6520e41103ca">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
    <rdfs:label>ataxic gait</rdfs:label>
    <dc:identifier>HP:0002066</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68ab0b0d-fa9d-4b6f-bb65-d75cd100e423">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8caf56ec-f70f-4dc3-8003-180ceaf1dc1a"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a432c56-ede8-402a-9b0a-5c5582a09028">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001396</dc:identifier>
    <rdfs:label>Bile flow defect</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/729aa4b0-0de7-4157-9bd0-28bd4efb6ee0">
    <rdfs:label>liver fibrosis progression</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
    <dc:identifier>HP:0001395</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82c4c8ed-2d13-496f-9ea7-dcd5293a8650">
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
    <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/baa71e79-1fe3-45de-8e48-c56116d2094f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55f40082-fadd-43a3-bf93-62464c0824e3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0107a5a9-d7fd-4b82-95a2-58286042500e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/14df4d81-e4b8-47df-b389-3ae6a942d9d3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4fd8fece-b6b9-40d0-b94a-6a2bd08bcfc0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <rdfs:label>Allopurinol</rdfs:label>
    <dc:identifier>DB00437</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90c23faa-e9ad-4f72-8613-70c610a79aa3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
    <dc:identifier>HP:0006670</dc:identifier>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>Impaired myocardial contractility</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85ff3d99-ab2a-4e24-8742-be3a77b89eca">
    <rdfs:label>high serum bilirubin level</rdfs:label>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <dc:identifier>HP:0002904</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5314f7cd-6548-48c9-b90b-f5fe76709653">
    <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a947db3d-695c-43f1-a6f0-81f0588746d9">
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>behavior al abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad818b91-31cb-477a-aaea-e9223a44d54f">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
    <dc:identifier>HP:0031798</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/313c4e71-db87-4926-b9ce-ce7515525bc9">
    <dc:identifier>DB00028</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8801a43-b830-49a6-9500-e111b5d0e6d0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3bfe5d0-7bb2-44ac-8097-bfa0ac220210"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cedc80c-fb5e-414d-943c-f214c78242d3">
    <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0002135</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80db5ce0-48c1-4ad2-9dce-f8577ed73b45">
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:label>Epileptic seizures</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ea6fdcf9-1182-456f-9023-fa03fa1c32d2"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
    <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
    <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
    <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aecd5d78-afeb-4f00-98ff-b1b21f0e0946">
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>Metabolic Decompensation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a730beca-8d1a-4274-8029-e55d962ede63">
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:label>Heart failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/3cea1d26-660e-4645-be35-a7b637e55b17">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a4f8164-bbf7-40c8-b28b-bd232942b1c4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/3226fe3b-a277-49a5-8bc5-3bbe8cdb5529"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/095b0197-65d9-4646-a4e6-9b949fb835cf"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/313d1b45-5014-46a2-b010-52f2f5218323">
    <dc:identifier>HP:0002240</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <rdfs:label>Hepatomeglay</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5bc999a5-790c-418a-846e-23122589ed6f">
    <rdfs:label>ARC-AAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57e5b0af-d7cb-48c9-80db-31c07b33b73d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcab8520-40fc-4e10-96dd-af0e2a9fd18a">
    <rdfs:label>Tazobactam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/621be890-7699-4a98-a935-f0a4ab1954c1"/>
    <dc:identifier>DB01606</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d146e83b-11b7-409f-bacd-856e8a680cfb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70a5a4e6-6aed-451e-809c-60e303f0874b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0833065d-3171-4718-83c9-fa1740308de3">
    <rdfs:label>Protoporphyrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0456293d-9c62-44e1-94ed-07ff9683ad14"/>
    <dc:identifier>DB02285</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20fb0224-55d9-482a-8c00-d4018b0f0ffa">
    <rdfs:label>Idebenone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27f3b09c-2dee-46ca-9119-fb555780a457"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3759705b-3518-404a-b35a-75cd3f73a69c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24ca6d23-9428-44f2-a96c-58cfc7d5d2f3"/>
    <dc:identifier>DB09081</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c493cad9-b0f9-4fac-b42a-3b60068dd240"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4f9ae31-52fa-4a80-8261-43bc4a85889a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b656966-60c6-4a94-92ad-422c10eb7ff1"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11820a92-6d3c-46d1-a0b2-ae8f37c89a9a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78055f2f-ae09-4ddd-852e-c2f817cf5524"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17db00cd-724d-45ec-8ec9-f89272c7dead">
    <dc:identifier>HP:0003690</dc:identifier>
    <rdfs:label>Limb muscle weakness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3394cfb0-edb0-41f4-b4ea-bb44a230557f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ab342b2-165f-4e40-855c-b4f9f59d1601"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e30b04db-32aa-41e8-af7f-da6e6f9802ac">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
    <rdfs:label>Gemcabene</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4cdcb9e-4c0d-4506-91b1-7c541c873e56"/>
    <dc:identifier>DB05123</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b801defc-8238-4cfb-abd2-459200e10839">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d0bbd8d0-f8c9-45f9-9058-48844d6432eb"/>
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c66ccb3a-0846-408f-83e5-8475ac51816a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e18b64ea-2d94-469d-a228-245586df52b0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7492dc96-6c26-4497-b79d-6f1ded45de1a"/>
    <rdfs:label>Acetazolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1eaf6f06-5e50-4d02-9be0-2329c80252a4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22955ed7-d2b6-49eb-be60-4ca76b4ae6e9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a34a0d4-0b62-434d-9917-e5aafea146e3"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
        <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1608293-1aa7-4018-b327-f538548d5cf9"/>
        <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c669b255-a1e8-4230-b166-2a037aba4088"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/477f6527-9c5d-4711-8404-68cf3dd9692a"/>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ef30f21-5739-44ef-9f03-f0bb40b54d3e">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd68fd86-782e-4128-bc09-1755be5de289">
        <rdfs:label>Methotrimeprazine</rdfs:label>
        <dc:identifier>DB01403</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9d38916-48fb-47a3-aea9-933a3bb17088"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7585b9b8-34e3-4134-a6b5-68a36ed49db4">
    <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
    <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
    <dc:identifier>HP:0012212</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8d5f5ea-d98b-46b0-bc18-ec80f7def9ee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd31a16a-7d16-4153-ad4c-23514e72f344"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/671a2df8-8d98-435e-ad75-a3284f1e6e60">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <rdfs:label>Sodium acetate</rdfs:label>
    <dc:identifier>DB09395</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/77bbb0da-9dba-40cf-b18b-f483a03a550b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2716d27a-cb3a-468f-92e5-b0b2141f9cae">
    <rdfs:label>fine motor dysfunction</rdfs:label>
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2cf8bec-afce-4a44-b40e-89ffff59dfd9">
    <rdfs:label>Splenomegly</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <dc:identifier>HP:0001744</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5444b628-c213-4ff3-aa04-80fa5acc3320">
    <rdfs:label>Kidney failure</rdfs:label>
    <dc:identifier>HP:0000083</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f09e9c53-7c0e-4caa-8dc4-5784b6ee497a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <rdfs:label>Mannose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b65dcf7-b7e2-47c0-852e-2af79b95107a"/>
    <dc:identifier>DB12907</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/938f0635-66bc-4d61-8f15-f0676dc1374b"/>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39910cb4-3da6-4bae-bf49-d8c578f93fc0">
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <dc:identifier>HP:0000496</dc:identifier>
    <rdfs:label>Defective eye motor function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36fc7adf-418e-430a-bca6-8e5477b2de2c">
    <rdfs:label>fiber necrosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003713</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a60cf845-9315-4282-802d-618d0457126d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7dc84ed-6e35-4f7b-9585-c55189d4537a"/>
    <rdfs:label>Metoclopramide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <dc:identifier>DB01233</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b6da577-4d02-4a2f-ada2-d71ec2d6a125">
    <rdfs:label>Abnormal Body fat composition</rdfs:label>
    <dc:identifier>HP:0025521</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8bb87e4e-2361-4b36-a089-205a3aa26e09">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6099d63e-78bd-4598-a7f7-a282b902990a"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bea927a9-438a-4d60-9c60-b1cb3224230c">
    <dc:identifier>HP:0000002</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
    <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b9c238a-a388-4b17-a5f4-c3d193b3e9a1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased red blood cell production</rdfs:label>
    <dc:identifier>HP:0012133*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/12df71af-dc1c-4ec9-9160-c43200029b3e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81331d08-ea4f-49b5-ac65-bc9bf0b82138"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19f36c2c-d5d0-4d40-bf8f-dbaf4f8d9afd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </ddiem:TheraputicProcedure>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/fe5b0411-e211-4513-96f8-2ea32f5be209">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d3ad8d1d-159f-43cd-acfb-bd0fa86ad991"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ddecda0-9bd9-4260-8684-4c8dfa6f2f78"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f712d70c-64e9-4c84-bacc-43ccf4cc1559"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </ddiem:TheraputicProcedure>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69415f99-77ba-4e7c-816d-62df50e4fc5f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a8c8a22d-cda5-435c-a666-b34a4b65e980"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0b21503d-017e-4de7-ba78-205c72e03bb3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f462f60-0616-4ad8-bf17-0705b970600a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43a34a61-f5f5-4431-88ab-7029d6e73477">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5128cfe-a7ac-426a-aade-d96f2adabbf4"/>
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <dc:identifier>CHEBI_25548</dc:identifier>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
    <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4fda82b-4732-4a2b-b218-19e246e2baa8"/>
    <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/88176c3f-4fa2-4e54-976e-3f928a5b1c17">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e907971-8b49-45f5-a118-b0abe9670f4e"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8372f676-01d6-450c-942f-7f732eb1bee1"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/411a4044-d0a9-4ac9-8f14-041dfe80da68">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/503dba82-e57d-4e92-a42c-8c9d0c7aaabe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ded7ee64-70ce-43c4-9cdd-1a5a5e9efee8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4669956-72cf-4d37-9b98-a3275f4facde"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d82eaed3-d297-41af-9e8b-02593e314664">
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <rdfs:label>progressive leukodystrophy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
    <dc:identifier>HP:0002415</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7523c82d-5142-4012-a189-099d6bda55da">
    <rdfs:label>Low energy level</rdfs:label>
    <dc:identifier>HP:0003473</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10b362d8-c742-485f-8309-1cd0cac521ae">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07516c03-8136-4452-8376-dd6ac044a6ad"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a593c3d-d176-4761-bb09-acd38eedc280"/>
    <dc:identifier>DB01022</dc:identifier>
    <rdfs:label>Phylloquinone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9df0788-ba4c-4cdd-8eb5-556daca3ba73">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
    <dc:identifier>M01AX</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f693bb7e-af5e-43e9-a3d3-9f44c8cfe559"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25ef6ee0-43a7-4955-94c3-9e3b7ce47696">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/accbcc8c-506b-4ce2-9960-5204a2bd5973"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c78550e6-4d6b-46c0-a73f-03805e2139ea">
    <rdfs:label>Retrovirus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91932193-d3a0-41d4-8857-ec4afa085a8a"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c129cd2-8c29-46ac-bc78-974112979135"/>
    <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c82c99ed-e70b-4dee-adc8-6087eaa001df"/>
    <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/80f24d09-638b-4464-8268-110fbb2ba454">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81b27e5c-213a-40c5-9008-7916c26bcb94"/>
    <rdfs:label>Desmopressin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb4fe85f-ec95-4958-ab2b-536e818596d9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <dc:identifier>DB00035</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/03cc2936-2604-474d-a249-ca2365f76c01">
    <rdfs:label>Gene therapy *</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4c526e2-f30c-444d-aaef-4981bab709df"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3e7bd91f-ca68-49d2-802f-91d53080fbfe">
    <rdfs:label>Tempol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/069c855b-cc7e-47cd-9c22-f6de64f8820f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <dc:identifier>DB12449</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd6c5b1b-6fd7-478c-868c-e9da8e26aa79">
    <rdfs:label>high plasma RAAS activity</rdfs:label>
    <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
    <dc:identifier>HP:0000847*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/71adb3be-99c7-46d6-850f-e54914008c96">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93a5a562-ddc9-4312-abe9-7250f8b8549b"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/6a2a533b-d295-4da9-b952-3573b8e588bf"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9ecb275-586a-4df0-9936-34ce4b7fbf93"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecdee5f0-3f7a-4fe2-8575-e14b8c5d0c69">
    <dc:identifier>HP:0005978*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c8c8d48-4aea-4a4c-b41e-3a572b5792d7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002453*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
    <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4223bbe-20aa-459e-80e8-17f6f6d382e9">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9bd4706-beee-469b-a931-528043535f97">
    <rdfs:label>scaling</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <dc:identifier>HP:0040189</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af009c5d-c92d-4c2b-a92e-0ded1118e437">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c2666fd-311f-4bc2-bc5a-143dc90bdac6"/>
    <rdfs:label>GNeo-IDUA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8395c262-057b-446f-a115-d8fbaf80b995">
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fabe27ec-3344-43b7-a872-8735db76e747"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a11b24a-8838-448d-9f8d-e3f0e8b97fe9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
    <dc:identifier>DB00755</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f8bae24-e4e6-4c3c-895a-d261b017ff7c"/>
    <rdfs:label>Tretinoin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/defed2c1-5031-42fd-a9f8-7426c0c0033c">
    <rdfs:label>lipid peroxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50a4aec2-1dd3-47c7-bb1b-9fc4a296213c">
    <dc:identifier>DB00051</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b99992cc-244a-4136-a2df-4aecabda1c5c"/>
    <rdfs:label>Adalimumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9bca2f07-6cf5-4544-8696-292c8b4cfa56">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b05c422-0e12-44bc-9184-03dd94b833de"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1b6e268-002a-416b-b3f3-4fab62430df2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3cea1d26-660e-4645-be35-a7b637e55b17"/>
    <rdfs:label>GNT0003</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1da71e14-002c-4827-b8c2-b82ae1da40c5">
    <dc:identifier>HP:0001714</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>ventricular hypertrophy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5228076a-bc72-4012-81ce-89b210a91dfb">
    <dc:identifier>HP:0001129</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
    <rdfs:label>Large central visual field defect</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/ee3f8cf0-f2ff-4969-a65c-c09e80595f15">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/28165ec0-f618-4900-839b-b83e5c4b93a3"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33bf4320-b6e8-44ae-89b9-a6290129f89f"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/499934ad-7279-4771-b124-0cce87238dd2">
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad83533b-1a86-4c62-8142-81b66a43810a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b85cf90-0aaf-4212-8b20-f2b253ceddd0">
    <dc:identifier>HP:0002904</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c9d38916-48fb-47a3-aea9-933a3bb17088">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ef30f21-5739-44ef-9f03-f0bb40b54d3e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6101629c-957c-4427-8dbc-1e524bc2f016">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000752</dc:identifier>
        <rdfs:label>elicited hyperactivity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000752</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26020857-9014-4c98-b5f1-673a7bfa8414"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06dc37f6-b41d-4b68-aedb-17385ef6225e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97e0d4e5-b8d1-4906-927c-955b4bcd08c9"/>
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4bc76912-3b67-4d6c-be9f-7e654239f92f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/68a2dd8d-8bb3-49d3-9d5d-e0a837fff48d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/454a1cef-dff1-4ab8-b5ec-3b95f87baa24">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12a32e84-cda4-43b5-9ee7-cd2b35685e70"/>
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1702a0f5-af6a-40d6-9b95-e5124dbeb719">
    <dc:identifier>A11E</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c24e2a39-cca1-4446-9f46-ca8fab90fddc"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00e2ac00-84c2-418b-9363-f7128ba9d16e">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
    <dc:identifier>N06AB</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a147f77c-c9e7-46ab-9d83-87fd24147a71"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74a5dde6-1130-4aa1-906b-e6aed239954b">
    <rdfs:label>Rituximab</rdfs:label>
    <dc:identifier>DB00073</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2e14373-0081-4c10-bed6-a2b1d1cd9bde"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b923d53-628e-46e3-931d-46eca245933c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
    <rdfs:label>Bulbar dysfunction</rdfs:label>
    <dc:identifier>HP:0001283</dc:identifier>
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8c246bc-d9a6-4167-8bd4-d6b98234e003">
    <rdfs:label>NO revealed clinical benefit</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/1d1f9824-7ff7-4bb6-bb8e-4cf5f5ddf7cf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00223-011-9562-5</dc:provenance>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/131935ea-e91e-489c-ae39-060321834975"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e468dbc-1b16-40ff-a20c-dc4637342a07"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f39a51fd-8a15-45cc-9857-dc361ced023a">
    <dc:identifier>M02AA</dc:identifier>
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a127a566-0960-4bfd-a1bb-169afcd816e5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02933213-3feb-45f4-8028-0bbf3a59d6d7">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
    <rdfs:label>abnormal interactivity</rdfs:label>
    <dc:identifier>HP:0012433</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b70b97bd-96fd-4343-9e93-37954a23c9d5">
    <rdfs:label>High ganglioside accumulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f80dbe02-41a9-4830-9df7-10958a6d7553">
    <rdfs:label>AAV-treated βgal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b908dacc-8e30-4beb-ab0c-d821f658ee49"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbbf499d-0489-4025-9ae5-23697c819972">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d3e06cf7-047f-4080-a5ef-d457af4d921b"/>
    <dc:identifier>DB00999</dc:identifier>
  </ddiem:Drug>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/cfb44861-b19a-47d7-bbe8-f65e53e67168">
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/d360a9d5-34d0-4bd4-9c18-4f98a50573a5"/>
    <obo:RO_0002606>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
        <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c7792c7-2177-4ed3-9ca9-0b4888e277dd"/>
      </ddiem:Disease>
    </obo:RO_0002606>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05fe32a9-ab1e-45af-9222-d51bf0ec2a45">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9a52e5d-178e-42a8-95bb-2bef8ee46e79"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c428cea3-2292-4609-91ad-a7377932720a">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:label>Low IQ score</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b82cebf4-cf29-4169-9678-9469fa4867cc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1b41297-14b5-4bff-8778-743c6d419a98"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/50f1f284-516e-40e6-9117-8e639d212520">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e68d77d-f043-42ef-bf7d-77dc408a3f46"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51e97d0c-25a8-4e33-8418-2941b24203fb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52f9b569-ab19-4943-8353-c91ee6fda946"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4a1e7d9-fc56-43d8-93bc-0d2a4b466877">
    <rdfs:label>High calcium excretion</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002150</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f381f732-7077-4249-b9eb-40bd1dc482ee">
    <dc:identifier>DB12783</dc:identifier>
    <rdfs:label>Benserazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2eeaa608-1538-49e0-bf66-925d372a632c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08a2ecb7-97d2-4049-8a33-39c6f2dad14d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b6d75e87-f7fc-4002-801c-7ac4fa8729fb"/>
    <rdfs:label>Linoleic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <dc:identifier>DB14104</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5050dc4a-0370-4f33-abf3-338d612f7bf2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
    <rdfs:label>Acute decompensation</rdfs:label>
    <dc:identifier>HP:0001958</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/209e5568-7bdc-4730-ad2f-9014ef353677">
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>elevated CSF GHB levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4671e55-18a8-4563-9d4e-f6e1fcb938fd">
    <rdfs:label>Fenofibric acid</rdfs:label>
    <dc:identifier>DB13873</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b7cc369-42cb-423a-9095-0bde91d90601"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b68378c7-a40a-4a5f-86fb-99559d223fe5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e269472b-0cc4-4f07-9ce0-08c41721305d">
    <rdfs:label>Somatotropin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7991afb-2131-445a-8114-cd7a9e6b0633"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ec28fce-bbae-4895-b9fb-719a1a00ebd3"/>
    <dc:identifier>DB00052</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ad52fbc-2aae-43e6-8daf-bff28551cee9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7660f182-f222-4b4d-bc9c-30bfed86a87f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb985dfd-2317-43d2-84f5-42ac61ec847c"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d3830de-3b2c-4052-86ee-9fc75f408ae4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5c831d0-461b-421c-9717-f9abf0429d4c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68878919-b73f-4d18-897f-4bb6098e4415">
    <rdfs:label>Abnormal developmental milestones</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012759</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7fc1183e-8d93-40d8-95c5-a6d3c8142712">
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6360dece-590c-4a98-94f9-c6482b8f52ab"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
    <dc:identifier>B01A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d03887a0-d600-4cea-ab46-39555131582a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001332</dc:identifier>
    <rdfs:label>Parkinsonism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d65afd4f-54f4-4a8b-8646-b8f28827b08a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cdabeccd-d97f-443f-8f4b-aa5310922145"/>
  </rdf:Alt>
  <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/c4761e46-6fbf-4d25-8598-b2b0e246b1b1">
    <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/52f9b569-ab19-4943-8353-c91ee6fda946"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK220444</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
    <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc9dd885-7b35-4297-8c6f-8c9bf8e238b5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79b20a54-351d-475d-ad62-83d63d9584e3"/>
  </ddiem:TheraputicProcedure>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78a97571-6fa3-489f-a40b-975fe88500c9">
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
    <rdfs:comment>In the mouse model syudy</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/35754a89-cff5-49fd-b7f5-37bdceec798c">
    <dc:identifier>DB01109</dc:identifier>
    <rdfs:label>Heparin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e0ad35c-86ab-44ed-adf0-0f7de4eb340f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d66dbb29-ec24-4409-a207-56883f080747">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f3e960b-2466-4930-8870-c8776f83a1e8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
    <dc:identifier>DB06273</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0ffbba9f-698a-49c4-a82f-b5a7582275e3"/>
    <rdfs:label>Tocilizumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d187914-0efb-47a2-8d55-3b6fadf86270">
    <rdfs:label>recombinant human tripeptidyl peptidase-1 (rhTPP1)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c813c55-d6c4-4ed1-9d22-a4349805c846"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7239f1d8-d6cd-46ac-a7cf-bc70b61d5e47">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebf581a1-56ea-405b-b23a-79055ff0a690"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2748fed4-6a26-4787-b36d-9822e50aabe3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
    <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/898d6cc8-d398-40b2-9bbd-537930ddbd8b">
    <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
    <dc:identifier>HP:0004355</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0e861ea-f1ea-49ba-9449-9113a6b745f0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/685c6525-44a0-49fa-9d07-fde3632d6a72"/>
    <dc:identifier>DB01626</dc:identifier>
    <rdfs:label>Pargyline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ced5be53-aea6-4fb7-8fc7-6733067c7780">
    <rdfs:comment>The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.</rdfs:comment>
    <rdfs:label>Functional motoe deficit</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
    <dc:identifier>HP:0004302</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22f5db6c-acd6-45a1-9410-bc2969dbf3f5">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bf19dea-4a9d-4f85-a946-e6faac700903">
    <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
    <dc:identifier>HP:0001992*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d09b011-c1b1-4f5e-80b4-c5ad189cb1bd">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>Behavioural Disability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab1db195-0851-4a64-a8bf-4f7756559356">
    <rdfs:label>Afamelanotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
    <dc:identifier>DB04931</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7f897cef-c710-4b2f-b084-5593f848a2fc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7cc7b8b9-2189-4643-85e6-cc663c660b4f">
    <rdfs:label>Complex Carbohydrates</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32d0c744-861b-43c3-a787-7c9143a01af5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52b6493b-4ebf-4098-bb2e-5ab0602b48d9">
    <dc:identifier>DB00186</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ada3db3a-cf5d-455a-b47e-594b35e4a365"/>
    <rdfs:label>Lorazepam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4203f9b8-4439-4c55-ae73-2e9b95a4d2c9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/066f54dc-e412-42d6-ac9f-d226c8885b11"/>
    <dc:identifier>DB00563</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <rdfs:label>Methotrexate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/54dba8c1-8401-4c81-9840-fe014e94f394">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <dc:identifier>DB11981</dc:identifier>
    <rdfs:label>Elamipretide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80201cf8-8d0f-4202-83e8-ec17b871668f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3cf40053-f69a-40b9-afae-238f96cbb931"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ceb010c-a278-4985-8fd8-186a5a6b7c60">
    <dc:identifier>HP:0010903</dc:identifier>
    <rdfs:label>low plasma glutamine levels</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ed4d068-92cb-4d09-a126-c858a882a78d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0345858f-4ab0-4500-9cee-4a3722666126"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <dc:identifier>A11</dc:identifier>
    <rdfs:label>VITAMINS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b8d8397-921e-4d0c-9b0d-dd0d12c332f0">
    <rdfs:label>Rickets</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002748</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a05725ee-9f7c-41e0-a211-9b7e29d0d554">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000817</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:label>defect in eye contect</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af25a28a-3cd1-4450-ac84-3e3973e8ff5a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
    <rdfs:label>orotic aciduria</rdfs:label>
    <dc:identifier>HP:0003218</dc:identifier>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78e26c85-c139-48a2-be3c-26486b174ea2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7c4fbbe-5957-4130-8f46-fa76de448190"/>
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6b6938c-4f56-4f3e-8d47-9bf13e3182a6">
    <dc:identifier>DB00435</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc84decd-afdc-47fe-8945-3d33b9b718dd"/>
    <rdfs:label>Nitric Oxide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34e46d77-fdd7-4908-adbb-1d3aaf90dd96">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa507351-0e08-4847-aed6-b4c39d49c7f1"/>
    <dc:identifier>DB14500</dc:identifier>
    <rdfs:label>Potassium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45bf99ac-5b5c-497d-842c-a201df2c33bf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3a309b9-8910-4ce4-8eb0-3d4ca502405e">
    <rdfs:label>language impairment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
    <dc:identifier>HP:0002463</dc:identifier>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/616392e7-20f3-4d9d-a8fc-422999e5f4cd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d1eb83a-70b1-48c4-8d47-48bf3e3a2fe8"/>
    <rdfs:label>Cabozantinib</rdfs:label>
    <dc:identifier>DB08875</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1590e331-527f-4af2-96b6-2883a24af72c">
    <rdfs:label>Fructose</rdfs:label>
    <dc:identifier>DB04173</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b47f764b-a317-4b3f-9d48-959ccaab26e6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e89fa9a-1159-4fb3-ae97-bc01cec5f52a">
    <rdfs:label>Metformin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <dc:identifier>DB00331</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa03ec81-a2d4-4d2b-a892-360dd84ddaf3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcd5f3bd-7530-4efa-a6bc-213a1e4bfedd">
    <dc:identifier>DB12537</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
    <rdfs:label>Benzodiazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf7c940e-d14b-4b58-bbcd-c7f32dd37f67"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1b3d351-bfe5-4224-9467-75a2edd9f55e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed6e829b-d0a5-4a10-be43-4f3727543fb0"/>
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af7d7cb6-8d54-47de-8b80-d9674b40092b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fd2b683f-6f4a-4107-83a4-dc5fe94df2f4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ea4f499-efdf-43a0-9fe5-1e19f32d80ae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcb5b8f7-ed4c-45a5-b2e2-8623f746cecf"/>
    <rdfs:label>Sodium citrate</rdfs:label>
    <dc:identifier>DB09154</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17f0354c-958c-4bfb-b871-d6c7bba08470"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71ffd057-ad11-4d2d-875b-6ef56a7f6779">
    <dc:identifier>HP:0012321</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
    <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17def98a-815e-49f5-9115-afa735086de1">
    <rdfs:label>hemolytic anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
    <dc:identifier>HP:0001878</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25f123f6-c9ad-4a02-b7da-f75975b219b1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0001640</dc:identifier>
    <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2be06e7c-475a-42f5-affb-d17225d4ca6e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
    <dc:identifier>DB04272</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f53824b-53b5-41ba-b6ab-836e784cabc2"/>
    <rdfs:label>Citric acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c17eef7d-a745-4897-93b1-9e15428ea6bf">
    <rdfs:label>Neuronal vacuolation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17e9173b-a355-4e80-a620-502996bad47d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf72bc11-095b-4694-a8e2-b3efa7f66e7e"/>
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81ae4d6c-aa49-433c-ad48-42713b9f3adf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
    <dc:identifier>DB00571</dc:identifier>
    <rdfs:label>Propranolol</rdfs:label>
    <obo:RO_0000056>
      <ddiem:TheraputicProcedure rdf:about="http://ddiem.phenomebrowser.net/b74af4df-839c-4a5c-b518-8cc1f1ff4d98">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6dc10ba-fe3a-466d-9d12-2ebfbab84481"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f68d4954-45be-42b5-8213-02168f6e318d"/>
        <rdfs:subClassOf rdf:resource="http://ddiem.phenomebrowser.net/da3fd9ed-562d-45b0-a4da-1c14cdf8707d"/>
        <obo:RO_0002606 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22e6f3d5-b80d-4d4b-ba9e-49a75f7a03cf"/>
      </ddiem:TheraputicProcedure>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/380e84fc-3246-4290-82c7-c2768da2fd25">
    <rdfs:label>Functional interaction(Mechanistic B)+Direct interaction (Mechanistic A)</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34e46b8f-bf29-46cc-a9ae-2a83b6329880">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal circulating renin</rdfs:label>
    <dc:identifier>HP:0040084</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47da26eb-fea7-4b38-bed8-518024b9c727">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/689dc1bf-6763-413b-97c8-71d88e8cceb7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8aee9fb1-1133-4d6e-b057-c1d47d1bc34b"/>
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65d124d9-35bd-443e-a928-93c42eb0ee29">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>Decreased muscle mass</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd00eef5-b4bc-4954-9b66-dd1a097afc44">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <dc:identifier>HP:0004356*</dc:identifier>
    <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/579689fb-73af-48dc-91b0-4ec40234666f">
    <dc:identifier>HP:0001270</dc:identifier>
    <rdfs:label>Delayed motor development</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a09f61e-c67c-4548-bbbd-d8545623a5a0">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76fdf908-536b-4eec-9c9b-0fd339b6175b"/>
    <dc:identifier>CHEBI_23456</dc:identifier>
    <rdfs:label>cyclodextrins</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e92f8625-1bfd-4e1d-abec-98245957025d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9ec6495-771c-4371-95a4-e50fdbf0592b"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9855b64c-0556-4922-8b2f-4031388689be">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a1e0f59-1fbc-49f6-9c24-1fe69800bcb0"/>
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b21eb15-2590-4370-bd2a-90d2cc09fadb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
    <dc:identifier>HP:0012240</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased muscle lipid droplets</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b6c6276-6ea3-49ee-919d-ab6c360916f9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/423ec7fa-fbbe-4dd8-8ea4-c50addb53c45"/>
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6640b7d-b0f2-4252-a32b-07b499961aeb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Subcortical calcification</rdfs:label>
    <dc:identifier>HP:0007346</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53134350-d979-48e9-965a-ebe3e6a95152">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <dc:identifier>HP:0011925*</dc:identifier>
    <rdfs:label>Decreased cellular ATP level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc736ec5-cec4-485b-bc6d-06ddfe17d4c5">
    <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
    <dc:identifier>HP:0009830*</dc:identifier>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b22590e-504d-4668-980b-1fe520b20656">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5967fb6e-8294-4128-95d0-d5982de07a06"/>
    <rdfs:label>Triheptanoin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4524093-c9e8-4b23-95cf-f3d83d59b8a0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/67ccc672-456f-438c-8e25-b31f90804163"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ec7ada9-ea03-420f-9c8e-ac30c6538036"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd60e879-4154-406d-9bbf-53d9ce3426c6"/>
    <dc:identifier>DB11677</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c8b74bf0-9f5f-4997-a3e5-38b3767c29df"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d83ceff-f6f2-4c78-8990-7a341998443d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>Abnormal Folate level</rdfs:label>
    <dc:identifier>HP:0040087</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a7c3026-bec1-4392-887f-49f34bc08aed">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b2fe6c7-848f-4dee-865a-d1d3b4410fe0"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e60d7ef-96df-463e-ab19-057437870102">
    <rdfs:label>Left ventricular hypertrophy</rdfs:label>
    <dc:identifier>HP:0001712</dc:identifier>
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/503dba82-e57d-4e92-a42c-8c9d0c7aaabe">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/88176c3f-4fa2-4e54-976e-3f928a5b1c17"/>
    <rdfs:label>Entacapone</rdfs:label>
    <dc:identifier>DB00494</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77436b6a-0982-4717-9ea3-bf4f4b572f70">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8971df7-fe06-43da-84dd-5fc0010555df"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79d1c31d-b23c-4237-9d2c-3517745e02c8">
    <rdfs:label>Ezetimibe</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85b4b2d2-9999-4f84-9218-2b45db8658ec"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <dc:identifier>DB00973</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7991fc51-f953-4535-9e7b-2501f22e18fa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/487991fd-fecc-4a8b-97eb-53979bb903d3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c7f87fe3-8b0a-4ce2-8cb4-6b62ff6787d4"/>
    <rdfs:label>Prednisone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41528aed-b9dc-4aea-978a-7e2be0646317"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb54d37a-44ad-4c8d-ad0b-4993cf635945"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <dc:identifier>DB00635</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e7d30fc-2f03-4ee7-aca9-d32961fd3c9d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000093</dc:identifier>
    <rdfs:label>Proteinuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3cdf6fce-5a3a-43df-9a4e-7e5ca4c317d4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8eaf2857-7edc-4759-892f-6e3fdcc681c8"/>
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c981a156-8200-4016-b8f7-14d483b6805e">
    <rdfs:label>Bone mass loss</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35e5693c-9ab5-461c-a76b-2359be9c95b3">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0010909*</dc:identifier>
    <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d45de092-5bd8-48a7-b463-931c736e0016">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c3618c8-26d6-4ae1-b4f2-ab293e9ee340"/>
    <dc:identifier>DB00533</dc:identifier>
    <rdfs:label>Rofecoxib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/589e302f-e390-413b-8be8-dd8bbf1c9e9e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <dc:identifier>HP:0040006*</dc:identifier>
    <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6dc10ba-fe3a-466d-9d12-2ebfbab84481">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low physical capacity</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
    <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7af10360-74d1-41f7-9e62-f9f48c0f806a"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
    <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6642369-4491-4a88-9224-e22c99f81f7c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d852b5f-ab1a-40d3-85d1-99825a64164a"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c670b535-9706-4d71-b881-dc488ca75711"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d341aab3-fc9d-4da3-9cc1-59de4105642d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24481fb0-916a-41d6-8e86-d05e711354a4">
    <dc:identifier>DB08830</dc:identifier>
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f27b94a-2fce-408d-810e-b4f35c0e86c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4abcc58-1cd5-4640-a31e-327b250ff5f6">
    <rdfs:label>Psychiatric disturbance</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b68f50ad-55fd-4735-ad9c-f28bf9320f4b">
    <rdfs:label>Chlorpropamide</rdfs:label>
    <dc:identifier>DB00672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51caf982-8a10-400d-963c-ef1fa6a62d4e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fff8b107-bf75-413f-81a8-08f20603db07">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
    <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0003362</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e190cf80-899b-4fa9-9a48-63aa50419d2c">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <dc:identifier>HP:0000518</dc:identifier>
    <rdfs:label>Cataract</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e832eda-8e71-4516-9666-e111a07e5a59">
    <dc:identifier>HP:0010836</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
    <rdfs:label>hypocupraemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15c5b047-7d23-44e1-8664-946d7151a0d5">
    <dc:identifier>HP:0001257</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
    <rdfs:label>spasticity</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/caadcd7e-0960-4452-be41-c1c6b0ab6c67">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/80bb87c2-3a23-48f9-a4ae-da0598c75646"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8659635-b7c9-4cf4-bd7b-8745abf9a8df">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50499ba6-a2eb-48e4-b212-45458a46e3f2"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6080af56-bd4b-44ed-8d6c-ab507aabd2ee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/881e03a1-93f6-4330-9155-e263b5727b54"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c141ec3c-313c-49ff-899f-98f6654747f8">
    <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffa9df37-3549-44e4-bfb0-31446bdebb68">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
    <dc:identifier>DB02329</dc:identifier>
    <rdfs:label>Carbenoxolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2f30233-edb8-4c11-a48b-be64b9dcc842"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e060a518-a6a2-4277-abf3-d2d25ee9e1c0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41194f20-dcba-42df-bf73-c1c61cb142e6">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
    <dc:identifier>HP:0003200</dc:identifier>
    <rdfs:label>mitochondrial proliferation in the muscle.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5468b765-2565-4f22-a43e-ad65fd5fd57e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defected ClC-Kb expression</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d16e277d-24dc-4959-9d95-57f2a3a21cc6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed53b89a-1a66-4896-9247-2a8fd4b34c99"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <rdfs:label>Velmanase alfa</rdfs:label>
    <dc:identifier>DB12374</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/add7e764-cb78-45cb-8542-7ae7b607a0a5">
    <rdfs:label>Rigidity</rdfs:label>
    <dc:identifier>HP:0002063</dc:identifier>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/464c5d39-7ce8-4a1f-8500-012e10d4aabe">
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b179d799-45b5-422c-a069-ed33598ea07a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
    <dc:identifier>DB08876</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90a25a3b-6d86-4a8d-9a6e-7828ba185e8a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15d30fd1-f492-4b95-bc88-ebaece2e7b1b"/>
    <rdfs:label>Spirapril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <dc:identifier>DB01348</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4108a8b-9d15-49ba-a4e1-6d5fb14cdb15">
    <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b02cbc0f-30af-4cf5-9d41-c649c76fc69e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c5ab16d-fef5-4d65-bd84-9522a12f6d01"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c756a390-5d6f-47dc-9597-5df8fa4686d4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
    <rdfs:label>Mesalazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a8f44bb-f9d6-4ab3-8b7e-fc15a220f95c"/>
    <dc:identifier>DB00244</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a1fa805-bb7d-4f47-87dd-e9561f941c9c">
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
    <dc:identifier>HP:0006279</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07934d8c-73eb-4064-910c-969a0f41b565">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012103</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
    <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4289a87-1c6d-4bf8-a302-48ce7f4e42a7">
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <dc:identifier>HP:0000982</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4b5bd14-516b-45f1-92d1-8964d876d6d7">
    <dc:identifier>HP:0040189*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56dc4162-eca0-47c4-902c-871c14627909">
    <dc:identifier>MP:0013438</dc:identifier>
    <rdfs:label>Hypomyelination</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe055639-7db7-405e-aa21-22b21e015ce9">
    <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
    <dc:identifier>HP:0001958</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/09386019-b422-4358-9752-7950d0081c86">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ca88d72-2401-4ca6-8b46-26dd406e875e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56ada6b6-4999-4c78-bbbb-a13cf3821baf">
    <dc:identifier>MP:0012604*</dc:identifier>
    <rdfs:comment>In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications</rdfs:comment>
    <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27e305ea-20f7-4bb8-b069-8e3ababc2fa5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/abbefb84-724d-4cef-897f-6a95ea04acc1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9183ed94-736b-4214-9a5b-3971e9293c38">
    <rdfs:label>Probucol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf2bddd6-36c2-4d7a-9f30-f2989afd5f99"/>
    <dc:identifier>DB01599</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3b69bcd-de1a-417a-914a-2bb82417bfee">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d85c4628-950e-41fd-955d-85a35ee6e42d"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48975f8b-a3de-4ac7-b193-b8b69839588d"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcd5f3bd-7530-4efa-a6bc-213a1e4bfedd"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3edd0b44-2b64-45c1-b285-b5abab705fda"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/88135ffc-d0d5-4138-b2fa-56279164454d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b219d3d1-7b2c-4ef8-b238-bcbabdc696a7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:label>lack of strenght</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0003750</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9d33ecb-fd59-4ce8-8943-6363f7f79208">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d9eb274-1305-460d-affe-abe0c759d722"/>
    <rdfs:label>hepcidin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2da3ba8-1650-4988-a822-d3a801ebd7ae">
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13a9b172-af59-4c4b-888e-f6060a2bcbe5">
    <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0025142</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e969d5e2-14bd-4c2e-8415-0bad59f7d9cb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e4d9247-1469-4336-8bde-9b003e6afad8"/>
    <rdfs:label>NA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90d006ef-18e0-4631-8d97-0d0813bc362a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
    <rdfs:label>Optic nerve damage</rdfs:label>
    <dc:identifier>HP:0001138</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7dc1850-be44-477b-ad4f-3c039f337ee5">
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <rdfs:label>diarrhoea</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
    <dc:identifier>HP:0002014</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:TheraputicProcedureType rdf:about="http://ddiem.phenomebrowser.net/aa0a5e30-b9b2-46fc-8901-6947ab8f1aac">
    <rdfs:label>Functional intearction (Mecahnistic B)</rdfs:label>
  </ddiem:TheraputicProcedureType>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2b06dcc-afc7-458d-bcb7-88ac6e247bfc">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/728b0bd6-11f2-419a-8cf3-06957214383c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a13fc37e-5e11-4e38-82f1-27c8f876c0d8">
    <dc:identifier>DB00166</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4761e46-6fbf-4d25-8598-b2b0e246b1b1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c16584fd-9c1f-41a3-a877-5e0ac04b40d1"/>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50f1f284-516e-40e6-9117-8e639d212520"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b1a15b3-a9b8-4edf-97fa-8ebe04d1d2fb">
    <dc:identifier>DB03085</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e15f8b35-f4f5-4c7c-ad1b-677ebbfc8eb8"/>
    <rdfs:label>Glycolic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98a1f593-0d3c-4379-bf05-762b2318b309">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c475a259-3673-4a45-b321-863082f92e97"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
    <rdfs:label>Urea</rdfs:label>
    <dc:identifier>DB03904</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53746ade-171a-4e60-a775-5b8b5d8237b8">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Abnormality of movement</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5d95ca9-c3f1-40d3-9b0e-dc07b842d76a">
    <rdfs:label>Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87b9df61-8c8d-460c-a5e9-e9b7b8c2b359"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1126f5c-a04b-4d93-8a69-11468ec7d3bc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dab3d0dd-0638-45ed-87a6-6b3195d6889b"/>
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a03bbd04-cbc7-4ae9-8799-85bc64887e25">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9cbba85e-9a12-46ba-8113-e882e21da037"/>
    <rdfs:label>Niflumic acid</rdfs:label>
    <dc:identifier>DB04552</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c56f47d-2a5c-4d92-98f6-cbd303b45e91">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc2b78f9-d903-4464-9e46-66cd25a5df3c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2546b362-45c9-4593-9625-08f453e1e8eb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Delayed CNS mylinaton</rdfs:label>
    <dc:identifier>HP:0002188</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/772de7dc-8a04-45b3-a78f-bb5076a5bc60">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f48f38f-9d65-4131-9af9-02aa42eaea3d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65b9ecfa-6e9e-4eaa-8ee9-53bfe00509ab">
    <rdfs:label>Lamotrigine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/747ff943-5fe0-4dee-9f81-2f32dea1834b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
    <dc:identifier>DB00555</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65e53768-e2fd-4f9a-93a9-071944dab71c">
    <rdfs:label>Myelopathy</rdfs:label>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
    <dc:identifier>HP:0002196</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ce76469-459a-4173-a26e-75190e01f3ba">
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
    <dc:identifier>DB12528</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9877164-2692-40b1-8d42-6fc1b2d88e26"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1ee224a8-477b-4b5e-a89a-3b7239e6a9cd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb896c84-72d3-43d1-a70a-1dad6f339d08"/>
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e67184bb-0021-4d94-8e09-b6ca48ebf7a6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/142a844c-a28e-426a-9983-c85bbf2084fc"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/061dbf67-4c7d-4138-b413-88166070fe0f"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fa125ff-cdaf-4102-9059-37771626a446"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ebad508-405c-4177-8a52-fc35df828867">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4d39c5f4-30d2-41c9-82d4-bdd774ce1a48"/>
    <dc:identifier>N05A</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0d95ef3-ea43-4b5d-8bb4-f07d8460ff94">
    <dc:identifier>DB04729</dc:identifier>
    <rdfs:label>Gentamicin C1a</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5130d21c-7378-475e-8314-afa93ba0e1d1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7235a637-7fd8-41ef-94bb-3ceb1e152153">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9927e504-f5f6-4b12-9be8-2ed6e976d05b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fd0c32c-7429-41a0-bc67-b8c73bc1482f">
    <rdfs:label>Limb dystonia</rdfs:label>
    <dc:identifier>HP:0001332</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acc093ed-0569-49ec-abc2-ad9bc8658a6c">
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/087ff044-e52a-4256-bd10-15d3772fa840">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3008e8a6-4db5-42fb-ab32-05e1e81d06c9"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22e6f3d5-b80d-4d4b-ba9e-49a75f7a03cf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81ae4d6c-aa49-433c-ad48-42713b9f3adf"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3cca4fb-888e-4aa0-8517-27135f79cfa5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/496616db-696e-4d45-8d4e-dfecdb582f7b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
    <rdfs:comment>Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/</rdfs:comment>
    <dc:identifier>HP:0002317</dc:identifier>
    <rdfs:label>Gait instability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e2912e6-8163-41bd-9f6e-feb813485298">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ddbcf39-2660-4e13-814e-613f67634d0f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <dc:identifier>DB00155</dc:identifier>
    <rdfs:label>L-Citrulline</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0cef4e36-4ac4-41dc-9672-6722e79cea01">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98d409d4-e94b-464e-ac88-986824923f18"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc7d0361-14f1-48c9-9a89-74464e7a6737">
    <dc:identifier>DB13257</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/515af704-c3b7-47ed-9c31-0147eb98fc01"/>
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/482f947b-0e01-454d-8ca3-966cfaccae08">
    <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
    <dc:identifier>HP:0500014</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73aa3845-2372-48ea-b71a-3b18cf4366d9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a380b03-fae6-41c4-9560-2326f34f1a10"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38e004c0-1bdc-418a-9e29-fd756527edac">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17661033-fb0e-44d0-9c25-311c7103247d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f17ae95-ff90-4b33-aefc-f3d3b077bfec">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f90de47b-f971-49dc-bed9-e666b05cc886"/>
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7aee37f3-4ad0-4cd8-b68e-57656b39f73c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/277c7006-059c-45f3-a9fe-44e59bb6a1af"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f302ad57-28ce-416b-9fdc-9621831b297b">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <rdfs:label>vitamine K</rdfs:label>
    <dc:identifier>CHEBI_28384</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/71adb3be-99c7-46d6-850f-e54914008c96"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03a944aa-43cf-4501-bfeb-7d5f7943a4cc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>biochemical abnormalities</rdfs:label>
    <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ab3206c-b382-4713-a6ba-e23597594245">
    <dc:identifier>HP:0006462</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
    <rdfs:label>poor skeletal mineralization</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c10d81b9-6384-49c5-8e47-2fb56586b8ae">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f4fb1f9c-9626-4384-b78d-b2ec0b235203"/>
    <dc:identifier>DB00114</dc:identifier>
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/927fd94d-0361-48a5-af90-3e4e3cf67644"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8f1692e-929f-4ef2-9a95-0170452421fa">
    <dc:identifier>HP:0011804</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal muscle physiology</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02131381-d6b4-45be-bdc5-e6c53b4a78e6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fcf626d-4579-4f61-aba8-846a83724ae2"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ae6378e-e1ed-4f02-b3bf-c99ac2722897">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7c1ac058-e1a0-486d-be2f-2a0f2d2f30c4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9a52e5d-178e-42a8-95bb-2bef8ee46e79">
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cfb44861-b19a-47d7-bbe8-f65e53e67168"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1f63da6-13ba-435a-907a-61394dd01b09">
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3b42e89-8be3-4aa0-8a47-e9d47c12857e"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9e25ac1-a96f-4620-8981-39c84751a1d8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/573cd4dc-8cca-48e5-adf2-7e49d8190c63"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b541052-c1b1-43b1-bdb8-36b6e4d7c6c9">
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2bbb32e2-ac70-443e-90d5-9b565abcceb4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec31c786-449f-4c62-b890-02190679c272">
    <dc:identifier>HP:0002474*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
    <rdfs:label>communicative skills abnormalities</rdfs:label>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a030ba63-e599-47a8-8dff-28278d3f36c4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ede570b-6f51-476a-96a9-58d4eda85063"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5230fc35-1da2-4732-81f0-956199d2d923">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b6f6c9a-b554-4c88-8cb0-d037b9c3ff07"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2ae89f49-3b83-40e7-84b8-444cd4c108b7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28acc487-b711-478a-83fe-11b260e3abd0"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f62c5437-e7b2-4a70-af89-262b227eeb0e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2b656966-60c6-4a94-92ad-422c10eb7ff1"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7537a85-3153-4be6-975b-db855cd8b487"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c60ccc82-fba8-4846-9cae-fc1b03fa90c1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3725f076-7992-40a5-ba10-52ba50ebe2b3"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ec9666b-11e1-41d1-9759-1f18e7397497">
    <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/646d941a-ef7f-47e6-bfda-f681528c2938">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8d942e4-f001-44ab-b06e-e6b451fe064b"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2abeb702-8b37-4ae6-b211-a842556c0a99">
    <rdfs:label>High serum osmolality</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34c17b22-8391-4bf4-a1b2-6ff15b7e9e58">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7f1c9017-61d6-46a5-b400-3b9e4d996570"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3a9e63e-7408-4d02-8c09-759b1375b94a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f3b011d-8aeb-47e1-9882-2bc2e25be642"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3325c26-5ce7-4609-9155-01ab6591572b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc35ab5a-bed5-4b95-b464-5f38c5c56e5c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e2cc1bf-fb4e-4942-a80a-b8d16d95555e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05a45cb5-7a01-4c19-a1e4-1013db8c4018"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
    <dc:identifier>DB01205</dc:identifier>
    <rdfs:label>Flumazenil</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de389633-e330-4dbb-a636-2dd8c33e23fb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5994609d-5b8f-4d35-8f02-6815ebb7e1cc"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aafcdd03-8bd0-4cb3-ae00-db6447574150">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c513f23-ffae-4955-bbd4-0cf4cddce6dd"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfcb39eb-58fc-4515-90d4-01d07341d1bc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4441361a-966b-4f9f-8ebf-36048488dedc"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f758dd65-7c8b-4a42-9ed0-9c95ffd9a187">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a5e5378b-52c3-41f0-950d-5eb4424706d6"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81ff3eef-471a-4d79-b5d1-6c6e35418f30">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b85865d5-c203-4e6e-8959-b97409518f74"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3edb39c7-77ca-426b-9239-910a2901c72e">
    <rdfs:label>Modified Atkins diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/002a3528-35db-45e2-8f2a-a94ce8a8bb02"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4757bf23-2422-44da-85bd-d92ea798aeeb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f8f8bec-71eb-4a30-b35b-7e57b3b2dc44"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/352066f7-389d-44d2-8a44-de2d8a47e831">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07baa9a5-c0d7-4223-aa29-9a5740bd2b66"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46c7a888-e8b9-43d8-ac2d-e485eb1f61e2">
    <rdfs:comment>Niacin was the only effective drug to increase HDL cholesterol.</rdfs:comment>
    <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/731ddcf1-4218-4888-a0aa-eb0c72a2cd52">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1affcac7-c941-430a-8d09-06b0bf25c785"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e7d522b-9ea7-4a8e-a293-8e90ec3c12ba">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f2649810-45b5-4421-9d59-4a221e8abe41"/>
  </rdf:Alt>
</rdf:RDF>
